

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1r_wp295, Report 1

Request ID: cder_mpl1r_wp295_nsdv_v01

Request Description: In this report we characterized dispensing and administration patterns of 26 New Molecular Entities (NMEs) approved from January 1, 2019 through August 31, 2019, stratified by age and sex in the Sentinel Distributed Database (SDD).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis module (CIDA), version 14.2.0.

Data Source: We distributed this request to 13 Sentinel Data Partners on May 22, 2025. The study period included data from January 1, 2019 to December 31, 2024. Report 2 includes NMEs approved from September 1, 2019 to December 31, 2019. Please see Appendix A for a list of dates of available data for each Data Partner.

Study Design: We identified individuals initiating any of the 26 NMEs of interest. We described demographic and clinical characteristics for individuals initiating each NME based on history recorded in the six months prior to initiation of treatment with the relevant drug. The analyses characterized dispensing patterns by examining cumulative exposure episode duration, first exposure episode duration, all exposure episode durations, days supplied per dispensing, and lengths of gaps between episodes, overall and stratified by age group and sex. This was a Type 5 analysis in the Query Request Package (QRP) documentation.

Exposures of Interest: Our exposures of interest were NMEs approved between January 1, 2019 through August 31, 2019, administered or dispensed in any care setting. These were defined using National Drug Codes (NDCs), Healthcare Common Procedure Coding System (HCPCS) procedure codes and International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) procedure codes. Please see Appendix B for a list of non-proprietary and proprietary names of medical products, and Appendix C for a list of procedure codes used to define exposures in this request. All valid exposure episodes were included.

Cohort Eligibility Criteria: We defined index exposure as the first qualifying administration or dispensing of a given NME to an individual during the study period. We required individuals to be enrolled in health plans with both medical and drug coverage for at least 183 days prior to their index exposure, during which gaps in coverage of up to 45 days were allowed. The following age groups were included: 0-17, 18-24, 25-40, 41-64, 65+ years.

Baseline Characteristics: We described demographic characteristics such as sex, age, race/ethnicity and calendar year on the day of each index NME exposure. We also described 33 clinical characteristics based on history recorded in the six months prior to the index exposure. The set of clinical characteristics included 28 chronic conditions and 5 lifestyle-related conditions. Most of the chronic conditions (26 out of 28) were defined using Centers for Medicare and Medicaid Services' (CMS) Chronic Conditions Data Warehouse¹ (CCW) algorithms and included: acute myocardial infarction, Alzheimer's disease, non-Alzheimer's disease, atrial fibrillation, diabetes mellitus, heart failure, hyperlipidemia, hypertension, depression, ischemic heart disease, rheumatoid arthritis/osteoarthritis, stroke/transient ischemic attack (TIA), breast cancer, colorectal cancer, prostate cancer, lung cancer, endometrial cancer, acquired hypothyroidism, anemia, asthma, benign prostatic hyperplasia, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and bronchiectasis, glaucoma, osteoporosis, and liver disease. History of cardiac arrest, and history of coronary angioplasty or bypass were also included. Lifestyle-related conditions included: obesity, overweight, smoking, alcohol abuse or dependence and drug abuse or dependence. International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) diagnosis codes, ICD-10-PCS procedure codes, HCPCS procedure codes, Current Procedural Terminology, Fourth Edition (CPT-4) procedure codes, and NDCs were used to define the clinical characteristics. Please see Appendix D for a list of diagnosis and procedure codes, and Appendix E for a list of non-proprietary and proprietary names of medical products used to define baseline characteristics in this request.

Please refer to Appendices F, G, and H for the specifications of parameters used in this request, baseline characteristics used in this request, and a design diagram.

Overview for Request: cder_mpl1r_wp295, Report 1

Limitations: Algorithms used to define exposures and inclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

Table of Contents

Glossary (CIDA) List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report

Table 1a Aggregated Characteristics of PrabotulinumtoxinA-xvfs Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table 1b Aggregated Characteristics of Caplacizumab-yhdp Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table 1c Aggregated Characteristics of Triclabendazole Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table 1d Aggregated Characteristics of Brexanolone Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table 1e Aggregated Characteristics of Solriamfetol Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table 1f Aggregated Characteristics of Siponimod Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table 1g Aggregated Characteristics of Romosozumab-aqqg Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table 1h Aggregated Characteristics of Erdafitinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table 1i Aggregated Characteristics of Risankizumab-rzaa Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table 1j Aggregated Characteristics of Tafamidis Meglumine Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table 1k Aggregated Characteristics of Alpelisib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table 1l Aggregated Characteristics of Polatuzumab Vedotin-piiq Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table 1m Aggregated Characteristics of Bremelanotide Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table 1n Aggregated Characteristics of Selinexor Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table 1o Aggregated Characteristics of Imipenem, Cilastatin and Relebactam Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table 1p Aggregated Characteristics of Ferric Maltol Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table 1q Aggregated Characteristics of Darolutamide Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table 1r Aggregated Characteristics of Pexidartinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table 1s Aggregated Characteristics of Pretomanid Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table of Contents

<u>Table 1t</u>	Aggregated Characteristics of Pitolisant Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 1u</u>	Aggregated Characteristics of Entrectinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 1v</u>	Aggregated Characteristics of Fedratinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 1w</u>	Aggregated Characteristics of Upadacitinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 1x</u>	Aggregated Characteristics of Lefamulin Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 1y</u>	Aggregated Characteristics of Ga-68-DOTATOC Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 1z</u>	Aggregated Characteristics of Istradefylline Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 2a</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 2b</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 2c</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex
<u>Table 2d</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex
<u>Table 2e</u>	Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group
<u>Table 2f</u>	Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group
<u>Table 3a</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 3b</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 3c</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex
<u>Table 3d</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex
<u>Table 3e</u>	Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group
<u>Table 3f</u>	Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group
<u>Table 4a</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table of Contents

<u>Table 4b</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 4c</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex
<u>Table 4d</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex
<u>Table 4e</u>	Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group
<u>Table 4f</u>	Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group
<u>Table 5a</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 5b</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 5c</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex
<u>Table 5d</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex
<u>Table 5e</u>	Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group
<u>Table 5f</u>	Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group
<u>Table 6a</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 6b</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 6c</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex
<u>Table 6d</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex
<u>Table 6e</u>	Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group
<u>Table 6f</u>	Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group
<u>Table 7a</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 7b</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex
<u>Table 7c</u>	Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

Table of Contents

<u>Table 8a</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 8b</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex
<u>Table 8c</u>	Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group
<u>Table 9</u>	Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Table 10</u>	Summary of Patient Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Figure 1a</u>	Patient Entry into Study by Month for PrabotulinumtoxinA-xvfs in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Figure 1b</u>	Patient Entry into Study by Month for Caplacizumab-yhdp in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Figure 1c</u>	Patient Entry into Study by Month for Triclabendazole in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Figure 1d</u>	Patient Entry into Study by Month for Brexanolone in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Figure 1e</u>	Patient Entry into Study by Month for Solriamfetol in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Figure 1f</u>	Patient Entry into Study by Month for Siponimod in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Figure 1g</u>	Patient Entry into Study by Month for Romosozumab-aqqg in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Figure 1h</u>	Patient Entry into Study by Month for Erdafitinib in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Figure 1i</u>	Patient Entry into Study by Month for Risankizumab-rzaa in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Figure 1j</u>	Patient Entry into Study by Month for Tafamidis Meglumine in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Figure 1k</u>	Patient Entry into Study by Month for Alpelisib in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Figure 1l</u>	Patient Entry into Study by Month for Polatuzumab Vedotin-piiq in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Figure 1m</u>	Patient Entry into Study by Month for Bremelanotide in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Figure 1n</u>	Patient Entry into Study by Month for Selinexor in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024
<u>Figure 1o</u>	Patient Entry into Study by Month for Imipenem, Cilastatin and Relebactam in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Table of Contents

Figure 1p Patient Entry into Study by Month for Ferric Maltol in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Figure 1q Patient Entry into Study by Month for Darolutamide in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Figure 1r Patient Entry into Study by Month for Pexidartinib in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Figure 1s Patient Entry into Study by Month for Pretomanid in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Figure 1t Patient Entry into Study by Month for Pitolisant in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Figure 1u Patient Entry into Study by Month for Entrectinib in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Figure 1v Patient Entry into Study by Month for Fedratinib in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Figure 1w Patient Entry into Study by Month for Upadacitinib in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Figure 1x Patient Entry into Study by Month for Lefamulin in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Figure 1y Patient Entry into Study by Month for Ga-68-DOTATOC in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Figure 1z Patient Entry into Study by Month for Istradefylline in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Appendix A Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (May 22, 2025)

Appendix B List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request

Appendix C List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exposures in this Request

Appendix D List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Appendix E List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Appendix F Specifications for Type 5 Request: cder_mpl1r_wp295_nsdv_v01

Appendix G Design Diagram Used in this Request

Appendix H Health Characteristics used to Define Covariates in this Request

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded.

Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the CareSetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Characteristics of PrabotulinumtoxinA-xvfs Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

PrabotulinumtoxinA-xvfs		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	41.2	15.2
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	0	0.0%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	*****	*****
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	*****	*****
Unknown	*****	*****
Year		
2019	0	0.0%
2020	*****	*****
2021	*****	*****
2022	*****	*****
2023	*****	*****
2024	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%

Table 1a. Aggregated Characteristics of PrabotulinumtoxinA-xvfs Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	PrabotulinumtoxinA-xvfs	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	0	0.0%
Diabetes	0	0.0%
Heart Failure	0	0.0%
Hyperlipidemia	*****	*****
Hypertension	*****	*****
Depression	*****	*****
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/Transient Ischemic Attack (TIA)	0	0.0%
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	*****	*****
Asthma	0	0.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity (Diagnosis or Procedure Codes)	0	0.0%
Obesity (Dispensing Codes)	0	0.0%
Overweight	0	0.0%
Smoking (Diagnosis or Procedure Codes)	0	0.0%
Smoking (Dispensing Codes)	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease CCW	*****	*****
Liver Disease Extended	*****	*****

Table 1a. Aggregated Characteristics of PrabotulinumtoxinA-xvfs Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

PrabotulinumtoxinA-xvfs		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	13.8	17.2
Mean number of emergency room encounters	0.2	0.4
Mean number of inpatient hospital encounters	0	NaN
Mean number of non-acute institutional encounters	0	NaN
Mean number of other ambulatory encounters	3.3	6.4
Mean number of filled prescriptions	13.5	7.1
Mean number of generics dispensed	6	4.8
Mean number of unique drug classes dispensed	5.4	4.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1b. Aggregated Characteristics of Caplacizumab-yhdp Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Caplacizumab-yhdp		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	390	N/A
Demographic Characteristics		
Age (years)	52.9	15.4
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	81	20.8%
41-64 years	156	40.0%
≥ 65 years	122	31.3%
Sex		
Female	254	65.1%
Male	136	34.9%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	16	4.1%
Black or African American	131	33.6%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	95	24.4%
White	136	34.9%
Hispanic origin		
Yes	21	5.4%
No	260	66.7%
Unknown	109	27.9%
Year		
2019	42	10.8%
2020	75	19.2%
2021	118	30.3%
2022	58	14.9%
2023	55	14.1%
2024	42	10.8%
Health Characteristics		
Acute Myocardial Infarction	29	7.4%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	19	4.9%

Table 1b. Aggregated Characteristics of Caplacizumab-yhdp Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Caplacizumab-yhdp	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	29	7.4%
Diabetes	102	26.2%
Heart Failure	55	14.1%
Hyperlipidemia	137	35.1%
Hypertension	209	53.6%
Depression	81	20.8%
Ischemic Heart Disease	68	17.4%
Rheumatoid Arthritis/Osteoarthritis	44	11.3%
Stroke/Transient Ischemic Attack (TIA)	93	23.8%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	37	9.5%
Anemia	252	64.6%
Asthma	32	8.2%
Benign Prostatic Hyperplasia	21	5.4%
Chronic Kidney Disease	83	21.3%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	41	10.5%
Glaucoma	19	4.9%
Osteoporosis	*****	*****
Obesity (Diagnosis or Procedure Codes)	126	32.3%
Obesity (Dispensing Codes)	*****	*****
Overweight	29	7.4%
Smoking (Diagnosis or Procedure Codes)	132	33.8%
Smoking (Dispensing Codes)	*****	*****
Alcohol Abuse or Dependence	15	3.8%
Drug Abuse or Dependence	32	8.2%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	13	3.3%
Liver Disease CCW	52	13.3%
Liver Disease Extended	52	13.3%

Table 1b. Aggregated Characteristics of Caplacizumab-yhdp Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Caplacizumab-yhdp		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	13.8	18.6
Mean number of emergency room encounters	1.1	1.6
Mean number of inpatient hospital encounters	1	1.2
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	11.8	20.2
Mean number of filled prescriptions	15.9	17.5
Mean number of generics dispensed	7.2	5.3
Mean number of unique drug classes dispensed	6.7	4.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1c. Aggregated Characteristics of Triclabendazole Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Triclabendazole		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	*****	N/A
Demographic Characteristics		
Age (years)	31.3	11.5
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	0	0.0%
≥ 65 years	0	0.0%
Sex		
Female	*****	*****
Male	0	0.0%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	0	0.0%
Black or African American	0	0.0%
Multi-racial	0	0.0%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	0	0.0%
Hispanic origin		
Yes	0	0.0%
No	0	0.0%
Unknown	*****	*****
Year		
2019	0	0.0%
2020	0	0.0%
2021	0	0.0%
2022	*****	*****
2023	0	0.0%
2024	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%

Table 1c. Aggregated Characteristics of Triclabendazole Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Triclabendazole	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	0	0.0%
Diabetes	0	0.0%
Heart Failure	0	0.0%
Hyperlipidemia	0	0.0%
Hypertension	0	0.0%
Depression	*****	*****
Ischemic Heart Disease	0	0.0%
Rheumatoid Arthritis/Osteoarthritis	0	0.0%
Stroke/Transient Ischemic Attack (TIA)	0	0.0%
Breast Cancer	0	0.0%
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	0	0.0%
Anemia	0	0.0%
Asthma	0	0.0%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	0	0.0%
Glaucoma	0	0.0%
Osteoporosis	0	0.0%
Obesity (Diagnosis or Procedure Codes)	0	0.0%
Obesity (Dispensing Codes)	0	0.0%
Overweight	0	0.0%
Smoking (Diagnosis or Procedure Codes)	0	0.0%
Smoking (Dispensing Codes)	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	0	0.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease CCW	0	0.0%
Liver Disease Extended	0	0.0%

Table 1c. Aggregated Characteristics of Triclabendazole Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Triclabendazole		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	6.5	7.8
Mean number of emergency room encounters	0.5	0.7
Mean number of inpatient hospital encounters	0	NaN
Mean number of non-acute institutional encounters	0	NaN
Mean number of other ambulatory encounters	1	1.4
Mean number of filled prescriptions	16	8.5
Mean number of generics dispensed	3	1.4
Mean number of unique drug classes dispensed	3	1.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1d. Aggregated Characteristics of Brexanolone Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Brexanolone		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	164	N/A
Demographic Characteristics		
Age (years)	33.6	10.1
Age		
0-17 years	0	0.0%
18-24 years	20	12.2%
25-40 years	133	81.1%
41-64 years	*****	*****
≥ 65 years	*****	*****
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	51	31.1%
White	99	60.4%
Hispanic origin		
Yes	*****	*****
No	99	60.4%
Unknown	*****	*****
Year		
2019	*****	*****
2020	24	14.6%
2021	35	21.3%
2022	34	20.7%
2023	53	32.3%
2024	*****	*****
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****

Table 1d. Aggregated Characteristics of Brexanolone Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Brexanolone	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	*****	*****
Diabetes	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	11	6.7%
Hypertension	12	7.3%
Depression	111	67.7%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/Transient Ischemic Attack (TIA)	0	0.0%
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	18	11.0%
Anemia	32	19.5%
Asthma	13	7.9%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	*****	*****
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	0	0.0%
Obesity (Diagnosis or Procedure Codes)	48	29.3%
Obesity (Dispensing Codes)	*****	*****
Overweight	*****	*****
Smoking (Diagnosis or Procedure Codes)	16	9.8%
Smoking (Dispensing Codes)	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	0	0.0%
Liver Disease CCW	*****	*****
Liver Disease Extended	*****	*****

Table 1d. Aggregated Characteristics of Brexanolone Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Brexanolone		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.5	13
Mean number of emergency room encounters	1	1.7
Mean number of inpatient hospital encounters	1	0.7
Mean number of non-acute institutional encounters	0.1	0.2
Mean number of other ambulatory encounters	6.7	14.9
Mean number of filled prescriptions	15.6	12.8
Mean number of generics dispensed	8	5
Mean number of unique drug classes dispensed	7.4	4.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1e. Aggregated Characteristics of Solriamfetol Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Solriamfetol		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	15,947	N/A
Demographic Characteristics		
Age (years)	48.2	13.9
Age		
0-17 years	74	0.5%
18-24 years	1,135	7.1%
25-40 years	4,481	28.1%
41-64 years	7,488	47.0%
≥ 65 years	2,769	17.4%
Sex		
Female	9,717	60.9%
Male	6,230	39.1%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	208	1.3%
Black or African American	805	5.0%
Multi-racial	351	2.2%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	4,756	29.8%
White	9,766	61.2%
Hispanic origin		
Yes	435	2.7%
No	8,992	56.4%
Unknown	6,520	40.9%
Year		
2019	1,143	7.2%
2020	3,057	19.2%
2021	4,344	27.2%
2022	2,557	16.0%
2023	2,727	17.1%
2024	2,119	13.3%
Health Characteristics		
Acute Myocardial Infarction	18	0.1%
Alzheimer's Disease	37	0.2%
Non-Alzheimer's Dementia	183	1.1%

Table 1e. Aggregated Characteristics of Solriamfetol Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Solriamfetol	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	434	2.7%
Diabetes	2,428	15.2%
Heart Failure	607	3.8%
Hyperlipidemia	3,309	20.7%
Hypertension	4,261	26.7%
Depression	6,900	43.3%
Ischemic Heart Disease	1,205	7.6%
Rheumatoid Arthritis/Osteoarthritis	2,565	16.1%
Stroke/Transient Ischemic Attack (TIA)	189	1.2%
Breast Cancer	187	1.2%
Colorectal Cancer	40	0.3%
Prostate Cancer	92	0.6%
Lung Cancer	29	0.2%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	1,653	10.4%
Anemia	1,883	11.8%
Asthma	1,181	7.4%
Benign Prostatic Hyperplasia	424	2.7%
Chronic Kidney Disease	683	4.3%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	826	5.2%
Glaucoma	605	3.8%
Osteoporosis	247	1.5%
Obesity (Diagnosis or Procedure Codes)	5,118	32.1%
Obesity (Dispensing Codes)	1,093	6.9%
Overweight	1,324	8.3%
Smoking (Diagnosis or Procedure Codes)	2,181	13.7%
Smoking (Dispensing Codes)	228	1.4%
Alcohol Abuse or Dependence	322	2.0%
Drug Abuse or Dependence	896	5.6%
History of Cardiac Arrest	17	0.1%
History of Coronary Angioplasty or Bypass	288	1.8%
Liver Disease CCW	442	2.8%
Liver Disease Extended	450	2.8%

Table 1e. Aggregated Characteristics of Solriamfetol Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Solriamfetol		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.8	13.6
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0	0.1
Mean number of other ambulatory encounters	4.7	9.9
Mean number of filled prescriptions	26.5	21.8
Mean number of generics dispensed	9.9	6.6
Mean number of unique drug classes dispensed	9.3	5.9

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1f. Aggregated Characteristics of Siponimod Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Siponimod		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	2,286	N/A
Demographic Characteristics		
Age (years)	51.8	10.8
Age		
0-17 years	0	0.0%
18-24 years	26	1.1%
25-40 years	429	18.8%
41-64 years	1,516	66.3%
≥ 65 years	315	13.8%
Sex		
Female	1,710	74.8%
Male	576	25.2%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	283	12.4%
Multi-racial	21	0.9%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	602	26.3%
White	1,358	59.4%
Hispanic origin		
Yes	87	3.8%
No	1,464	64.0%
Unknown	735	32.2%
Year		
2019	346	15.1%
2020	740	32.4%
2021	564	24.7%
2022	256	11.2%
2023	273	11.9%
2024	107	4.7%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	43	1.9%

Table 1f. Aggregated Characteristics of Siponimod Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Siponimod	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	16	0.7%
Diabetes	175	7.7%
Heart Failure	39	1.7%
Hyperlipidemia	356	15.6%
Hypertension	489	21.4%
Depression	704	30.8%
Ischemic Heart Disease	73	3.2%
Rheumatoid Arthritis/Osteoarthritis	231	10.1%
Stroke/Transient Ischemic Attack (TIA)	27	1.2%
Breast Cancer	25	1.1%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	166	7.3%
Anemia	272	11.9%
Asthma	82	3.6%
Benign Prostatic Hyperplasia	34	1.5%
Chronic Kidney Disease	51	2.2%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	57	2.5%
Glaucoma	148	6.5%
Osteoporosis	89	3.9%
Obesity (Diagnosis or Procedure Codes)	371	16.2%
Obesity (Dispensing Codes)	28	1.2%
Overweight	131	5.7%
Smoking (Diagnosis or Procedure Codes)	369	16.1%
Smoking (Dispensing Codes)	33	1.4%
Alcohol Abuse or Dependence	27	1.2%
Drug Abuse or Dependence	86	3.8%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	11	0.5%
Liver Disease CCW	42	1.8%
Liver Disease Extended	42	1.8%

Table 1f. Aggregated Characteristics of Siponimod Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Siponimod		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	12.9	11.2
Mean number of emergency room encounters	0.4	0.9
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0	0.3
Mean number of other ambulatory encounters	7.4	19.8
Mean number of filled prescriptions	20.9	19.4
Mean number of generics dispensed	7.7	5.5
Mean number of unique drug classes dispensed	7.3	5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1g. Aggregated Characteristics of Romosozumab-aqqg Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Romosozumab-aqqg		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	87,634	N/A
Demographic Characteristics		
Age (years)	73.6	7.9
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	201	0.2%
41-64 years	7,993	9.1%
≥ 65 years	79,409	90.6%
Sex		
Female	85,733	97.8%
Male	1,901	2.2%
Race ²		
American Indian or Alaska Native	196	0.2%
Asian	2,837	3.2%
Black or African American	1,372	1.6%
Multi-racial	236	0.3%
Native Hawaiian or Other Pacific Islander	77	0.1%
Unknown	7,667	8.7%
White	75,249	85.9%
Hispanic origin		
Yes	1,278	1.5%
No	75,328	86.0%
Unknown	11,028	12.6%
Year		
2019	3,344	3.8%
2020	8,603	9.8%
2021	13,364	15.2%
2022	18,230	20.8%
2023	26,593	30.3%
2024	17,500	20.0%
Health Characteristics		
Acute Myocardial Infarction	213	0.2%
Alzheimer's Disease	1,079	1.2%
Non-Alzheimer's Dementia	3,219	3.7%

Table 1g. Aggregated Characteristics of Romosozumab-aqqg Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Romosozumab-aqqg	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	6,286	7.2%
Diabetes	10,451	11.9%
Heart Failure	6,531	7.5%
Hyperlipidemia	34,996	39.9%
Hypertension	38,279	43.7%
Depression	20,647	23.6%
Ischemic Heart Disease	11,473	13.1%
Rheumatoid Arthritis/Osteoarthritis	36,260	41.4%
Stroke/Transient Ischemic Attack (TIA)	1,542	1.8%
Breast Cancer	5,050	5.8%
Colorectal Cancer	857	1.0%
Prostate Cancer	209	0.2%
Lung Cancer	909	1.0%
Endometrial Cancer	418	0.5%
Acquired Hypothyroidism	18,438	21.0%
Anemia	21,625	24.7%
Asthma	5,263	6.0%
Benign Prostatic Hyperplasia	367	0.4%
Chronic Kidney Disease	8,637	9.9%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	9,028	10.3%
Glaucoma	10,152	11.6%
Osteoporosis	71,724	81.8%
Obesity (Diagnosis or Procedure Codes)	9,607	11.0%
Obesity (Dispensing Codes)	1,239	1.4%
Overweight	7,874	9.0%
Smoking (Diagnosis or Procedure Codes)	15,874	18.1%
Smoking (Dispensing Codes)	302	0.3%
Alcohol Abuse or Dependence	1,378	1.6%
Drug Abuse or Dependence	3,001	3.4%
History of Cardiac Arrest	96	0.1%
History of Coronary Angioplasty or Bypass	1,816	2.1%
Liver Disease CCW	2,752	3.1%
Liver Disease Extended	2,878	3.3%

Table 1g. Aggregated Characteristics of Romosozumab-aqqg Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Romosozumab-aqqg		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.4	13.2
Mean number of emergency room encounters	0.3	0.9
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	5.3	8.7
Mean number of filled prescriptions	17.8	16.5
Mean number of generics dispensed	8.1	5.5
Mean number of unique drug classes dispensed	7.6	5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1h. Aggregated Characteristics of Erdafitinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Erdafitinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	848	N/A
Demographic Characteristics		
Age (years)	69.8	10.9
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	18	2.1%
41-64 years	195	23.0%
≥ 65 years	624	73.6%
Sex		
Female	324	38.2%
Male	524	61.8%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	44	5.2%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	147	17.3%
White	614	72.4%
Hispanic origin		
Yes	26	3.1%
No	635	74.9%
Unknown	187	22.1%
Year		
2019	142	16.7%
2020	192	22.6%
2021	165	19.5%
2022	130	15.3%
2023	133	15.7%
2024	86	10.1%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	22	2.6%

Table 1h. Aggregated Characteristics of Erdafitinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Erdafitinib	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	89	10.5%
Diabetes	187	22.1%
Heart Failure	90	10.6%
Hyperlipidemia	346	40.8%
Hypertension	517	61.0%
Depression	163	19.2%
Ischemic Heart Disease	230	27.1%
Rheumatoid Arthritis/Osteoarthritis	144	17.0%
Stroke/Transient Ischemic Attack (TIA)	26	3.1%
Breast Cancer	34	4.0%
Colorectal Cancer	35	4.1%
Prostate Cancer	92	10.8%
Lung Cancer	73	8.6%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	141	16.6%
Anemia	547	64.5%
Asthma	29	3.4%
Benign Prostatic Hyperplasia	93	11.0%
Chronic Kidney Disease	349	41.2%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	139	16.4%
Glaucoma	66	7.8%
Osteoporosis	29	3.4%
Obesity (Diagnosis or Procedure Codes)	127	15.0%
Obesity (Dispensing Codes)	*****	*****
Overweight	104	12.3%
Smoking (Diagnosis or Procedure Codes)	387	45.6%
Smoking (Dispensing Codes)	*****	*****
Alcohol Abuse or Dependence	16	1.9%
Drug Abuse or Dependence	28	3.3%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	80	9.4%
Liver Disease CCW	112	13.2%
Liver Disease Extended	116	13.7%

Table 1h. Aggregated Characteristics of Erdafitinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Erdafitinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	32.3	15.2
Mean number of emergency room encounters	0.7	1.2
Mean number of inpatient hospital encounters	0.7	1.1
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	11.9	13.8
Mean number of filled prescriptions	22.4	17.7
Mean number of generics dispensed	10.2	5.5
Mean number of unique drug classes dispensed	9.3	4.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1i. Aggregated Characteristics of Risankizumab-rzaa Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Risankizumab-rzaa		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	76,821	N/A
Demographic Characteristics		
Age (years)	50.8	13.8
Age		
0-17 years	195	0.3%
18-24 years	3,936	5.1%
25-40 years	18,558	24.2%
41-64 years	37,857	49.3%
≥ 65 years	16,275	21.2%
Sex		
Female	39,454	51.4%
Male	37,367	48.6%
Race ²		
American Indian or Alaska Native	297	0.4%
Asian	2,152	2.8%
Black or African American	3,061	4.0%
Multi-racial	1,494	1.9%
Native Hawaiian or Other Pacific Islander	99	0.1%
Unknown	30,450	39.6%
White	39,268	51.1%
Hispanic origin		
Yes	2,822	3.7%
No	36,084	47.0%
Unknown	37,915	49.4%
Year		
2019	2,932	3.8%
2020	7,742	10.1%
2021	10,625	13.8%
2022	14,618	19.0%
2023	21,672	28.2%
2024	19,232	25.0%
Health Characteristics		
Acute Myocardial Infarction	159	0.2%
Alzheimer's Disease	146	0.2%
Non-Alzheimer's Dementia	546	0.7%

Table 1i. Aggregated Characteristics of Risankizumab-rzaa Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Risankizumab-rzaa	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	2,008	2.6%
Diabetes	11,275	14.7%
Heart Failure	3,148	4.1%
Hyperlipidemia	14,528	18.9%
Hypertension	18,528	24.1%
Depression	14,513	18.9%
Ischemic Heart Disease	5,812	7.6%
Rheumatoid Arthritis/Osteoarthritis	14,724	19.2%
Stroke/Transient Ischemic Attack (TIA)	580	0.8%
Breast Cancer	713	0.9%
Colorectal Cancer	276	0.4%
Prostate Cancer	517	0.7%
Lung Cancer	201	0.3%
Endometrial Cancer	81	0.1%
Acquired Hypothyroidism	4,978	6.5%
Anemia	9,481	12.3%
Asthma	2,446	3.2%
Benign Prostatic Hyperplasia	1,315	1.7%
Chronic Kidney Disease	3,680	4.8%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	3,253	4.2%
Glaucoma	2,735	3.6%
Osteoporosis	1,543	2.0%
Obesity (Diagnosis or Procedure Codes)	17,282	22.5%
Obesity (Dispensing Codes)	3,821	5.0%
Overweight	5,163	6.7%
Smoking (Diagnosis or Procedure Codes)	11,382	14.8%
Smoking (Dispensing Codes)	651	0.8%
Alcohol Abuse or Dependence	1,887	2.5%
Drug Abuse or Dependence	2,344	3.1%
History of Cardiac Arrest	70	0.1%
History of Coronary Angioplasty or Bypass	1,526	2.0%
Liver Disease CCW	2,806	3.7%
Liver Disease Extended	2,848	3.7%

Table 1i. Aggregated Characteristics of Risankizumab-rzaa Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Risankizumab-rzaa		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	10.4	10.8
Mean number of emergency room encounters	0.3	1.1
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0	0.1
Mean number of other ambulatory encounters	3.2	8
Mean number of filled prescriptions	17.9	17.5
Mean number of generics dispensed	7.6	5.5
Mean number of unique drug classes dispensed	7	5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

Table 1j. Aggregated Characteristics of Tafamidis Meglumine Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Tafamidis Meglumine		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	11,217	N/A
Demographic Characteristics		
Age (years)	79.6	7.6
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	10,806	96.3%
Sex		
Female	2,105	18.8%
Male	9,112	81.2%
Race ²		
American Indian or Alaska Native	11	0.1%
Asian	79	0.7%
Black or African American	2,265	20.2%
Multi-racial	41	0.4%
Native Hawaiian or Other Pacific Islander	15	0.1%
Unknown	733	6.5%
White	8,073	72.0%
Hispanic origin		
Yes	87	0.8%
No	9,353	83.4%
Unknown	1,777	15.8%
Year		
2019	1,289	11.5%
2020	1,104	9.8%
2021	1,349	12.0%
2022	1,619	14.4%
2023	2,504	22.3%
2024	3,352	29.9%
Health Characteristics		
Acute Myocardial Infarction	630	5.6%
Alzheimer's Disease	162	1.4%
Non-Alzheimer's Dementia	612	5.5%

Table 1j. Aggregated Characteristics of Tafamidis Meglumine Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Tafamidis Meglumine	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	6,509	58.0%
Diabetes	3,026	27.0%
Heart Failure	10,674	95.2%
Hyperlipidemia	7,106	63.4%
Hypertension	8,647	77.1%
Depression	1,438	12.8%
Ischemic Heart Disease	6,182	55.1%
Rheumatoid Arthritis/Osteoarthritis	2,880	25.7%
Stroke/Transient Ischemic Attack (TIA)	655	5.8%
Breast Cancer	187	1.7%
Colorectal Cancer	129	1.2%
Prostate Cancer	1,094	9.8%
Lung Cancer	99	0.9%
Endometrial Cancer	19	0.2%
Acquired Hypothyroidism	1,505	13.4%
Anemia	3,881	34.6%
Asthma	703	6.3%
Benign Prostatic Hyperplasia	2,127	19.0%
Chronic Kidney Disease	4,306	38.4%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	1,390	12.4%
Glaucoma	1,699	15.1%
Osteoporosis	403	3.6%
Obesity (Diagnosis or Procedure Codes)	2,212	19.7%
Obesity (Dispensing Codes)	176	1.6%
Overweight	1,421	12.7%
Smoking (Diagnosis or Procedure Codes)	3,208	28.6%
Smoking (Dispensing Codes)	12	0.1%
Alcohol Abuse or Dependence	199	1.8%
Drug Abuse or Dependence	184	1.6%
History of Cardiac Arrest	95	0.8%
History of Coronary Angioplasty or Bypass	1,825	16.3%
Liver Disease CCW	710	6.3%
Liver Disease Extended	712	6.3%

Table 1j. Aggregated Characteristics of Tafamidis Meglumine Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Tafamidis Meglumine	
	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	21.3	13.8
Mean number of emergency room encounters	0.6	1.2
Mean number of inpatient hospital encounters	0.5	0.9
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	7.7	10.9
Mean number of filled prescriptions	21.6	13.5
Mean number of generics dispensed	10.2	4.7
Mean number of unique drug classes dispensed	9.6	4.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1k. Aggregated Characteristics of Alpelisib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Alpelisib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	6,242	N/A
Demographic Characteristics		
Age (years)	65.3	11.4
Age		
0-17 years	78	1.2%
18-24 years	15	0.2%
25-40 years	172	2.8%
41-64 years	2,314	37.1%
≥ 65 years	3,663	58.7%
Sex		
Female	6,061	97.1%
Male	181	2.9%
Race ²		
American Indian or Alaska Native	26	0.4%
Asian	186	3.0%
Black or African American	538	8.6%
Multi-racial	41	0.7%
Native Hawaiian or Other Pacific Islander	16	0.3%
Unknown	1,155	18.5%
White	4,280	68.6%
Hispanic origin		
Yes	251	4.0%
No	4,721	75.6%
Unknown	1,270	20.3%
Year		
2019	1,131	18.1%
2020	1,673	26.8%
2021	1,307	20.9%
2022	898	14.4%
2023	903	14.5%
2024	330	5.3%
Health Characteristics		
Acute Myocardial Infarction	38	0.6%
Alzheimer's Disease	12	0.2%
Non-Alzheimer's Dementia	82	1.3%

Table 1k. Aggregated Characteristics of Alpelisib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Alpelisib	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	336	5.4%
Diabetes	1,065	17.1%
Heart Failure	539	8.6%
Hyperlipidemia	1,462	23.4%
Hypertension	2,309	37.0%
Depression	1,340	21.5%
Ischemic Heart Disease	593	9.5%
Rheumatoid Arthritis/Osteoarthritis	768	12.3%
Stroke/Transient Ischemic Attack (TIA)	130	2.1%
Breast Cancer	5,926	94.9%
Colorectal Cancer	106	1.7%
Prostate Cancer	18	0.3%
Lung Cancer	186	3.0%
Endometrial Cancer	64	1.0%
Acquired Hypothyroidism	847	13.6%
Anemia	2,518	40.3%
Asthma	277	4.4%
Benign Prostatic Hyperplasia	17	0.3%
Chronic Kidney Disease	646	10.3%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	416	6.7%
Glaucoma	361	5.8%
Osteoporosis	431	6.9%
Obesity (Diagnosis or Procedure Codes)	924	14.8%
Obesity (Dispensing Codes)	55	0.9%
Overweight	494	7.9%
Smoking (Diagnosis or Procedure Codes)	1,314	21.1%
Smoking (Dispensing Codes)	26	0.4%
Alcohol Abuse or Dependence	63	1.0%
Drug Abuse or Dependence	179	2.9%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	103	1.7%
Liver Disease CCW	806	12.9%
Liver Disease Extended	812	13.0%

Table 1k. Aggregated Characteristics of Alpelisib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Alpelisib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	25	13.2
Mean number of emergency room encounters	0.5	1.1
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0	0.3
Mean number of other ambulatory encounters	9.1	14.3
Mean number of filled prescriptions	23.1	16.3
Mean number of generics dispensed	9.4	5.4
Mean number of unique drug classes dispensed	8.7	4.8

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 11. Aggregated Characteristics of Polatuzumab Vedotin-piiq Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Polatuzumab Vedotin-piiq		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	6,512	N/A
Demographic Characteristics		
Age (years)	72.4	9.2
Age		
0-17 years	0	0.0%
18-24 years	14	0.2%
25-40 years	117	1.8%
41-64 years	920	14.1%
≥ 65 years	5,461	83.9%
Sex		
Female	2,782	42.7%
Male	3,730	57.3%
Race ²		
American Indian or Alaska Native	13	0.2%
Asian	153	2.3%
Black or African American	316	4.9%
Multi-racial	29	0.4%
Native Hawaiian or Other Pacific Islander	13	0.2%
Unknown	902	13.9%
White	5,086	78.1%
Hispanic origin		
Yes	164	2.5%
No	4,995	76.7%
Unknown	1,353	20.8%
Year		
2019	45	0.7%
2020	856	13.1%
2021	804	12.3%
2022	1,112	17.1%
2023	2,013	30.9%
2024	1,682	25.8%
Health Characteristics		
Acute Myocardial Infarction	99	1.5%
Alzheimer's Disease	31	0.5%
Non-Alzheimer's Dementia	236	3.6%

Table 11. Aggregated Characteristics of Polatuzumab Vedotin-piiq Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Polatuzumab Vedotin-piiq	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	1,105	17.0%
Diabetes	1,730	26.6%
Heart Failure	1,361	20.9%
Hyperlipidemia	3,340	51.3%
Hypertension	4,097	62.9%
Depression	1,323	20.3%
Ischemic Heart Disease	2,010	30.9%
Rheumatoid Arthritis/Osteoarthritis	1,422	21.8%
Stroke/Transient Ischemic Attack (TIA)	265	4.1%
Breast Cancer	299	4.6%
Colorectal Cancer	183	2.8%
Prostate Cancer	374	5.7%
Lung Cancer	180	2.8%
Endometrial Cancer	56	0.9%
Acquired Hypothyroidism	1,068	16.4%
Anemia	4,030	61.9%
Asthma	381	5.9%
Benign Prostatic Hyperplasia	892	13.7%
Chronic Kidney Disease	1,343	20.6%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	769	11.8%
Glaucoma	555	8.5%
Osteoporosis	374	5.7%
Obesity (Diagnosis or Procedure Codes)	1,582	24.3%
Obesity (Dispensing Codes)	113	1.7%
Overweight	983	15.1%
Smoking (Diagnosis or Procedure Codes)	2,428	37.3%
Smoking (Dispensing Codes)	27	0.4%
Alcohol Abuse or Dependence	138	2.1%
Drug Abuse or Dependence	220	3.4%
History of Cardiac Arrest	25	0.4%
History of Coronary Angioplasty or Bypass	641	9.8%
Liver Disease CCW	959	14.7%
Liver Disease Extended	970	14.9%

Table 1I. Aggregated Characteristics of Polatuzumab Vedotin-piiq Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Polatuzumab Vedotin-piiq		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	28	14.6
Mean number of emergency room encounters	0.8	1.3
Mean number of inpatient hospital encounters	1	1.4
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	11	13.9
Mean number of filled prescriptions	23.9	15.7
Mean number of generics dispensed	12.8	5.9
Mean number of unique drug classes dispensed	11.8	5.2

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

Table 1m. Aggregated Characteristics of Bremelanotide Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Bremelanotide		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	2,426	N/A
Demographic Characteristics		
Age (years)	43.4	9.2
Age		
0-17 years	*****	*****
18-24 years	43	1.8%
25-40 years	928	38.3%
41-64 years	1,437	59.2%
≥ 65 years	*****	*****
Sex		
Female	2,372	97.8%
Male	54	2.2%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	101	4.2%
Multi-racial	64	2.6%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	1,277	52.6%
White	958	39.5%
Hispanic origin		
Yes	64	2.6%
No	827	34.1%
Unknown	1,535	63.3%
Year		
2019	70	2.9%
2020	179	7.4%
2021	341	14.1%
2022	402	16.6%
2023	744	30.7%
2024	690	28.4%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%

Table 1m. Aggregated Characteristics of Bremelanotide Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Bremelanotide	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	*****	*****
Diabetes	99	4.1%
Heart Failure	*****	*****
Hyperlipidemia	183	7.5%
Hypertension	188	7.7%
Depression	707	29.1%
Ischemic Heart Disease	15	0.6%
Rheumatoid Arthritis/Osteoarthritis	162	6.7%
Stroke/Transient Ischemic Attack (TIA)	*****	*****
Breast Cancer	47	1.9%
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	0	0.0%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	164	6.8%
Anemia	181	7.5%
Asthma	42	1.7%
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	19	0.8%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	*****	*****
Glaucoma	30	1.2%
Osteoporosis	*****	*****
Obesity (Diagnosis or Procedure Codes)	446	18.4%
Obesity (Dispensing Codes)	292	12.0%
Overweight	258	10.6%
Smoking (Diagnosis or Procedure Codes)	157	6.5%
Smoking (Dispensing Codes)	13	0.5%
Alcohol Abuse or Dependence	34	1.4%
Drug Abuse or Dependence	48	2.0%
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease CCW	26	1.1%
Liver Disease Extended	26	1.1%

Table 1m. Aggregated Characteristics of Bremelanotide Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Bremelanotide	
	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	8.9	8.7
Mean number of emergency room encounters	0.1	0.5
Mean number of inpatient hospital encounters	0	0.2
Mean number of non-acute institutional encounters	0	0
Mean number of other ambulatory encounters	2	3.3
Mean number of filled prescriptions	14.9	14.6
Mean number of generics dispensed	6.5	5.1
Mean number of unique drug classes dispensed	6.2	4.7

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1n. Aggregated Characteristics of Selinexor Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Selinexor		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	3,486	N/A
Demographic Characteristics		
Age (years)	70.6	9.4
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	753	21.6%
≥ 65 years	2,696	77.3%
Sex		
Female	1,661	47.6%
Male	1,825	52.4%
Race ²		
American Indian or Alaska Native	14	0.4%
Asian	66	1.9%
Black or African American	523	15.0%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	465	13.3%
White	2,400	68.8%
Hispanic origin		
Yes	102	2.9%
No	2,806	80.5%
Unknown	578	16.6%
Year		
2019	365	10.5%
2020	683	19.6%
2021	764	21.9%
2022	709	20.3%
2023	639	18.3%
2024	326	9.4%
Health Characteristics		
Acute Myocardial Infarction	60	1.7%
Alzheimer's Disease	17	0.5%
Non-Alzheimer's Dementia	110	3.2%

Table 1n. Aggregated Characteristics of Selinexor Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Selinexor	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	535	15.3%
Diabetes	764	21.9%
Heart Failure	778	22.3%
Hyperlipidemia	1,214	34.8%
Hypertension	2,034	58.3%
Depression	762	21.9%
Ischemic Heart Disease	707	20.3%
Rheumatoid Arthritis/Osteoarthritis	666	19.1%
Stroke/Transient Ischemic Attack (TIA)	143	4.1%
Breast Cancer	126	3.6%
Colorectal Cancer	50	1.4%
Prostate Cancer	139	4.0%
Lung Cancer	43	1.2%
Endometrial Cancer	11	0.3%
Acquired Hypothyroidism	491	14.1%
Anemia	2,625	75.3%
Asthma	194	5.6%
Benign Prostatic Hyperplasia	325	9.3%
Chronic Kidney Disease	1,100	31.6%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	363	10.4%
Glaucoma	310	8.9%
Osteoporosis	214	6.1%
Obesity (Diagnosis or Procedure Codes)	609	17.5%
Obesity (Dispensing Codes)	28	0.8%
Overweight	389	11.2%
Smoking (Diagnosis or Procedure Codes)	1,006	28.9%
Smoking (Dispensing Codes)	*****	*****
Alcohol Abuse or Dependence	46	1.3%
Drug Abuse or Dependence	173	5.0%
History of Cardiac Arrest	16	0.5%
History of Coronary Angioplasty or Bypass	207	5.9%
Liver Disease CCW	218	6.3%
Liver Disease Extended	221	6.3%

Table 1n. Aggregated Characteristics of Selinexor Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Selinexor		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	37.6	18.9
Mean number of emergency room encounters	0.7	1.3
Mean number of inpatient hospital encounters	0.8	1.3
Mean number of non-acute institutional encounters	0.1	0.4
Mean number of other ambulatory encounters	12.9	14.5
Mean number of filled prescriptions	31.3	16.8
Mean number of generics dispensed	13.4	5.7
Mean number of unique drug classes dispensed	12.4	5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1o. Aggregated Characteristics of Imipenem, Cilastatin and Relebactam Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Imipenem, Cilastatin and Relebactam		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	152	N/A
Demographic Characteristics		
Age (years)	55.9	17.9
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	57	37.5%
≥ 65 years	56	36.8%
Sex		
Female	79	52.0%
Male	73	48.0%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	33	21.7%
White	98	64.5%
Hispanic origin		
Yes	*****	*****
No	107	70.4%
Unknown	*****	*****
Year		
2019	0	0.0%
2020	14	9.2%
2021	59	38.8%
2022	29	19.1%
2023	29	19.1%
2024	21	13.8%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	17	11.2%

Table 1o. Aggregated Characteristics of Imipenem, Cilastatin and Relebactam Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Imipenem, Cilastatin and Relebactam		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	33	21.7%
Diabetes	69	45.4%
Heart Failure	44	28.9%
Hyperlipidemia	59	38.8%
Hypertension	87	57.2%
Depression	68	44.7%
Ischemic Heart Disease	39	25.7%
Rheumatoid Arthritis/Osteoarthritis	38	25.0%
Stroke/Transient Ischemic Attack (TIA)	14	9.2%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	32	21.1%
Anemia	88	57.9%
Asthma	18	11.8%
Benign Prostatic Hyperplasia	13	8.6%
Chronic Kidney Disease	51	33.6%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	51	33.6%
Glaucoma	*****	*****
Osteoporosis	12	7.9%
Obesity (Diagnosis or Procedure Codes)	50	32.9%
Obesity (Dispensing Codes)	*****	*****
Overweight	11	7.2%
Smoking (Diagnosis or Procedure Codes)	43	28.3%
Smoking (Dispensing Codes)	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	15	9.9%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	17	11.2%
Liver Disease CCW	35	23.0%
Liver Disease Extended	35	23.0%

Table 1o. Aggregated Characteristics of Imipenem, Cilastatin and Relebactam Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Imipenem, Cilastatin and Relebactam		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	32.3	33.7
Mean number of emergency room encounters	1.5	4.4
Mean number of inpatient hospital encounters	2	2.1
Mean number of non-acute institutional encounters	0.3	0.9
Mean number of other ambulatory encounters	47.5	48.5
Mean number of filled prescriptions	34.3	28.3
Mean number of generics dispensed	13.2	8.7
Mean number of unique drug classes dispensed	11.9	7.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1p. Aggregated Characteristics of Ferric Maltol Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Ferric Maltol		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	4,069	N/A
Demographic Characteristics		
Age (years)	40.9	12.5
Age		
0-17 years	42	1.0%
18-24 years	276	6.8%
25-40 years	1,914	47.0%
41-64 years	1,666	40.9%
≥ 65 years	171	4.2%
Sex		
Female	3,801	93.4%
Male	268	6.6%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	249	6.1%
Black or African American	493	12.1%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	1,939	47.7%
White	1,244	30.6%
Hispanic origin		
Yes	298	7.3%
No	1,518	37.3%
Unknown	2,253	55.4%
Year		
2019	0	0.0%
2020	0	0.0%
2021	35	0.9%
2022	412	10.1%
2023	1,348	33.1%
2024	2,274	55.9%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****

Table 1p. Aggregated Characteristics of Ferric Maltol Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Ferric Maltol	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	47	1.2%
Diabetes	376	9.2%
Heart Failure	67	1.6%
Hyperlipidemia	624	15.3%
Hypertension	669	16.4%
Depression	648	15.9%
Ischemic Heart Disease	122	3.0%
Rheumatoid Arthritis/Osteoarthritis	208	5.1%
Stroke/Transient Ischemic Attack (TIA)	24	0.6%
Breast Cancer	29	0.7%
Colorectal Cancer	11	0.3%
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	414	10.2%
Anemia	2,197	54.0%
Asthma	149	3.7%
Benign Prostatic Hyperplasia	32	0.8%
Chronic Kidney Disease	127	3.1%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	37	0.9%
Glaucoma	73	1.8%
Osteoporosis	35	0.9%
Obesity (Diagnosis or Procedure Codes)	1,192	29.3%
Obesity (Dispensing Codes)	417	10.2%
Overweight	396	9.7%
Smoking (Diagnosis or Procedure Codes)	259	6.4%
Smoking (Dispensing Codes)	*****	*****
Alcohol Abuse or Dependence	40	1.0%
Drug Abuse or Dependence	44	1.1%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	31	0.8%
Liver Disease CCW	79	1.9%
Liver Disease Extended	79	1.9%

Table 1p. Aggregated Characteristics of Ferric Maltol Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Ferric Maltol		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	9.5	8.5
Mean number of emergency room encounters	0.4	1
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0	0.1
Mean number of other ambulatory encounters	2.9	4.2
Mean number of filled prescriptions	10.4	12.6
Mean number of generics dispensed	5.3	5.1
Mean number of unique drug classes dispensed	4.9	4.6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1q. Aggregated Characteristics of Darolutamide Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Darolutamide		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	9,618	N/A
Demographic Characteristics		
Age (years)	75.4	8.5
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	8,549	88.9%
Sex		
Female	*****	*****
Male	*****	*****
Race ²		
American Indian or Alaska Native	19	0.2%
Asian	171	1.8%
Black or African American	1,373	14.3%
Multi-racial	50	0.5%
Native Hawaiian or Other Pacific Islander	13	0.1%
Unknown	1,260	13.1%
White	6,732	70.0%
Hispanic origin		
Yes	169	1.8%
No	7,429	77.2%
Unknown	2,020	21.0%
Year		
2019	235	2.4%
2020	1,017	10.6%
2021	1,315	13.7%
2022	1,771	18.4%
2023	2,797	29.1%
2024	2,483	25.8%
Health Characteristics		
Acute Myocardial Infarction	105	1.1%
Alzheimer's Disease	111	1.2%
Non-Alzheimer's Dementia	406	4.2%

Table 1q. Aggregated Characteristics of Darolutamide Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Darolutamide	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	1,508	15.7%
Diabetes	2,525	26.3%
Heart Failure	1,416	14.7%
Hyperlipidemia	4,182	43.5%
Hypertension	5,502	57.2%
Depression	1,238	12.9%
Ischemic Heart Disease	2,881	30.0%
Rheumatoid Arthritis/Osteoarthritis	1,569	16.3%
Stroke/Transient Ischemic Attack (TIA)	353	3.7%
Breast Cancer	942	9.8%
Colorectal Cancer	177	1.8%
Prostate Cancer	9,517	98.9%
Lung Cancer	140	1.5%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	707	7.4%
Anemia	3,169	32.9%
Asthma	263	2.7%
Benign Prostatic Hyperplasia	1,985	20.6%
Chronic Kidney Disease	1,635	17.0%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	775	8.1%
Glaucoma	1,017	10.6%
Osteoporosis	502	5.2%
Obesity (Diagnosis or Procedure Codes)	1,815	18.9%
Obesity (Dispensing Codes)	209	2.2%
Overweight	1,179	12.3%
Smoking (Diagnosis or Procedure Codes)	2,768	28.8%
Smoking (Dispensing Codes)	32	0.3%
Alcohol Abuse or Dependence	261	2.7%
Drug Abuse or Dependence	235	2.4%
History of Cardiac Arrest	37	0.4%
History of Coronary Angioplasty or Bypass	902	9.4%
Liver Disease CCW	431	4.5%
Liver Disease Extended	435	4.5%

Table 1q. Aggregated Characteristics of Darolutamide Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Darolutamide		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.1	12.7
Mean number of emergency room encounters	0.5	1.2
Mean number of inpatient hospital encounters	0.3	0.7
Mean number of non-acute institutional encounters	0	0.3
Mean number of other ambulatory encounters	5.7	9
Mean number of filled prescriptions	19	14.9
Mean number of generics dispensed	8.7	5
Mean number of unique drug classes dispensed	8.1	4.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1r. Aggregated Characteristics of Pexidartinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Pexidartinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	160	N/A
Demographic Characteristics		
Age (years)	42	13.6
Age		
0-17 years	*****	*****
18-24 years	17	10.6%
25-40 years	56	35.0%
41-64 years	73	45.6%
≥ 65 years	*****	*****
Sex		
Female	102	63.8%
Male	58	36.3%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	12	7.5%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	74	46.3%
White	61	38.1%
Hispanic origin		
Yes	14	8.8%
No	72	45.0%
Unknown	74	46.3%
Year		
2019	15	9.4%
2020	33	20.6%
2021	45	28.1%
2022	17	10.6%
2023	28	17.5%
2024	22	13.8%
Health Characteristics		
Acute Myocardial Infarction	0	0.0%
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%

Table 1r. Aggregated Characteristics of Pexidartinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Pexidartinib	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	*****	*****
Diabetes	*****	*****
Heart Failure	*****	*****
Hyperlipidemia	19	11.9%
Hypertension	21	13.1%
Depression	35	21.9%
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	18	11.3%
Stroke/Transient Ischemic Attack (TIA)	0	0.0%
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	0	0.0%
Lung Cancer	0	0.0%
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	11	6.9%
Anemia	20	12.5%
Asthma	*****	*****
Benign Prostatic Hyperplasia	0	0.0%
Chronic Kidney Disease	0	0.0%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	0	0.0%
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity (Diagnosis or Procedure Codes)	25	15.6%
Obesity (Dispensing Codes)	*****	*****
Overweight	14	8.8%
Smoking (Diagnosis or Procedure Codes)	22	13.8%
Smoking (Dispensing Codes)	0	0.0%
Alcohol Abuse or Dependence	0	0.0%
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease CCW	*****	*****
Liver Disease Extended	*****	*****

Table 1r. Aggregated Characteristics of Pexidartinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Pexidartinib	
	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	13.6	10.1
Mean number of emergency room encounters	0.3	0.8
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0	0.1
Mean number of other ambulatory encounters	5	12.4
Mean number of filled prescriptions	13.2	13.3
Mean number of generics dispensed	5.6	4.6
Mean number of unique drug classes dispensed	5.2	4.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1s. Aggregated Characteristics of Pretomanid Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Pretomanid		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	51	N/A
Demographic Characteristics		
Age (years)	51.5	17.1
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	15	29.4%
41-64 years	*****	*****
≥ 65 years	20	39.2%
Sex		
Female	28	54.9%
Male	23	45.1%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	33	64.7%
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	*****	*****
White	*****	*****
Hispanic origin		
Yes	*****	*****
No	38	74.5%
Unknown	*****	*****
Year		
2019	*****	*****
2020	*****	*****
2021	23	45.1%
2022	*****	*****
2023	*****	*****
2024	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	0	0.0%
Non-Alzheimer's Dementia	0	0.0%

Table 1s. Aggregated Characteristics of Pretomanid Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Pretomanid	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	*****	*****
Diabetes	12	23.5%
Heart Failure	*****	*****
Hyperlipidemia	15	29.4%
Hypertension	20	39.2%
Depression	*****	*****
Ischemic Heart Disease	*****	*****
Rheumatoid Arthritis/Osteoarthritis	*****	*****
Stroke/Transient Ischemic Attack (TIA)	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	0	0.0%
Prostate Cancer	0	0.0%
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	*****	*****
Anemia	15	29.4%
Asthma	*****	*****
Benign Prostatic Hyperplasia	*****	*****
Chronic Kidney Disease	*****	*****
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	*****	*****
Glaucoma	*****	*****
Osteoporosis	*****	*****
Obesity (Diagnosis or Procedure Codes)	*****	*****
Obesity (Dispensing Codes)	0	0.0%
Overweight	*****	*****
Smoking (Diagnosis or Procedure Codes)	11	21.6%
Smoking (Dispensing Codes)	0	0.0%
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	*****	*****
Liver Disease CCW	*****	*****
Liver Disease Extended	*****	*****

Table 1s. Aggregated Characteristics of Pretomanid Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Pretomanid		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.1	20.6
Mean number of emergency room encounters	2.2	10.3
Mean number of inpatient hospital encounters	0.8	0.8
Mean number of non-acute institutional encounters	0	NaN
Mean number of other ambulatory encounters	18.7	29.8
Mean number of filled prescriptions	20.8	20
Mean number of generics dispensed	9.9	6.5
Mean number of unique drug classes dispensed	8.1	5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 1t. Aggregated Characteristics of Pitolisant Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Pitolisant		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	5,055	N/A
Demographic Characteristics		
Age (years)	42.7	13.7
Age		
0-17 years	48	0.9%
18-24 years	631	12.5%
25-40 years	1,877	37.1%
41-64 years	1,943	38.4%
≥ 65 years	556	11.0%
Sex		
Female	3,508	69.4%
Male	1,547	30.6%
Race ²		
American Indian or Alaska Native	26	0.5%
Asian	82	1.6%
Black or African American	380	7.5%
Multi-racial	95	1.9%
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	1,344	26.6%
White	3,128	61.9%
Hispanic origin		
Yes	158	3.1%
No	3,145	62.2%
Unknown	1,752	34.7%
Year		
2019	138	2.7%
2020	1,204	23.8%
2021	1,282	25.4%
2022	859	17.0%
2023	927	18.3%
2024	645	12.8%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	46	0.9%

Table 1t. Aggregated Characteristics of Pitolisant Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Pitolisant	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	73	1.4%
Diabetes	539	10.7%
Heart Failure	121	2.4%
Hyperlipidemia	684	13.5%
Hypertension	948	18.8%
Depression	2,184	43.2%
Ischemic Heart Disease	257	5.1%
Rheumatoid Arthritis/Osteoarthritis	656	13.0%
Stroke/Transient Ischemic Attack (TIA)	55	1.1%
Breast Cancer	41	0.8%
Colorectal Cancer	*****	*****
Prostate Cancer	27	0.5%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	416	8.2%
Anemia	556	11.0%
Asthma	355	7.0%
Benign Prostatic Hyperplasia	79	1.6%
Chronic Kidney Disease	143	2.8%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	167	3.3%
Glaucoma	126	2.5%
Osteoporosis	77	1.5%
Obesity (Diagnosis or Procedure Codes)	1,137	22.5%
Obesity (Dispensing Codes)	206	4.1%
Overweight	413	8.2%
Smoking (Diagnosis or Procedure Codes)	678	13.4%
Smoking (Dispensing Codes)	65	1.3%
Alcohol Abuse or Dependence	132	2.6%
Drug Abuse or Dependence	321	6.4%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	64	1.3%
Liver Disease CCW	94	1.9%
Liver Disease Extended	94	1.9%

Table 1t. Aggregated Characteristics of Pitolisant Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Pitolisant		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	14.4	14.3
Mean number of emergency room encounters	0.3	1
Mean number of inpatient hospital encounters	0.1	0.3
Mean number of non-acute institutional encounters	0	0.1
Mean number of other ambulatory encounters	4.5	10.8
Mean number of filled prescriptions	26.9	22.5
Mean number of generics dispensed	9.5	6.6
Mean number of unique drug classes dispensed	9	6

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1u. Aggregated Characteristics of Entrectinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Entrectinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	602	N/A
Demographic Characteristics		
Age (years)	64.7	12.2
Age		
0-17 years	*****	*****
18-24 years	*****	*****
25-40 years	32	5.3%
41-64 years	223	37.0%
≥ 65 years	336	55.8%
Sex		
Female	357	59.3%
Male	245	40.7%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	75	12.5%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	131	21.8%
White	339	56.3%
Hispanic origin		
Yes	23	3.8%
No	431	71.6%
Unknown	148	24.6%
Year		
2019	28	4.7%
2020	109	18.1%
2021	140	23.3%
2022	130	21.6%
2023	127	21.1%
2024	68	11.3%
Health Characteristics		
Acute Myocardial Infarction	13	2.2%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	19	3.2%

Table 1u. Aggregated Characteristics of Entrectinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Entrectinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	70	11.6%
Diabetes	124	20.6%
Heart Failure	79	13.1%
Hyperlipidemia	240	39.9%
Hypertension	282	46.8%
Depression	134	22.3%
Ischemic Heart Disease	132	21.9%
Rheumatoid Arthritis/Osteoarthritis	91	15.1%
Stroke/Transient Ischemic Attack (TIA)	41	6.8%
Breast Cancer	49	8.1%
Colorectal Cancer	28	4.7%
Prostate Cancer	14	2.3%
Lung Cancer	489	81.2%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	92	15.3%
Anemia	243	40.4%
Asthma	53	8.8%
Benign Prostatic Hyperplasia	39	6.5%
Chronic Kidney Disease	100	16.6%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	116	19.3%
Glaucoma	37	6.1%
Osteoporosis	35	5.8%
Obesity (Diagnosis or Procedure Codes)	116	19.3%
Obesity (Dispensing Codes)	13	2.2%
Overweight	55	9.1%
Smoking (Diagnosis or Procedure Codes)	235	39.0%
Smoking (Dispensing Codes)	*****	*****
Alcohol Abuse or Dependence	18	3.0%
Drug Abuse or Dependence	15	2.5%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	30	5.0%
Liver Disease CCW	74	12.3%
Liver Disease Extended	76	12.6%

Table 1u. Aggregated Characteristics of Entrectinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Entrectinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	23.6	13.1
Mean number of emergency room encounters	0.7	1.4
Mean number of inpatient hospital encounters	0.8	1.1
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	11.2	14.6
Mean number of filled prescriptions	21.8	15.6
Mean number of generics dispensed	10.5	6
Mean number of unique drug classes dispensed	9.6	5.3

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1v. Aggregated Characteristics of Fedratinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Fedratinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	1,055	N/A
Demographic Characteristics		
Age (years)	73.1	8.2
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	*****	*****
41-64 years	*****	*****
≥ 65 years	902	85.5%
Sex		
Female	509	48.2%
Male	546	51.8%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	68	6.4%
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	96	9.1%
White	852	80.8%
Hispanic origin		
Yes	15	1.4%
No	894	84.7%
Unknown	146	13.8%
Year		
2019	169	16.0%
2020	271	25.7%
2021	222	21.0%
2022	186	17.6%
2023	149	14.1%
2024	58	5.5%
Health Characteristics		
Acute Myocardial Infarction	13	1.2%
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	27	2.6%

Table 1v. Aggregated Characteristics of Fedratinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Fedratinib	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	129	12.2%
Diabetes	207	19.6%
Heart Failure	245	23.2%
Hyperlipidemia	398	37.7%
Hypertension	604	57.3%
Depression	220	20.9%
Ischemic Heart Disease	266	25.2%
Rheumatoid Arthritis/Osteoarthritis	167	15.8%
Stroke/Transient Ischemic Attack (TIA)	29	2.7%
Breast Cancer	38	3.6%
Colorectal Cancer	*****	*****
Prostate Cancer	49	4.6%
Lung Cancer	*****	*****
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	202	19.1%
Anemia	995	94.3%
Asthma	41	3.9%
Benign Prostatic Hyperplasia	91	8.6%
Chronic Kidney Disease	312	29.6%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	141	13.4%
Glaucoma	96	9.1%
Osteoporosis	43	4.1%
Obesity (Diagnosis or Procedure Codes)	138	13.1%
Obesity (Dispensing Codes)	*****	*****
Overweight	117	11.1%
Smoking (Diagnosis or Procedure Codes)	331	31.4%
Smoking (Dispensing Codes)	*****	*****
Alcohol Abuse or Dependence	23	2.2%
Drug Abuse or Dependence	34	3.2%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	81	7.7%
Liver Disease CCW	190	18.0%
Liver Disease Extended	190	18.0%

Table 1v. Aggregated Characteristics of Fedratinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Fedratinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	26.3	15.9
Mean number of emergency room encounters	0.7	1.7
Mean number of inpatient hospital encounters	0.5	0.9
Mean number of non-acute institutional encounters	0	0.3
Mean number of other ambulatory encounters	8.6	12.6
Mean number of filled prescriptions	24.4	15.8
Mean number of generics dispensed	10.3	5.6
Mean number of unique drug classes dispensed	9.7	5.1

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1w. Aggregated Characteristics of Upadacitinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Upadacitinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	54,390	N/A
Demographic Characteristics		
Age (years)	53.7	13.7
Age		
0-17 years	738	1.4%
18-24 years	2,209	4.1%
25-40 years	8,252	15.2%
41-64 years	29,770	54.7%
≥ 65 years	13,421	24.7%
Sex		
Female	39,189	72.1%
Male	15,201	27.9%
Race ²		
American Indian or Alaska Native	378	0.7%
Asian	1,420	2.6%
Black or African American	4,354	8.0%
Multi-racial	953	1.8%
Native Hawaiian or Other Pacific Islander	76	0.1%
Unknown	18,304	33.7%
White	28,905	53.1%
Hispanic origin		
Yes	3,049	5.6%
No	29,924	55.0%
Unknown	21,417	39.4%
Year		
2019	1,336	2.5%
2020	7,899	14.5%
2021	9,104	16.7%
2022	9,351	17.2%
2023	14,052	25.8%
2024	12,648	23.3%
Health Characteristics		
Acute Myocardial Infarction	117	0.2%
Alzheimer's Disease	111	0.2%
Non-Alzheimer's Dementia	398	0.7%

Table 1w. Aggregated Characteristics of Upadacitinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Upadacitinib	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	1,269	2.3%
Diabetes	7,675	14.1%
Heart Failure	2,230	4.1%
Hyperlipidemia	11,750	21.6%
Hypertension	15,426	28.4%
Depression	12,361	22.7%
Ischemic Heart Disease	4,046	7.4%
Rheumatoid Arthritis/Osteoarthritis	37,846	69.6%
Stroke/Transient Ischemic Attack (TIA)	424	0.8%
Breast Cancer	538	1.0%
Colorectal Cancer	133	0.2%
Prostate Cancer	237	0.4%
Lung Cancer	109	0.2%
Endometrial Cancer	39	0.1%
Acquired Hypothyroidism	5,321	9.8%
Anemia	10,315	19.0%
Asthma	2,956	5.4%
Benign Prostatic Hyperplasia	749	1.4%
Chronic Kidney Disease	2,761	5.1%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	3,123	5.7%
Glaucoma	2,588	4.8%
Osteoporosis	4,009	7.4%
Obesity (Diagnosis or Procedure Codes)	13,098	24.1%
Obesity (Dispensing Codes)	2,307	4.2%
Overweight	4,936	9.1%
Smoking (Diagnosis or Procedure Codes)	8,485	15.6%
Smoking (Dispensing Codes)	468	0.9%
Alcohol Abuse or Dependence	727	1.3%
Drug Abuse or Dependence	2,333	4.3%
History of Cardiac Arrest	35	0.1%
History of Coronary Angioplasty or Bypass	840	1.5%
Liver Disease CCW	1,797	3.3%
Liver Disease Extended	1,858	3.4%

Table 1w. Aggregated Characteristics of Upadacitinib Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Upadacitinib		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	12.9	10.7
Mean number of emergency room encounters	0.3	1
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0	0.1
Mean number of other ambulatory encounters	4	9.5
Mean number of filled prescriptions	25.3	19.8
Mean number of generics dispensed	10	6.1
Mean number of unique drug classes dispensed	9.3	5.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

Table 1x. Aggregated Characteristics of Lefamulin Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Lefamulin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	209	N/A
Demographic Characteristics		
Age (years)	63.7	13.2
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	80	38.3%
≥ 65 years	107	51.2%
Sex		
Female	124	59.3%
Male	85	40.7%
Race ²		
American Indian or Alaska Native	0	0.0%
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	54	25.8%
White	135	64.6%
Hispanic origin		
Yes	*****	*****
No	129	61.7%
Unknown	*****	*****
Year		
2019	*****	*****
2020	49	23.4%
2021	85	40.7%
2022	45	21.5%
2023	*****	*****
2024	*****	*****
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****

Table 1x. Aggregated Characteristics of Lefamulin Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Lefamulin	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	24	11.5%
Diabetes	61	29.2%
Heart Failure	43	20.6%
Hyperlipidemia	86	41.1%
Hypertension	108	51.7%
Depression	63	30.1%
Ischemic Heart Disease	65	31.1%
Rheumatoid Arthritis/Osteoarthritis	54	25.8%
Stroke/Transient Ischemic Attack (TIA)	*****	*****
Breast Cancer	*****	*****
Colorectal Cancer	*****	*****
Prostate Cancer	*****	*****
Lung Cancer	*****	*****
Endometrial Cancer	0	0.0%
Acquired Hypothyroidism	40	19.1%
Anemia	72	34.4%
Asthma	35	16.7%
Benign Prostatic Hyperplasia	19	9.1%
Chronic Kidney Disease	39	18.7%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	65	31.1%
Glaucoma	19	9.1%
Osteoporosis	11	5.3%
Obesity (Diagnosis or Procedure Codes)	54	25.8%
Obesity (Dispensing Codes)	*****	*****
Overweight	23	11.0%
Smoking (Diagnosis or Procedure Codes)	68	32.5%
Smoking (Dispensing Codes)	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	13	6.2%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	15	7.2%
Liver Disease CCW	15	7.2%
Liver Disease Extended	15	7.2%

Table 1x. Aggregated Characteristics of Lefamulin Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Lefamulin		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	19.3	15.2
Mean number of emergency room encounters	0.7	1.8
Mean number of inpatient hospital encounters	0.5	1.3
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	10.1	20
Mean number of filled prescriptions	35.3	29.2
Mean number of generics dispensed	13.7	8.7
Mean number of unique drug classes dispensed	12.5	7.4

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1y. Aggregated Characteristics of Ga-68-DOTATOC Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Ga-68-DOTATOC		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	358	N/A
Demographic Characteristics		
Age (years)	66.9	10.5
Age		
0-17 years	0	0.0%
18-24 years	*****	*****
25-40 years	*****	*****
41-64 years	90	25.1%
≥ 65 years	252	70.4%
Sex		
Female	200	55.9%
Male	158	44.1%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	*****	*****
Black or African American	*****	*****
Multi-racial	*****	*****
Native Hawaiian or Other Pacific Islander	0	0.0%
Unknown	62	17.3%
White	279	77.9%
Hispanic origin		
Yes	*****	*****
No	253	70.7%
Unknown	*****	*****
Year		
2019	0	0.0%
2020	34	9.5%
2021	100	27.9%
2022	82	22.9%
2023	87	24.3%
2024	55	15.4%
Health Characteristics		
Acute Myocardial Infarction	*****	*****
Alzheimer's Disease	*****	*****
Non-Alzheimer's Dementia	*****	*****

Table 1y. Aggregated Characteristics of Ga-68-DOTATOC Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Ga-68-DOTATOC	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	24	6.7%
Diabetes	104	29.1%
Heart Failure	40	11.2%
Hyperlipidemia	114	31.8%
Hypertension	169	47.2%
Depression	77	21.5%
Ischemic Heart Disease	52	14.5%
Rheumatoid Arthritis/Osteoarthritis	43	12.0%
Stroke/Transient Ischemic Attack (TIA)	*****	*****
Breast Cancer	16	4.5%
Colorectal Cancer	*****	*****
Prostate Cancer	17	4.7%
Lung Cancer	14	3.9%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	62	17.3%
Anemia	98	27.4%
Asthma	19	5.3%
Benign Prostatic Hyperplasia	24	6.7%
Chronic Kidney Disease	49	13.7%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	24	6.7%
Glaucoma	37	10.3%
Osteoporosis	14	3.9%
Obesity (Diagnosis or Procedure Codes)	77	21.5%
Obesity (Dispensing Codes)	14	3.9%
Overweight	22	6.1%
Smoking (Diagnosis or Procedure Codes)	89	24.9%
Smoking (Dispensing Codes)	*****	*****
Alcohol Abuse or Dependence	*****	*****
Drug Abuse or Dependence	*****	*****
History of Cardiac Arrest	0	0.0%
History of Coronary Angioplasty or Bypass	16	4.5%
Liver Disease CCW	43	12.0%
Liver Disease Extended	43	12.0%

Table 1y. Aggregated Characteristics of Ga-68-DOTATOC Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Ga-68-DOTATOC		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	18.4	13.5
Mean number of emergency room encounters	0.5	1.4
Mean number of inpatient hospital encounters	0.2	0.5
Mean number of non-acute institutional encounters	0	0.2
Mean number of other ambulatory encounters	3.7	5.4
Mean number of filled prescriptions	18.3	17.3
Mean number of generics dispensed	7.9	5.5
Mean number of unique drug classes dispensed	7.4	5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 1z. Aggregated Characteristics of Istradefylline Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Istradefylline		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Unique patients	6,005	N/A
Demographic Characteristics		
Age (years)	73.2	8.1
Age		
0-17 years	0	0.0%
18-24 years	0	0.0%
25-40 years	18	0.3%
41-64 years	856	14.3%
≥ 65 years	5,131	85.4%
Sex		
Female	2,465	41.0%
Male	3,540	59.0%
Race ²		
American Indian or Alaska Native	*****	*****
Asian	210	3.5%
Black or African American	174	2.9%
Multi-racial	17	0.3%
Native Hawaiian or Other Pacific Islander	*****	*****
Unknown	694	11.6%
White	4,889	81.4%
Hispanic origin		
Yes	171	2.8%
No	4,842	80.6%
Unknown	992	16.5%
Year		
2019	103	1.7%
2020	1,917	31.9%
2021	1,492	24.8%
2022	987	16.4%
2023	976	16.3%
2024	530	8.8%
Health Characteristics		
Acute Myocardial Infarction	24	0.4%
Alzheimer's Disease	137	2.3%
Non-Alzheimer's Dementia	915	15.2%

Table 1z. Aggregated Characteristics of Istradefylline Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Patient Characteristics	Istradefylline	
	Number/Mean	Percent/ Standard Deviation ¹
Atrial Fibrillation	479	8.0%
Diabetes	976	16.3%
Heart Failure	528	8.8%
Hyperlipidemia	2,083	34.7%
Hypertension	2,520	42.0%
Depression	1,867	31.1%
Ischemic Heart Disease	1,111	18.5%
Rheumatoid Arthritis/Osteoarthritis	1,220	20.3%
Stroke/Transient Ischemic Attack (TIA)	233	3.9%
Breast Cancer	102	1.7%
Colorectal Cancer	34	0.6%
Prostate Cancer	225	3.7%
Lung Cancer	16	0.3%
Endometrial Cancer	*****	*****
Acquired Hypothyroidism	672	11.2%
Anemia	1,166	19.4%
Asthma	171	2.8%
Benign Prostatic Hyperplasia	622	10.4%
Chronic Kidney Disease	499	8.3%
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	277	4.6%
Glaucoma	649	10.8%
Osteoporosis	399	6.6%
Obesity (Diagnosis or Procedure Codes)	654	10.9%
Obesity (Dispensing Codes)	61	1.0%
Overweight	554	9.2%
Smoking (Diagnosis or Procedure Codes)	741	12.3%
Smoking (Dispensing Codes)	*****	*****
Alcohol Abuse or Dependence	53	0.9%
Drug Abuse or Dependence	112	1.9%
History of Cardiac Arrest	*****	*****
History of Coronary Angioplasty or Bypass	291	4.8%
Liver Disease CCW	87	1.4%
Liver Disease Extended	89	1.5%

Table 1z. Aggregated Characteristics of Istradefylline Users in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

Istradefylline		
Patient Characteristics	Number/Mean	Percent/ Standard Deviation ¹
Health Service Utilization Intensity Metrics		
Mean number of ambulatory encounters	17.3	14.6
Mean number of emergency room encounters	0.4	1.1
Mean number of inpatient hospital encounters	0.1	0.4
Mean number of non-acute institutional encounters	0.1	0.3
Mean number of other ambulatory encounters	6.6	14.8
Mean number of filled prescriptions	25.9	18.9
Mean number of generics dispensed	9.6	4.9
Mean number of unique drug classes dispensed	9.1	4.5

¹Value represents standard deviation where no % follows the value.

²Race data may not be completely populated at all Data Partners; therefore, data about race may be incomplete.

N/A: Not Applicable

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<i>PrabotulinumtoxinA-xvfs</i>	11	11	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Caplacizumab-yhdp</i>	1,202	*****	*****	*****	*****	*****	*****	0	0.0%
<i>Triclabendazole</i>	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Brexanolone</i>	348	348	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Solriamfetol</i>	118,929	110,888	93.2%	1,582	1.3%	6,432	5.4%	27	0.0%
<i>Siponimod</i>	31,450	29,348	93.3%	567	1.8%	1,503	4.8%	32	0.1%
<i>Romosozumab-aqqg</i>	716,200	715,197	99.9%	*****	*****	745	0.1%	*****	*****
<i>Erdafitinib</i>	3,566	3,432	96.2%	*****	*****	*****	*****	0	0.0%
<i>Risankizumab-rzaa</i>	406,944	134,550	33.1%	78,450	19.3%	193,674	47.6%	270	0.1%
<i>Tafamidis Meglumine</i>	132,670	122,433	92.3%	965	0.7%	9,253	7.0%	19	0.0%
<i>Alpelisib</i>	31,076	30,640	98.6%	409	1.3%	*****	*****	*****	*****
<i>Polatuzumab Vedotin-piiq</i>	24,701	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Bremelanotide</i>	5,657	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Selinexor</i>	10,802	10,589	98.0%	195	1.8%	*****	*****	*****	*****
<i>Imipenem, Cilastatin and Relebactam</i>	2,150	2,150	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ferric Maltol</i>	13,719	12,911	94.1%	200	1.5%	608	4.4%	0	0.0%
<i>Darolutamide</i>	88,900	88,432	99.5%	*****	*****	260	0.3%	*****	*****
<i>Pexidartinib</i>	1,410	*****	*****	*****	*****	0	0.0%	*****	*****
<i>Pretomanid</i>	272	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Pitolisant</i>	43,881	42,973	97.9%	498	1.1%	*****	*****	*****	*****
<i>Entrectinib</i>	3,361	3,291	97.9%	*****	*****	*****	*****	0	0.0%
<i>Fedratinib</i>	8,545	8,513	99.6%	14	0.2%	18	0.2%	0	0.0%

Table 2a. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
<i>Upadacitinib</i>	502,055	488,568	97.3%	2,234	0.4%	11,217	2.2%	36	0.0%
<i>Lefamulin</i>	417	417	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ga-68-DOTATOC</i>	473	473	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Istradefylline</i>	49,328	40,421	81.9%	749	1.5%	8,147	16.5%	11	0.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>PrabotulinumtoxinA-xvfs</i>	11	1	1	1	1	1	1.0	0.0
<i>Caplacizumab-yhdp</i>	1,202	1	1	1	30	68	12.3	13.4
<i>Triclabendazole</i>	*****	2	2	2	2	2	2.0	0.0
<i>Brexanolone</i>	348	1	1	1	1	30	1.1	1.6
<i>Solriamfetol</i>	118,929	1	30	30	30	180	32.4	14.6
<i>Siponimod</i>	31,450	1	30	30	30	180	32.1	13.8
<i>Romosozumab-aqqg</i>	716,200	1	1	1	1	362	3.0	7.7
<i>Erdafitinib</i>	3,566	1	28	28	28	90	27.6	7.5
<i>Risankizumab-rzaa</i>	406,944	1	28	56	84	336	54.5	29.9
<i>Tafamidis Meglumine</i>	132,670	1	30	30	30	180	33.5	15.9
<i>Alpelisib</i>	31,076	1	28	28	28	118	27.8	4.7
<i>Polatuzumab Vedotin-piiq</i>	24,701	1	1	1	1	56	1.1	1.4
<i>Bremelanotide</i>	5,657	1	15	23	30	60	22.3	7.3
<i>Selinexor</i>	10,802	1	28	28	28	168	27.4	5.4
<i>Imipenem, Cilastatin and Relebactam</i>	2,150	1	1	1	1	28	2.0	2.4
<i>Ferric Maltol</i>	13,719	1	30	30	30	90	31.3	13.7
<i>Darolutamide</i>	88,900	1	30	30	30	120	29.2	5.5
<i>Pexidartinib</i>	1,410	1	30	30	30	288	29.4	8.3
<i>Pretomanid</i>	272	2	26	26	26	52	26.2	5.9
<i>Pitolisant</i>	43,881	1	30	30	30	180	29.7	7.7
<i>Entrectinib</i>	3,361	1	30	30	30	90	28.5	6.9
<i>Fedratinib</i>	8,545	1	30	30	30	90	29.3	4.7
<i>Upadacitinib</i>	502,055	1	30	30	30	300	30.6	9.9
<i>Lefamulin</i>	417	1	1	2	5	30	3.8	4.0

Table 2b. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Ga-68-DOTATOC</i>	473	1	1	1	1	1	1.0	0.0
<i>Istradefylline</i>	49,328	1	30	30	30	180	39.6	22.7

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
PrabotulinumtoxinA-xvfs	11	11	100.0%	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN
Caplacizumab-yhdp	1,202	*****	100.0%	*****	100.0%	*****	100.0%	0	NaN
Female	671	*****	55.8%	*****	50.0%	*****	100.0%	0	NaN
Male	531	*****	44.2%	*****	50.0%	0	0.0%	0	NaN
Triclabendazole	*****	*****	100.0%	0	NaN	0	NaN	0	NaN
Female	*****	*****	100.0%	0	NaN	0	NaN	0	NaN
Male	0	0	0.0%	0	NaN	0	NaN	0	NaN
Brexanolone	348	348	100.0%	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN
Solriamfetol	118,929	110,888	100.0%	1,582	100.0%	6,432	100.0%	27	100.0%
Female	72,569	68,012	61.3%	*****	*****	3,645	56.7%	*****	*****
Male	46,360	42,876	38.7%	*****	*****	2,787	43.3%	*****	*****
Siponimod	31,450	29,348	100.0%	567	100.0%	1,503	100.0%	32	100.0%
Female	23,542	21,943	74.8%	*****	*****	1,163	77.4%	*****	*****
Male	7,908	7,405	25.2%	*****	*****	340	22.6%	*****	*****
Romosozumab-aqqg	716,200	715,197	100.0%	*****	*****	745	100.0%	*****	100.0%
Female	702,785	701,840	98.1%	*****	90.3%	712	95.6%	*****	90.0%
Male	13,415	13,357	1.9%	*****	9.7%	33	4.4%	*****	10.0%
Erdafitinib	3,566	3,432	100.0%	*****	100.0%	*****	100.0%	0	NaN
Female	1,274	1,225	35.7%	*****	37.5%	*****	16.7%	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Male	2,292	2,207	64.3%	*****	62.5%	*****	83.3%	0	NaN
Risankizumab-rzaa	406,944	134,550	100.0%	78,450	100.0%	193,674	100.0%	270	100.0%
Female	202,393	68,691	51.1%	38,292	48.8%	95,256	49.2%	154	57.0%
Male	204,551	65,859	48.9%	40,158	51.2%	98,418	50.8%	116	43.0%
Tafamidis Meglumine	132,670	122,433	100.0%	965	100.0%	9,253	100.0%	19	100.0%
Female	22,514	20,537	16.8%	174	18.0%	1,803	19.5%	0	0.0%
Male	110,156	101,896	83.2%	791	82.0%	7,450	80.5%	19	100.0%
Alpelisib	31,076	30,640	100.0%	409	100.0%	*****	100.0%	*****	100.0%
Female	29,923	*****	*****	*****	*****	*****	100.0%	*****	66.7%
Male	1,153	*****	*****	*****	*****	0	0.0%	*****	33.3%
Polatuzumab Vedotin-piiq	24,701	*****	100.0%	*****	100.0%	0	NaN	0	NaN
Female	10,672	*****	43.2%	*****	33.3%	0	NaN	0	NaN
Male	14,029	*****	56.8%	*****	66.7%	0	NaN	0	NaN
Bremelanotide	5,657	*****	100.0%	*****	100.0%	0	NaN	0	NaN
Female	5,468	*****	96.7%	*****	*****	0	NaN	0	NaN
Male	189	*****	3.3%	*****	*****	0	NaN	0	NaN
Selinexor	10,802	10,589	100.0%	195	100.0%	*****	100.0%	*****	100.0%
Female	5,344	5,258	49.7%	*****	*****	*****	33.3%	*****	33.3%
Male	5,458	5,331	50.3%	*****	*****	*****	66.7%	*****	66.7%
Imipenem, Cilastatin and Relebactam	2,150	2,150	100.0%	0	NaN	0	NaN	0	NaN
Female	786	786	36.6%	0	NaN	0	NaN	0	NaN
Male	1,364	1,364	63.4%	0	NaN	0	NaN	0	NaN

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Ferric Maltol	13,719	12,911	100.0%	200	100.0%	608	100.0%	0	NaN
Female	12,824	12,102	93.7%	180	90.0%	542	89.1%	0	NaN
Male	895	809	6.3%	20	10.0%	66	10.9%	0	NaN
Darolutamide	88,900	88,432	100.0%	*****	100.0%	260	100.0%	*****	100.0%
Female	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Male	*****	*****	*****	*****	100.0%	260	100.0%	*****	100.0%
Pexidartinib	1,410	*****	100.0%	*****	100.0%	0	NaN	*****	100.0%
Female	923	*****	65.3%	*****	100.0%	0	NaN	0	0.0%
Male	487	*****	34.7%	0	0.0%	*****	NaN	*****	100.0%
Pretomanid	272	*****	100.0%	*****	100.0%	0	NaN	0	NaN
Female	144	*****	51.5%	*****	90.0%	0	NaN	0	NaN
Male	128	*****	48.5%	*****	10.0%	0	NaN	0	NaN
Pitolisant	43,881	42,973	100.0%	498	100.0%	*****	100.0%	*****	100.0%
Female	29,984	29,408	68.4%	313	62.9%	*****	64.2%	*****	62.5%
Male	13,897	13,565	31.6%	185	37.1%	*****	35.8%	*****	37.5%
Entrectinib	3,361	3,291	100.0%	*****	100.0%	*****	100.0%	0	NaN
Female	2,138	2,109	64.1%	*****	40.9%	*****	50.0%	0	NaN
Male	1,223	1,182	35.9%	*****	59.1%	*****	50.0%	0	NaN
Fedratinib	8,545	8,513	100.0%	14	100.0%	18	100.0%	0	NaN
Female	4,200	*****	*****	*****	*****	*****	*****	0	NaN
Male	4,345	*****	*****	*****	*****	*****	*****	0	NaN
Upadacitinib	502,055	488,568	100.0%	2,234	100.0%	11,217	100.0%	36	100.0%
Female	369,967	360,174	73.7%	1,472	65.9%	8,296	74.0%	25	69.4%

Table 2c. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Male	132,088	128,394	26.3%	762	34.1%	2,921	26.0%	11	30.6%
Lefamulin	417	417	100.0%	0	NaN	0	NaN	0	NaN
Female	224	224	53.7%	0	NaN	0	NaN	0	NaN
Male	193	193	46.3%	0	NaN	0	NaN	0	NaN
Ga-68-DOTATOC	473	473	100.0%	0	NaN	0	NaN	0	NaN
Female	252	252	53.3%	0	NaN	0	NaN	0	NaN
Male	221	221	46.7%	0	NaN	0	NaN	0	NaN
Istradefylline	49,328	40,421	100.0%	749	100.0%	8,147	100.0%	11	100.0%
Female	19,956	16,443	40.7%	*****	*****	3,251	39.9%	*****	*****
Male	29,372	23,978	59.3%	*****	*****	4,896	60.1%	*****	*****

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
PrabotulinumtoxinA-xvfs	11	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Caplacizumab-yhdp	1,202	1	1	1	30	68	12.3	13.4
Female	671	1	1	10	30	68	14.6	13.5
Male	531	1	1	1	28	60	9.4	12.7
Triclabendazole	*****	2	2	2	2	2	2.0	0.0
Female	*****	2	2	2	2	2	2.0	0.0
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Brexanolone	348	1	1	1	1	30	1.1	1.6
Female	*****	1	1	1	1	30	1.1	1.6
Male	*****	1	1	1	1	1	1.0	0.0
Solriamfetol	118,929	1	30	30	30	180	32.4	14.6
Female	72,569	1	30	30	30	180	32.2	14.2
Male	46,360	1	30	30	30	180	32.8	15.2
Siponimod	31,450	1	30	30	30	180	32.1	13.8
Female	23,542	1	30	30	30	95	32.2	13.9
Male	7,908	1	30	30	30	180	31.9	13.4
Romosozumab-aqqg	716,200	1	1	1	1	362	3.0	7.7
Female	702,785	1	1	1	1	362	3.0	7.6
Male	13,415	1	1	1	1	100	4.6	10.3
Erdafitinib	3,566	1	28	28	28	90	27.6	7.5
Female	1,274	1	28	28	28	84	27.4	7.3
Male	2,292	1	28	28	28	90	27.7	7.7

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Risankizumab-rzaa	406,944	1	28	56	84	336	54.5	29.9
Female	202,393	1	28	56	84	198	54.2	30.0
Male	204,551	1	28	56	84	336	54.8	29.7
Tafamidis Meglumine	132,670	1	30	30	30	180	33.5	15.9
Female	22,514	1	30	30	30	90	34.0	16.8
Male	110,156	1	30	30	30	180	33.3	15.7
Alpelisib	31,076	1	28	28	28	118	27.8	4.7
Female	29,923	1	28	28	28	118	27.8	4.7
Male	1,153	1	28	28	28	114	27.4	5.1
Polatuzumab Vedotin-piiq	24,701	1	1	1	1	56	1.1	1.4
Female	10,672	1	1	1	1	42	1.1	1.1
Male	14,029	1	1	1	1	56	1.1	1.6
Bremelanotide	5,657	1	15	23	30	60	22.3	7.3
Female	5,468	1	15	23	30	60	22.3	7.3
Male	189	1	15	15	30	30	21.0	7.8
Selinexor	10,802	1	28	28	28	168	27.4	5.4
Female	5,344	1	28	28	28	168	27.3	5.1
Male	5,458	1	28	28	28	168	27.6	5.7
Imipenem, Cilastatin and Relebactam	2,150	1	1	1	1	28	2.0	2.4
Female	786	1	1	1	1	17	2.2	2.7
Male	1,364	1	1	1	1	28	1.9	2.3
Ferric Maltol	13,719	1	30	30	30	90	31.3	13.7
Female	12,824	1	30	30	30	90	31.2	13.5

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	895	1	30	30	30	90	33.3	16.7
Darolutamide	88,900	1	30	30	30	120	29.2	5.5
Female	*****	30	30	30	30	30	30.0	0.0
Male	*****	1	30	30	30	120	29.2	5.5
Pexidartinib	1,410	1	30	30	30	288	29.4	8.3
Female	923	1	30	30	30	60	29.4	4.8
Male	487	3	30	30	30	288	29.4	12.5
Pretomanid	272	2	26	26	26	52	26.2	5.9
Female	144	4	26	26	26	52	26.7	6.9
Male	128	2	26	26	26	52	25.6	4.5
Pitolisant	43,881	1	30	30	30	180	29.7	7.7
Female	29,984	1	30	30	30	180	29.6	7.5
Male	13,897	1	30	30	30	112	29.9	7.9
Entrectinib	3,361	1	30	30	30	90	28.5	6.9
Female	2,138	1	30	30	30	90	28.4	6.6
Male	1,223	1	30	30	30	90	28.7	7.3
Fedratinib	8,545	1	30	30	30	90	29.3	4.7
Female	4,200	1	30	30	30	90	29.4	5.3
Male	4,345	1	30	30	30	90	29.2	4.1
Upadacitinib	502,055	1	30	30	30	300	30.6	9.9
Female	369,967	1	30	30	30	300	30.6	9.8
Male	132,088	1	30	30	30	300	30.4	10.0
Lefamulin	417	1	1	2	5	30	3.8	4.0
Female	224	1	1	5	5	28	4.3	4.4

Table 2d. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	193	1	1	1	5	30	3.3	3.5
Ga-68-DOTATOC	473	1	1	1	1	1	1.0	0.0
Female	252	1	1	1	1	1	1.0	0.0
Male	221	1	1	1	1	1	1.0	0.0
Istradefylline	49,328	1	30	30	30	180	39.6	22.7
Female	19,956	1	30	30	30	120	39.4	22.6
Male	29,372	1	30	30	30	180	39.7	22.8

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
PrabotulinumtoxinA-xvfs	11	11	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
Caplacizumab-yhdp	1,202	*****	100.0%	*****	100.0%	*****	100.0%	0	NaN
0-17 years	17	*****	*****	0	0.0%	*****	100.0%	0	NaN
18-24 years	46	46	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	371	371	*****	0	0.0%	0	0.0%	0	NaN
41-64 years	501	*****	*****	*****	100.0%	0	0.0%	0	NaN
≥ 65 years	267	267	*****	0	0.0%	0	0.0%	0	NaN
Triclabendazole	*****	*****	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
Brexanolone	348	348	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	49	49	14.1%	0	NaN	0	NaN	0	NaN
25-40 years	285	285	81.9%	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
Solriamfetol	118,929	110,888	100.0%	1,582	100.0%	6,432	100.0%	27	100.0%
0-17 years	650	603	0.5%	*****	*****	31	0.5%	*****	*****
18-24 years	8,465	7,912	7.1%	*****	*****	416	6.5%	*****	*****
25-40 years	32,305	30,790	27.8%	*****	*****	1,129	17.6%	*****	*****
41-64 years	59,394	55,565	50.1%	716	45.3%	3,102	48.2%	11	40.7%
≥ 65 years	18,115	16,018	14.4%	*****	*****	1,754	27.3%	*****	*****
Siponimod	31,450	29,348	100.0%	567	100.0%	1,503	100.0%	32	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	299	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	5,363	5,135	17.5%	94	16.6%	*****	*****	*****	*****
41-64 years	21,912	20,487	69.8%	383	67.5%	1,021	67.9%	21	65.6%
≥ 65 years	3,876	*****	*****	*****	*****	347	23.1%	*****	*****
Romosozumab-aqqg	716,200	715,197	100.0%	*****	100.0%	745	100.0%	*****	100.0%
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	1,243	*****	*****	0	0.0%	*****	*****	0	0.0%
41-64 years	59,766	59,624	8.3%	*****	14.5%	*****	*****	*****	10.0%
≥ 65 years	655,033	*****	*****	*****	85.5%	637	85.5%	*****	90.0%
Erdafitinib	3,566	3,432	100.0%	*****	100.0%	*****	100.0%	0	NaN
0-17 years	23	*****	*****	0	0.0%	*****	50.0%	0	NaN
18-24 years	16	16	0.5%	0	0.0%	0	0.0%	0	NaN
25-40 years	74	*****	*****	*****	0.8%	0	0.0%	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
41-64 years	895	851	24.8%	*****	32.8%	*****	33.3%	0	NaN
≥ 65 years	2,558	2,472	72.0%	*****	66.4%	*****	16.7%	0	NaN
Risankizumab-rzaa	406,944	134,550	100.0%	78,450	100.0%	193,674	100.0%	270	100.0%
0-17 years	1,031	482	0.4%	286	0.4%	*****	*****	*****	*****
18-24 years	20,343	7,672	5.7%	5,285	6.7%	*****	*****	*****	*****
25-40 years	97,055	33,116	24.6%	23,029	29.4%	40,860	21.1%	50	18.5%
41-64 years	209,121	67,673	50.3%	42,110	53.7%	99,228	51.2%	110	40.7%
≥ 65 years	79,394	25,607	19.0%	7,740	9.9%	45,950	23.7%	97	35.9%
Tafamidis Meglumine	132,670	122,433	100.0%	965	100.0%	9,253	100.0%	19	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	62	62	0.1%	0	0.0%	0	0.0%	0	0.0%
41-64 years	5,026	4,881	4.0%	13	1.3%	132	1.4%	0	0.0%
≥ 65 years	127,582	117,490	96.0%	952	98.7%	9,121	98.6%	19	100.0%
Alpelisib	31,076	30,640	100.0%	409	100.0%	*****	100.0%	*****	100.0%
0-17 years	880	*****	*****	*****	*****	*****	0.0%	0	0.0%
18-24 years	117	105	0.3%	*****	*****	0	0.0%	*****	33.3%
25-40 years	884	*****	*****	*****	*****	*****	4.2%	0	0.0%
41-64 years	12,123	12,014	39.2%	95	23.2%	*****	54.2%	*****	33.3%
≥ 65 years	17,072	16,766	54.7%	295	72.1%	*****	41.7%	*****	33.3%
Polatuzumab Vedotin-piiq	24,701	*****	100.0%	*****	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	38	38	*****	0	0.0%	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
25-40 years	362	*****	*****	*****	33.3%	0	NaN	0	NaN
41-64 years	3,083	*****	*****	*****	66.7%	0	NaN	0	NaN
≥ 65 years	21,218	21,218	*****	0	0.0%	0	NaN	0	NaN
Bremelanotide	5,657	*****	100.0%	*****	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
18-24 years	94	94	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	1,988	*****	0	0.0%	0	NaN	0	NaN
41-64 years	3,507	*****	*****	*****	100.0%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Selinexor	10,802	10,589	100.0%	195	100.0%	*****	100.0%	*****	100.0%
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	77	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	2,478	2,434	23.0%	*****	*****	*****	16.7%	0	0.0%
≥ 65 years	8,229	8,061	76.1%	152	77.9%	*****	83.3%	*****	100.0%
Imipenem, Cilastatin and Relebactam	2,150	2,150	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	907	907	42.2%	0	NaN	0	NaN	0	NaN
41-64 years	531	531	24.7%	0	NaN	0	NaN	0	NaN
≥ 65 years	595	595	27.7%	0	NaN	0	NaN	0	NaN
Ferric Maltol	13,719	12,911	100.0%	200	100.0%	608	100.0%	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
0-17 years	201	201	1.6%	0	0.0%	0	0.0%	0	NaN
18-24 years	829	782	6.1%	*****	*****	*****	*****	0	NaN
25-40 years	6,198	5,967	46.2%	67	33.5%	164	27.0%	0	NaN
41-64 years	6,034	5,589	43.3%	112	56.0%	333	54.8%	0	NaN
≥ 65 years	457	372	2.9%	*****	*****	*****	*****	0	NaN
Darolutamide	88,900	88,432	100.0%	*****	100.0%	260	100.0%	*****	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	14	*****	31	11.9%	0	0.0%
≥ 65 years	79,412	78,989	89.3%	*****	*****	229	88.1%	*****	100.0%
Pexidartinib	1,410	*****	100.0%	*****	100.0%	0	NaN	*****	100.0%
0-17 years	46	46	*****	0	0.0%	0	NaN	0	0.0%
18-24 years	123	123	*****	0	0.0%	0	NaN	0	0.0%
25-40 years	517	*****	*****	*****	50.0%	0	NaN	*****	100.0%
41-64 years	679	*****	*****	*****	50.0%	0	NaN	0	0.0%
≥ 65 years	45	45	*****	0	0.0%	0	NaN	0	0.0%
Pretomanid	272	*****	100.0%	*****	100.0%	0	NaN	0	NaN
0-17 years	14	14	*****	0	0.0%	0	NaN	0	NaN
18-24 years	18	18	*****	0	0.0%	0	NaN	0	NaN
25-40 years	66	66	*****	0	0.0%	0	NaN	0	NaN
41-64 years	61	*****	*****	*****	20.0%	0	NaN	0	NaN
≥ 65 years	113	*****	*****	*****	80.0%	0	NaN	0	NaN

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
Pitolisant	43,881	42,973	100.0%	498	100.0%	*****	100.0%	*****	100.0%
0-17 years	482	461	1.1%	*****	*****	*****	*****	0	0.0%
18-24 years	5,528	5,398	12.6%	64	12.9%	*****	*****	*****	25.0%
25-40 years	15,065	14,821	34.5%	167	33.5%	77	*****	0	0.0%
41-64 years	17,974	17,554	40.8%	243	48.8%	*****	*****	*****	62.5%
≥ 65 years	4,832	4,739	11.0%	*****	*****	76	*****	*****	12.5%
Entrectinib	3,361	3,291	100.0%	*****	100.0%	*****	100.0%	0	NaN
0-17 years	65	*****	*****	*****	*****	0	0.0%	0	NaN
18-24 years	22	*****	*****	*****	*****	0	0.0%	0	NaN
25-40 years	200	177	5.4%	23	*****	0	0.0%	0	NaN
41-64 years	1,365	*****	*****	*****	*****	0	0.0%	0	NaN
≥ 65 years	1,709	1,677	51.0%	*****	*****	*****	100.0%	0	NaN
Fedratinib	8,545	8,513	100.0%	14	100.0%	18	100.0%	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	108	108	1.3%	0	0.0%	0	0.0%	0	NaN
41-64 years	1,171	1,171	13.8%	0	0.0%	0	0.0%	0	NaN
≥ 65 years	7,266	7,234	85.0%	14	100.0%	18	100.0%	0	NaN
Upadacitinib	502,055	488,568	100.0%	2,234	100.0%	11,217	100.0%	36	100.0%
0-17 years	5,633	5,503	1.1%	*****	*****	100	0.9%	*****	*****
18-24 years	15,944	15,542	3.2%	*****	*****	251	2.2%	*****	*****
25-40 years	63,289	61,797	12.6%	*****	*****	1,098	9.8%	*****	*****
41-64 years	281,617	275,302	56.3%	925	41.4%	5,373	47.9%	17	47.2%

Table 2e. Categorical Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Dispensings	Number of Dispensings by Days Supplied							
		1-30 Days		31-60 Days		61-90 Days		91+ Days	
		Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings	Number of Dispensings	Percent of Total Dispensings
≥ 65 years	135,572	130,424	26.7%	*****	*****	4,395	39.2%	*****	*****
Lefamulin	417	417	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	215	215	51.6%	0	NaN	0	NaN	0	NaN
≥ 65 years	167	167	40.0%	0	NaN	0	NaN	0	NaN
Ga-68-DOTATOC	473	473	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	110	110	23.3%	0	NaN	0	NaN	0	NaN
≥ 65 years	346	346	73.2%	0	NaN	0	NaN	0	NaN
Istradefylline	49,328	40,421	100.0%	749	100.0%	8,147	100.0%	11	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	176	167	0.4%	*****	*****	*****	*****	0	0.0%
41-64 years	7,037	5,954	14.7%	96	12.8%	*****	*****	*****	*****
≥ 65 years	42,115	34,300	84.9%	*****	*****	7,153	87.8%	*****	*****

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
PrabotulinumtoxinA-xvfs	11	1	1	1	1	1	1.0	0.0
0-17 years	*****	1	1	1	1	1	1.0	*****
18-24 years	*****	1	1	1	1	1	1.0	*****
25-40 years	*****	1	1	1	1	1	1.0	*****
41-64 years	*****	1	1	1	1	1	1.0	*****
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Caplacizumab-yhdp	1,202	1	1	1	30	68	12.3	13.4
0-17 years	17	1	1	28	30	68	21.4	17.9
18-24 years	46	1	1	5	25	30	11.6	11.5
25-40 years	371	1	1	5	30	30	12.5	13.1
41-64 years	501	1	1	7	30	60	14.3	13.8
≥ 65 years	267	1	1	1	10	30	7.8	11.7
Triclabendazole	*****	2	2	2	2	2	2.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	2	2	2	2	2	2.0	*****
25-40 years	*****	2	2	2	2	2	2.0	*****
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Brexanolone	348	1	1	1	1	30	1.1	1.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	49	1	1	1	1	1	1.0	0.0
25-40 years	285	1	1	1	1	30	1.1	1.7
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	*****	1	1	1	1	1	1.0	0.0

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Solriamfetol	118,929	1	30	30	30	180	32.4	14.6
0-17 years	650	1	30	30	30	180	33.3	18.7
18-24 years	8,465	1	30	30	30	180	32.3	14.1
25-40 years	32,305	1	30	30	30	120	31.2	12.1
41-64 years	59,394	1	30	30	30	180	32.3	14.3
≥ 65 years	18,115	1	30	30	30	180	35.0	18.7
Siponimod	31,450	1	30	30	30	180	32.1	13.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	299	1	30	30	30	90	29.3	9.0
25-40 years	5,363	1	30	30	30	95	30.5	10.6
41-64 years	21,912	1	30	30	30	180	32.1	13.6
≥ 65 years	3,876	1	30	30	30	97	34.7	17.9
Romosozumab-aqqg	716,200	1	1	1	1	362	3.0	7.7
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	28	30	9.4	13.1
25-40 years	1,243	1	1	1	1	90	4.6	10.0
41-64 years	59,766	1	1	1	1	112	4.6	9.9
≥ 65 years	655,033	1	1	1	1	362	2.9	7.4
Erdafitinib	3,566	1	28	28	28	90	27.6	7.5
0-17 years	23	4	14	28	30	90	30.0	25.2
18-24 years	16	3	28	28	28	28	26.4	6.3
25-40 years	74	2	28	28	28	48	26.5	6.3
41-64 years	895	1	28	28	28	68	26.9	8.4
≥ 65 years	2,558	1	28	28	28	84	27.9	6.9

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Risankizumab-rzaa	406,944	1	28	56	84	336	54.5	29.9
0-17 years	1,031	1	1	31	71	112	39.2	31.7
18-24 years	20,343	1	28	31	84	336	48.4	29.9
25-40 years	97,055	1	28	47	84	168	51.8	29.4
41-64 years	209,121	1	30	56	84	198	54.7	29.2
≥ 65 years	79,394	1	28	84	84	255	59.0	31.2
Tafamidis Meglumine	132,670	1	30	30	30	180	33.5	15.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	62	3	30	30	30	30	28.4	6.1
41-64 years	5,026	1	30	30	30	90	30.8	10.5
≥ 65 years	127,582	1	30	30	30	180	33.6	16.1
Alpelisib	31,076	1	28	28	28	118	27.8	4.7
0-17 years	880	1	28	28	28	56	27.0	4.6
18-24 years	117	6	28	28	28	114	30.3	12.1
25-40 years	884	2	28	28	28	84	27.3	4.8
41-64 years	12,123	1	28	28	28	112	27.5	4.6
≥ 65 years	17,072	1	28	28	28	118	28.0	4.6
Polatuzumab Vedotin-piiq	24,701	1	1	1	1	56	1.1	1.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	38	1	1	1	1	1	1.0	0.0
25-40 years	362	1	1	1	1	42	1.3	2.8
41-64 years	3,083	1	1	1	1	56	1.1	1.7
≥ 65 years	21,218	1	1	1	1	21	1.1	1.3

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Bremelanotide	5,657	1	15	23	30	60	22.3	7.3
0-17 years	*****	15	15	15	15	15	15.0	*****
18-24 years	94	2	15	23	30	30	23.3	6.9
25-40 years	1,988	1	15	23	30	30	22.6	7.5
41-64 years	3,507	1	15	23	30	60	22.1	7.3
≥ 65 years	*****	7	15	15	23	30	17.9	5.0
Selinexor	10,802	1	28	28	28	168	27.4	5.4
0-17 years	*****	11	21	28	28	28	24.5	5.7
18-24 years	*****	17	28	28	28	28	26.2	4.5
25-40 years	77	1	28	28	28	56	26.0	7.3
41-64 years	2,478	1	28	28	28	84	27.4	4.9
≥ 65 years	8,229	1	28	28	28	168	27.5	5.5
Imipenem, Cilastatin and Relebactam	2,150	1	1	1	1	28	2.0	2.4
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	8	2.0	2.1
25-40 years	907	1	1	1	1	28	1.5	2.1
41-64 years	531	1	1	1	1	10	1.9	2.1
≥ 65 years	595	1	1	1	4	14	2.7	3.1
Ferric Maltol	13,719	1	30	30	30	90	31.3	13.7
0-17 years	201	4	30	30	30	30	28.6	4.7
18-24 years	829	1	30	30	30	90	31.5	14.1
25-40 years	6,198	1	30	30	30	90	30.1	11.3
41-64 years	6,034	1	30	30	30	90	32.1	14.9
≥ 65 years	457	1	30	30	30	90	38.3	23.0

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Darolutamide	88,900	1	30	30	30	120	29.2	5.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	9	28	30	30	30	26.2	8.4
41-64 years	*****	1	30	30	30	90	27.9	6.8
≥ 65 years	79,412	1	30	30	30	120	29.4	5.2
Pexidartinib	1,410	1	30	30	30	288	29.4	8.3
0-17 years	46	3	30	30	30	30	29.4	4.0
18-24 years	123	2	30	30	30	30	28.8	4.4
25-40 years	517	1	30	30	30	288	29.7	12.4
41-64 years	679	1	30	30	30	60	29.3	4.6
≥ 65 years	45	6	30	30	30	30	29.5	3.6
Pretomanid	272	2	26	26	26	52	26.2	5.9
0-17 years	14	10	26	26	26	30	25.4	4.7
18-24 years	18	4	26	26	26	30	24.2	6.3
25-40 years	66	2	26	26	26	30	24.8	4.8
41-64 years	61	26	26	26	26	34	26.3	1.4
≥ 65 years	113	3	26	26	26	52	27.4	7.6
Pitolisant	43,881	1	30	30	30	180	29.7	7.7
0-17 years	482	6	30	30	30	90	31.1	10.8
18-24 years	5,528	1	30	30	30	180	29.7	8.4
25-40 years	15,065	1	30	30	30	90	29.3	6.5
41-64 years	17,974	1	30	30	30	180	29.9	7.9
≥ 65 years	4,832	1	30	30	30	97	30.2	8.6

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Entrectinib	3,361	1	30	30	30	90	28.5	6.9
0-17 years	65	15	30	30	30	60	30.6	8.6
18-24 years	22	9	30	30	30	60	31.1	10.8
25-40 years	200	3	30	30	30	60	30.3	10.8
41-64 years	1,365	1	30	30	30	60	27.4	6.5
≥ 65 years	1,709	1	30	30	30	90	29.1	6.3
Fedratinib	8,545	1	30	30	30	90	29.3	4.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	108	9	30	30	30	30	29.0	3.7
41-64 years	1,171	1	30	30	30	30	28.4	5.0
≥ 65 years	7,266	1	30	30	30	90	29.5	4.7
Upadacitinib	502,055	1	30	30	30	300	30.6	9.9
0-17 years	5,633	1	30	30	30	114	29.8	9.6
18-24 years	15,944	1	30	30	30	136	29.9	9.1
25-40 years	63,289	1	30	30	30	300	30.0	9.3
41-64 years	281,617	1	30	30	30	300	30.4	9.3
≥ 65 years	135,572	1	30	30	30	174	31.4	11.3
Lefamulin	417	1	1	2	5	30	3.8	4.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	3	10	15	5.9	5.8
25-40 years	*****	1	5	5	10	14	6.5	4.0
41-64 years	215	1	1	1	5	30	3.5	4.6
≥ 65 years	167	1	1	5	5	10	3.8	2.8

Table 2f. Continuous Summary of Days Supplied per Dispensing for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Dispensings	Distribution of Days Supplied by Dispensing						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Ga-68-DOTATOC	473	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	*****
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	110	1	1	1	1	1	1.0	0.0
≥ 65 years	346	1	1	1	1	1	1.0	0.0
Istradefylline	49,328	1	30	30	30	180	39.6	22.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	176	3	30	30	30	90	32.0	13.2
41-64 years	7,037	1	30	30	30	180	37.8	21.5
≥ 65 years	42,115	1	30	30	30	180	39.9	22.9

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>PrabotulinumtoxinA-xvfs</i>	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Caplacizumab-yhdp</i>	390	260	66.7%	112	28.7%	*****	*****	*****	*****	*****	*****
<i>Triclabendazole</i>	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Brexanolone</i>	164	164	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Solriamfetol</i>	15,947	3,606	22.6%	3,713	23.3%	5,295	33.2%	2,038	12.8%	1,295	8.1%
<i>Siponimod</i>	2,286	166	7.3%	305	13.3%	840	36.7%	512	22.4%	463	20.3%
<i>Romosozumab-aqqg</i>	87,634	81,220	92.7%	1,502	1.7%	4,331	4.9%	568	0.6%	13	0.0%
<i>Erdafitinib</i>	848	229	27.0%	259	30.5%	326	38.4%	*****	*****	*****	*****
<i>Risankizumab-rzaa</i>	76,821	10,364	13.5%	11,558	15.0%	33,873	44.1%	14,198	18.5%	6,828	8.9%
<i>Tafamidis Meglumine</i>	11,217	822	7.3%	1,457	13.0%	4,935	44.0%	2,081	18.6%	1,922	17.1%
<i>Alpelisib</i>	6,242	1,737	27.8%	1,709	27.4%	2,339	37.5%	388	6.2%	69	1.1%
<i>Polatuzumab Vedotin-piiq</i>	6,512	6,478	99.5%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Bremelanotide</i>	2,426	1,556	64.1%	538	22.2%	*****	*****	*****	*****	*****	*****
<i>Selinexor</i>	3,486	1,302	37.3%	1,280	36.7%	823	23.6%	*****	*****	*****	*****
<i>Imipenem, Cilastatin and Relebactam</i>	152	118	77.6%	23	15.1%	*****	*****	*****	*****	0	0.0%
<i>Ferric Maltol</i>	4,069	1,144	28.1%	1,348	33.1%	1,486	36.5%	91	2.2%	0	0.0%
<i>Darolutamide</i>	9,618	1,327	13.8%	1,769	18.4%	4,075	42.4%	1,766	18.4%	681	7.1%
<i>Pexidartinib</i>	160	23	14.4%	32	20.0%	69	43.1%	23	14.4%	13	8.1%
<i>Pretomanid</i>	51	*****	*****	*****	*****	34	66.7%	0	0.0%	0	0.0%
<i>Pitolisant</i>	5,055	928	18.4%	1,149	22.7%	1,825	36.1%	734	14.5%	419	8.3%
<i>Entrectinib</i>	602	181	30.1%	169	28.1%	180	29.9%	58	9.6%	14	2.3%

Table 3a. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

		Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
Total Number of Patients		Percent of		Percent of		Percent of		Percent of		Percent of	
		Number of Patients	Total Patients	Number of Patients	Total Patients	Number of Patients	Total Patients	Number of Patients	Total Patients	Number of Patients	Total Patients
<i>Fedratinib</i>	1,055	252	23.9%	225	21.3%	365	34.6%	121	11.5%	92	8.7%
<i>Upadacitinib</i>	54,390	7,141	13.1%	10,694	19.7%	22,362	41.1%	9,468	17.4%	4,725	8.7%
<i>Lefamulin</i>	209	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Ga-68-DOTATOC</i>	358	358	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Istradefylline</i>	6,005	1,027	17.1%	1,258	20.9%	1,861	31.0%	1,008	16.8%	851	14.2%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>PrabotulinumtoxinA-xvfs</i>	*****	1	1	1	1	2	1.1	0.3
<i>Caplacizumab-yhdp</i>	390	1	1	28	31	1,378	37.7	105.1
<i>Triclabendazole</i>	*****	2	2	2	2	2	2.0	0.0
<i>Brexanolone</i>	164	1	1	3	3	30	2.4	2.4
<i>Solriamfetol</i>	15,947	1	45	120	307	1,950	241.8	301.5
<i>Siponimod</i>	2,286	1	119	300	630	1,946	441.8	426.9
<i>Romosozumab-aqqg</i>	87,634	1	4	11	12	990	24.6	68.1
<i>Erdafitinib</i>	848	1	30	84	148	1,154	116.0	125.6
<i>Risankizumab-rzaa</i>	76,821	1	84	196	399	1,997	288.7	292.7
<i>Tafamidis Meglumine</i>	11,217	1	114	228	535	2,010	394.9	413.4
<i>Alpelisib</i>	6,242	2	28	84	168	1,512	138.3	158.6
<i>Polatuzumab Vedotin-piiq</i>	6,512	1	2	4	6	159	4.2	6.0
<i>Bremelanotide</i>	2,426	1	15	30	60	814	51.9	61.5
<i>Selinexor</i>	3,486	1	28	56	102	850	85.1	94.7
<i>Imipenem, Cilastatin and Relebactam</i>	152	1	2	10	27	686	27.8	64.5
<i>Ferric Maltol</i>	4,069	1	30	87	148	720	105.6	95.1
<i>Darolutamide</i>	9,618	1	72	180	374	1,760	270.2	274.5
<i>Pexidartinib</i>	160	30	60	150	357	1,466	259.2	264.3
<i>Pretomanid</i>	51	3	60	156	182	364	139.7	84.5
<i>Pitolisant</i>	5,055	1	60	139	340	1,892	258	306.4
<i>Entrectinib</i>	602	1	30	81	191	1,576	159.3	208.4
<i>Fedratinib</i>	1,055	2	49	120	295	1,776	237.5	297.9
<i>Upadacitinib</i>	54,390	1	75	180	386	1,948	282.3	297.2
<i>Lefamulin</i>	209	1	5	5	7	93	7.7	9.9

Table 3b. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Ga-68-DOTATOC</i>	358	1	1	1	1	6	1.3	0.8
<i>Istradefylline</i>	6,005	1	60	180	473	1,832	324.9	359.3

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
PrabotulinumtoxinA-xvfs	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	80.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	20.0%	0	NaN	0	NaN	0	NaN	0	NaN
Caplacizumab-yhdp	390	260	100.0%	112	100.0%	*****	100.0%	*****	100.0%	*****	100.0%
Female	254	165	63.5%	*****	*****	*****	53.3%	*****	100.0%	*****	50.0%
Male	136	95	36.5%	*****	*****	*****	46.7%	0	0.0%	*****	50.0%
Triclabendazole	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Brexanolone	164	164	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Solriamfetol	15,947	3,606	100.0%	3,713	100.0%	5,295	100.0%	2,038	100.0%	1,295	100.0%
Female	9,717	2,177	60.4%	2,276	61.3%	3,244	61.3%	1,237	60.7%	783	60.5%
Male	6,230	1,429	39.6%	1,437	38.7%	2,051	38.7%	801	39.3%	512	39.5%
Siponimod	2,286	166	100.0%	305	100.0%	840	100.0%	512	100.0%	463	100.0%
Female	1,710	122	73.5%	228	74.8%	630	75.0%	380	74.2%	350	75.6%
Male	576	44	26.5%	77	25.2%	210	25.0%	132	25.8%	113	24.4%
Romosozumab-aqqg	87,634	81,220	100.0%	1,502	100.0%	4,331	100.0%	568	100.0%	13	100.0%
Female	85,733	79,526	97.9%	1,453	96.7%	4,188	96.7%	*****	*****	*****	*****
Male	1,901	1,694	2.1%	49	3.3%	143	3.3%	*****	*****	*****	*****

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Erdafitinib	848	229	100.0%	259	100.0%	326	100.0%	*****	100.0%	*****	100.0%
Female	324	96	41.9%	101	39.0%	115	35.3%	*****	37.9%	*****	20.0%
Male	524	133	58.1%	158	61.0%	211	64.7%	*****	62.1%	*****	80.0%
Risankizumab-rzaa	76,821	10,364	100.0%	11,558	100.0%	33,873	100.0%	14,198	100.0%	6,828	100.0%
Female	39,454	5,657	54.6%	6,038	52.2%	17,529	51.7%	7,023	49.5%	3,207	47.0%
Male	37,367	4,707	45.4%	5,520	47.8%	16,344	48.3%	7,175	50.5%	3,621	53.0%
Tafamidis Meglumine	11,217	822	100.0%	1,457	100.0%	4,935	100.0%	2,081	100.0%	1,922	100.0%
Female	2,105	182	22.1%	317	21.8%	912	18.5%	376	18.1%	318	16.5%
Male	9,112	640	77.9%	1,140	78.2%	4,023	81.5%	1,705	81.9%	1,604	83.5%
Alpelisib	6,242	1,737	100.0%	1,709	100.0%	2,339	100.0%	388	100.0%	69	100.0%
Female	6,061	1,688	97.2%	1,667	97.5%	2,277	97.3%	*****	*****	*****	*****
Male	181	49	2.8%	42	2.5%	62	2.7%	*****	*****	*****	*****
Polatuzumab Vedotin-piiq	6,512	6,478	100.0%	*****	100.0%	*****	100.0%	0	NaN	0	NaN
Female	2,782	*****	*****	*****	23.1%	*****	37.5%	0	NaN	0	NaN
Male	3,730	*****	*****	*****	76.9%	*****	62.5%	0	NaN	0	NaN
Bremelanotide	2,426	1,556	100.0%	538	100.0%	*****	100.0%	*****	100.0%	*****	100.0%
Female	2,372	1,525	98.0%	526	97.8%	*****	96.9%	*****	80.0%	*****	100.0%
Male	54	31	2.0%	12	2.2%	*****	3.1%	*****	20.0%	0	0.0%
Selinexor	3,486	1,302	100.0%	1,280	100.0%	823	100.0%	*****	100.0%	*****	100.0%
Female	1,661	608	46.7%	606	47.3%	401	48.7%	*****	56.2%	*****	62.5%
Male	1,825	694	53.3%	674	52.7%	422	51.3%	*****	43.8%	*****	37.5%

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Imipenem, Cilastatin and Relebactam	152	118	100.0%	23	100.0%	*****	100.0%	*****	100.0%	0	NaN
Female	79	65	55.1%	*****	*****	*****	50.0%	0	0.0%	0	NaN
Male	73	53	44.9%	*****	*****	*****	50.0%	*****	100.0%	0	NaN
Ferric Maltol	4,069	1,144	100.0%	1,348	100.0%	1,486	100.0%	91	100.0%	0	NaN
Female	3,801	*****	*****	1,270	94.2%	1,388	93.4%	*****	*****	0	NaN
Male	268	*****	*****	78	5.8%	98	6.6%	*****	*****	0	NaN
Darolutamide	9,618	1,327	100.0%	1,769	100.0%	4,075	100.0%	1,766	100.0%	681	100.0%
Female	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	*****	*****
Male	*****	1,327	100.0%	*****	*****	4,075	100.0%	1,766	100.0%	*****	*****
Pexidartinib	160	23	100.0%	32	100.0%	69	100.0%	23	100.0%	13	100.0%
Female	102	*****	*****	*****	*****	45	65.2%	*****	*****	*****	*****
Male	58	*****	*****	*****	*****	24	34.8%	*****	*****	*****	*****
Pretomanid	51	*****	100.0%	*****	100.0%	34	100.0%	0	NaN	0	NaN
Female	28	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	23	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Pitolisant	5,055	928	100.0%	1,149	100.0%	1,825	100.0%	734	100.0%	419	100.0%
Female	3,508	674	72.6%	813	70.8%	1,217	66.7%	518	70.6%	286	68.3%
Male	1,547	254	27.4%	336	29.2%	608	33.3%	216	29.4%	133	31.7%
Entrectinib	602	181	100.0%	169	100.0%	180	100.0%	58	100.0%	14	100.0%
Female	357	108	59.7%	98	58.0%	98	54.4%	*****	*****	*****	*****
Male	245	73	40.3%	71	42.0%	82	45.6%	*****	*****	*****	*****

Table 3c. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Fedratinib	1,055	252	100.0%	225	100.0%	365	100.0%	121	100.0%	92	100.0%
Female	509	133	52.8%	104	46.2%	165	45.2%	61	50.4%	46	50.0%
Male	546	119	47.2%	121	53.8%	200	54.8%	60	49.6%	46	50.0%
Upadacitinib	54,390	7,141	100.0%	10,694	100.0%	22,362	100.0%	9,468	100.0%	4,725	100.0%
Female	39,189	5,179	72.5%	7,660	71.6%	15,872	71.0%	6,757	71.4%	3,721	78.8%
Male	15,201	1,962	27.5%	3,034	28.4%	6,490	29.0%	2,711	28.6%	1,004	21.2%
Lefamulin	209	*****	100.0%	*****	100.0%	*****	100.0%	0	NaN	0	NaN
Female	124	*****	58.8%	*****	75.0%	*****	100.0%	0	NaN	0	NaN
Male	85	*****	41.2%	*****	25.0%	0	0.0%	0	NaN	0	NaN
Ga-68-DOTATOC	358	358	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	200	200	55.9%	0	NaN	0	NaN	0	NaN	0	NaN
Male	158	158	44.1%	0	NaN	0	NaN	0	NaN	0	NaN
Istradefylline	6,005	1,027	100.0%	1,258	100.0%	1,861	100.0%	1,008	100.0%	851	100.0%
Female	2,465	449	43.7%	505	40.1%	777	41.8%	397	39.4%	337	39.6%
Male	3,540	578	56.3%	753	59.9%	1,084	58.2%	611	60.6%	514	60.4%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
PrabotulinumtoxinA-xvfs	*****	1	1	1	1	2	1.1	0.3
Female	*****	1	1	1	1	2	1.1	0.4
Male	*****	1	1	1	1	1	1.0	0.0
Caplacizumab-yhdp	390	1	1	28	31	1,378	37.7	105.1
Female	254	1	1	30	31	1,378	38.4	98.9
Male	136	1	1	20	31	1,300	36.4	116.1
Triclabendazole	*****	2	2	2	2	2	2.0	0.0
Female	*****	2	2	2	2	2	2.0	0.0
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Brexanolone	164	1	1	3	3	30	2.4	2.4
Female	*****	1	1	3	3	30	2.4	2.4
Male	*****	1	1	1	1	1	1.0	0.0
Solriamfetol	15,947	1	45	120	307	1,950	241.8	301.5
Female	9,717	1	45	120	301	1,950	240.4	299.5
Male	6,230	1	45	120	318	1,925	244	304.7
Siponimod	2,286	1	119	300	630	1,946	441.8	426.9
Female	1,710	2	120	298	630	1,946	443.3	428.4
Male	576	1	116	300	622	1,810	437.3	422.8
Romosozumab-aqqg	87,634	1	4	11	12	990	24.6	68.1
Female	85,733	1	5	11	12	990	24.4	67.7
Male	1,901	1	3	9	12	829	32.6	85.1
Erdafitinib	848	1	30	84	148	1,154	116	125.6
Female	324	1	28	84	140	1,154	107.8	115

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Male	524	1	30	84	152	1,149	121.1	131.5
Risankizumab-rzaa	76,821	1	84	196	399	1,997	288.7	292.7
Female	39,454	1	80	192	380	1,997	277.9	285.1
Male	37,367	1	84	197	420	1,947	300.2	300.1
Tafamidis Meglumine	11,217	1	114	228	535	2,010	394.9	413.4
Female	2,105	1	99	210	488	1,996	362.8	383.9
Male	9,112	1	117	233	540	2,010	402.2	419.6
Alpelisib	6,242	2	28	84	168	1,512	138.3	158.6
Female	6,061	2	28	84	168	1,512	137.2	157.3
Male	181	8	28	87	232	857	174.2	193.2
Polatuzumab Vedotin-piiq	6,512	1	2	4	6	159	4.2	6.0
Female	2,782	1	2	4	6	128	4.1	5.0
Male	3,730	1	2	4	6	159	4.2	6.6
Bremelanotide	2,426	1	15	30	60	814	51.9	61.5
Female	2,372	1	15	30	60	814	51.5	60.5
Male	54	1	15	30	66	390	73.4	95.7
Selinexor	3,486	1	28	56	102	850	85.1	94.7
Female	1,661	1	28	56	112	840	87.9	99.2
Male	1,825	2	28	56	91	850	82.4	90.4
Imipenem, Cilastatin and Relebactam	152	1	2	10	27	686	27.8	64.5
Female	79	1	1	9	24	206	21.5	35.6
Male	73	1	2	10	34	686	34.7	85.2
Ferric Maltol	4,069	1	30	87	148	720	105.6	95.1

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	3,801	1	30	87	148	720	105.2	94.4
Male	268	1	30	87	150	540	111.2	104.2
Darolutamide	9,618	1	72	180	374	1,760	270.2	274.5
Female	*****	60	60	60	60	60	60	*****
Male	*****	1	72	180	374	1,760	270.2	274.5
Pexidartinib	160	30	60	150	357	1,466	259.2	264.3
Female	102	30	71	150	355	1,466	266.3	281.1
Male	58	30	60	180	358	870	246.6	233.7
Pretomanid	51	3	60	156	182	364	139.7	84.5
Female	28	11	58	158	182	307	137.3	77.9
Male	23	3	60	156	190	364	142.6	93.5
Pitolisant	5,055	1	60	139	340	1,892	258	306.4
Female	3,508	1	60	122	337	1,892	253.3	301.6
Male	1,547	1	60	150	346	1,760	268.5	316.7
Entrectinib	602	1	30	81	191	1,576	159.3	208.4
Female	357	2	30	81	197	1,548	170.2	224.6
Male	245	1	30	80	180	1,576	143.4	181.5
Fedratinib	1,055	2	49	120	295	1,776	237.5	297.9
Female	509	6	30	120	300	1,776	242.7	312
Male	546	2	60	120	284	1,662	232.7	284.3
Upadacitinib	54,390	1	75	180	386	1,948	282.3	297.2
Female	39,189	1	77	180	390	1,834	289.3	306.2
Male	15,201	1	73	176	360	1,948	264.4	271.9

Table 3d. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Lefamulin	209	1	5	5	7	93	7.7	9.9
Female	124	1	5	5	7	93	7.7	11.1
Male	85	1	5	5	8	64	7.6	7.8
Ga-68-DOTATOC	358	1	1	1	1	6	1.3	0.8
Female	200	1	1	1	1	6	1.3	0.7
Male	158	1	1	1	2	6	1.4	0.8
Istradefylline	6,005	1	60	180	473	1,832	324.9	359.3
Female	2,465	2	60	175	450	1,832	318.6	358.6
Male	3,540	1	60	180	480	1,760	329.3	359.8

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

		Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
PrabotulinumtoxinA-xvfs	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	10.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	10.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	20.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	60.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Caplacizumab-yhdp	390	260	100.0%	112	100.0%	*****	100.0%	*****	100.0%	*****	100.0%
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	81	40	15.4%	*****	*****	*****	26.7%	0	0.0%	*****	50.0%
41-64 years	156	93	35.8%	*****	*****	*****	53.3%	0	0.0%	*****	50.0%
≥ 65 years	122	102	39.2%	*****	*****	*****	*****	*****	100.0%	0	0.0%
Triclabendazole	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	50.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	50.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Brexanolone	164	164	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	20	20	12.2%	0	NaN	0	NaN	0	NaN	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	133	133	81.1%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Solriamfetol	15,947	3,606	100.0%	3,713	100.0%	5,295	100.0%	2,038	100.0%	1,295	100.0%
0-17 years	74	17	0.5%	13	0.4%	21	0.4%	*****	*****	*****	*****
18-24 years	1,135	267	7.4%	269	7.2%	352	6.6%	*****	*****	*****	*****
25-40 years	4,481	980	27.2%	1,098	29.6%	1,556	29.4%	546	26.8%	301	23.2%
41-64 years	7,488	1,575	43.7%	1,685	45.4%	2,536	47.9%	1,020	50.0%	672	51.9%
≥ 65 years	2,769	767	21.3%	648	17.5%	830	15.7%	295	14.5%	229	17.7%
Siponimod	2,286	166	100.0%	305	100.0%	840	100.0%	512	100.0%	463	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	26	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
25-40 years	429	27	16.3%	70	23.0%	162	19.3%	106	20.7%	64	13.8%
41-64 years	1,516	110	66.3%	184	60.3%	544	64.8%	345	67.4%	333	71.9%
≥ 65 years	315	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
Romosozumab-aqqg	87,634	81,220	100.0%	1,502	100.0%	4,331	100.0%	568	100.0%	13	100.0%
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	201	181	0.2%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	7,993	7,056	8.7%	*****	*****	653	15.1%	81	14.3%	*****	*****
≥ 65 years	79,409	73,957	91.1%	1,296	86.3%	3,661	84.5%	*****	*****	*****	*****

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Number of Patients by Cumulative Treatment Episode Duration									
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Erdafitinib	848	100.0%	229	100.0%	259	100.0%	326	100.0%	****	100.0%
0-17 years	****	****	****	****	****	****	****	****	0	0.0%
18-24 years	****	0	0.0%	****	****	****	****	****	0	0.0%
25-40 years	18	****	****	****	****	****	****	****	0	0.0%
41-64 years	195	****	****	****	****	88	27.0%	****	24.1%	****
≥ 65 years	624	185	80.8%	188	72.6%	225	69.0%	****	75.9%	****
Risankizumab-rzaa	76,821	100.0%	10,364	100.0%	11,558	100.0%	33,873	100.0%	14,198	100.0%
0-17 years	195	50	0.5%	31	0.3%	79	0.2%	****	****	****
18-24 years	3,936	573	5.5%	618	5.3%	1,827	5.4%	****	****	****
25-40 years	18,558	2,277	22.0%	3,107	26.9%	8,598	25.4%	3,236	22.8%	1,340
41-64 years	37,857	3,975	38.4%	5,716	49.5%	17,232	50.9%	7,316	51.5%	3,618
≥ 65 years	16,275	3,489	33.7%	2,086	18.0%	6,137	18.1%	2,909	20.5%	1,654
Tafamidis Meglumine	11,217	100.0%	822	100.0%	1,457	100.0%	4,935	100.0%	2,081	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0
25-40 years	****	****	****	****	****	****	****	0	0.0%	****
41-64 years	****	****	****	****	****	****	****	98	4.7%	****
≥ 65 years	10,806	787	95.7%	1,399	96.0%	4,780	96.9%	1,983	95.3%	1,857
Alpelisib	6,242	100.0%	1,737	100.0%	1,709	100.0%	2,339	100.0%	388	100.0%
0-17 years	78	****	****	****	****	****	****	23	5.9%	****
18-24 years	15	****	****	****	****	****	****	****	****	0

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

		Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Total Number of Patients	Percent of Total Patients	Total Number of Patients	Percent of Total Patients	Total Number of Patients	Percent of Total Patients	Total Number of Patients	Percent of Total Patients	Total Number of Patients	Percent of Total Patients
25-40 years	172	43	2.5%	51	3.0%	64	2.7%	*****	*****	*****	*****
41-64 years	2,314	532	30.6%	636	37.2%	984	42.1%	*****	*****	*****	*****
≥ 65 years	3,663	1,150	66.2%	1,006	58.9%	1,260	53.9%	211	54.4%	36	52.2%
Polatuzumab Vedotin- piiq	6,512	6,478	100.0%	*****	100.0%	*****	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	14	14	0.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	117	*****	*****	0	0.0%	*****	12.5%	0	NaN	0	NaN
41-64 years	920	*****	*****	*****	3.8%	*****	25.0%	0	NaN	0	NaN
≥ 65 years	5,461	5,431	83.8%	*****	96.2%	*****	62.5%	0	NaN	0	NaN
Bremelanotide	2,426	1,556	100.0%	538	100.0%	*****	100.0%	*****	100.0%	*****	100.0%
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	43	28	1.8%	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	928	608	39.1%	*****	*****	108	*****	*****	20.0%	0	0.0%
41-64 years	1,437	906	58.2%	317	58.9%	*****	*****	*****	80.0%	0	0.0%
≥ 65 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	*****	100.0%
Selinexor	3,486	1,302	100.0%	1,280	100.0%	823	100.0%	*****	100.0%	*****	100.0%
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	753	249	19.1%	288	22.5%	*****	*****	*****	26.0%	*****	37.5%
≥ 65 years	2,696	1,041	80.0%	973	76.0%	623	75.7%	*****	74.0%	*****	62.5%

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Relebactam	152	118	100.0%	23	100.0%	*****	100.0%	*****	100.0%	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	20.0%	*****	100.0%	0	NaN
41-64 years	57	*****	*****	*****	*****	*****	10.0%	0	0.0%	0	NaN
≥ 65 years	56	42	35.6%	*****	*****	*****	70.0%	0	0.0%	0	NaN
Ferric Maltol	4,069	1,144	100.0%	1,348	100.0%	1,486	100.0%	91	100.0%	0	NaN
0-17 years	42	11	1.0%	14	1.0%	*****	*****	*****	*****	0	NaN
18-24 years	276	97	*****	93	6.9%	*****	*****	*****	*****	0	NaN
25-40 years	1,914	556	48.6%	663	49.2%	674	45.4%	21	23.1%	0	NaN
41-64 years	1,666	417	36.5%	527	39.1%	666	44.8%	56	61.5%	0	NaN
≥ 65 years	171	63	5.5%	51	3.8%	*****	*****	*****	*****	0	NaN
Darolutamide	9,618	1,327	100.0%	1,769	100.0%	4,075	100.0%	1,766	100.0%	681	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%	0	0.0%
41-64 years	*****	140	10.6%	177	10.0%	*****	*****	209	11.8%	45	6.6%
≥ 65 years	8,549	1,187	89.4%	1,592	90.0%	3,577	87.8%	1,557	88.2%	636	93.4%
Pexidartinib	160	23	100.0%	32	100.0%	69	100.0%	23	100.0%	13	100.0%
0-17 years	*****	*****	*****	0	0.0%	*****	*****	*****	*****	0	0.0%
18-24 years	17	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	56	*****	*****	*****	*****	27	39.1%	*****	*****	*****	*****
41-64 years	73	*****	*****	17	53.1%	27	39.1%	*****	*****	*****	*****
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
Pretomanid	51	*****	100.0%	*****	100.0%	34	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	15	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	20	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Pitolisant	5,055	928	100.0%	1,149	100.0%	1,825	100.0%	734	100.0%	419	100.0%
0-17 years	48	*****	*****	*****	*****	16	0.9%	11	1.5%	*****	*****
18-24 years	631	*****	*****	*****	*****	236	12.9%	104	14.2%	*****	*****
25-40 years	1,877	342	36.9%	460	40.0%	701	38.4%	256	34.9%	118	28.2%
41-64 years	1,943	354	38.1%	414	36.0%	693	38.0%	284	38.7%	198	47.3%
≥ 65 years	556	109	11.7%	139	12.1%	179	9.8%	79	10.8%	50	11.9%
Entrectinib	602	181	100.0%	169	100.0%	180	100.0%	58	100.0%	14	100.0%
0-17 years	*****	*****	*****	0	0.0%	*****	*****	*****	*****	0	0.0%
18-24 years	*****	0	0.0%	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	32	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	223	*****	*****	59	34.9%	78	43.3%	*****	*****	*****	*****
≥ 65 years	336	115	63.5%	99	58.6%	84	46.7%	*****	*****	*****	*****

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

		Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Total Number of Patients	Percent of Total Patients	Total Number of Patients	Percent of Total Patients	Total Number of Patients	Percent of Total Patients	Total Number of Patients	Percent of Total Patients	Total Number of Patients	Percent of Total Patients
Fedratinib	1,055	252	100.0%	225	100.0%	365	100.0%	121	100.0%	92	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	0	0.0%	*****	*****	*****	*****	0	0.0%	*****	*****
41-64 years	*****	32	12.7%	*****	*****	*****	*****	18	14.9%	*****	*****
≥ 65 years	902	220	87.3%	187	83.1%	313	85.8%	103	85.1%	79	85.9%
Upadacitinib	54,390	7,141	100.0%	10,694	100.0%	22,362	100.0%	9,468	100.0%	4,725	100.0%
0-17 years	738	106	1.5%	140	1.3%	334	1.5%	138	1.5%	20	0.4%
18-24 years	2,209	294	4.1%	487	4.6%	1,036	4.6%	325	3.4%	67	1.4%
25-40 years	8,252	1,099	15.4%	1,834	17.1%	3,684	16.5%	1,292	13.6%	343	7.3%
41-64 years	29,770	3,654	51.2%	5,810	54.3%	12,364	55.3%	5,261	55.6%	2,681	56.7%
≥ 65 years	13,421	1,988	27.8%	2,423	22.7%	4,944	22.1%	2,452	25.9%	1,614	34.2%
Lefamulin	209	*****	100.0%	*****	100.0%	*****	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
41-64 years	80	*****	*****	*****	*****	*****	100.0%	0	NaN	0	NaN
≥ 65 years	107	107	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
Ga-68-DOTATOC	358	358	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN

Table 3e. Categorical Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by Cumulative Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	90	90	25.1%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	252	252	70.4%	0	NaN	0	NaN	0	NaN	0	NaN
Istradefylline	6,005	1,027	100.0%	1,258	100.0%	1,861	100.0%	1,008	100.0%	851	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	18	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
41-64 years	856	*****	*****	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	5,131	880	85.7%	1,068	84.9%	1,576	84.7%	862	85.5%	745	87.5%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
PrabotulinumtoxinA-xvfs	*****	1	1	1	1	2	1.1	0.3
0-17 years	*****	1	1	1	1	1	1.0	*****
18-24 years	*****	1	1	1	1	1	1.0	*****
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	2	1.2	0.4
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Caplacizumab-yhdp	390	1	1	28	31	1,378	37.7	105.1
0-17 years	*****	1	1	27	86	118	40.3	47.3
18-24 years	*****	1	19	25	30	59	24.2	15.1
25-40 years	81	1	25	31	58	1,300	57.3	146.3
41-64 years	156	1	16	30	45	1,378	45.4	116.6
≥ 65 years	122	1	1	1	27	566	17.0	54.4
Triclabendazole	*****	2	2	2	2	2	2.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	2	2	2	2	2	2.0	*****
25-40 years	*****	2	2	2	2	2	2.0	*****
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Brexanolone	164	1	1	3	3	30	2.4	2.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	20	1	2	3	3	3	2.5	0.9
25-40 years	133	1	1	3	3	30	2.5	2.6
41-64 years	*****	1	1	2	3	3	1.8	1.0

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Solriamfetol	15,947	1	45	120	307	1,950	241.8	301.5
0-17 years	74	1	45	157	450	1,327	292.8	328.8
18-24 years	1,135	1	44	120	305	1,831	240.6	302.2
25-40 years	4,481	1	45	120	280	1,950	224.8	281.2
41-64 years	7,488	1	58	122	330	1,925	256.4	310.9
≥ 65 years	2,769	1	30	90	278	1,719	228.8	304.7
Siponimod	2,286	1	119	300	630	1,946	441.8	426.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	26	27	65	298	464	1,461	337.5	311.0
25-40 years	429	5	113	267	543	1,795	381.9	357.1
41-64 years	1,516	1	120	315	665	1,946	463.6	439.6
≥ 65 years	315	4	97	249	575	1,817	426.9	452.0
Romosozumab-aqqg	87,634	1	4	11	12	990	24.6	68.1
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	3	9	360	49.8	113.7
25-40 years	201	1	2	6	12	486	28.4	80.0
41-64 years	7,993	1	4	9	12	864	34.1	85.4
≥ 65 years	79,409	1	5	11	12	990	23.6	66.0
Erdafitinib	848	1	30	84	148	1,154	116.0	125.6
0-17 years	*****	4	14	70	140	333	98.6	114.4
18-24 years	*****	31	58	112	154	168	105.8	60.9
25-40 years	18	14	56	87	168	224	108.9	72.6

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
41-64 years	195	1	42	90	160	1,149	123.4	123.0
≥ 65 years	624	1	28	84	140	1,154	114.2	128.1
Risankizumab-rzaa	76,821	1	84	196	399	1,997	288.7	292.7
0-17 years	195	1	28	114	280	1,334	207.3	252.4
18-24 years	3,936	1	73	176	361	1,697	250.1	245.1
25-40 years	18,558	1	84	186	364	1,947	270.7	273.7
41-64 years	37,857	1	90	201	420	1,997	302.3	294.0
≥ 65 years	16,275	1	56	182	418	1,888	288.0	318.7
Tafamidis Meglumine	11,217	1	114	228	535	2,010	394.9	413.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	33	124	187	1,264	293.5	479.2
41-64 years	*****	1	104	270	540	1,836	381.6	356.8
≥ 65 years	10,806	1	115	226	534	2,010	395.4	415.3
Alpelisib	6,242	2	28	84	168	1,512	138.3	158.6
0-17 years	78	7	79	242	504	883	304.3	253.4
18-24 years	15	28	56	196	387	709	236.3	190.6
25-40 years	172	4	37	84	168	799	140.4	158.7
41-64 years	2,314	2	43	86	196	1,512	144.1	161.4
≥ 65 years	3,663	3	28	84	168	1,501	130.6	151.7
Polatuzumab Vedotin-piiq	6,512	1	2	4	6	159	4.2	6.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	14	1	2	3	3	6	2.7	1.6

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
25-40 years	117	1	1	2	5	105	4.0	9.6
41-64 years	920	1	1	3	5	126	3.7	6.0
≥ 65 years	5,461	1	2	4	6	159	4.2	5.9
Bremelanotide	2,426	1	15	30	60	814	51.9	61.5
0-17 years	*****	15	15	15	15	15	15.0	*****
18-24 years	43	15	21	30	60	180	51.0	49.2
25-40 years	928	1	15	30	60	390	48.5	52.2
41-64 years	1,437	1	15	30	60	569	54.0	64.3
≥ 65 years	*****	7	15	28	30	814	70.6	191.9
Selinexor	3,486	1	28	56	102	850	85.1	94.7
0-17 years	*****	11	28	42	56	84	42.0	23.5
18-24 years	*****	28	28	56	73	73	52.3	22.7
25-40 years	*****	11	28	56	87	336	74.3	63.5
41-64 years	753	1	28	56	112	840	90.1	98.9
≥ 65 years	2,696	3	28	56	95	850	83.9	93.9
Imipenem, Cilastatin and Relebactam	152	1	2	10	27	686	27.8	64.5
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	10	23	40	80	28.4	25.5
25-40 years	*****	1	3	10	34	686	47.7	129.3
41-64 years	57	1	1	7	22	137	17.7	26.2
≥ 65 years	56	1	3	10	32	172	28.7	42.3
Ferric Maltol	4,069	1	30	87	148	720	105.6	95.1
0-17 years	42	9	30	90	180	717	136.9	152.6

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	276	1	30	60	120	542	94.8	87.3
25-40 years	1,914	1	30	75	121	660	97.4	83.3
41-64 years	1,666	1	30	90	150	720	116.2	104.8
≥ 65 years	171	1	30	84	120	570	102.5	102.3
Darolutamide	9,618	1	72	180	374	1,760	270.2	274.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	157	157	157	157	157	157.0	*****
41-64 years	*****	1	78	180	360	1,538	247.6	224.9
≥ 65 years	8,549	1	70	180	377	1,760	273.0	280.0
Pexidartinib	160	30	60	150	357	1,466	259.2	264.3
0-17 years	*****	30	180	183	240	720	270.6	263.0
18-24 years	17	30	90	137	219	840	208.4	212.8
25-40 years	56	30	81	166	359	1,466	273.9	288.5
41-64 years	73	30	60	150	435	1,124	272.7	268.4
≥ 65 years	*****	30	30	60	270	396	147.3	140.0
Pretomanid	51	3	60	156	182	364	139.7	84.5
0-17 years	*****	10	10	156	190	190	118.7	95.6
18-24 years	*****	30	34	99	184	208	108.8	89.1
25-40 years	15	15	60	106	156	208	109.3	57.6
41-64 years	*****	26	172	182	208	364	178.0	93.3
≥ 65 years	20	3	68	182	192	312	154.6	92.3
Pitolisant	5,055	1	60	139	340	1,892	258.0	306.4

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
0-17 years	48	18	60	180	428	1,705	312.5	349.4
18-24 years	631	1	60	150	360	1,760	260.3	290.9
25-40 years	1,877	2	60	123	316	1,848	235.4	280.0
41-64 years	1,943	1	60	150	362	1,892	276.4	328.4
≥ 65 years	556	3	60	120	330	1,566	262.2	320.5
Entrectinib	602	1	30	81	191	1,576	159.3	208.4
0-17 years	*****	30	240	300	405	420	284.4	130.6
18-24 years	*****	45	53	90	290	459	171.0	194.7
25-40 years	32	3	57	120	240	912	189.4	208.9
41-64 years	223	1	30	90	210	1,548	167.5	214.4
≥ 65 years	336	3	30	60	180	1,576	148.2	205.4
Fedratinib	1,055	2	49	120	295	1,776	237.5	297.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	60	75	480	879	1,156	521.7	467.3
41-64 years	*****	4	60	120	240	1,776	226.2	288.4
≥ 65 years	902	2	39	120	300	1,662	237.5	297.6
Upadacitinib	54,390	1	75	180	386	1,948	282.3	297.2
0-17 years	738	2	60	172	332	1,628	227.1	203.6
18-24 years	2,209	1	60	150	300	1,518	215.7	205.0
25-40 years	8,252	1	61	150	320	1,815	230.1	232.5
41-64 years	29,770	1	83	180	390	1,948	287.5	300.6
≥ 65 years	13,421	1	75	183	448	1,834	316.8	333.8

Table 3f. Continuous Summary of Patients' Cumulative Treatment Episode Durations for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of Cumulative Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Lefamulin	209	1	5	5	7	93	7.7	9.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	5	5	5	49	49	19.7	25.4
25-40 years	*****	1	5	5	14	30	8.5	7.5
41-64 years	80	1	5	5	10	93	9.3	14.0
≥ 65 years	107	1	5	5	7	26	6.0	4.0
Ga-68-DOTATOC	358	1	1	1	1	6	1.3	0.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	*****
25-40 years	*****	1	1	1	1	2	1.1	0.3
41-64 years	90	1	1	1	1	4	1.2	0.5
≥ 65 years	252	1	1	1	1	6	1.4	0.8
Istradefylline	6,005	1	60	180	473	1,832	324.9	359.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	18	30	49	198	386	1,290	312.5	368.6
41-64 years	856	2	60	173	439	1,760	310.7	352.5
≥ 65 years	5,131	1	60	180	480	1,832	327.3	360.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>PrabotulinumtoxinA-xvfs</i>	11	11	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Caplacizumab-yhdp</i>	635	547	86.1%	73	11.5%	*****	*****	*****	*****	0	0.0%
<i>Triclabendazole</i>	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Brexanolone</i>	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Solriamfetol</i>	65,731	44,407	67.6%	15,159	23.1%	5,255	8.0%	639	1.0%	271	0.4%
<i>Siponimod</i>	8,469	3,741	44.2%	2,319	27.4%	1,848	21.8%	378	4.5%	183	2.2%
<i>Romosozumab-aqqg</i>	679,745	670,079	98.6%	6,090	0.9%	3,387	0.5%	*****	*****	*****	*****
<i>Erdafitinib</i>	1,869	1,163	62.2%	486	26.0%	*****	*****	*****	*****	*****	*****
<i>Risankizumab-rzaa</i>	242,622	80,555	33.2%	105,915	43.7%	47,695	19.7%	6,776	2.8%	1,681	0.7%
<i>Tafamidis Meglumine</i>	29,291	9,962	34.0%	7,937	27.1%	8,600	29.4%	1,854	6.3%	938	3.2%
<i>Alpelisib</i>	13,819	8,290	60.0%	3,420	24.7%	1,933	14.0%	155	1.1%	21	0.2%
<i>Polatuzumab Vedotin-piiq</i>	24,599	24,574	99.9%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Bremelanotide</i>	4,208	3,573	84.9%	524	12.5%	111	2.6%	0	0.0%	0	0.0%
<i>Selinexor</i>	6,671	4,561	68.4%	1,639	24.6%	459	6.9%	12	0.2%	0	0.0%
<i>Imipenem, Cilastatin and Relebactam</i>	438	409	93.4%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Ferric Maltol</i>	5,968	2,956	49.5%	1,748	29.3%	1,229	20.6%	35	0.6%	0	0.0%
<i>Darolutamide</i>	30,357	15,659	51.6%	7,995	26.3%	5,745	18.9%	801	2.6%	157	0.5%
<i>Pexidartinib</i>	649	400	61.6%	160	24.7%	*****	*****	*****	*****	*****	*****
<i>Pretomanid</i>	122	62	50.8%	36	29.5%	24	19.7%	0	0.0%	0	0.0%
<i>Pitolisant</i>	13,556	6,835	50.4%	3,584	26.4%	2,517	18.6%	450	3.3%	170	1.3%
<i>Entrectinib</i>	1,448	910	62.8%	333	23.0%	173	11.9%	*****	*****	*****	*****

Table 4a. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

		Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
Total Number of Episodes		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Fedratinib	3,331	1,915	57.5%	832	25.0%	501	15.0%	62	1.9%	21	0.6%
Upadacitinib	183,200	96,207	52.5%	49,858	27.2%	31,480	17.2%	4,510	2.5%	1,145	0.6%
Lefamulin	358	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
Ga-68-DOTATOC	473	473	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Istradefylline	14,046	5,523	39.3%	3,921	27.9%	3,386	24.1%	843	6.0%	373	2.7%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>PrabotulinumtoxinA-xvfs</i>	11	1	1	1	1	1	1.0	0.0
<i>Caplacizumab-yhdp</i>	635	1	1	10	30	600	23.1	47.0
<i>Triclabendazole</i>	*****	2	2	2	2	2	2.0	0.0
<i>Brexanolone</i>	*****	1	1	3	3	30	2.3	2.4
<i>Solriamfetol</i>	65,731	1	30	30	60	1,785	58.7	90.9
<i>Siponimod</i>	8,469	1	30	60	120	1,763	119.2	190.6
<i>Romosozumab-aqqg</i>	679,745	1	1	1	1	910	3.2	17.7
<i>Erdafitinib</i>	1,869	1	28	28	56	998	52.6	56.6
<i>Risankizumab-rzaa</i>	242,622	1	28	56	84	1,997	91.4	124.9
<i>Tafamidis Meglumine</i>	29,291	1	30	76	164	2,010	151.2	219.8
<i>Alpelisib</i>	13,819	1	28	28	56	1,512	62.5	80.7
<i>Polatuzumab Vedotin-piiq</i>	24,599	1	1	1	1	126	1.1	2.3
<i>Bremelanotide</i>	4,208	1	15	23	30	360	29.9	29.0
<i>Selinexor</i>	6,671	1	28	28	56	616	44.4	39.9
<i>Imipenem, Cilastatin and Relebactam</i>	438	1	1	1	9	310	9.7	24.0
<i>Ferric Maltol</i>	5,968	1	30	35	90	720	72.0	69.3
<i>Darolutamide</i>	30,357	1	30	30	90	1,760	85.6	116.3
<i>Pexidartinib</i>	649	1	30	30	60	857	63.9	82.9
<i>Pretomanid</i>	122	3	26	30	78	338	58.4	52.3
<i>Pitolisant</i>	13,556	1	30	30	90	1,760	96.2	150.9
<i>Entrectinib</i>	1,448	1	30	30	60	1,246	66.2	98.6
<i>Fedratinib</i>	3,331	1	30	30	72	1,260	75.2	109.2
<i>Upadacitinib</i>	183,200	1	30	30	90	1,948	83.8	119.3
<i>Lefamulin</i>	358	1	1	5	5	70	4.5	5.9
<i>Ga-68-DOTATOC</i>	473	1	1	1	1	1	1.0	0.0

Table 4b. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Istradefylline</i>	14,046	1	30	60	150	1,718	138.9	200.4

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
PrabotulinumtoxinA-xvfs	11	11	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Caplacizumab-yhdp	635	547	100.0%	73	100.0%	*****	100.0%	*****	100.0%	0	NaN
Female	408	353	64.5%	*****	*****	*****	54.5%	*****	50.0%	0	NaN
Male	227	194	35.5%	*****	*****	*****	45.5%	*****	50.0%	0	NaN
Triclabendazole	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Brexanolone	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Solriamfetol	65,731	44,407	100.0%	15,159	100.0%	5,255	100.0%	639	100.0%	271	100.0%
Female	40,601	27,535	62.0%	9,328	61.5%	3,233	61.5%	346	54.1%	159	58.7%
Male	25,130	16,872	38.0%	5,831	38.5%	2,022	38.5%	293	45.9%	112	41.3%
Siponimod	8,469	3,741	100.0%	2,319	100.0%	1,848	100.0%	378	100.0%	183	100.0%
Female	6,227	2,730	73.0%	1,696	73.1%	1,373	74.3%	285	75.4%	143	78.1%
Male	2,242	1,011	27.0%	623	26.9%	475	25.7%	93	24.6%	40	21.9%
Romosozumab-aqqg	679,745	670,079	100.0%	6,090	100.0%	3,387	100.0%	*****	100.0%	*****	100.0%
Female	667,436	658,075	98.2%	5,902	96.9%	*****	*****	*****	95.2%	*****	100.0%
Male	12,309	12,004	1.8%	188	3.1%	*****	*****	*****	4.8%	0	0.0%

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Erdafitinib	1,869	1,163	100.0%	486	100.0%	*****	100.0%	*****	100.0%	*****	100.0%
Female	721	461	39.6%	190	39.1%	*****	32.4%	*****	22.2%	*****	0.0%
Male	1,148	702	60.4%	296	60.9%	*****	67.6%	*****	77.8%	*****	100.0%
Risankizumab-rzaa	242,622	80,555	100.0%	105,915	100.0%	47,695	100.0%	6,776	100.0%	1,681	100.0%
Female	119,098	40,834	50.7%	49,892	47.1%	24,127	50.6%	3,398	50.1%	847	50.4%
Male	123,524	39,721	49.3%	56,023	52.9%	23,568	49.4%	3,378	49.9%	834	49.6%
Tafamidis Meglumine	29,291	9,962	100.0%	7,937	100.0%	8,600	100.0%	1,854	100.0%	938	100.0%
Female	5,640	2,121	21.3%	1,586	20.0%	1,471	17.1%	318	17.2%	144	15.4%
Male	23,651	7,841	78.7%	6,351	80.0%	7,129	82.9%	1,536	82.8%	794	84.6%
Alpelisib	13,819	8,290	100.0%	3,420	100.0%	1,933	100.0%	155	100.0%	21	100.0%
Female	13,304	7,982	96.3%	3,282	96.0%	*****	*****	*****	*****	*****	*****
Male	515	308	3.7%	138	4.0%	*****	*****	*****	*****	*****	*****
Polatuzumab Vedotin-piiq	24,599	24,574	100.0%	*****	100.0%	*****	100.0%	0	NaN	0	NaN
Female	10,644	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	13,955	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Bremelanotide	4,208	3,573	100.0%	524	100.0%	111	100.0%	0	NaN	0	NaN
Female	4,100	3,484	97.5%	*****	*****	*****	*****	0	NaN	0	NaN
Male	108	89	2.5%	*****	*****	*****	*****	0	NaN	0	NaN
Selinexor	6,671	4,561	100.0%	1,639	100.0%	459	100.0%	12	100.0%	0	NaN
Female	3,244	2,209	48.4%	790	48.2%	*****	*****	*****	*****	0	NaN

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	3,427	2,352	51.6%	849	51.8%	*****	*****	*****	*****	0	NaN
Imipenem, Cilastatin and Relebactam	438	409	100.0%	*****	100.0%	*****	100.0%	0	NaN	0	NaN
Female	271	*****	*****	*****	34.8%	*****	16.7%	0	NaN	0	NaN
Male	167	*****	*****	*****	65.2%	*****	83.3%	0	NaN	0	NaN
Ferric Maltol	5,968	2,956	100.0%	1,748	100.0%	1,229	100.0%	35	100.0%	0	NaN
Female	5,534	2,739	92.7%	1,610	92.1%	*****	*****	*****	*****	0	NaN
Male	434	217	7.3%	138	7.9%	*****	*****	*****	*****	0	NaN
Darolutamide	30,357	15,659	100.0%	7,995	100.0%	5,745	100.0%	801	100.0%	157	100.0%
Female	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
Male	*****	15,659	100.0%	*****	*****	5,745	100.0%	801	100.0%	157	100.0%
Pexidartinib	649	400	100.0%	160	100.0%	*****	100.0%	*****	100.0%	*****	100.0%
Female	413	248	62.0%	107	66.9%	*****	64.3%	*****	50.0%	*****	100.0%
Male	236	152	38.0%	53	33.1%	*****	*****	*****	50.0%	0	0.0%
Pretomanid	122	62	*****	36	100.0%	24	100.0%	0	NaN	0	NaN
Female	71	40	64.5%	18	50.0%	13	54.2%	0	NaN	0	NaN
Male	51	22	35.5%	18	50.0%	11	45.8%	0	NaN	0	NaN
Pitolisant	13,556	6,835	100.0%	3,584	100.0%	2,517	100.0%	450	100.0%	170	100.0%
Female	9,367	4,781	69.9%	2,450	68.4%	1,709	67.9%	310	68.9%	117	68.8%
Male	4,189	2,054	30.1%	1,134	31.6%	808	32.1%	140	31.1%	53	31.2%
Entrectinib	1,448	910	100.0%	333	100.0%	173	100.0%	*****	100.0%	*****	100.0%
Female	893	563	61.9%	202	60.7%	*****	*****	*****	*****	*****	*****

Table 4c. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	555	347	38.1%	131	39.3%	*****	*****	*****	*****	*****	*****
Fedratinib	3,331	1,915	100.0%	832	100.0%	501	100.0%	62	100.0%	21	100.0%
Female	1,663	980	51.2%	412	49.5%	232	46.3%	*****	*****	*****	*****
Male	1,668	935	48.8%	420	50.5%	269	53.7%	*****	*****	*****	*****
Upadacitinib	183,200	96,207	100.0%	49,858	100.0%	31,480	100.0%	4,510	100.0%	1,145	100.0%
Female	136,523	72,260	75.1%	37,147	74.5%	23,024	73.1%	3,230	71.6%	862	75.3%
Male	46,677	23,947	24.9%	12,711	25.5%	8,456	26.9%	1,280	28.4%	283	24.7%
Lefamulin	358	*****	100.0%	*****	100.0%	0	NaN	0	NaN	0	NaN
Female	206	*****	57.6%	*****	50.0%	0	NaN	0	NaN	0	NaN
Male	152	*****	42.4%	*****	50.0%	0	NaN	0	NaN	0	NaN
Ga-68-DOTATOC	473	473	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	252	252	53.3%	0	NaN	0	NaN	0	NaN	0	NaN
Male	221	221	46.7%	0	NaN	0	NaN	0	NaN	0	NaN
Istradefylline	14,046	5,523	100.0%	3,921	100.0%	3,386	100.0%	843	100.0%	373	100.0%
Female	5,803	2,382	43.1%	1,549	39.5%	1,384	40.9%	342	40.6%	146	39.1%
Male	8,243	3,141	56.9%	2,372	60.5%	2,002	59.1%	501	59.4%	227	60.9%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
PrabotulinumtoxinA-xvfs	11	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Caplacizumab-yhdp	635	1	1	10	30	600	23.1	47.0
Female	408	1	1	17	30	600	23.9	49.2
Male	227	1	1	4	30	390	21.8	42.9
Triclabendazole	*****	2	2	2	2	2	2.0	0.0
Female	*****	2	2	2	2	2	2.0	0.0
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Brexanolone	*****	1	1	3	3	30	2.3	2.4
Female	*****	1	1	3	3	30	2.4	2.4
Male	*****	1	1	1	1	1	1.0	0.0
Solriamfetol	65,731	1	30	30	60	1,785	58.7	90.9
Female	40,601	1	30	30	60	1,682	57.5	88.0
Male	25,130	1	30	30	60	1,785	60.5	95.4
Siponimod	8,469	1	30	60	120	1,763	119.2	190.6
Female	6,227	1	30	60	120	1,763	121.7	195.8
Male	2,242	1	30	60	120	1,705	112.4	175.0
Romosozumab-aqqg	679,745	1	1	1	1	910	3.2	17.7
Female	667,436	1	1	1	1	910	3.1	17.5
Male	12,309	1	1	1	1	689	5.0	24.8
Erdafitinib	1,869	1	28	28	56	998	52.6	56.6
Female	721	1	28	28	56	448	48.4	45.7
Male	1,148	1	28	28	56	998	55.3	62.4

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Risankizumab-rzaa	242,622	1	28	56	84	1,997	91.4	124.9
Female	119,098	1	28	56	84	1,997	92.1	126.3
Male	123,524	1	30	56	84	1,831	90.8	123.7
Tafamidis Meglumine	29,291	1	30	76	164	2,010	151.2	219.8
Female	5,640	1	30	60	150	1,899	135.4	195.7
Male	23,651	1	30	87	172	2,010	155.0	225.0
Alpelisib	13,819	1	28	28	56	1,512	62.5	80.7
Female	13,304	1	28	28	56	1,512	62.5	80.8
Male	515	2	28	28	56	801	61.2	78.9
Polatuzumab Vedotin-piiq	24,599	1	1	1	1	126	1.1	2.3
Female	10,644	1	1	1	1	105	1.1	1.8
Male	13,955	1	1	1	1	126	1.1	2.6
Bremelanotide	4,208	1	15	23	30	360	29.9	29.0
Female	4,100	1	15	23	30	360	29.8	28.1
Male	108	1	15	15	30	330	36.7	52.7
Selinexor	6,671	1	28	28	56	616	44.4	39.9
Female	3,244	1	28	28	56	544	45.0	40.6
Male	3,427	1	28	28	56	616	43.9	39.1
Imipenem, Cilastatin and Relebactam	438	1	1	1	9	310	9.7	24.0
Female	271	1	1	1	7	145	6.3	13.5
Male	167	1	1	5	14	310	15.2	34.2
Ferric Maltol	5,968	1	30	35	90	720	72.0	69.3
Female	5,534	1	30	35	90	720	72.2	69.8
Male	434	1	30	32	90	368	68.7	62.6

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Darolutamide	30,357	1	30	30	90	1,760	85.6	116.3
Female	*****	60	60	60	60	60	60.0	*****
Male	*****	1	30	30	90	1,760	85.6	116.4
Pexidartinib	649	1	30	30	60	857	63.9	82.9
Female	413	1	30	30	60	857	65.8	89.4
Male	236	6	30	30	60	599	60.6	70.1
Pretomanid	122	3	26	30	78	338	58.4	52.3
Female	71	4	26	26	56	182	54.1	47.3
Male	51	3	26	52	78	338	64.3	58.5
Pitolisant	13,556	1	30	30	90	1,760	96.2	150.9
Female	9,367	1	30	30	90	1,678	94.9	147.7
Male	4,189	1	30	40	90	1,760	99.1	158.0
Entrectinib	1,448	1	30	30	60	1,246	66.2	98.6
Female	893	2	30	30	60	1,170	68.0	102.0
Male	555	1	30	30	60	1,246	63.3	93.0
Fedratinib	3,331	1	30	30	72	1,260	75.2	109.2
Female	1,663	1	30	30	60	1,260	74.3	112.6
Male	1,668	2	30	30	90	1,257	76.2	105.8
Upadacitinib	183,200	1	30	30	90	1,948	83.8	119.3
Female	136,523	1	30	30	90	1,834	83.0	118.6
Male	46,677	1	30	30	90	1,948	86.1	121.1
Lefamulin	358	1	1	5	5	70	4.5	5.9
Female	206	1	1	5	5	70	4.7	6.3
Male	152	1	1	3	5	55	4.2	5.5

Table 4d. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Ga-68-DOTATOC	473	1	1	1	1	1	1.0	0.0
Female	252	1	1	1	1	1	1.0	0.0
Male	221	1	1	1	1	1	1.0	0.0
Istradefylline	14,046	1	30	60	150	1,718	138.9	200.4
Female	5,803	1	30	60	150	1,613	135.3	193.6
Male	8,243	1	30	60	150	1,718	141.4	205.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
 Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
PrabotulinumtoxinA-xvfs	11	11	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Caplacizumab-yhdp	635	547	100.0%	73	100.0%	*****	100.0%	*****	100.0%	0	NaN
0-17 years	11	*****	*****	*****	*****	*****	9.1%	0	0.0%	0	NaN
18-24 years	40	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	147	120	21.9%	*****	*****	*****	27.3%	*****	50.0%	0	NaN
41-64 years	273	231	42.2%	*****	*****	*****	36.4%	*****	50.0%	0	NaN
≥ 65 years	164	152	27.8%	*****	*****	*****	27.3%	0	0.0%	0	NaN
Triclabendazole	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	50.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	50.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Brexanolone	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	20	20	*****	0	NaN	0	NaN	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	135	135	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Solriamfetol	65,731	44,407	100.0%	15,159	100.0%	5,255	100.0%	639	100.0%	271	100.0%
0-17 years	330	231	0.5%	65	0.4%	*****	*****	*****	*****	*****	*****
18-24 years	4,966	3,582	8.1%	1,008	6.6%	*****	*****	*****	*****	*****	*****
25-40 years	18,066	12,529	28.2%	4,003	26.4%	1,308	24.9%	154	24.1%	72	26.6%
41-64 years	32,067	21,474	48.4%	7,430	49.0%	2,686	51.1%	340	53.2%	137	50.6%
≥ 65 years	10,302	6,591	14.8%	2,653	17.5%	924	17.6%	97	15.2%	37	13.7%
Siponimod	8,469	3,741	100.0%	2,319	100.0%	1,848	100.0%	378	100.0%	183	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	76	34	0.9%	*****	*****	23	1.2%	0	0.0%	*****	*****
25-40 years	1,575	758	20.3%	412	17.8%	327	17.7%	52	13.8%	26	14.2%
41-64 years	5,784	2,560	68.4%	1,571	67.7%	1,241	67.2%	281	74.3%	131	71.6%
≥ 65 years	1,034	389	10.4%	*****	*****	257	13.9%	45	11.9%	*****	*****
Romosozumab-aqqg	679,745	670,079	100.0%	6,090	100.0%	3,387	100.0%	*****	100.0%	*****	100.0%
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	11	0.2%	*****	*****	0	0.0%	0	0.0%
25-40 years	1,125	1,091	0.2%	22	0.4%	*****	*****	*****	0.5%	0	0.0%
41-64 years	54,426	53,004	7.9%	882	14.5%	517	15.3%	23	12.3%	0	0.0%
≥ 65 years	624,081	615,883	91.9%	5,175	85.0%	2,858	84.4%	*****	87.2%	*****	100.0%

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Erdafitinib	1,869	1,163	100.0%	486	100.0%	*****	100.0%	*****	100.0%	*****	100.0%
0-17 years	*****	*****	*****	*****	*****	*****	1.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	0.5%	0	0.0%	0	0.0%
25-40 years	30	15	1.3%	*****	*****	*****	2.9%	0	0.0%	0	0.0%
41-64 years	406	222	19.1%	118	24.3%	*****	30.5%	*****	22.2%	0	0.0%
≥ 65 years	1,412	912	78.4%	355	73.0%	*****	65.2%	*****	77.8%	*****	100.0%
Risankizumab-rzaa	242,622	80,555	100.0%	105,915	100.0%	47,695	100.0%	6,776	100.0%	1,681	100.0%
0-17 years	697	351	0.4%	242	0.2%	*****	*****	*****	*****	*****	*****
18-24 years	13,384	5,006	6.2%	5,899	5.6%	*****	*****	*****	*****	*****	*****
25-40 years	61,364	20,434	25.4%	28,468	26.9%	10,877	22.8%	1,325	19.6%	260	15.5%
41-64 years	124,188	39,289	48.8%	56,401	53.3%	24,142	50.6%	3,480	51.4%	876	52.1%
≥ 65 years	42,989	15,475	19.2%	14,905	14.1%	10,363	21.7%	1,735	25.6%	511	30.4%
Tafamidis Meglumine	29,291	9,962	100.0%	7,937	100.0%	8,600	100.0%	1,854	100.0%	938	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	11	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
41-64 years	1,206	*****	*****	*****	*****	*****	*****	68	3.7%	*****	*****
≥ 65 years	28,074	9,435	94.7%	7,624	96.1%	8,322	96.8%	1,786	96.3%	907	96.7%
Alpelisib	13,819	8,290	100.0%	3,420	100.0%	1,933	100.0%	155	100.0%	21	100.0%
0-17 years	380	233	2.8%	96	2.8%	44	2.3%	*****	*****	*****	*****
18-24 years	54	31	0.4%	*****	*****	*****	*****	*****	*****	0	0.0%

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	393	239	2.9%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	5,120	3,032	36.6%	1,258	36.8%	754	39.0%	*****	*****	*****	*****
≥ 65 years	7,872	4,755	57.4%	1,957	57.2%	1,074	55.6%	*****	*****	*****	*****
piiq	24,599	24,574	100.0%	*****	100.0%	*****	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	38	38	0.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	360	*****	*****	*****	9.1%	0	0.0%	0	NaN	0	NaN
41-64 years	3,072	*****	*****	*****	13.6%	*****	33.3%	0	NaN	0	NaN
≥ 65 years	21,129	21,110	85.9%	*****	77.3%	*****	66.7%	0	NaN	0	NaN
Bremelanotide	4,208	3,573	100.0%	524	100.0%	111	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	56	1.6%	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	1,484	1,259	35.2%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	2,612	2,221	62.2%	322	61.5%	69	62.2%	0	NaN	0	NaN
≥ 65 years	43	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Selinexor	6,671	4,561	100.0%	1,639	100.0%	459	100.0%	12	100.0%	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	52	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	1,476	988	21.7%	373	22.8%	*****	*****	*****	*****	0	NaN
≥ 65 years	5,130	3,522	77.2%	1,255	76.6%	*****	*****	*****	*****	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Imipenem, Cilastatin and Relebactam	438	409	100.0%	*****	100.0%	*****	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	8.7%	0	0.0%	0	NaN	0	NaN
25-40 years	90	*****	*****	*****	21.7%	*****	*****	0	NaN	0	NaN
41-64 years	219	*****	*****	*****	21.7%	0	0.0%	0	NaN	0	NaN
≥ 65 years	106	93	22.7%	*****	47.8%	*****	*****	0	NaN	0	NaN
Ferric Maltol	5,968	2,956	100.0%	1,748	100.0%	1,229	100.0%	35	100.0%	0	NaN
0-17 years	58	26	0.9%	16	0.9%	*****	*****	*****	*****	0	NaN
18-24 years	386	215	7.3%	106	6.1%	*****	*****	*****	*****	0	NaN
25-40 years	2,610	1,262	42.7%	766	43.8%	*****	*****	*****	*****	0	NaN
41-64 years	2,614	1,275	43.1%	766	43.8%	553	45.0%	20	57.1%	0	NaN
≥ 65 years	300	178	6.0%	94	5.4%	*****	*****	*****	*****	0	NaN
Darolutamide	30,357	15,659	100.0%	7,995	100.0%	5,745	100.0%	801	100.0%	157	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	784	9.8%	*****	*****	110	13.7%	13	8.3%
≥ 65 years	27,172	13,929	89.0%	7,211	90.2%	5,197	90.5%	691	86.3%	144	91.7%
Pexidartinib	649	400	100.0%	160	100.0%	*****	100.0%	*****	100.0%	*****	100.0%
0-17 years	15	*****	*****	*****	*****	*****	6.0%	0	0.0%	0	0.0%
18-24 years	53	26	6.5%	*****	*****	*****	7.1%	*****	50.0%	0	0.0%

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	228	140	35.0%	51	31.9%	*****	41.7%	0	0.0%	*****	66.7%
41-64 years	326	206	51.5%	83	51.9%	*****	41.7%	*****	50.0%	*****	33.3%
≥ 65 years	27	*****	*****	*****	*****	*****	3.6%	0	0.0%	0	0.0%
Pretomanid	122	62	100.0%	36	100.0%	24	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	33	17	27.4%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	20	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	57	30	48.4%	*****	*****	*****	*****	0	NaN	0	NaN
Pitolisant	13,556	6,835	100.0%	3,584	100.0%	2,517	100.0%	450	100.0%	170	100.0%
0-17 years	101	43	0.6%	22	0.6%	24	1.0%	*****	*****	*****	*****
18-24 years	1,805	982	14.4%	440	12.3%	310	12.3%	*****	*****	*****	*****
25-40 years	5,075	2,669	39.0%	1,344	37.5%	881	35.0%	133	29.6%	48	28.2%
41-64 years	5,162	2,551	37.3%	1,355	37.8%	970	38.5%	200	44.4%	86	50.6%
≥ 65 years	1,413	590	8.6%	423	11.8%	332	13.2%	59	13.1%	*****	5.3%
Entrectinib	1,448	910	100.0%	333	100.0%	173	100.0%	*****	100.0%	*****	100.0%
0-17 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	0.0%
25-40 years	80	50	5.5%	16	4.8%	*****	*****	*****	*****	*****	*****
41-64 years	557	329	36.2%	142	42.6%	74	42.8%	*****	*****	*****	*****
≥ 65 years	780	513	56.4%	170	51.1%	81	46.8%	*****	*****	*****	*****

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Fedratinib	3,331	1,915	100.0%	832	100.0%	501	100.0%	62	100.0%	21	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	44	26	1.4%	*****	*****	*****	*****	*****	*****	0	0.0%
41-64 years	491	302	15.8%	*****	*****	*****	*****	*****	*****	*****	*****
≥ 65 years	2,796	1,587	82.9%	699	84.0%	438	87.4%	*****	*****	*****	*****
Upadacitinib	183,200	96,207	100.0%	49,858	100.0%	31,480	100.0%	4,510	100.0%	1,145	100.0%
0-17 years	2,022	1,028	1.1%	572	1.1%	359	1.1%	*****	*****	*****	*****
18-24 years	6,772	3,908	4.1%	1,711	3.4%	1,025	3.3%	*****	*****	*****	*****
25-40 years	25,785	14,431	15.0%	6,788	13.6%	3,994	12.7%	500	11.1%	72	6.3%
41-64 years	102,993	54,681	56.8%	27,833	55.8%	17,347	55.1%	2,460	54.5%	672	58.7%
≥ 65 years	45,628	22,159	23.0%	12,954	26.0%	8,755	27.8%	1,383	30.7%	377	32.9%
Lefamulin	358	*****	100.0%	*****	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	189	187	*****	*****	100.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	140	140	*****	0	0.0%	0	NaN	0	NaN	0	NaN
Ga-68-DOTATOC	473	473	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN

Table 4e. Categorical Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	110	110	23.3%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	346	346	73.2%	0	NaN	0	NaN	0	NaN	0	NaN
Istradefylline	14,046	5,523	100.0%	3,921	100.0%	3,386	100.0%	843	100.0%	373	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	40	13	0.2%	11	0.3%	*****	*****	0	0.0%	*****	*****
41-64 years	2,034	843	15.3%	566	14.4%	*****	*****	116	13.8%	*****	*****
≥ 65 years	11,972	4,667	84.5%	3,344	85.3%	2,908	85.9%	727	86.2%	326	87.4%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
PrabotulinumtoxinA-xvfs	*****	1	1	1	1	1	1.0	0.0
0-17 years	*****	1	1	1	1	1	1.0	*****
18-24 years	*****	1	1	1	1	1	1.0	*****
25-40 years	*****	1	1	1	1	1	1.0	0.0
41-64 years	*****	1	1	1	1	1	1.0	0.0
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Caplacizumab-yhdp	635	1	1	10	30	600	23.1	47.0
0-17 years	11	1	1	28	58	98	33.0	32.2
18-24 years	40	1	1	5	25	58	13.3	15.5
25-40 years	147	1	4	28	30	390	31.6	52.5
41-64 years	273	1	1	21	30	600	25.9	54.7
≥ 65 years	164	1	1	1	21	254	12.6	28.1
Triclabendazole	*****	2	2	2	2	2	2.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	2	2	2	2	2	2.0	*****
25-40 years	*****	2	2	2	2	2	2.0	*****
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Brexanolone	*****	1	1	3	3	30	2.3	2.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	20	1	2	3	3	3	2.5	0.9
25-40 years	135	1	1	3	3	30	2.4	2.6
41-64 years	*****	1	1	2	3	3	1.8	1.0
≥ 65 years	*****	1	1	1	1	1	1.0	0.0

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Solriamfetol	65,731	1	30	30	60	1,785	58.7	90.9
0-17 years	330	1	30	30	60	1,327	65.7	134.8
18-24 years	4,966	1	30	30	60	1,785	55.0	95.0
25-40 years	18,066	1	30	30	60	1,634	55.8	86.4
41-64 years	32,067	1	30	30	60	1,635	59.9	93.6
≥ 65 years	10,302	1	30	30	60	1,640	61.5	86.4
Siponimod	8,469	1	30	60	120	1,763	119.2	190.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	76	5	30	58	168	1,461	115.5	183.5
25-40 years	1,575	1	30	40	99	1,705	104.0	162.8
41-64 years	5,784	1	30	60	120	1,763	121.5	195.1
≥ 65 years	1,034	3	30	60	144	1,748	130.0	202.9
Romosozumab-aqqg	679,745	1	1	1	1	910	3.2	17.7
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	230	13.0	29.8
25-40 years	1,125	1	1	1	1	390	5.1	23.6
41-64 years	54,426	1	1	1	1	480	5.0	23.3
≥ 65 years	624,081	1	1	1	1	910	3.0	17.0
Erdafitinib	1,869	1	28	28	56	998	52.6	56.6
0-17 years	*****	4	21	30	50	303	57.5	82.6
18-24 years	*****	28	28	28	56	112	47.0	31.1
25-40 years	30	4	28	43	84	224	65.4	55.2
41-64 years	406	1	28	30	84	460	59.3	58.8
≥ 65 years	1,412	1	28	28	56	998	50.5	55.8

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Risankizumab-rzaa	242,622	1	28	56	84	1,997	91.4	124.9
0-17 years	697	1	1	30	84	1,250	58.0	98.8
18-24 years	13,384	1	28	31	84	1,679	73.6	96.6
25-40 years	61,364	1	30	41	84	1,831	81.9	109.5
41-64 years	124,188	1	30	56	84	1,997	92.1	124.6
≥ 65 years	42,989	1	28	84	112	1,791	109.0	150.0
Tafamidis Meglumine	29,291	1	30	76	164	2,010	151.2	219.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	11	30	30	30	97	1,264	160.1	368.4
41-64 years	1,206	1	30	60	128	1,578	128.1	190.3
≥ 65 years	28,074	1	30	80	166	2,010	152.2	220.8
Alpelisib	13,819	1	28	28	56	1,512	62.5	80.7
0-17 years	380	2	28	28	56	855	62.5	93.7
18-24 years	54	21	28	28	56	513	65.6	92.4
25-40 years	393	2	28	28	56	644	61.5	75.3
41-64 years	5,120	1	28	28	56	1,512	65.1	90.3
≥ 65 years	7,872	2	28	28	56	1,148	60.8	73.3
Polatuzumab Vedotin-piiq	24,599	1	1	1	1	126	1.1	2.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	38	1	1	1	1	1	1.0	0.0
25-40 years	360	1	1	1	1	63	1.3	3.9
41-64 years	3,072	1	1	1	1	112	1.1	2.6
≥ 65 years	21,129	1	1	1	1	126	1.1	2.2

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Bremelanotide	4,208	1	15	23	30	360	29.9	29.0
0-17 years	*****	15	15	15	15	15	15.0	*****
18-24 years	*****	10	15	23	30	168	32.2	29.5
25-40 years	1,484	1	15	28	30	360	30.3	28.3
41-64 years	2,612	1	15	23	30	360	29.7	29.1
≥ 65 years	43	7	15	15	28	280	27.9	41.3
Selinexor	6,671	1	28	28	56	616	44.4	39.9
0-17 years	*****	11	21	28	28	84	32.7	23.0
18-24 years	*****	28	28	28	51	73	39.3	22.5
25-40 years	52	7	28	28	29	168	38.6	28.9
41-64 years	1,476	1	28	28	56	616	46.0	45.5
≥ 65 years	5,130	2	28	28	56	504	44.1	38.2
Imipenem, Cilastatin and Relebactam	438	1	1	1	9	310	9.7	24.0
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	6	18	47	10.8	13.0
25-40 years	90	1	1	5	13	310	15.4	40.1
41-64 years	219	1	1	1	5	87	4.6	9.7
≥ 65 years	106	1	1	7	14	172	15.2	26.2
Ferric Maltol	5,968	1	30	35	90	720	72.0	69.3
0-17 years	58	9	30	58	98	717	99.2	131.3
18-24 years	386	1	30	30	90	368	67.7	67.3
25-40 years	2,610	1	30	42	90	570	71.5	65.7
41-64 years	2,614	1	30	39	90	720	74.1	72.5
≥ 65 years	300	1	30	30	90	374	58.4	53.9

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Darolutamide	30,357	1	30	30	90	1,760	85.6	116.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	28	28	79	129	129	78.5	71.4
41-64 years	*****	1	30	30	90	1,538	83.1	117.3
≥ 65 years	27,172	1	30	30	90	1,760	85.9	116.2
Pexidartinib	649	1	30	30	60	857	63.9	82.9
0-17 years	15	30	30	33	150	330	90.2	87.0
18-24 years	53	2	30	58	79	599	66.8	84.1
25-40 years	228	11	30	30	60	857	67.3	92.0
41-64 years	326	1	30	30	60	734	61.1	77.7
≥ 65 years	27	6	30	30	30	270	49.1	53.2
Pretomanid	122	3	26	30	78	338	58.4	52.3
0-17 years	*****	10	18	91	160	164	89.0	82.3
18-24 years	*****	4	19	28	78	182	54.4	60.2
25-40 years	33	15	26	26	52	144	49.7	35.5
41-64 years	20	26	26	52	104	338	80.1	79.0
≥ 65 years	57	3	26	30	72	182	54.2	44.2
Pitolisant	13,556	1	30	30	90	1,760	96.2	150.9
0-17 years	101	14	30	60	150	1,323	148.5	212.2
18-24 years	1,805	1	30	30	90	1,760	91.0	152.6
25-40 years	5,075	1	30	30	90	1,650	87.1	134.7
41-64 years	5,162	1	30	37	90	1,678	104.1	167.9
≥ 65 years	1,413	2	30	60	120	1,140	103.2	129.2

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Entrectinib	1,448	1	30	30	60	1,246	66.2	98.6
0-17 years	*****	28	30	30	90	420	76.6	89.7
18-24 years	*****	30	30	45	120	459	136.8	183.9
25-40 years	80	3	30	30	60	882	75.8	125.2
41-64 years	557	1	30	30	60	1,170	67.1	100.0
≥ 65 years	780	3	30	30	60	1,246	63.8	94.1
Fedratinib	3,331	1	30	30	72	1,260	75.2	109.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	44	15	30	30	60	690	71.1	121.2
41-64 years	491	1	30	30	60	1,075	67.7	103.1
≥ 65 years	2,796	1	30	30	83	1,260	76.6	110.1
Upadacitinib	183,200	1	30	30	90	1,948	83.8	119.3
0-17 years	2,022	1	30	30	90	985	82.9	107.0
18-24 years	6,772	1	30	30	70	1,462	70.4	92.3
25-40 years	25,785	1	30	30	85	1,785	73.6	98.7
41-64 years	102,993	1	30	30	90	1,948	83.1	119.6
≥ 65 years	45,628	1	30	50	90	1,834	93.2	131.9
Lefamulin	358	1	1	5	5	70	4.5	5.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	14	20	6.6	7.6
25-40 years	*****	1	3	5	12	30	8.1	7.5
41-64 years	189	1	1	1	5	70	3.9	7.2
≥ 65 years	140	1	2	5	5	14	4.6	2.7

Table 4f. Continuous Summary of All Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Ga-68-DOTATOC	473	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	*****
25-40 years	*****	1	1	1	1	1	1.0	*****
41-64 years	110	1	1	1	1	1	1.0	0.0
≥ 65 years	346	1	1	1	1	1	1.0	0.0
Istradefylline	14,046	1	30	60	150	1,718	138.9	200.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	40	30	30	75	180	960	140.6	197.6
41-64 years	2,034	2	30	60	150	1,650	130.8	196.8
≥ 65 years	11,972	1	30	60	150	1,718	140.3	201.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
 Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
<i>PrabotulinumtoxinA-xvfs</i>	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Caplacizumab-yhdp</i>	390	350	89.7%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Triclabendazole</i>	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Brexanolone</i>	164	164	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Solriamfetol</i>	15,947	10,332	64.8%	3,582	22.5%	1,593	10.0%	297	1.9%	143	0.9%
<i>Siponimod</i>	2,286	870	38.1%	616	26.9%	563	24.6%	141	6.2%	96	4.2%
<i>Romosozumab-aqqg</i>	87,634	84,625	96.6%	1,630	1.9%	1,232	1.4%	*****	*****	*****	*****
<i>Erdafitinib</i>	848	490	57.8%	223	26.3%	*****	*****	*****	*****	*****	*****
<i>Risankizumab-rzaa</i>	76,821	36,908	48.0%	19,412	25.3%	17,054	22.2%	2,715	3.5%	732	1.0%
<i>Tafamidis Meglumine</i>	11,217	2,796	24.9%	2,482	22.1%	4,211	37.5%	1,089	9.7%	639	5.7%
<i>Alpelisib</i>	6,242	3,780	60.6%	1,438	23.0%	931	14.9%	*****	*****	*****	*****
<i>Polatuzumab Vedotin-piiq</i>	6,512	6,498	99.8%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Bremelanotide</i>	2,426	2,086	86.0%	279	11.5%	61	2.5%	0	0.0%	0	0.0%
<i>Selinexor</i>	3,486	2,362	67.8%	879	25.2%	*****	*****	*****	*****	0	0.0%
<i>Relebactam</i>	152	140	92.1%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Ferric Maltol</i>	4,069	1,787	43.9%	1,251	30.7%	1,002	24.6%	29	0.7%	0	0.0%
<i>Darolutamide</i>	9,618	4,410	45.9%	2,336	24.3%	2,336	24.3%	439	4.6%	97	1.0%
<i>Pexidartinib</i>	160	92	57.5%	36	22.5%	*****	*****	*****	*****	*****	*****
<i>Pretomanid</i>	51	28	54.9%	11	21.6%	12	23.5%	0	0.0%	0	0.0%
<i>Pitolisant</i>	5,055	2,262	44.7%	1,295	25.6%	1,132	22.4%	250	4.9%	116	2.3%
<i>Entrectinib</i>	602	381	63.3%	141	23.4%	63	10.5%	17	2.8%	0	0.0%

Table 5a. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Number of Patients by First Treatment Episode Duration									
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Percent of Total Patients	Total Number of Patients	Percent of Total Patients	Total Number of Patients	Percent of Total Patients	Total Number of Patients	Percent of Total Patients	Total Number of Patients	Percent of Total Patients
<i>Fedratinib</i>	1,055	57.7%	609	22.5%	237	16.7%	176	2.1%	22	1.0%
<i>Upadacitinib</i>	54,390	45.3%	24,621	26.6%	14,486	22.5%	12,253	4.4%	2,369	1.2%
<i>Lefamulin</i>	209	100.0%	209	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Ga-68-DOTATOC</i>	358	100.0%	358	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Istradefylline</i>	6,005	36.7%	2,203	27.0%	1,619	25.0%	1,499	7.6%	459	3.7%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>PrabotulinumtoxinA-xvfs</i>	*****	1	1	1	1	1	1.0	0.0
<i>Caplacizumab-yhdp</i>	390	1	1	1	30	144	14.4	19.4
<i>Triclabendazole</i>	*****	2	2	2	2	2	2.0	0.0
<i>Brexanolone</i>	164	1	1	3	3	30	2.3	2.4
<i>Solriamfetol</i>	15,947	1	30	30	60	1,785	70.9	128.4
<i>Siponimod</i>	2,286	1	30	60	150	1,763	152.2	247.2
<i>Romosozumab-aqqg</i>	87,634	1	1	1	1	910	7.1	33.6
<i>Erdafitinib</i>	848	1	28	28	75	998	59.0	66.5
<i>Risankizumab-rzaa</i>	76,821	1	28	31	112	1,997	94.6	142.3
<i>Tafamidis Meglumine</i>	11,217	1	31	112	240	2,010	206.8	272.7
<i>Alpelisib</i>	6,242	2	28	28	56	1,512	65.0	86.7
<i>Polatuzumab Vedotin-piiq</i>	6,512	1	1	1	1	126	1.2	3.7
<i>Bremelanotide</i>	2,426	1	15	28	30	360	29.9	29.0
<i>Selinexor</i>	3,486	1	28	28	56	616	44.2	38.5
<i>Imipenem, Cilastatin and Relebactam</i>	152	1	1	4	12	172	11.4	22.7
<i>Ferric Maltol</i>	4,069	1	30	60	94	720	78.8	73.7
<i>Darolutamide</i>	9,618	1	30	60	120	1,760	108.8	148.3
<i>Pexidartinib</i>	160	15	30	30	73	857	84.8	125.7
<i>Pretomanid</i>	51	3	26	26	78	338	64.7	65.6
<i>Pitolisant</i>	5,055	1	30	60	120	1,760	120.6	190.8
<i>Entrectinib</i>	602	1	30	30	60	720	66.0	93.3
<i>Fedratinib</i>	1,055	2	30	30	90	1,260	81.8	127.2
<i>Upadacitinib</i>	54,390	1	30	60	120	1,948	108.4	155.6

Table 5b. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Lefamulin</i>	209	1	3	5	5	30	5.2	4.0
<i>Ga-68-DOTATOC</i>	358	1	1	1	1	1	1.0	0.0
<i>Istradefylline</i>	6,005	1	30	89	180	1,718	161.3	231.9

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
PrabotulinumtoxinA-xvfs	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	80.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	20.0%	0	NaN	0	NaN	0	NaN	0	NaN
Caplacizumab-yhdp	390	350	100.0%	*****	100.0%	*****	100.0%	0	NaN	0	NaN
Female	254	228	65.1%	*****	65.8%	*****	50.0%	0	NaN	0	NaN
Male	136	122	34.9%	*****	34.2%	*****	50.0%	0	NaN	0	NaN
Triclabendazole	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Brexanolone	164	164	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Male	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Solriamfetol	15,947	10,332	100.0%	3,582	100.0%	1,593	100.0%	297	100.0%	143	100.0%
Female	9,717	6,323	61.2%	2,187	61.1%	962	60.4%	163	54.9%	82	57.3%
Male	6,230	4,009	38.8%	1,395	38.9%	631	39.6%	134	45.1%	61	42.7%
Siponimod	2,286	870	100.0%	616	100.0%	563	100.0%	141	100.0%	96	100.0%
Female	1,710	654	75.2%	455	73.9%	420	74.6%	105	74.5%	76	79.2%
Male	576	216	24.8%	161	26.1%	143	25.4%	36	25.5%	20	20.8%
Romosozumab-aqqg	87,634	84,625	100.0%	1,630	100.0%	1,232	100.0%	*****	100.0%	*****	100.0%
Female	85,733	82,825	97.9%	1,576	96.7%	*****	*****	*****	95.9%	*****	100.0%
Male	1,901	1,800	2.1%	54	3.3%	*****	*****	*****	4.1%	0	0.0%

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Erdafitinib	848	490	100.0%	223	100.0%	*****	100.0%	*****	100.0%	*****	100.0%
Female	324	206	42.0%	82	36.8%	*****	26.9%	*****	25.0%	0	0.0%
Male	524	284	58.0%	141	63.2%	*****	73.1%	*****	75.0%	*****	100.0%
Risankizumab-rzaa	76,821	36,908	100.0%	19,412	100.0%	17,054	100.0%	2,715	100.0%	732	100.0%
Female	39,454	19,124	51.8%	9,662	49.8%	8,902	52.2%	1,400	51.6%	366	50.0%
Male	37,367	17,784	48.2%	9,750	50.2%	8,152	47.8%	1,315	48.4%	366	50.0%
Tafamidis Meglumine	11,217	2,796	100.0%	2,482	100.0%	4,211	100.0%	1,089	100.0%	639	100.0%
Female	2,105	585	20.9%	515	20.7%	732	17.4%	174	16.0%	99	15.5%
Male	9,112	2,211	79.1%	1,967	79.3%	3,479	82.6%	915	84.0%	540	84.5%
Alpelisib	6,242	3,780	100.0%	1,438	100.0%	931	100.0%	*****	100.0%	*****	100.0%
Female	6,061	3,670	97.1%	1,391	96.7%	*****	*****	*****	97.6%	*****	100.0%
Male	181	110	2.9%	47	3.3%	*****	*****	*****	2.4%	0	0.0%
Polatuzumab Vedotin-piiq	6,512	6,498	100.0%	*****	100.0%	*****	100.0%	0	NaN	0	NaN
Female	2,782	*****	*****	*****	18.2%	*****	33.3%	0	NaN	0	NaN
Male	3,730	*****	*****	*****	81.8%	*****	66.7%	0	NaN	0	NaN
Bremelanotide	2,426	2,086	100.0%	279	100.0%	61	100.0%	0	NaN	0	NaN
Female	2,372	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	54	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Selinexor	3,486	2,362	100.0%	879	100.0%	*****	100.0%	*****	100.0%	0	NaN
Female	1,661	1,133	48.0%	404	46.0%	*****	50.8%	*****	40.0%	0	NaN
Male	1,825	1,229	52.0%	475	54.0%	*****	49.2%	*****	60.0%	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

		Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Imipenem, Cilastatin and											
Relebactam	152	140	100.0%	*****	100.0%	*****	100.0%	0	NaN	0	NaN
Female	79	*****	*****	*****	20.0%	*****	50.0%	0	NaN	0	NaN
Male	73	*****	*****	*****	80.0%	*****	50.0%	0	NaN	0	NaN
Ferric Maltol											
Female	3,801	1,663	93.1%	1,168	93.4%	941	93.9%	29	100.0%	0	NaN
Male	268	124	6.9%	83	6.6%	61	6.1%	0	0.0%	0	NaN
Darolutamide											
Female	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%	0	0.0%
Male	*****	4,410	100.0%	*****	*****	2,336	100.0%	439	100.0%	97	100.0%
Pexidartinib											
Female	102	56	60.9%	*****	*****	*****	67.9%	*****	50.0%	*****	100.0%
Male	58	36	39.1%	*****	*****	*****	32.1%	*****	50.0%	0	0.0%
Pretomanid											
Female	28	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	23	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Pitolisant											
Female	3,508	1,591	70.3%	904	69.8%	760	67.1%	168	67.2%	85	73.3%
Male	1,547	671	29.7%	391	30.2%	372	32.9%	82	32.8%	31	26.7%
Entrectinib											
Female	357	227	59.6%	82	58.2%	*****	*****	*****	*****	0	NaN
Male	245	154	40.4%	59	41.8%	*****	*****	*****	*****	0	NaN

Table 5c. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Fedratinib	1,055	609	100.0%	237	100.0%	176	100.0%	22	100.0%	11	100.0%
Female	509	313	51.4%	105	44.3%	77	43.8%	*****	*****	*****	*****
Male	546	296	48.6%	132	55.7%	99	56.3%	*****	*****	*****	*****
Upadacitinib	54,390	24,621	100.0%	14,486	100.0%	12,253	100.0%	2,369	100.0%	661	100.0%
Female	39,189	17,946	72.9%	10,446	72.1%	8,697	71.0%	1,619	68.3%	481	72.8%
Male	15,201	6,675	27.1%	4,040	27.9%	3,556	29.0%	750	31.7%	180	27.2%
Lefamulin	209	209	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	124	124	59.3%	0	NaN	0	NaN	0	NaN	0	NaN
Male	85	85	40.7%	0	NaN	0	NaN	0	NaN	0	NaN
Ga-68-DOTATOC	358	358	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	200	200	55.9%	0	NaN	0	NaN	0	NaN	0	NaN
Male	158	158	44.1%	0	NaN	0	NaN	0	NaN	0	NaN
Istradefylline	6,005	2,203	100.0%	1,619	100.0%	1,499	100.0%	459	100.0%	225	100.0%
Female	2,465	922	41.9%	651	40.2%	626	41.8%	183	39.9%	83	36.9%
Male	3,540	1,281	58.1%	968	59.8%	873	58.2%	276	60.1%	142	63.1%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
PrabotulinumtoxinA-xvfs	*****	1	1	1	1	1	1.0	0.0
Female	*****	1	1	1	1	1	1.0	0.0
Male	*****	1	1	1	1	1	1.0	0.0
Caplacizumab-yhdp	390	1	1	1	30	144	14.4	19.4
Female	254	1	1	1	30	98	15.0	18.6
Male	136	1	1	1	28	144	13.1	20.7
Triclabendazole	*****	2	2	2	2	2	2.0	0.0
Female	*****	2	2	2	2	2	2.0	0.0
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Brexanolone	164	1	1	3	3	30	2.3	2.4
Female	*****	1	1	3	3	30	2.4	2.4
Male	*****	1	1	1	1	1	1.0	0.0
Solriamfetol	15,947	1	30	30	60	1,785	70.9	128.4
Female	9,717	1	30	30	60	1,634	69.2	124.8
Male	6,230	1	30	30	60	1,785	73.6	133.8
Siponimod	2,286	1	30	60	150	1,763	152.2	247.2
Female	1,710	2	30	60	155	1,763	154.8	255.2
Male	576	1	30	60	150	1,549	144.2	221.6
Romosozumab-aqqg	87,634	1	1	1	1	910	7.1	33.6
Female	85,733	1	1	1	1	910	7.0	33.4
Male	1,901	1	1	1	1	480	11.1	44.2
Erdafitinib	848	1	28	28	75	998	59.0	66.5
Female	324	1	28	28	56	396	49.6	48.3

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Male	524	1	28	30	84	998	64.9	75.1
Risankizumab-rzaa	76,821	1	28	31	112	1,997	94.6	142.3
Female	39,454	1	28	31	112	1,997	94.7	142.0
Male	37,367	1	28	31	112	1,831	94.5	142.5
Tafamidis Meglumine	11,217	1	31	112	240	2,010	206.8	272.7
Female	2,105	1	30	90	210	1,899	183.4	242.2
Male	9,112	1	39	119	240	2,010	212.2	279.1
Alpelisib	6,242	2	28	28	56	1,512	65.0	86.7
Female	6,061	2	28	28	56	1,512	65.2	87.2
Male	181	8	28	28	56	476	59.0	69.4
Polatuzumab Vedotin-piiq	6,512	1	1	1	1	126	1.2	3.7
Female	2,782	1	1	1	1	105	1.1	2.8
Male	3,730	1	1	1	1	126	1.3	4.2
Bremelanotide	2,426	1	15	28	30	360	29.9	29.0
Female	2,372	1	15	28	30	360	29.8	28.2
Male	54	1	15	15	30	300	35.8	52.2
Selinexor	3,486	1	28	28	56	616	44.2	38.5
Female	1,661	1	28	28	56	420	44.5	39.5
Male	1,825	2	28	28	56	616	43.8	37.6
Imipenem, Cilastatin and Relebactam	152	1	1	4	12	172	11.4	22.7
Female	79	1	1	2	10	145	8.8	19.1
Male	73	1	1	5	14	172	14.2	26.0
Ferric Maltol	4,069	1	30	60	94	720	78.8	73.7

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Female	3,801	1	30	60	95	720	79.2	74.3
Male	268	1	30	47	90	332	73.5	63.9
Darolutamide	9,618	1	30	60	120	1,760	108.8	148.3
Female	*****	60	60	60	60	60	60.0	*****
Male	*****	1	30	60	120	1,760	108.8	148.3
Pexidartinib	160	15	30	30	73	857	84.8	125.7
Female	102	15	30	30	90	857	88.8	135.9
Male	58	28	30	30	60	599	77.7	106.0
Pretomanid	51	3	26	26	78	338	64.7	65.6
Female	28	11	26	26	91	182	61.5	61.1
Male	23	3	26	52	78	338	68.5	72.0
Pitolisant	5,055	1	30	60	120	1,760	120.6	190.8
Female	3,508	1	30	60	120	1,678	119.0	188.3
Male	1,547	1	30	60	128	1,760	124.3	196.4
Entrectinib	602	1	30	30	60	720	66.0	93.3
Female	357	2	30	30	60	720	67.4	95.5
Male	245	1	30	30	60	690	64.1	90.1
Fedratinib	1,055	2	30	30	90	1,260	81.8	127.2
Female	509	6	30	30	64	1,260	80.9	138.4
Male	546	2	30	30	90	1,057	82.6	116.0
Upadacitinib	54,390	1	30	60	120	1,948	108.4	155.6
Female	39,189	1	30	60	120	1,834	107.0	154.9
Male	15,201	1	30	58	120	1,948	112.0	157.2

Table 5d. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Lefamulin	209	1	3	5	5	30	5.2	4.0
Female	124	1	3	5	5	28	5.2	4.0
Male	85	1	3	5	7	30	5.3	4.0
Ga-68-DOTATOC	358	1	1	1	1	1	1.0	0.0
Female	200	1	1	1	1	1	1.0	0.0
Male	158	1	1	1	1	1	1.0	0.0
Istradefylline	6,005	1	30	89	180	1,718	161.3	231.9
Female	2,465	1	30	80	180	1,613	155.2	217.1
Male	3,540	1	30	90	180	1,718	165.5	241.7

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
PrabotulinumtoxinA-xvfs	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	*****	*****	10.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	10.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	20.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	60.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Caplacizumab-yhdp	390	350	100.0%	*****	100.0%	*****	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	*****	5.3%	*****	50.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	5.3%	0	0.0%	0	NaN	0	NaN
25-40 years	81	*****	*****	*****	34.2%	0	0.0%	0	NaN	0	NaN
41-64 years	156	138	39.4%	*****	44.7%	*****	50.0%	0	NaN	0	NaN
≥ 65 years	122	*****	*****	*****	10.5%	0	0.0%	0	NaN	0	NaN
Triclabendazole	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	50.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	50.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Brexanolone	164	164	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	20	20	12.2%	0	NaN	0	NaN	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Number of Patients by First Treatment Episode Duration										
	1-30 Days			31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	133	133	81.1%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
Solriamfetol	15,947	10,332	100.0%	3,582	100.0%	1,593	100.0%	297	100.0%	143	100.0%
0-17 years	74	47	0.5%	13	0.4%	*****	*****	*****	*****	*****	*****
18-24 years	1,135	787	7.6%	221	6.2%	*****	*****	*****	*****	*****	*****
25-40 years	4,481	2,915	28.2%	1,034	28.9%	416	26.1%	81	27.3%	35	24.5%
41-64 years	7,488	4,737	45.8%	1,692	47.2%	833	52.3%	154	51.9%	72	50.3%
≥ 65 years	2,769	1,846	17.9%	622	17.4%	246	15.4%	39	13.1%	16	11.2%
Siponimod	2,286	870	100.0%	616	100.0%	563	100.0%	141	100.0%	96	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	26	12	1.4%	*****	*****	*****	*****	0	0.0%	*****	*****
25-40 years	429	175	20.1%	120	19.5%	91	16.2%	26	18.4%	17	17.7%
41-64 years	1,516	578	66.4%	396	64.3%	377	67.0%	97	68.8%	68	70.8%
≥ 65 years	315	105	12.1%	*****	*****	*****	*****	18	12.8%	*****	*****
Romosozumab-aqqg	87,634	84,625	100.0%	1,630	100.0%	1,232	100.0%	*****	100.0%	*****	100.0%
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
25-40 years	201	*****	*****	*****	*****	*****	*****	*****	0.7%	0	0.0%
41-64 years	7,993	7,553	8.9%	*****	*****	*****	*****	*****	11.6%	0	0.0%
≥ 65 years	79,409	76,853	90.8%	1,374	84.3%	1,053	85.5%	*****	87.7%	*****	100.0%

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Erdafitinib	848	490	100.0%	223	100.0%	*****	100.0%	*****	100.0%	*****	100.0%
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	18	*****	*****	*****	*****	*****	3.8%	0	0.0%	0	0.0%
41-64 years	195	91	18.6%	*****	*****	*****	32.3%	*****	25.0%	0	0.0%
≥ 65 years	624	385	78.6%	152	68.2%	*****	63.8%	*****	75.0%	*****	100.0%
Risankizumab-rzaa	76,821	36,908	100.0%	19,412	100.0%	17,054	100.0%	2,715	100.0%	732	100.0%
0-17 years	195	146	0.4%	21	0.1%	*****	*****	*****	*****	0	0.0%
18-24 years	3,936	2,209	6.0%	954	4.9%	*****	*****	*****	*****	14	1.9%
25-40 years	18,558	9,008	24.4%	5,205	26.8%	3,732	21.9%	500	18.4%	113	15.4%
41-64 years	37,857	17,412	47.2%	10,143	52.3%	8,574	50.3%	1,374	50.6%	354	48.4%
≥ 65 years	16,275	8,133	22.0%	3,089	15.9%	4,056	23.8%	746	27.5%	251	34.3%
Tafamidis Meglumine	11,217	2,796	100.0%	2,482	100.0%	4,211	100.0%	1,089	100.0%	639	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	*****	*****
41-64 years	*****	*****	*****	*****	*****	123	2.9%	39	3.6%	*****	*****
≥ 65 years	10,806	2,659	95.1%	2,392	96.4%	4,088	97.1%	1,050	96.4%	617	96.6%
Alpelisib	6,242	3,780	100.0%	1,438	100.0%	931	100.0%	*****	100.0%	*****	100.0%
0-17 years	78	*****	*****	17	1.2%	16	1.7%	*****	1.2%	*****	10.0%
18-24 years	15	*****	*****	*****	*****	*****	*****	*****	1.2%	0	0.0%

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
25-40 years	172	115	3.0%	*****	*****	*****	*****	*****	2.4%	0	0.0%
41-64 years	2,314	1,276	33.8%	561	39.0%	424	45.5%	*****	54.2%	*****	80.0%
≥ 65 years	3,663	2,337	61.8%	829	57.6%	462	49.6%	*****	41.0%	*****	10.0%
Polatuzumab Vedotin- piiq	6,512	6,498	100.0%	*****	100.0%	*****	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	14	14	0.2%	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	117	*****	*****	*****	9.1%	0	0.0%	0	NaN	0	NaN
41-64 years	920	*****	*****	*****	9.1%	*****	33.3%	0	NaN	0	NaN
≥ 65 years	5,461	5,450	83.9%	*****	81.8%	*****	66.7%	0	NaN	0	NaN
Bremelanotide	2,426	2,086	100.0%	279	100.0%	61	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	43	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	928	793	38.0%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	1,437	1,239	59.4%	157	56.3%	41	67.2%	0	NaN	0	NaN
≥ 65 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
Selinexor	3,486	2,362	100.0%	879	100.0%	*****	100.0%	*****	100.0%	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	0.8%	0	0.0%	0	NaN
41-64 years	753	487	20.6%	206	23.4%	*****	23.8%	*****	60.0%	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	2,696	1,847	78.2%	666	75.8%	*****	75.4%	*****	40.0%	0	NaN
Imipenem, Cilastatin and Relebactam	152	140	100.0%	*****	100.0%	*****	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	NaN	0	NaN
25-40 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
41-64 years	57	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
≥ 65 years	56	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Ferric Maltol	4,069	1,787	100.0%	1,251	100.0%	1,002	100.0%	29	100.0%	0	NaN
0-17 years	42	16	0.9%	11	0.9%	*****	*****	*****	*****	0	NaN
18-24 years	276	140	7.8%	81	6.5%	*****	*****	*****	*****	0	NaN
25-40 years	1,914	829	46.4%	589	47.1%	*****	*****	*****	*****	0	NaN
41-64 years	1,666	704	39.4%	519	41.5%	427	42.6%	16	55.2%	0	NaN
≥ 65 years	171	98	5.5%	51	4.1%	*****	*****	*****	*****	0	NaN
Darolutamide	9,618	4,410	100.0%	2,336	100.0%	2,336	100.0%	439	100.0%	97	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	227	9.7%	241	10.3%	*****	*****	*****	*****
≥ 65 years	8,549	3,889	88.2%	2,109	90.3%	2,095	89.7%	*****	*****	*****	*****
Pexidartinib	160	92	100.0%	36	100.0%	*****	100.0%	*****	100.0%	*****	100.0%
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	17	*****	*****	*****	*****	*****	*****	*****	50.0%	0	0.0%
25-40 years	56	30	32.6%	*****	*****	14	*****	0	0.0%	*****	100.0%
41-64 years	73	47	51.1%	*****	*****	*****	*****	*****	50.0%	0	0.0%
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
Pretomanid	51	28	100.0%	11	100.0%	12	100.0%	0	NaN	0	NaN
0-17 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	NaN	0	NaN
25-40 years	15	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	20	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Pitolisant	5,055	2,262	100.0%	1,295	100.0%	1,132	100.0%	250	100.0%	116	100.0%
0-17 years	48	24	1.1%	*****	*****	*****	*****	*****	*****	*****	*****
18-24 years	631	299	13.2%	*****	*****	*****	*****	31	12.4%	*****	*****
25-40 years	1,877	865	38.2%	500	38.6%	412	36.4%	70	28.0%	30	25.9%
41-64 years	1,943	837	37.0%	480	37.1%	446	39.4%	120	48.0%	60	51.7%
≥ 65 years	556	237	10.5%	157	12.1%	133	11.7%	*****	*****	*****	*****
Entrectinib	602	381	100.0%	141	100.0%	63	100.0%	17	100.0%	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	0.0%	*****	*****	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	*****	*****	*****	0	NaN
25-40 years	32	*****	*****	*****	*****	*****	*****	0	0.0%	0	NaN
41-64 years	223	132	34.6%	57	40.4%	*****	*****	*****	*****	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
≥ 65 years	336	226	59.3%	72	51.1%	*****	*****	*****	*****	0	NaN
Fedratinib	1,055	609	100.0%	237	100.0%	176	100.0%	22	100.0%	11	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	0	0.0%	*****	*****	0	0.0%
41-64 years	*****	*****	*****	43	18.1%	17	9.7%	*****	*****	*****	*****
≥ 65 years	902	523	85.9%	194	81.9%	159	90.3%	*****	*****	*****	*****
Upadacitinib	54,390	24,621	100.0%	14,486	100.0%	12,253	100.0%	2,369	100.0%	661	100.0%
0-17 years	738	330	1.3%	206	1.4%	157	1.3%	*****	*****	*****	*****
18-24 years	2,209	1,103	4.5%	549	3.8%	471	3.8%	*****	*****	*****	*****
25-40 years	8,252	3,806	15.5%	2,325	16.0%	1,779	14.5%	297	12.5%	45	6.8%
41-64 years	29,770	13,377	54.3%	7,913	54.6%	6,769	55.2%	1,311	55.3%	400	60.5%
≥ 65 years	13,421	6,005	24.4%	3,493	24.1%	3,077	25.1%	648	27.4%	198	30.0%
Lefamulin	209	209	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	80	80	38.3%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	107	107	51.2%	0	NaN	0	NaN	0	NaN	0	NaN
Ga-68-DOTATOC	358	358	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN

Table 5e. Categorical Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Number of Patients by First Treatment Episode Duration									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
18-24 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	90	90	25.1%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	252	252	70.4%	0	NaN	0	NaN	0	NaN	0	NaN
Istradefylline	6,005	2,203	100.0%	1,619	100.0%	1,499	100.0%	459	100.0%	225	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	18	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
41-64 years	856	*****	*****	*****	*****	*****	*****	62	13.5%	*****	*****
≥ 65 years	5,131	1,869	84.8%	1,399	86.4%	1,268	84.6%	397	86.5%	198	88.0%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
PrabotulinumtoxinA-xvfs	*****	1	1	1	1	1	1.0	0.0
0-17 years	*****	1	1	1	1	1	1.0	*****
18-24 years	*****	1	1	1	1	1	1.0	*****
25-40 years	*****	1	1	1	1	1	1.0	*****
41-64 years	*****	1	1	1	1	1	1.0	*****
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Caplacizumab-yhdp	390	1	1	1	30	144	14.4	19.4
0-17 years	*****	1	1	27	58	98	30.6	34.6
18-24 years	*****	1	1	7	29	58	14.2	16.0
25-40 years	81	1	1	25	30	60	20.0	18.9
41-64 years	156	1	1	5	30	144	17.2	21.2
≥ 65 years	122	1	1	1	1	58	5.8	12.2
Triclabendazole	*****	2	2	2	2	2	2.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	2	2	2	2	2	2.0	*****
25-40 years	*****	2	2	2	2	2	2.0	*****
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Brexanolone	164	1	1	3	3	30	2.3	2.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	20	1	2	3	3	3	2.5	0.9
25-40 years	133	1	1	3	3	30	2.4	2.6
41-64 years	*****	1	1	2	3	3	1.8	1.0

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
≥ 65 years	*****	1	1	1	1	1	1.0	0.0
Solriamfetol	15,947	1	30	30	60	1,785	70.9	128.4
0-17 years	74	1	30	30	67	1,327	107.6	228.9
18-24 years	1,135	1	30	30	60	1,785	73.8	155.6
25-40 years	4,481	1	30	30	60	1,634	67.4	120.7
41-64 years	7,488	1	30	30	60	1,635	74.5	133.1
≥ 65 years	2,769	1	30	30	60	1,640	64.5	109.9
Siponimod	2,286	1	30	60	150	1,763	152.2	247.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	26	9	30	54	150	1,461	141.5	282.2
25-40 years	429	4	30	60	128	1,472	141.4	226.9
41-64 years	1,516	1	30	60	162	1,763	156.7	254.5
≥ 65 years	315	4	30	60	155	1,748	145.6	235.1
Romosozumab-aqqg	87,634	1	1	1	1	910	7.1	33.6
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	1	1	230	13.8	44.3
25-40 years	201	1	1	1	1	390	8.6	34.8
41-64 years	7,993	1	1	1	1	480	10.5	39.6
≥ 65 years	79,409	1	1	1	1	910	6.8	33.0
Erdafitinib	848	1	28	28	75	998	59.0	66.5
0-17 years	*****	4	14	28	30	70	29.1	20.6
18-24 years	*****	28	28	30	58	84	42.8	27.5
25-40 years	18	14	30	58	118	224	80.9	62.6

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
41-64 years	195	1	28	42	86	460	69.1	66.8
≥ 65 years	624	1	28	28	56	998	55.7	66.6
Risankizumab-rzaa	76,821	1	28	31	112	1,997	94.6	142.3
0-17 years	195	1	1	1	32	700	51.4	111.0
18-24 years	3,936	1	28	28	84	1,679	69.7	109.6
25-40 years	18,558	1	28	31	87	1,831	83.6	124.7
41-64 years	37,857	1	28	35	112	1,997	97.3	141.8
≥ 65 years	16,275	1	28	31	112	1,659	107.2	165.9
Tafamidis Meglumine	11,217	1	31	112	240	2,010	206.8	272.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	30	33	1,264	236.2	503.5
41-64 years	*****	1	30	90	240	1,578	189.6	254.8
≥ 65 years	10,806	1	33	115	240	2,010	207.4	273.2
Alpelisib	6,242	2	28	28	56	1,512	65.0	86.7
0-17 years	78	7	28	28	84	846	83.4	121.5
18-24 years	15	28	28	28	56	422	72.2	103.7
25-40 years	172	4	28	28	56	644	60.2	75.2
41-64 years	2,314	2	28	28	84	1,512	75.5	107.9
≥ 65 years	3,663	3	28	28	56	846	58.2	68.8
Polatuzumab Vedotin-piiq	6,512	1	1	1	1	126	1.2	3.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	14	1	1	1	1	1	1.0	0.0

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
25-40 years	117	1	1	1	1	42	1.4	3.8
41-64 years	920	1	1	1	1	112	1.2	4.2
≥ 65 years	5,461	1	1	1	1	126	1.2	3.6
Bremelanotide	2,426	1	15	28	30	360	29.9	29.0
0-17 years	*****	15	15	15	15	15	15.0	*****
18-24 years	43	15	15	28	30	168	29.6	24.6
25-40 years	928	1	15	30	30	360	30.3	27.7
41-64 years	1,437	1	15	23	30	360	29.8	30.0
≥ 65 years	*****	7	15	15	15	45	18.3	9.3
Selinexor	3,486	1	28	28	56	616	44.2	38.5
0-17 years	*****	11	21	28	56	84	36.6	25.0
18-24 years	*****	28	28	28	73	73	43.0	26.0
25-40 years	*****	11	28	28	29	112	38.3	25.7
41-64 years	753	1	28	28	56	616	46.7	45.4
≥ 65 years	2,696	2	28	28	56	504	43.5	36.5
Imipenem, Cilastatin and Relebactam	152	1	1	4	12	172	11.4	22.7
0-17 years	*****	1	1	1	1	1	1.0	0.0
18-24 years	*****	1	1	9	19	26	10.6	10.2
25-40 years	*****	1	1	1	12	37	7.3	9.2
41-64 years	57	1	1	2	7	87	7.9	14.1
≥ 65 years	56	1	1	8	14	172	17.5	33.1
Ferric Maltol	4,069	1	30	60	94	720	78.8	73.7
0-17 years	42	9	30	60	150	717	115.9	146.4

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	276	1	30	30	90	367	73.1	68.8
25-40 years	1,914	1	30	60	98	570	77.3	69.5
41-64 years	1,666	1	30	60	107	720	82.1	77.1
≥ 65 years	171	1	30	30	90	374	63.8	60.6
Darolutamide	9,618	1	30	60	120	1,760	108.8	148.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	28	28	28	28	28	28.0	*****
41-64 years	*****	1	30	44	120	1,538	110.6	154.2
≥ 65 years	8,549	1	30	60	120	1,760	108.5	147.6
Pexidartinib	160	15	30	30	73	857	84.8	125.7
0-17 years	*****	30	30	30	30	150	54.0	53.7
18-24 years	17	30	58	60	90	599	104.4	133.6
25-40 years	56	28	30	30	107	857	102.1	157.3
41-64 years	73	15	30	30	60	626	72.1	102.5
≥ 65 years	*****	30	30	30	30	270	60.0	79.4
Pretomanid	51	3	26	26	78	338	64.7	65.6
0-17 years	*****	10	10	26	156	156	64.0	80.1
18-24 years	*****	26	26	28	41	52	33.5	12.5
25-40 years	15	15	26	52	106	144	63.7	44.7
41-64 years	*****	26	26	26	34	338	78.9	109.9
≥ 65 years	20	3	26	26	91	182	65.4	61.5
Pitolisant	5,055	1	30	60	120	1,760	120.6	190.8

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
0-17 years	48	14	30	45	120	1,323	143.8	252.3
18-24 years	631	1	30	54	120	1,760	126.4	211.1
25-40 years	1,877	1	30	60	120	1,650	105.7	161.8
41-64 years	1,943	1	30	60	137	1,678	137.3	219.4
≥ 65 years	556	3	30	60	120	840	104.0	128.8
Entrectinib	602	1	30	30	60	720	66.0	93.3
0-17 years	*****	30	30	30	60	420	94.3	144.3
18-24 years	*****	30	38	83	290	459	163.5	200.9
25-40 years	32	3	30	30	63	345	67.6	77.1
41-64 years	223	1	30	30	60	720	66.1	91.2
≥ 65 years	336	3	30	30	60	690	64.1	93.1
Fedratinib	1,055	2	30	30	90	1,260	81.8	127.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	15	30	30	30	690	137.5	270.7
41-64 years	*****	4	30	30	81	1,075	86.1	157.3
≥ 65 years	902	2	30	30	90	1,260	80.7	120.4
Upadacitinib	54,390	1	30	60	120	1,948	108.4	155.6
0-17 years	738	1	30	56	120	985	104.9	137.5
18-24 years	2,209	1	30	31	100	1,462	91.2	122.3
25-40 years	8,252	1	30	56	102	1,725	95.3	126.4
41-64 years	29,770	1	30	60	120	1,948	110.1	159.4
≥ 65 years	13,421	1	30	60	120	1,834	115.8	167.8

Table 5f. Continuous Summary of First Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Lefamulin	209	1	3	5	5	30	5.2	4.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	5	14	14	6.7	6.7
25-40 years	*****	1	5	5	14	30	8.5	7.5
41-64 years	80	1	2	5	5	28	4.9	4.0
≥ 65 years	107	1	3	5	5	14	4.9	2.6
Ga-68-DOTATOC	358	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	1	1	1.0	*****
25-40 years	*****	1	1	1	1	1	1.0	*****
41-64 years	90	1	1	1	1	1	1.0	0.0
≥ 65 years	252	1	1	1	1	1	1.0	0.0
Istradefylline	6,005	1	30	89	180	1,718	161.3	231.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	18	30	49	135	180	892	163.9	197.6
41-64 years	856	2	30	60	180	1,650	154.0	226.6
≥ 65 years	5,131	1	30	90	180	1,718	162.5	232.9

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>PrabotulinumtoxinA-xvfs</i>	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Caplacizumab-yhdp</i>	245	197	80.4%	35	14.3%	*****	*****	*****	*****	0	0.0%
<i>Triclabendazole</i>	0	-	-	-	-	-	-	-	-	-	-
<i>Brexanolone</i>	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Solriamfetol</i>	49,784	34,075	68.4%	11,577	23.3%	3,662	7.4%	342	0.7%	128	0.3%
<i>Siponimod</i>	6,183	2,871	46.4%	1,703	27.5%	1,285	20.8%	237	3.8%	87	1.4%
<i>Romosozumab-aqqg</i>	592,111	585,454	98.9%	4,460	0.8%	2,155	0.4%	*****	*****	*****	*****
<i>Erdafitinib</i>	1,021	673	65.9%	263	25.8%	*****	*****	*****	*****	0	0.0%
<i>Risankizumab-rzaa</i>	165,801	43,647	26.3%	86,503	52.2%	30,641	18.5%	4,061	2.4%	949	0.6%
<i>Tafamidis Meglumine</i>	18,074	7,166	39.6%	5,455	30.2%	4,389	24.3%	765	4.2%	299	1.7%
<i>Alpelisib</i>	7,577	4,510	59.5%	1,982	26.2%	1,002	13.2%	72	1.0%	11	0.1%
<i>Polatuzumab Vedotin-piiq</i>	18,087	18,076	99.9%	11	0.1%	0	0.0%	0	0.0%	0	0.0%
<i>Bremelanotide</i>	1,782	1,487	83.4%	245	13.7%	50	2.8%	0	0.0%	0	0.0%
<i>Selinexor</i>	3,185	2,199	69.0%	760	23.9%	*****	*****	*****	*****	0	0.0%
<i>Imipenem, Cilastatin and Relebactam</i>	286	269	94.1%	*****	*****	*****	*****	0	0.0%	0	0.0%
<i>Ferric Maltol</i>	1,899	1,169	61.6%	497	26.2%	*****	*****	*****	*****	0	0.0%
<i>Darolutamide</i>	20,739	11,249	54.2%	5,659	27.3%	3,409	16.4%	362	1.7%	60	0.3%
<i>Pexidartinib</i>	489	308	63.0%	124	25.4%	*****	*****	0	0.0%	*****	*****
<i>Pretomanid</i>	71	34	47.9%	25	35.2%	12	16.9%	0	0.0%	0	0.0%
<i>Pitolisant</i>	8,501	4,573	53.8%	2,289	26.9%	1,385	16.3%	200	2.4%	54	0.6%

Table 6a. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Entrectinib</i>	846	529	62.5%	192	22.7%	110	13.0%	*****	*****	*****	*****
<i>Fedratinib</i>	2,276	1,306	57.4%	595	26.1%	325	14.3%	*****	*****	*****	*****
<i>Upadacitinib</i>	128,810	71,586	55.6%	35,372	27.5%	19,227	14.9%	2,141	1.7%	484	0.4%
<i>Lefamulin</i>	149	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
<i>Ga-68-DOTATOC</i>	115	115	100.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
<i>Istradefylline</i>	8,041	3,320	41.3%	2,302	28.6%	1,887	23.5%	384	4.8%	148	1.8%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
 Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>PrabotulinumtoxinA-xvfs</i>	*****	1	1	1	1	1	1.0	*****
<i>Caplacizumab-yhdp</i>	245	1	7	28	30	600	37.1	69.4
<i>Triclabendazole</i>	0	-	-	-	-	-	-	-
<i>Brexanolone</i>	*****	1	1	2	3	3	2.0	1.4
<i>Solriamfetol</i>	49,784	1	30	30	60	1,682	54.7	74.7
<i>Siponimod</i>	6,183	1	30	60	112	1,705	107.1	163.2
<i>Romosozumab-aqqg</i>	592,111	1	1	1	1	776	2.6	13.7
<i>Erdafitinib</i>	1,021	1	28	28	56	484	47.4	46.3
<i>Risankizumab-rzaa</i>	165,801	1	30	60	84	1,810	89.9	116.0
<i>Tafamidis Meglumine</i>	18,074	1	30	60	120	1,857	116.7	170.3
<i>Alpelisib</i>	7,577	1	28	28	56	1,389	60.4	75.4
<i>Polatuzumab Vedotin-piiq</i>	18,087	1	1	1	1	75	1.1	1.5
<i>Bremelanotide</i>	1,782	1	15	23	30	360	30.0	29.0
<i>Selinexor</i>	3,185	1	28	28	56	546	44.8	41.3
<i>Imipenem, Cilastatin and Relebactam</i>	286	1	1	1	7	310	8.7	24.6
<i>Ferric Maltol</i>	1,899	1	30	30	60	576	57.3	56.3
<i>Darolutamide</i>	20,739	1	30	30	90	1,524	74.9	96.2
<i>Pexidartinib</i>	489	1	30	30	60	734	57.1	61.6
<i>Pretomanid</i>	71	4	26	52	78	182	53.9	40.0
<i>Pitolisant</i>	8,501	1	30	30	90	1,557	81.7	118.8
<i>Entrectinib</i>	846	3	30	30	60	1,246	66.4	102.3
<i>Fedratinib</i>	2,276	1	30	30	60	1,257	72.2	99.7
<i>Upadacitinib</i>	128,810	1	30	30	90	1,785	73.4	98.3

Table 6b. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
<i>Lefamulin</i>	149	1	1	1	2	70	3.4	7.8
<i>Ga-68-DOTATOC</i>	115	1	1	1	1	1	1.0	0.0
<i>Istradefylline</i>	8,041	1	30	60	120	1,572	122.2	171.4

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
 Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
PrabotulinumtoxinA-xvfs	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Caplacizumab-yhdp	245	197	100.0%	35	100.0%	*****	100.0%	*****	100.0%	0	NaN
Female	154	125	63.5%	*****	*****	*****	55.6%	*****	50.0%	0	NaN
Male	91	72	36.5%	*****	*****	*****	44.4%	*****	50.0%	0	NaN
Triclabendazole	0	-	-	-	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-	-	-	-
Brexanolone	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Male	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Solriamfetol	49,784	34,075	100.0%	11,577	100.0%	3,662	100.0%	342	100.0%	128	100.0%
Female	30,884	21,212	62.3%	7,141	61.7%	2,271	62.0%	183	53.5%	77	60.2%
Male	18,900	12,863	37.7%	4,436	38.3%	1,391	38.0%	159	46.5%	51	39.8%
Siponimod	6,183	2,871	100.0%	1,703	100.0%	1,285	100.0%	237	100.0%	87	100.0%
Female	4,517	2,076	72.3%	1,241	72.9%	953	74.2%	180	75.9%	67	77.0%
Male	1,666	795	27.7%	462	27.1%	332	25.8%	57	24.1%	20	23.0%
Romosozumab-aqqg	592,111	585,454	100.0%	4,460	100.0%	2,155	100.0%	*****	100.0%	*****	100.0%
Female	581,703	575,250	98.3%	4,326	97.0%	*****	*****	*****	92.7%	*****	100.0%
Male	10,408	10,204	1.7%	134	3.0%	*****	*****	*****	7.3%	0	0.0%

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Erdafitinib	1,021	673	100.0%	263	100.0%	*****	100.0%	*****	100.0%	0	NaN
Female	397	255	37.9%	108	41.1%	*****	41.3%	*****	*****	0	NaN
Male	624	418	62.1%	155	58.9%	*****	58.8%	*****	*****	0	NaN
Risankizumab-rzaa	165,801	43,647	100.0%	86,503	100.0%	30,641	100.0%	4,061	100.0%	949	100.0%
Female	79,644	21,710	49.7%	40,230	46.5%	15,225	49.7%	1,998	49.2%	481	50.7%
Male	86,157	21,937	50.3%	46,273	53.5%	15,416	50.3%	2,063	50.8%	468	49.3%
Tafamidis Meglumine	18,074	7,166	100.0%	5,455	100.0%	4,389	100.0%	765	100.0%	299	100.0%
Female	3,535	1,536	21.4%	1,071	19.6%	739	16.8%	144	18.8%	45	15.1%
Male	14,539	5,630	78.6%	4,384	80.4%	3,650	83.2%	621	81.2%	254	84.9%
Alpelisib	7,577	4,510	100.0%	1,982	100.0%	1,002	100.0%	72	100.0%	11	100.0%
Female	7,243	4,312	95.6%	1,891	95.4%	*****	*****	*****	*****	*****	*****
Male	334	198	4.4%	91	4.6%	*****	*****	*****	*****	*****	*****
Polatuzumab Vedotin-piiq	18,087	18,076	100.0%	11	100.0%	0	NaN	0	NaN	0	NaN
Female	7,862	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Male	10,225	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Bremelanotide	1,782	1,487	100.0%	245	100.0%	50	100.0%	0	NaN	0	NaN
Female	1,728	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Male	54	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Selinexor	3,185	2,199	100.0%	760	100.0%	*****	100.0%	*****	100.0%	0	NaN
Female	1,583	1,076	48.9%	386	50.8%	*****	53.4%	*****	57.1%	0	NaN
Male	1,602	1,123	51.1%	374	49.2%	*****	46.6%	*****	42.9%	0	NaN

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Imipenem, Cilastatin and Relebactam	286	269	100.0%	*****	100.0%	*****	100.0%	0	NaN	0	NaN
Female	192	*****	*****	*****	46.2%	0	0.0%	0	NaN	0	NaN
Male	94	*****	*****	*****	53.8%	*****	100.0%	0	NaN	0	NaN
Ferric Maltol	1,899	1,169	100.0%	497	100.0%	*****	100.0%	*****	100.0%	0	NaN
Female	1,733	1,076	92.0%	442	88.9%	*****	92.5%	*****	83.3%	0	NaN
Male	166	93	8.0%	55	11.1%	*****	7.5%	*****	16.7%	0	NaN
Darolutamide	20,739	11,249	100.0%	5,659	100.0%	3,409	100.0%	362	100.0%	60	100.0%
Female	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Male	20,739	11,249	100.0%	5,659	100.0%	3,409	100.0%	362	100.0%	60	100.0%
Pexidartinib	489	308	100.0%	124	100.0%	*****	100.0%	0	NaN	*****	100.0%
Female	311	192	62.3%	*****	*****	*****	62.5%	0	NaN	*****	100.0%
Male	178	116	37.7%	*****	*****	*****	37.5%	0	NaN	0	0.0%
Pretomanid	71	34	100.0%	25	100.0%	12	100.0%	0	NaN	0	NaN
Female	43	22	64.7%	*****	*****	*****	*****	0	NaN	0	NaN
Male	28	12	35.3%	*****	*****	*****	*****	0	NaN	0	NaN
Pitolisant	8,501	4,573	100.0%	2,289	100.0%	1,385	100.0%	200	100.0%	54	100.0%
Female	5,859	3,190	69.8%	1,546	67.5%	949	68.5%	142	71.0%	32	59.3%
Male	2,642	1,383	30.2%	743	32.5%	436	31.5%	58	29.0%	22	40.7%
Entrectinib	846	529	100.0%	192	100.0%	110	100.0%	*****	100.0%	*****	100.0%
Female	536	336	63.5%	120	62.5%	*****	*****	*****	70.0%	*****	80.0%

Table 6c. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Male	310	193	36.5%	72	37.5%	*****	*****	*****	30.0%	*****	20.0%
Fedratinib	2,276	1,306	100.0%	595	100.0%	325	100.0%	*****	100.0%	*****	100.0%
Female	1,154	667	51.1%	307	51.6%	155	47.7%	*****	47.5%	*****	60.0%
Male	1,122	639	48.9%	288	48.4%	170	52.3%	*****	52.5%	*****	40.0%
Upadacitinib	128,810	71,586	100.0%	35,372	100.0%	19,227	100.0%	2,141	100.0%	484	100.0%
Female	97,334	54,314	75.9%	26,701	75.5%	14,327	74.5%	1,611	75.2%	381	78.7%
Male	31,476	17,272	24.1%	8,671	24.5%	4,900	25.5%	530	24.8%	103	21.3%
Lefamulin	149	*****	100.0%	*****	100.0%	0	NaN	0	NaN	0	NaN
Female	82	*****	55.1%	*****	50.0%	0	NaN	0	NaN	0	NaN
Male	67	*****	44.9%	*****	50.0%	0	NaN	0	NaN	0	NaN
Ga-68-DOTATOC	115	115	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
Female	52	52	45.2%	0	NaN	0	NaN	0	NaN	0	NaN
Male	63	63	54.8%	0	NaN	0	NaN	0	NaN	0	NaN
Istradefylline	8,041	3,320	100.0%	2,302	100.0%	1,887	100.0%	384	100.0%	148	100.0%
Female	3,338	1,460	44.0%	898	39.0%	758	40.2%	159	41.4%	63	42.6%
Male	4,703	1,860	56.0%	1,404	61.0%	1,129	59.8%	225	58.6%	85	57.4%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
PrabotulinumtoxinA-xvfs	*****	1	1	1	1	1	1.0	NaN
Female	*****	1	1	1	1	1	1.0	*****
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Caplacizumab-yhdp	245	1	7	28	30	600	37.1	69.4
Female	154	1	10	30	30	600	38.5	74.2
Male	91	1	3	26	30	390	34.8	60.7
Triclabendazole	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Brexanolone	*****	1	1	2	3	3	2.0	1.4
Female	*****	1	1	2	3	3	2.0	1.4
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Solriamfetol	49,784	1	30	30	60	1,682	54.7	74.7
Female	30,884	1	30	30	60	1,682	53.9	72.4
Male	18,900	1	30	30	60	1,592	56.2	78.3
Siponimod	6,183	1	30	60	112	1,705	107.1	163.2
Female	4,517	1	30	60	120	1,697	109.2	166.3
Male	1,666	2	30	56	90	1,705	101.3	154.3
Romosozumab-aqqg	592,111	1	1	1	1	776	2.6	13.7
Female	581,703	1	1	1	1	776	2.6	13.6
Male	10,408	1	1	1	1	689	3.9	19.1
Erdafitinib	1,021	1	28	28	56	484	47.4	46.3
Female	397	1	28	28	56	448	47.5	43.6
Male	624	1	28	28	56	484	47.3	47.9
Risankizumab-rzaa	165,801	1	30	60	84	1,810	89.9	116.0

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Female	79,644	1	30	60	84	1,610	90.7	117.6
Male	86,157	1	30	61	84	1,810	89.2	114.5
Tafamidis Meglumine	18,074	1	30	60	120	1,857	116.7	170.3
Female	3,535	1	30	60	116	1,857	106.8	155.0
Male	14,539	1	30	60	120	1,813	119.1	173.7
Alpelisib	7,577	1	28	28	56	1,389	60.4	75.4
Female	7,243	1	28	28	56	1,389	60.3	75.0
Male	334	2	28	28	56	801	62.4	83.7
Polatuzumab Vedotin-piiq	18,087	1	1	1	1	75	1.1	1.5
Female	7,862	1	1	1	1	64	1.0	1.3
Male	10,225	1	1	1	1	75	1.1	1.7
Bremelanotide	1,782	1	15	23	30	360	30.0	29.0
Female	1,728	1	15	23	30	360	29.8	27.8
Male	54	15	15	27	30	330	37.5	53.7
Selinexor	3,185	1	28	28	56	546	44.8	41.3
Female	1,583	3	28	28	56	544	45.5	41.8
Male	1,602	1	28	28	56	546	44.0	40.8
Imipenem, Cilastatin and Relebactam	286	1	1	1	7	310	8.7	24.6
Female	192	1	1	1	6	80	5.2	10.3
Male	94	1	1	5	13	310	15.9	39.5
Ferric Maltol	1,899	1	30	30	60	576	57.3	56.3
Female	1,733	1	30	30	60	576	56.9	55.9
Male	166	2	30	30	73	368	60.9	59.8
Darolutamide	20,739	1	30	30	90	1,524	74.9	96.2
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Male	20,739	1	30	30	90	1,524	74.9	96.2
Pexidartinib	489	1	30	30	60	734	57.1	61.6
Female	311	1	30	30	60	734	58.2	66.2
Male	178	6	30	30	60	320	55.0	52.8
Pretomanid	71	4	26	52	78	182	53.9	40.0
Female	43	4	26	30	56	182	49.3	35.6
Male	28	6	26	52	78	182	60.9	45.7
Pitolisant	8,501	1	30	30	90	1,557	81.7	118.8
Female	5,859	1	30	30	90	1,557	80.5	114.4
Male	2,642	1	30	30	90	1,498	84.4	128.0
Entrectinib	846	3	30	30	60	1,246	66.4	102.3
Female	536	3	30	30	60	1,170	68.4	106.2
Male	310	4	30	30	60	1,246	62.7	95.3
Fedratinib	2,276	1	30	30	60	1,257	72.2	99.7
Female	1,154	1	30	30	60	1,081	71.4	99.1
Male	1,122	3	30	30	82	1,257	73.0	100.3
Upadacitinib	128,810	1	30	30	90	1,785	73.4	98.3
Female	97,334	1	30	30	90	1,666	73.4	98.8
Male	31,476	1	30	30	90	1,785	73.6	96.7
Lefamulin	149	1	1	1	2	70	3.4	7.8
Female	82	1	1	1	2	70	3.8	8.6
Male	67	1	1	1	2	55	2.9	6.7
Ga-68-DOTATOC	115	1	1	1	1	1	1.0	0.0
Female	52	1	1	1	1	1	1.0	0.0
Male	63	1	1	1	1	1	1.0	0.0

Table 6d. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Istradefylline	8,041	1	30	60	120	1,572	122.2	171.4
Female	3,338	1	30	60	120	1,440	120.7	172.9
Male	4,703	1	30	60	133	1,572	123.3	170.3

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
 Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
PrabotulinumtoxinA-xvfs	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Caplacizumab-yhdp	245	197	100.0%	35	100.0%	*****	100.0%	*****	100.0%	0	NaN
0-17 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	0	0.0%	0	0.0%	0	NaN
25-40 years	66	52	26.4%	*****	*****	*****	33.3%	*****	50.0%	0	NaN
41-64 years	117	93	47.2%	*****	*****	*****	33.3%	*****	50.0%	0	NaN
≥ 65 years	42	*****	*****	*****	*****	*****	33.3%	0	0.0%	0	NaN
Triclabendazole	0	-	-	-	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-	-	-	-
Brexanolone	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)										
	1-30 Days			31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	*****	*****	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
Solriamfetol	49,784	34,075	100.0%	11,577	100.0%	3,662	100.0%	342	100.0%	128	100.0%
0-17 years	256	184	0.5%	52	0.4%	*****	*****	0	0.0%	*****	*****
18-24 years	3,831	2,795	8.2%	787	6.8%	*****	*****	*****	*****	*****	*****
25-40 years	13,585	9,614	28.2%	2,969	25.6%	892	24.4%	73	21.3%	37	28.9%
41-64 years	24,579	16,737	49.1%	5,738	49.6%	1,853	50.6%	186	54.4%	65	50.8%
≥ 65 years	7,533	4,745	13.9%	2,031	17.5%	678	18.5%	*****	*****	*****	*****
Siponimod	6,183	2,871	100.0%	1,703	100.0%	1,285	100.0%	237	100.0%	87	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	50	22	0.8%	13	0.8%	15	1.2%	0	0.0%	0	0.0%
25-40 years	1,146	583	20.3%	292	17.1%	236	18.4%	*****	*****	*****	*****
41-64 years	4,268	1,982	69.0%	1,175	69.0%	864	67.2%	184	77.6%	63	72.4%
≥ 65 years	719	284	9.9%	223	13.1%	170	13.2%	*****	*****	*****	*****
Romosozumab-aqqg	592,111	585,454	100.0%	4,460	100.0%	2,155	100.0%	*****	100.0%	*****	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	82	*****	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%
25-40 years	924	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
41-64 years	46,433	45,451	7.8%	635	14.2%	*****	*****	*****	14.6%	0	0.0%
≥ 65 years	544,672	539,030	92.1%	3,801	85.2%	1,805	83.8%	*****	85.4%	*****	100.0%

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Erdafitinib	1,021	673	100.0%	263	100.0%	*****	100.0%	*****	100.0%	0	NaN
0-17 years	*****	*****	*****	0	0.0%	*****	2.5%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	*****	*****	*****	1.3%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	1.3%	0	0.0%	0	NaN
41-64 years	211	131	19.5%	*****	*****	*****	27.5%	*****	20.0%	0	NaN
≥ 65 years	788	527	78.3%	203	77.2%	*****	67.5%	*****	80.0%	0	NaN
Risankizumab-rzaa	165,801	43,647	100.0%	86,503	100.0%	30,641	100.0%	4,061	100.0%	949	100.0%
0-17 years	502	205	0.5%	221	0.3%	*****	*****	*****	*****	*****	*****
18-24 years	9,448	2,797	6.4%	4,945	5.7%	*****	*****	*****	*****	*****	*****
25-40 years	42,806	11,426	26.2%	23,263	26.9%	7,145	23.3%	825	20.3%	147	15.5%
41-64 years	86,331	21,877	50.1%	46,258	53.5%	15,568	50.8%	2,106	51.9%	522	55.0%
≥ 65 years	26,714	7,342	16.8%	11,816	13.7%	6,307	20.6%	989	24.4%	260	27.4%
Tafamidis Meglumine	18,074	7,166	100.0%	5,455	100.0%	4,389	100.0%	765	100.0%	299	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	*****	*****	*****	0	0.0%	*****	*****	0	0.0%	0	0.0%
41-64 years	*****	*****	*****	223	4.1%	*****	*****	29	3.8%	*****	*****
≥ 65 years	17,268	6,776	94.6%	5,232	95.9%	4,234	96.5%	736	96.2%	*****	*****
Alpelisib	7,577	4,510	100.0%	1,982	100.0%	1,002	100.0%	72	100.0%	11	100.0%
0-17 years	302	190	4.2%	79	4.0%	*****	*****	*****	*****	*****	*****
18-24 years	39	22	0.5%	13	0.7%	*****	*****	*****	*****	0	0.0%

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
25-40 years	221	124	2.7%	65	3.3%	*****	*****	*****	*****	0	0.0%
41-64 years	2,806	1,756	38.9%	697	35.2%	330	32.9%	*****	*****	*****	*****
≥ 65 years	4,209	2,418	53.6%	1,128	56.9%	612	61.1%	*****	*****	*****	*****
Polatuzumab Vedotin-piiq	18,087	18,076	100.0%	11	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	24	24	0.1%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	243	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
41-64 years	2,152	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
≥ 65 years	15,668	*****	*****	*****	*****	0	NaN	0	NaN	0	NaN
Bremelanotide	1,782	1,487	100.0%	245	100.0%	50	100.0%	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	NaN	0	NaN
18-24 years	25	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
25-40 years	556	466	31.3%	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	1,175	982	66.0%	165	67.3%	28	56.0%	0	NaN	0	NaN
≥ 65 years	26	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
Selinexor	3,185	2,199	100.0%	760	100.0%	*****	100.0%	*****	100.0%	0	NaN
0-17 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	NaN
25-40 years	*****	*****	*****	*****	*****	*****	0.5%	0	0.0%	0	NaN
41-64 years	723	501	22.8%	*****	*****	*****	23.7%	*****	42.9%	0	NaN
≥ 65 years	2,434	1,675	76.2%	589	77.5%	*****	75.8%	*****	57.1%	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
	1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
	Total Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Imipenem, Cilastatin and Relebactam	286	100.0%	269	100.0%	0	0.0%	0	0.0%	0	0.0%
0-17 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	13	4.6%	13	4.8%	0	0.0%	0	0.0%	0	0.0%
25-40 years	61	21.3%	61	22.7%	0	0.0%	0	0.0%	0	0.0%
41-64 years	162	56.6%	162	59.9%	0	0.0%	0	0.0%	0	0.0%
≥ 65 years	50	17.5%	50	18.5%	0	0.0%	0	0.0%	0	0.0%
Ferric Maltol	1,899	100.0%	1,169	61.6%	497	26.2%	0	0.0%	0	0.0%
0-17 years	16	0.8%	16	1.4%	0	0.0%	0	0.0%	0	0.0%
18-24 years	110	5.8%	75	6.5%	0	0.0%	0	0.0%	0	0.0%
25-40 years	696	36.7%	433	36.7%	177	9.3%	0	0.0%	0	0.0%
41-64 years	948	50.0%	571	48.1%	247	12.7%	0	0.0%	0	0.0%
≥ 65 years	129	6.8%	43	3.7%	0	0.0%	0	0.0%	0	0.0%
Darolutamide	20,739	100.0%	11,249	54.2%	5,659	27.3%	3,409	16.4%	60	0.3%
0-17 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
41-64 years	1,209	5.8%	557	4.9%	40	0.2%	0	0.0%	0	0.0%
≥ 65 years	18,623	89.3%	5,102	45.3%	3,102	16.5%	322	1.5%	0	0.0%
Pexidartinib	489	100.0%	308	62.9%	124	25.4%	0	0.0%	0	0.0%
0-17 years	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
18-24 years	36	*****	*****	*****	*****	*****	*****	0	NaN	0	0.0%
25-40 years	172	110	35.7%	41	33.1%	21	*****	0	NaN	0	0.0%
41-64 years	253	159	51.6%	67	54.0%	*****	*****	0	NaN	*****	100.0%
≥ 65 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	0.0%
Pretomanid	71	34	100.0%	25	100.0%	12	100.0%	0	NaN	0	NaN
0-17 years	*****	0	0.0%	0	0.0%	*****	*****	0	NaN	0	NaN
18-24 years	*****	*****	*****	0	0.0%	*****	*****	0	NaN	0	NaN
25-40 years	18	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
41-64 years	*****	*****	*****	*****	*****	*****	*****	0	NaN	0	NaN
≥ 65 years	37	19	55.9%	*****	*****	*****	*****	0	NaN	0	NaN
Pitolisant	8,501	4,573	100.0%	2,289	100.0%	1,385	100.0%	200	100.0%	54	100.0%
0-17 years	53	19	0.4%	12	0.5%	*****	*****	*****	*****	0	0.0%
18-24 years	1,174	683	14.9%	292	12.8%	*****	*****	*****	*****	*****	*****
25-40 years	3,198	1,804	39.4%	844	36.9%	469	33.9%	*****	*****	*****	*****
41-64 years	3,219	1,714	37.5%	875	38.2%	524	37.8%	80	40.0%	26	48.1%
≥ 65 years	857	353	7.7%	266	11.6%	199	14.4%	*****	*****	*****	*****
Entrectinib	846	529	100.0%	192	100.0%	110	100.0%	*****	100.0%	*****	100.0%
0-17 years	*****	*****	*****	*****	*****	*****	*****	0	0.0%	0	0.0%
18-24 years	*****	*****	*****	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	48	32	6.0%	*****	*****	*****	*****	*****	10.0%	*****	20.0%
41-64 years	334	197	37.2%	*****	*****	45	40.9%	*****	50.0%	*****	40.0%

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
≥ 65 years	444	287	54.3%	98	51.0%	*****	*****	*****	40.0%	*****	40.0%
Fedratinib	2,276	1,306	100.0%	595	100.0%	325	100.0%	*****	100.0%	*****	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	38	21	1.6%	*****	*****	*****	*****	*****	2.5%	0	0.0%
41-64 years	344	221	16.9%	*****	*****	*****	*****	*****	7.5%	0	0.0%
≥ 65 years	1,894	1,064	81.5%	505	84.9%	279	85.8%	*****	90.0%	*****	100.0%
Upadacitinib	128,810	71,586	100.0%	35,372	100.0%	19,227	100.0%	2,141	100.0%	484	100.0%
0-17 years	1,284	698	1.0%	366	1.0%	202	1.1%	*****	*****	*****	*****
18-24 years	4,563	2,805	3.9%	1,162	3.3%	554	2.9%	*****	*****	*****	*****
25-40 years	17,533	10,625	14.8%	4,463	12.6%	2,215	11.5%	203	9.5%	27	5.6%
41-64 years	73,223	41,304	57.7%	19,920	56.3%	10,578	55.0%	1,149	53.7%	272	56.2%
≥ 65 years	32,207	16,154	22.6%	9,461	26.7%	5,678	29.5%	735	34.3%	179	37.0%
Lefamulin	149	*****	100.0%	*****	100.0%	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	0.0%	0	NaN	0	NaN	0	NaN
18-24 years	*****	*****	4.1%	0	0.0%	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	0.7%	0	0.0%	0	NaN	0	NaN	0	NaN
41-64 years	109	*****	72.8%	*****	100.0%	0	NaN	0	NaN	0	NaN
≥ 65 years	*****	*****	22.4%	0	0.0%	0	NaN	0	NaN	0	NaN
Ga-68-DOTATOC	115	115	100.0%	0	NaN	0	NaN	0	NaN	0	NaN
0-17 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN

Table 6e. Categorical Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Number of Treatment Episodes by Duration (Excluding First Treatment Episode)									
		1-30 Days		31-90 Days		91-365 Days		366-730 Days		731+ Days	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
18-24 years	0	0	0.0%	0	NaN	0	NaN	0	NaN	0	NaN
25-40 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
41-64 years	*****	*****	*****	0	NaN	0	NaN	0	NaN	0	NaN
≥ 65 years	94	94	81.7%	0	NaN	0	NaN	0	NaN	0	NaN
Istradefylline	8,041	3,320	100.0%	2,302	100.0%	1,887	100.0%	384	100.0%	148	100.0%
0-17 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
18-24 years	0	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0	0.0%
25-40 years	22	*****	*****	*****	*****	*****	*****	0	0.0%	*****	*****
41-64 years	1,178	*****	*****	*****	*****	*****	*****	54	14.1%	*****	*****
≥ 65 years	6,841	2,798	84.3%	1,945	84.5%	1,640	86.9%	330	85.9%	128	86.5%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
PrabotulinumtoxinA-xvfs	*****	1	1	1	1	1	1.0	NaN
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	1	1	1	1	1	1.0	*****
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Caplacizumab-yhdp	245	1	7	28	30	600	37.1	69.4
0-17 years	*****	28	28	44	60	60	44.0	22.6
18-24 years	*****	1	1	5	23	58	12.2	15.3
25-40 years	66	1	14	30	30	390	45.8	73.4
41-64 years	117	1	7	30	30	600	37.6	78.5
≥ 65 years	42	1	1	27	30	254	32.3	46.5
Triclabendazole	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Brexanolone	*****	1	1	2	3	3	2.0	1.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	2	3	3	2.0	1.4
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Solriamfetol	49,784	1	30	30	60	1,682	54.7	74.7
0-17 years	256	5	30	30	60	1,236	53.5	88.3
18-24 years	3,831	1	30	30	60	1,682	49.4	66.2
25-40 years	13,585	1	30	30	60	1,380	51.9	71.2
41-64 years	24,579	1	30	30	60	1,592	55.4	77.1
≥ 65 years	7,533	1	30	30	60	1,253	60.4	75.9
Siponimod	6,183	1	30	60	112	1,705	107.1	163.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	50	5	30	58	180	330	101.9	101.8
25-40 years	1,146	1	30	30	90	1,705	90.0	128.4
41-64 years	4,268	1	30	60	112	1,647	109.0	167.4
≥ 65 years	719	3	30	60	120	1,697	123.2	186.9
Romosozumab-aqqg	592,111	1	1	1	1	776	2.6	13.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	82	1	1	1	28	90	12.7	23.0
25-40 years	924	1	1	1	1	270	4.3	20.3
41-64 years	46,433	1	1	1	1	470	4.1	19.0
≥ 65 years	544,672	1	1	1	1	776	2.4	13.1
Erdafitinib	1,021	1	28	28	56	484	47.4	46.3
0-17 years	*****	11	30	30	112	303	97.2	121.5
18-24 years	*****	28	28	28	56	112	50.4	36.5
25-40 years	*****	4	28	28	54	112	42.0	31.5
41-64 years	211	1	28	30	56	392	50.2	48.8
≥ 65 years	788	1	28	28	56	484	46.4	45.0

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Risankizumab-rzaa	165,801	1	30	60	84	1,810	89.9	116.0
0-17 years	502	1	1	31	84	1,250	60.6	93.7
18-24 years	9,448	1	30	56	84	1,209	75.2	90.6
25-40 years	42,806	1	30	56	84	1,512	81.1	102.2
41-64 years	86,331	1	30	56	84	1,810	89.9	116.2
≥ 65 years	26,714	1	30	84	127	1,791	110.2	139.4
Tafamidis Meglumine	18,074	1	30	60	120	1,857	116.7	170.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	30	30	30	97	157	68.8	57.2
41-64 years	*****	1	30	45	90	1,230	97.1	137.5
≥ 65 years	17,268	1	30	60	120	1,857	117.6	171.6
Alpelisib	7,577	1	28	28	56	1,389	60.4	75.4
0-17 years	302	2	28	28	56	855	57.0	84.5
18-24 years	39	21	28	28	56	513	63.1	89.0
25-40 years	221	2	28	28	66	579	62.4	75.5
41-64 years	2,806	1	28	28	56	1,389	56.6	71.6
≥ 65 years	4,209	2	28	28	56	1,148	63.1	76.9
Polatuzumab Vedotin-piiq	18,087	1	1	1	1	75	1.1	1.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	24	1	1	1	1	1	1.0	0.0
25-40 years	243	1	1	1	1	63	1.3	4.0
41-64 years	2,152	1	1	1	1	42	1.1	1.4
≥ 65 years	15,668	1	1	1	1	75	1.1	1.5

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Bremelanotide	1,782	1	15	23	30	360	30.0	29.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	25	10	15	21	30	147	36.7	36.7
25-40 years	556	1	15	23	30	330	30.3	29.3
41-64 years	1,175	1	15	23	30	360	29.6	27.9
≥ 65 years	26	15	15	15	30	280	34.2	52.1
Selinexor	3,185	1	28	28	56	546	44.8	41.3
0-17 years	*****	17	17	19	21	21	19.0	2.8
18-24 years	*****	28	28	28	28	28	28.0	*****
25-40 years	*****	7	28	28	29	168	38.8	32.5
41-64 years	723	1	28	28	56	546	45.2	45.5
≥ 65 years	2,434	2	28	28	56	448	44.7	40.1
Imipenem, Cilastatin and Relebactam	286	1	1	1	7	310	8.7	24.6
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	13	1	1	1	18	47	10.9	14.8
25-40 years	61	1	1	6	13	310	19.2	47.9
41-64 years	162	1	1	1	2	70	3.4	7.3
≥ 65 years	50	1	1	7	16	71	12.5	15.2
Ferric Maltol	1,899	1	30	30	60	576	57.3	56.3
0-17 years	16	16	30	30	60	284	55.3	64.2
18-24 years	110	3	30	30	60	368	54.3	61.7
25-40 years	696	2	30	30	60	480	55.3	50.5
41-64 years	948	1	30	30	71	576	59.9	60.9

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	129	2	30	30	60	316	51.3	42.5
Darolutamide	20,739	1	30	30	90	1,524	74.9	96.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	129	129	129	129	129	129.0	*****
41-64 years	*****	1	30	30	60	1,380	69.2	90.3
≥ 65 years	18,623	1	30	30	90	1,524	75.5	96.8
Pexidartinib	489	1	30	30	60	734	57.1	61.6
0-17 years	*****	30	30	75	150	330	108.3	96.9
18-24 years	36	2	30	30	60	150	49.1	36.4
25-40 years	172	11	30	30	60	320	56.0	52.5
41-64 years	253	1	30	30	60	734	57.9	68.9
≥ 65 years	*****	6	30	30	30	150	43.7	35.6
Pretomanid	71	4	26	52	78	182	53.9	40.0
0-17 years	*****	164	164	164	164	164	164.0	*****
18-24 years	*****	4	8	58	143	182	75.3	84.5
25-40 years	18	26	26	26	52	104	38.0	20.2
41-64 years	*****	26	52	78	104	182	81.1	46.7
≥ 65 years	37	6	26	30	52	130	48.2	30.6
Pitolisant	8,501	1	30	30	90	1,557	81.7	118.8
0-17 years	53	24	30	60	210	618	152.8	170.4
18-24 years	1,174	2	30	30	60	1,498	72.0	104.0
25-40 years	3,198	1	30	30	75	1,557	76.1	114.5
41-64 years	3,219	1	30	30	90	1,305	84.0	122.9

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	857	2	30	60	120	1,140	102.6	129.6
Entrectinib	846	3	30	30	60	1,246	66.4	102.3
0-17 years	*****	28	30	30	120	210	70.1	63.8
18-24 years	*****	30	30	30	30	30	30.0	*****
25-40 years	48	15	30	30	60	882	81.2	149.5
41-64 years	334	3	30	30	60	1,170	67.7	105.6
≥ 65 years	444	7	30	30	60	1,246	63.6	95.0
Fedratinib	2,276	1	30	30	60	1,257	72.2	99.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	38	15	30	30	60	480	60.7	79.6
41-64 years	344	1	30	30	60	510	59.9	66.7
≥ 65 years	1,894	1	30	30	71	1,257	74.7	104.8
Upadacitinib	128,810	1	30	30	90	1,785	73.4	98.3
0-17 years	1,284	1	30	30	89	742	70.3	82.1
18-24 years	4,563	1	30	30	60	1,158	60.3	71.4
25-40 years	17,533	1	30	30	60	1,785	63.5	80.5
41-64 years	73,223	1	30	30	81	1,666	72.1	96.8
≥ 65 years	32,207	1	30	30	90	1,726	83.8	112.3
Lefamulin	149	1	1	1	2	70	3.4	7.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	1	1	15	20	6.5	8.7
25-40 years	*****	1	1	1	1	1	1.0	*****
41-64 years	109	1	1	1	1	70	3.2	8.8

Table 6f. Continuous Summary of Second and Subsequent Treatment Episodes for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Episodes	Distribution of Treatment Episode Durations Excluding First Treatment Episode, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
≥ 65 years	*****	1	2	2	5	10	3.6	2.7
Ga-68-DOTATOC	115	1	1	1	1	1	1.0	0.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	1	1	1	1.0	*****
41-64 years	*****	1	1	1	1	1	1.0	*****
≥ 65 years	94	1	1	1	1	1	1.0	0.0
Istradefylline	8,041	1	30	60	120	1,572	122.2	171.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	22	30	30	52	133	960	121.6	200.2
41-64 years	1,178	2	30	60	120	1,447	113.9	169.9
≥ 65 years	6,841	1	30	60	133	1,572	123.6	171.5

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>PrabotulinumtoxinA-xvfs</i>	*****	55	55	55	55	55	55.0	*****
<i>Caplacizumab-yhdp</i>	245	1	3	8	19	1,201	43.3	131.9
<i>Triclabendazole</i>	0	-	-	-	-	-	-	-
<i>Brexanolone</i>	*****	1	1	428	854	854	427.5	603.2
<i>Solriamfetol</i>	49,784	1	3	7	19	1,648	24.2	70.0
<i>Siponimod</i>	6,183	1	3	6	14	1,229	18.5	55.5
<i>Romosozumab-aqqg</i>	592,111	1	27	29	33	1,733	32.5	26.0
<i>Erdafitinib</i>	1,021	1	4	9	22	845	20.4	45.7
<i>Risankizumab-rzaa</i>	165,801	1	8	27	49	1,881	40.4	71.4
<i>Tafamidis Meglumine</i>	18,074	1	2	5	13	1,623	36.1	136.4
<i>Alpelisib</i>	7,577	1	3	7	17	1,599	19.2	55.2
<i>Polatuzumab Vedotin-piiq</i>	18,087	1	20	20	21	1,001	24.4	26.2
<i>Bremelanotide</i>	1,782	1	3	8	20	799	27.0	65.1
<i>Selinexor</i>	3,185	1	4	10	25	1,411	28.6	77.7
<i>Imipenem, Cilastatin and Relebactam</i>	286	1	3	6	8	536	18.7	54.2
<i>Ferric Maltol</i>	1,899	1	6	16	41	740	37.4	65.0
<i>Darolutamide</i>	20,739	1	3	6	17	1,112	18.9	48.1
<i>Pexidartinib</i>	489	1	3	6	14	481	17.0	43.5
<i>Pretomanid</i>	71	1	2	4	8	136	8.4	17.3
<i>Pitolisant</i>	8,501	1	3	6	15	1,329	22.7	76.3
<i>Entrectinib</i>	846	1	3	7	21	1,048	22.4	60.9
<i>Fedratinib</i>	2,276	1	3	7	19	1,165	20.7	67.7
<i>Upadacitinib</i>	128,810	1	3	7	17	1,637	20.4	57.8
<i>Lefamulin</i>	149	1	23	27	55	664	51.7	77.7

Table 7a. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Ga-68-DOTATOC</i>	115	55	217	363	456	1,155	373.2	206.1
<i>Istradefylline</i>	8,041	1	3	7	19	1,288	25.6	75.0

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
PrabotulinumtoxinA-xvfs	*****	55	55	55	55	55	55.0	*****
Female	*****	55	55	55	55	55	55.0	*****
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Caplacizumab-yhdp	245	1	3	8	19	1,201	43.3	131.9
Female	154	1	3	7	19	1,029	39.8	118.6
Male	91	1	3	9	19	1,201	49.3	152.4
Triclabendazole	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Brexanolone	*****	1	1	428	854	854	427.5	603.2
Female	*****	1	1	428	854	854	427.5	603.2
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Solriamfetol	49,784	1	3	7	19	1,648	24.2	70.0
Female	30,884	1	3	7	19	1,558	23.2	65.0
Male	18,900	1	3	7	20	1,648	25.9	77.5
Siponimod	6,183	1	3	6	14	1,229	18.5	55.5
Female	4,517	1	3	6	15	1,170	19.4	56.5
Male	1,666	1	3	6	12	1,229	16.0	52.5
Romosozumab-aqqg	592,111	1	27	29	33	1,733	32.5	26.0
Female	581,703	1	27	29	33	1,733	32.5	26.0
Male	10,408	1	27	27	32	1,042	31.6	26.3
Erdafitinib	1,021	1	4	9	22	845	20.4	45.7
Female	397	1	4	10	25	845	22.5	57.6
Male	624	1	4	8	21	504	19.0	36.1

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Risankizumab-rzaa	165,801	1	8	27	49	1,881	40.4	71.4
Female	79,644	1	8	27	47	1,623	39.2	70.2
Male	86,157	1	8	27	50	1,881	41.5	72.4
Tafamidis Meglumine	18,074	1	2	5	13	1,623	36.1	136.4
Female	3,535	1	2	6	14	1,577	32.4	119.0
Male	14,539	1	2	5	12	1,623	37.0	140.2
Alpelisib	7,577	1	3	7	17	1,599	19.2	55.2
Female	7,243	1	3	7	18	1,599	19.2	55.5
Male	334	1	3	7	13	403	18.0	48.4
Polatuzumab Vedotin-piiq	18,087	1	20	20	21	1,001	24.4	26.2
Female	7,862	1	20	20	21	908	24.5	25.7
Male	10,225	1	20	20	21	1,001	24.4	26.5
Bremelanotide	1,782	1	3	8	20	799	27.0	65.1
Female	1,728	1	3	8	20	799	26.7	64.9
Male	54	1	3	9	31	375	36.6	73.0
Selinexor	3,185	1	4	10	25	1,411	28.6	77.7
Female	1,583	1	4	10	24	1,110	27.5	69.0
Male	1,602	1	4	10	26	1,411	29.6	85.5
Imipenem, Cilastatin and Relebactam	286	1	3	6	8	536	18.7	54.2
Female	192	1	3	6	7	411	17.0	47.4
Male	94	1	1	6	11	536	22.3	66.3
Ferric Maltol	1,899	1	6	16	41	740	37.4	65.0
Female	1,733	1	6	16	41	740	37.4	64.5
Male	166	1	4	13	37	474	37.5	69.5

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Darolutamide	20,739	1	3	6	17	1,112	18.9	48.1
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	20,739	1	3	6	17	1,112	18.9	48.1
Pexidartinib	489	1	3	6	14	481	17.0	43.5
Female	311	1	3	6	14	481	16.5	39.7
Male	178	1	3	7	13	380	18.0	49.4
Pretomanid	71	1	2	4	8	136	8.4	17.3
Female	43	1	2	4	7	136	8.6	20.9
Male	28	1	2	4	11	47	8.0	10.1
Pitolisant	8,501	1	3	6	15	1,329	22.7	76.3
Female	5,859	1	3	6	15	1,329	22.8	77.3
Male	2,642	1	3	6	15	1,275	22.6	73.9
Entrectinib	846	1	3	7	21	1,048	22.4	60.9
Female	536	1	3	7	22	1,048	23.5	65.8
Male	310	1	4	8	20	652	20.6	51.5
Fedratinib	2,276	1	3	7	19	1,165	20.7	67.7
Female	1,154	1	4	9	20	1,158	21.3	64.9
Male	1,122	1	3	6	18	1,165	20.1	70.5
Upadacitinib	128,810	1	3	7	17	1,637	20.4	57.8
Female	97,334	1	3	7	18	1,637	21.1	59.8
Male	31,476	1	3	6	16	1,482	18.5	51.2
Lefamulin	149	1	23	27	55	664	51.7	77.7
Female	82	1	26	27	52	664	59.2	96.8
Male	67	1	20	26	55	289	42.5	43.3

Table 7b. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Ga-68-DOTATOC	115	55	217	363	456	1,155	373.2	206.1
Female	52	55	265	377	509	1,133	414.2	222.9
Male	63	82	202	340	419	1,155	339.3	186.2
Istradefylline	8,041	1	3	7	19	1,288	25.6	75.0
Female	3,338	1	3	7	20	1,168	26.5	75.2
Male	4,703	1	3	7	19	1,288	24.9	74.8

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
PrabotulinumtoxinA-xvfs	*****	55	55	55	55	55	55.0	*****
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	55	55	55	55	55	55.0	*****
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Caplacizumab-yhdp	245	1	3	8	19	1,201	43.3	131.9
0-17 years	*****	9	9	59	108	108	58.5	70.0
18-24 years	*****	1	2	3	9	29	6.4	8.0
25-40 years	66	1	3	7	16	534	38.1	104.2
41-64 years	117	1	3	8	19	1,201	46.7	160.8
≥ 65 years	42	1	3	12	27	445	57.1	110.4
Triclabendazole	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Brexanolone	*****	1	1	428	854	854	427.5	603.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	428	854	854	427.5	603.2
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Solriamfetol	49,784	1	3	7	19	1,648	24.2	70.0
0-17 years	256	1	4	10	30	1,414	33.5	105.2
18-24 years	3,831	1	4	9	22	1,093	24.7	61.8
25-40 years	13,585	1	3	7	18	1,648	22.0	64.3
41-64 years	24,579	1	3	7	19	1,558	24.3	71.8
≥ 65 years	7,533	1	3	8	22	1,393	27.5	76.0
Siponimod	6,183	1	3	6	14	1,229	18.5	55.5
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	50	1	2	3	15	652	25.2	94.2
25-40 years	1,146	1	3	6	14	1,229	18.1	64.0
41-64 years	4,268	1	3	6	14	829	18.3	51.2
≥ 65 years	719	1	3	6	15	729	19.8	61.4
Romosozumab-aqqg	592,111	1	27	29	33	1,733	32.5	26.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	82	1	20	27	34	112	32.3	24.7
25-40 years	924	1	27	28	34	1,042	36.7	59.5
41-64 years	46,433	1	27	29	33	1,733	32.4	30.3
≥ 65 years	544,672	1	27	29	33	1,681	32.5	25.6
Erdafitinib	1,021	1	4	9	22	845	20.4	45.7
0-17 years	*****	7	24	28	44	60	32.6	20.2
18-24 years	*****	5	5	9	30	30	15.8	13.1
25-40 years	*****	2	6	10	41	97	25.1	30.9
41-64 years	211	1	4	9	21	112	17.1	20.5

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
≥ 65 years	788	1	4	9	22	845	21.1	50.7
Risankizumab-rzaa	165,801	1	8	27	49	1,881	40.4	71.4
0-17 years	502	1	9	26	32	1,306	33.0	71.9
18-24 years	9,448	1	9	27	49	1,422	42.6	77.1
25-40 years	42,806	1	9	27	50	1,590	43.0	75.7
41-64 years	86,331	1	8	27	50	1,881	41.1	70.2
≥ 65 years	26,714	1	6	18	34	1,386	33.2	65.1
Tafamidis Meglumine	18,074	1	2	5	13	1,623	36.1	136.4
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	4	7	9	64	72	31.2	33.8
41-64 years	*****	1	2	5	16	763	21.8	64.9
≥ 65 years	17,268	1	2	5	12	1,623	36.8	138.8
Alpelisib	7,577	1	3	7	17	1,599	19.2	55.2
0-17 years	302	1	3	6	12	378	14.9	35.5
18-24 years	39	1	5	12	24	163	24.7	34.5
25-40 years	221	1	3	6	12	359	14.4	39.8
41-64 years	2,806	1	3	7	16	845	17.8	50.5
≥ 65 years	4,209	1	3	7	19	1,599	20.6	59.9
Polatuzumab Vedotin-piiq	18,087	1	20	20	21	1,001	24.4	26.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	24	19	20	20	41	118	29.9	21.1
25-40 years	243	6	20	20	21	347	25.0	25.4

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
41-64 years	2,152	1	20	20	21	565	24.5	25.6
≥ 65 years	15,668	1	20	20	21	1,001	24.4	26.3
Bremelanotide	1,782	1	3	8	20	799	27.0	65.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	25	1	2	4	14	43	10.0	11.3
25-40 years	556	1	3	8	20	799	26.6	66.5
41-64 years	1,175	1	3	9	21	776	27.8	65.8
≥ 65 years	26	1	5	10	17	127	16.7	24.8
Selinexor	3,185	1	4	10	25	1,411	28.6	77.7
0-17 years	*****	6	6	23	40	40	23.0	24.0
18-24 years	*****	27	27	27	27	27	27.0	*****
25-40 years	*****	1	3	6	13	858	54.2	172.2
41-64 years	723	1	4	10	26	1,411	29.6	90.1
≥ 65 years	2,434	1	4	10	25	1,110	28.0	72.0
Imipenem, Cilastatin and Relebactam	286	1	3	6	8	536	18.7	54.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	13	3	5	7	13	89	14.5	22.8
25-40 years	61	1	2	4	8	536	29.7	92.8
41-64 years	162	1	3	6	7	266	10.4	24.6
≥ 65 years	50	1	2	6	34	327	33.3	62.0
Ferric Maltol	1,899	1	6	16	41	740	37.4	65.0
0-17 years	16	1	4	15	45	78	23.6	24.4
18-24 years	110	1	5	11	28	232	26.9	42.2

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
25-40 years	696	1	5	14	36	715	35.8	68.9
41-64 years	948	1	6	18	47	740	39.7	64.7
≥ 65 years	129	1	7	16	46	406	40.4	63.5
Darolutamide	20,739	1	3	6	17	1,112	18.9	48.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	86	86	86	86	86	86.0	*****
41-64 years	*****	1	3	6	15	506	15.5	33.8
≥ 65 years	18,623	1	2	6	17	1,112	19.3	49.4
Pexidartinib	489	1	3	6	14	481	17.0	43.5
0-17 years	*****	1	2	6	10	16	6.7	5.2
18-24 years	36	1	4	6	16	323	20.1	53.4
25-40 years	172	1	3	6	12	481	18.9	56.6
41-64 years	253	1	3	7	15	380	16.2	32.7
≥ 65 years	*****	2	3	8	16	27	10.4	8.5
Pretomanid	71	1	2	4	8	136	8.4	17.3
0-17 years	*****	4	4	4	4	4	4.0	*****
18-24 years	*****	1	2	5	72	136	36.5	66.4
25-40 years	18	1	2	4	5	39	5.6	8.7
41-64 years	*****	1	1	6	8	16	5.8	4.5
≥ 65 years	37	1	2	4	10	47	7.5	9.0
Pitolisant	8,501	1	3	6	15	1,329	22.7	76.3
0-17 years	53	1	3	7	18	709	38.5	110.0

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	1,174	1	3	7	17	751	22.6	63.9
25-40 years	3,198	1	3	7	15	1,329	22.3	75.4
41-64 years	3,219	1	3	6	14	1,277	24.1	84.0
≥ 65 years	857	1	3	6	13	971	18.4	60.1
Entrectinib	846	1	3	7	21	1,048	22.4	60.9
0-17 years	*****	1	4	7	14	56	10.8	12.1
18-24 years	*****	4	4	4	4	4	4.0	*****
25-40 years	48	1	3	6	11	61	10.1	12.5
41-64 years	334	1	3	6	19	1,048	22.1	74.0
≥ 65 years	444	1	4	9	25	652	24.5	54.0
Fedratinib	2,276	1	3	7	19	1,165	20.7	67.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	38	1	3	5	18	276	20.4	45.9
41-64 years	344	1	4	9	19	1,158	20.6	67.9
≥ 65 years	1,894	1	3	7	19	1,165	20.7	68.1
Upadacitinib	128,810	1	3	7	17	1,637	20.4	57.8
0-17 years	1,284	1	3	8	18	647	19.5	40.0
18-24 years	4,563	1	3	8	19	881	19.5	44.4
25-40 years	17,533	1	3	7	18	1,316	19.8	52.4
41-64 years	73,223	1	3	7	17	1,637	20.7	60.3
≥ 65 years	32,207	1	3	7	17	1,270	20.3	57.1
Lefamulin	149	1	23	27	55	664	51.7	77.7

Table 7c. Continuous Summary of All Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Gaps	Distribution of Treatment Episode Gap Durations, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	8	18	21	29	272	61.5	103.3
25-40 years	*****	20	20	20	20	20	20.0	*****
41-64 years	109	1	25	27	55	664	49.9	79.8
≥ 65 years	*****	3	26	26	43	289	56.9	68.4
Ga-68-DOTATOC	115	55	217	363	456	1,155	373.2	206.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	449	449	449	449	449	449.0	*****
41-64 years	*****	55	227	350	437	720	345.9	165.3
≥ 65 years	94	82	217	364	456	1,155	378.2	215.0
Istradefylline	8,041	1	3	7	19	1,288	25.6	75.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	22	1	2	4	7	21	5.7	5.7
41-64 years	1,178	1	3	6	18	1,288	27.6	91.7
≥ 65 years	6,841	1	3	7	20	1,280	25.3	71.9

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>PrabotulinumtoxinA-xvfs</i>	*****	55	55	55	55	55	55.0	*****
<i>Caplacizumab-yhdp</i>	151	1	5	10	20	1,201	41.2	139.7
<i>Triclabendazole</i>	0	-	-	-	-	-	-	-
<i>Brexanolone</i>	*****	1	1	428	854	854	427.5	603.2
<i>Solriamfetol</i>	9,907	1	3	9	24	1,648	34.3	103.3
<i>Siponimod</i>	1,506	1	3	6	16	829	21.5	63.7
<i>Romosozumab-aqqg</i>	78,273	1	27	29	33	1,733	33.5	37.1
<i>Erdafitinib</i>	404	1	4	7	20	845	20.5	59.0
<i>Risankizumab-rzaa</i>	52,756	1	6	22	41	1,881	36.4	72.6
<i>Tafamidis Meglumine</i>	5,447	1	2	6	17	1,623	61.1	189.9
<i>Alpelisib</i>	3,022	1	4	8	20	1,599	23.3	69.0
<i>Polatuzumab Vedotin-piiq</i>	5,098	1	20	20	21	908	24.7	27.3
<i>Bremelanotide</i>	783	1	4	10	27	799	31.9	75.8
<i>Selinexor</i>	1,477	1	4	10	27	1,110	31.2	81.5
<i>Imipenem, Cilastatin and Relebactam</i>	66	1	2	6	26	536	32.5	78.3
<i>Ferric Maltol</i>	1,100	1	6	15	42	740	38.0	69.5
<i>Darolutamide</i>	5,749	1	3	6	19	1,112	21.4	56.0
<i>Pexidartinib</i>	106	1	2	6	13	323	17.5	38.7
<i>Pretomanid</i>	32	1	2	6	9	136	11.8	24.5
<i>Pitolisant</i>	2,542	1	3	7	18	1,329	31.4	103.4
<i>Entrectinib</i>	302	1	4	8	20	1,048	26.4	81.6
<i>Fedratinib</i>	604	1	3	8	20	1,158	25.5	90.0
<i>Upadacitinib</i>	33,100	1	3	7	19	1,637	23.9	70.8

Table 8a. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
<i>Lefamulin</i>	46	1	13	26	52	664	57.5	108.4
<i>Ga-68-DOTATOC</i>	77	55	314	390	512	1,155	435.0	208.3
<i>Istradefylline</i>	2,793	1	3	8	23	1,288	33.2	96.7

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
PrabotulinumtoxinA-xvfs	*****	55	55	55	55	55	55.0	*****
Female	*****	55	55	55	55	55	55.0	*****
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Caplacizumab-yhdp	151	1	5	10	20	1,201	41.2	139.7
Female	100	1	5	9	19	1,029	29.5	108.8
Male	51	1	5	13	27	1,201	64.2	185.1
Triclabendazole	0	-	-	-	-	-	-	-
Female	0	-	-	-	-	-	-	-
Male	0	-	-	-	-	-	-	-
Brexanolone	*****	1	1	428	854	854	427.5	603.2
Female	*****	1	1	428	854	854	427.5	603.2
Male	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Solriamfetol	9,907	1	3	9	24	1,648	34.3	103.3
Female	6,085	1	3	9	23	1,440	32.4	96.9
Male	3,822	1	3	9	25	1,648	37.2	112.8
Siponimod	1,506	1	3	6	16	829	21.5	63.7
Female	1,129	1	3	7	16	829	21.8	64.4
Male	377	1	3	6	14	674	20.5	61.5
Romosozumab-aqqg	78,273	1	27	29	33	1,733	33.5	37.1
Female	76,734	1	27	29	33	1,733	33.5	36.9
Male	1,539	1	27	28	33	1,042	34.4	44.0
Erdafitinib	404	1	4	7	20	845	20.5	59.0
Female	163	1	4	10	23	845	24.4	82.2
Male	241	1	3	7	19	409	17.8	35.5

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Risankizumab-rzaa	52,756	1	6	22	41	1,881	36.4	72.6
Female	26,507	1	6	22	40	1,623	35.5	70.8
Male	26,249	1	7	21	41	1,881	37.2	74.4
Tafamidis Meglumine	5,447	1	2	6	17	1,623	61.1	189.9
Female	1,044	1	3	6	17	1,577	52.0	170.5
Male	4,403	1	2	5	17	1,623	63.3	194.2
Alpelisib	3,022	1	4	8	20	1,599	23.3	69.0
Female	2,926	1	4	8	20	1,599	23.4	69.4
Male	96	1	2	7	14	359	21.5	54.9
Polatuzumab Vedotin-piiq	5,098	1	20	20	21	908	24.7	27.3
Female	2,171	3	20	20	21	908	25.1	30.9
Male	2,927	1	20	20	21	671	24.3	24.3
Bremelanotide	783	1	4	10	27	799	31.9	75.8
Female	761	1	4	10	27	799	31.6	75.9
Male	22	1	5	18	36	265	44.2	73.9
Selinexor	1,477	1	4	10	27	1,110	31.2	81.5
Female	726	1	4	10	27	1,110	30.3	77.4
Male	751	1	4	11	28	1,086	32.0	85.3
Imipenem, Cilastatin and Relebactam	66	1	2	6	26	536	32.5	78.3
Female	37	1	2	6	30	229	27.6	50.4
Male	29	1	2	6	24	536	38.6	104.4
Ferric Maltol	1,100	1	6	15	42	740	38.0	69.5
Female	1,015	1	6	15	42	740	38.2	70.2
Male	85	1	4	12	40	369	35.4	61.0

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Darolutamide	5,749	1	3	6	19	1,112	21.4	56.0
Female	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Male	5,749	1	3	6	19	1,112	21.4	56.0
Pexidartinib	106	1	2	6	13	323	17.5	38.7
Female	66	1	3	7	14	323	20.0	45.6
Male	40	1	2	5	12	107	13.4	22.9
Pretomanid	32	1	2	6	9	136	11.8	24.5
Female	17	1	1	4	7	136	12.2	32.0
Male	15	1	2	7	20	47	11.4	12.3
Pitolisant	2,542	1	3	7	18	1,329	31.4	103.4
Female	1,755	1	3	7	18	1,329	31.2	101.6
Male	787	1	3	7	17	1,275	32.0	107.3
Entrectinib	302	1	4	8	20	1,048	26.4	81.6
Female	178	1	3	7	22	1,048	30.7	99.7
Male	124	1	4	8	19	417	20.2	44.0
Fedratinib	604	1	3	8	20	1,158	25.5	90.0
Female	294	1	4	9	21	1,158	29.9	106.9
Male	310	1	3	8	19	1,041	21.4	70.1
Upadacitinib	33,100	1	3	7	19	1,637	23.9	70.8
Female	24,189	1	3	7	19	1,637	25.0	73.9
Male	8,911	1	3	7	17	1,340	21.2	61.5
Lefamulin	46	1	13	26	52	664	57.5	108.4
Female	23	1	8	20	52	664	64.1	140.0
Male	23	4	19	26	54	289	50.8	65.9

Table 8b. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Sex

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Ga-68-DOTATOC	77	55	314	390	512	1,155	435.0	208.3
Female	36	55	361	434	614	1,133	486.4	219.4
Male	41	84	276	375	455	1,155	389.9	189.3
Istradefylline	2,793	1	3	8	23	1,288	33.2	96.7
Female	1,153	1	3	8	24	1,168	37.2	101.4
Male	1,640	1	3	7	21	1,288	30.3	93.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.
 Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
PrabotulinumtoxinA-xvfs	*****	55	55	55	55	55	55.0	*****
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
41-64 years	*****	55	55	55	55	55	55.0	*****
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Caplacizumab-yhdp	151	1	5	10	20	1,201	41.2	139.7
0-17 years	*****	9	9	59	108	108	58.5	70.0
18-24 years	*****	1	3	9	17	29	10.8	9.7
25-40 years	39	1	3	7	15	335	21.6	54.8
41-64 years	69	1	5	10	19	1,201	57.9	196.4
≥ 65 years	32	1	6	12	27	339	36.6	67.2
Triclabendazole	0	-	-	-	-	-	-	-
0-17 years	0	-	-	-	-	-	-	-
18-24 years	0	-	-	-	-	-	-	-
25-40 years	0	-	-	-	-	-	-	-
41-64 years	0	-	-	-	-	-	-	-
≥ 65 years	0	-	-	-	-	-	-	-
Brexanolone	*****	1	1	428	854	854	427.5	603.2
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	1	428	854	854	427.5	603.2
41-64 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
≥ 65 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
Solriamfetol	9,907	1	3	9	24	1,648	34.3	103.3
0-17 years	41	1	5	10	29	1,414	55.1	219.0
18-24 years	719	1	4	10	26	1,029	33.1	83.5
25-40 years	2,791	1	3	9	23	1,648	32.7	102.9
41-64 years	4,723	1	3	8	23	1,453	33.2	100.5
≥ 65 years	1,633	1	3	9	27	1,393	40.1	114.7
Siponimod	1,506	1	3	6	16	829	21.5	63.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	17	1	2	5	20	158	24.4	42.3
25-40 years	292	1	3	7	18	471	19.9	51.6
41-64 years	1,002	1	3	6	15	829	21.8	66.0
≥ 65 years	195	1	3	6	15	729	22.2	69.7
Romosozumab-aqqg	78,273	1	27	29	33	1,733	33.5	37.1
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	20	9	20	27	38	111	35.3	27.0
25-40 years	158	1	27	28	34	1,042	48.3	102.0
41-64 years	6,874	1	27	29	34	1,733	34.3	46.0
≥ 65 years	71,221	1	27	29	33	1,681	33.4	35.8
Erdafitinib	404	1	4	7	20	845	20.5	59.0
0-17 years	*****	24	24	28	60	60	37.3	19.7
18-24 years	*****	9	9	20	30	30	19.5	14.8
25-40 years	*****	3	5	11	25	66	18.6	22.2
41-64 years	87	1	3	7	19	110	14.7	19.9

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
≥ 65 years	305	1	4	8	20	845	22.0	66.9
Risankizumab-rzaa	52,756	1	6	22	41	1,881	36.4	72.6
0-17 years	144	1	13	27	27	194	25.5	23.1
18-24 years	2,901	1	8	27	40	1,422	39.7	80.7
25-40 years	13,104	1	7	25	42	1,590	38.0	75.8
41-64 years	26,255	1	6	21	42	1,881	36.4	72.7
≥ 65 years	10,352	1	6	21	33	1,379	33.5	65.9
Tafamidis Meglumine	5,447	1	2	6	17	1,623	61.1	189.9
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	4	4	7	9	9	6.7	2.5
41-64 years	*****	1	2	4	15	643	23.6	62.7
≥ 65 years	5,233	1	2	6	17	1,623	62.7	193.2
Alpelisib	3,022	1	4	8	20	1,599	23.3	69.0
0-17 years	56	1	4	10	16	156	17.3	27.1
18-24 years	11	3	10	12	21	47	18.0	14.9
25-40 years	94	1	3	7	13	359	21.3	58.9
41-64 years	1,113	1	4	7	19	845	23.6	69.8
≥ 65 years	1,748	1	4	8	21	1,599	23.5	70.1
Polatuzumab Vedotin-piiq	5,098	1	20	20	21	908	24.7	27.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	11	19	20	21	41	47	28.7	11.2
25-40 years	81	9	20	20	22	347	28.0	38.5

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
41-64 years	669	1	20	20	22	403	24.6	22.7
≥ 65 years	4,337	1	20	20	21	908	24.6	27.8
Bremelanotide	783	1	4	10	27	799	31.9	75.8
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	1	2	5	11	22	7.0	6.6
25-40 years	273	1	4	9	28	799	33.6	82.4
41-64 years	493	1	4	10	27	776	31.7	73.2
≥ 65 years	*****	5	7	10	32	38	18.4	15.4
Selinexor	1,477	1	4	10	27	1,110	31.2	81.5
0-17 years	*****	6	6	23	40	40	23.0	24.0
18-24 years	*****	27	27	27	27	27	27.0	*****
25-40 years	*****	1	5	12	44	858	92.5	226.2
41-64 years	335	1	3	9	26	526	26.2	59.0
≥ 65 years	1,125	1	4	10	27	1,110	31.9	83.9
Imipenem, Cilastatin and Relebactam	66	1	2	6	26	536	32.5	78.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	4	7	9	13	89	24.4	36.3
25-40 years	*****	1	2	7	10	536	57.4	135.4
41-64 years	22	1	1	6	24	60	13.4	16.0
≥ 65 years	21	1	2	6	34	164	32.9	53.4
Ferric Maltol	1,100	1	6	15	42	740	38.0	69.5
0-17 years	11	1	2	10	36	55	18.7	20.4
18-24 years	69	1	5	11	28	232	29.9	49.3

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
25-40 years	443	1	5	13	36	715	34.8	69.8
41-64 years	519	1	6	18	49	740	42.3	72.3
≥ 65 years	58	2	5	12	43	406	37.2	67.3
Darolutamide	5,749	1	3	6	19	1,112	21.4	56.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	86	86	86	86	86	86.0	*****
41-64 years	*****	1	3	6	17	481	18.4	42.1
≥ 65 years	5,115	1	3	6	19	1,112	21.8	57.5
Pexidartinib	106	1	2	6	13	323	17.5	38.7
0-17 years	*****	1	5	10	12	13	8.3	5.1
18-24 years	*****	1	5	9	18	323	48.7	104.7
25-40 years	37	1	2	5	12	107	11.1	18.9
41-64 years	51	1	2	6	14	144	17.8	30.1
≥ 65 years	*****	4	4	9	21	27	13.0	10.5
Pretomanid	32	1	2	6	9	136	11.8	24.5
0-17 years	*****	4	4	4	4	4	4.0	*****
18-24 years	*****	1	1	7	136	136	48.0	76.3
25-40 years	*****	1	1	3	5	9	3.3	2.9
41-64 years	*****	1	2	6	7	9	5.4	2.9
≥ 65 years	14	1	4	9	20	47	12.1	12.5
Pitolisant	2,542	1	3	7	18	1,329	31.4	103.4
0-17 years	25	1	3	7	34	709	62.3	153.3

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						Standard Deviation
		Minimum	Q1	Median	Q3	Maximum	Mean	
18-24 years	321	1	4	8	17	751	25.1	70.0
25-40 years	992	1	3	7	17	1,329	29.9	100.0
41-64 years	935	1	3	7	18	1,277	37.5	122.6
≥ 65 years	269	1	4	7	17	839	20.5	60.4
Entrectinib	302	1	4	8	20	1,048	26.4	81.6
0-17 years	*****	1	4	4	6	56	14.2	23.4
18-24 years	*****	4	4	4	4	4	4.0	*****
25-40 years	*****	1	3	5	10	40	9.0	10.3
41-64 years	111	1	4	7	19	1,048	34.2	119.9
≥ 65 years	164	1	3	9	24	487	23.8	49.8
Fedratinib	604	1	3	8	20	1,158	25.5	90.0
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	3	4	7	25	55	16.8	20.4
41-64 years	*****	1	3	9	21	1,158	33.0	128.1
≥ 65 years	512	1	3	8	20	1,092	24.4	82.5
Upadacitinib	33,100	1	3	7	19	1,637	23.9	70.8
0-17 years	430	1	3	7	18	647	19.3	49.9
18-24 years	1,368	1	3	8	20	666	22.2	48.7
25-40 years	4,979	1	3	7	18	972	21.0	56.1
41-64 years	18,274	1	3	7	18	1,637	24.2	75.4
≥ 65 years	8,049	1	3	8	20	1,270	25.7	72.2
Lefamulin	46	1	13	26	52	664	57.5	108.4

Table 8c. Continuous Summary of First Treatment Episode Gaps for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024, by Age Group

	Total Number of Patients	Distribution of First Treatment Episode Gap Duration, days						
		Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	*****	8	8	15	22	22	15.0	9.9
25-40 years	*****	20	20	20	20	20	20.0	*****
41-64 years	*****	1	5	21	35	664	54.9	136.0
≥ 65 years	19	3	25	27	119	289	67.1	73.0
Ga-68-DOTATOC	77	55	314	390	512	1,155	435.0	208.3
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	449	449	449	449	449	449.0	*****
41-64 years	*****	55	243	358	486	720	362.1	176.5
≥ 65 years	60	84	333	395	526	1,155	454.2	214.8
Istradefylline	2,793	1	3	8	23	1,288	33.2	96.7
0-17 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
18-24 years	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN
25-40 years	*****	1	2	3	4	6	3.0	1.8
41-64 years	*****	1	3	7	20	1,288	40.1	132.2
≥ 65 years	2,376	1	3	8	23	1,168	32.0	89.2

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Data represented by NaN (Not a Number) is due to their inability to be calculated.

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024^{1,2}

	Censoring Reason								
	End of Exposure Episode ³			Occurrence of User-Defined Censoring Criteria ⁴		Disenrollment ⁵		End of Data ⁶	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>PrabotulinumtoxinA-xvfs</i>	11	11	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Caplacizumab-yhdp</i>	635	633	99.7%	0	0.0%	26	4.1%	14	2.2%
<i>Triclabendazole</i>	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Brexanolone</i>	*****	*****	100.0%	0	0.0%	0	0.0%	0	0.0%
<i>Solriamfetol</i>	65,731	65,684	99.9%	0	0.0%	5,757	8.8%	3,202	4.9%
<i>Siponimod</i>	8,469	8,445	99.7%	0	0.0%	1,210	14.3%	613	7.2%
<i>Romosozumab-aqqg</i>	679,745	679,700	100.0%	0	0.0%	1,863	0.3%	1,410	0.2%
<i>Erdafitinib</i>	1,869	1,795	96.0%	0	0.0%	118	6.3%	59	3.2%
<i>Risankizumab-rzaa</i>	242,622	242,285	99.9%	0	0.0%	44,611	18.4%	26,323	10.8%
<i>Tafamidis Meglumine</i>	29,291	28,278	96.5%	0	0.0%	7,526	25.7%	6,092	20.8%
<i>Alpelisib</i>	13,819	13,479	97.5%	0	0.0%	820	5.9%	423	3.1%
<i>Polatuzumab Vedotin-piiq</i>	24,599	24,595	100.0%	0	0.0%	18	0.1%	18	0.1%
<i>Bremelanotide</i>	4,208	4,208	100.0%	0	0.0%	245	5.8%	140	3.3%
<i>Selinexor</i>	6,671	6,351	95.2%	0	0.0%	273	4.1%	160	2.4%
<i>Imipenem, Cilastatin and Relebactam</i>	438	437	99.8%	0	0.0%	*****	*****	*****	*****
<i>Ferric Maltol</i>	5,968	5,967	100.0%	0	0.0%	1,426	23.9%	990	16.6%
<i>Darolutamide</i>	30,357	30,040	99.0%	0	0.0%	4,299	14.2%	3,361	11.1%
<i>Pexidartinib</i>	649	649	100.0%	0	0.0%	71	10.9%	40	6.2%

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024^{1,2}

Censoring Reason									
	Total Number of Episodes	End of Exposure Episode ³		Occurrence of User-Defined Censoring Criteria ⁴		Disenrollment ⁵		End of Data ⁶	
		Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
<i>Pretomanid</i>	122	121	99.2%	0	0.0%	11	9.0%	*****	*****
<i>Pitolisant</i>	13,556	13,540	99.9%	0	0.0%	2,154	15.9%	1,246	9.2%
<i>Entrectinib</i>	1,448	1,394	96.3%	0	0.0%	153	10.6%	84	5.8%
<i>Fedratinib</i>	3,331	3,214	96.5%	0	0.0%	195	5.9%	129	3.9%
<i>Upadacitinib</i>	183,200	182,817	99.8%	0	0.0%	28,009	15.3%	17,466	9.5%
<i>Lefamulin</i>	358	358	100.0%	0	0.0%	*****	*****	0	0.0%
<i>Ga-68-DOTATOC</i>	473	473	100.0%	0	0.0%	*****	*****	0	0.0%
<i>Istradefylline</i>	14,046	13,668	97.3%	0	0.0%	1,693	12.1%	1,151	8.2%

Table 9. Summary of Reasons Treatment Episodes Ended for Exposures of Interest in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024^{1,2}

Censoring Reason								
	End of Exposure Episode ³		Occurrence of User-Defined Censoring Criteria ⁴		Disenrollment ⁵		End of Data ⁶	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Total Number of Episodes								

¹An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

²All reasons for censoring may not be displayed to prevent publication of small cells.

³Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

⁴Represents episodes censored due to occurrence of additional user-defined criteria using drug, procedure, diagnosis, and/or laboratory codes.

⁵Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

⁶Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	PrabotulinumtoxinA-xvfs		Caplacizumab-yhdp		Triclabendazole	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	318,817,616	N/A	318,817,616	N/A	318,817,616	N/A
Had required coverage type (medical and/or drug coverage)	237,760,359	81,057,257	237,760,359	81,057,257	237,760,359	81,057,257
Enrolled during specified age range	237,754,306	6,053	237,754,306	6,053	237,754,306	6,053
Had requestable medical charts	237,754,306	0	237,754,306	0	237,754,306	0
Met demographic requirements (sex, race, and Hispanic origin)	237,667,073	87,233	237,667,073	87,233	237,667,073	87,233
Members with a valid index event						
Had any cohort-defining claim during the query period	13	237,667,060	471	237,666,602	*****	*****
Claim recorded during specified age range	13	0	471	0	*****	0
Episode defining index claim recorded during the query period	13	0	471	0	*****	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	*****	*****	390	81	*****	0
Met inclusion and exclusion criteria	*****	*****	390	0	*****	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	*****	0	390	0	*****	0
Final cohort						
Number of members	*****	N/A	390	N/A	*****	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Brexanolone		Solriamfetol		Siponimod	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	318,817,616	N/A	318,817,616	N/A	318,817,616	N/A
Had required coverage type (medical and/or drug coverage)	237,760,359	81,057,257	237,760,359	81,057,257	237,760,359	81,057,257
Enrolled during specified age range	237,754,306	6,053	237,754,306	6,053	237,754,306	6,053
Had requestable medical charts	237,754,306	0	237,754,306	0	237,754,306	0
Met demographic requirements (sex, race, and Hispanic origin)	237,667,073	87,233	237,667,073	87,233	237,667,073	87,233
Members with a valid index event						
Had any cohort-defining claim during the query period	189	237,666,884	18,283	237,648,790	2,756	237,664,317
Claim recorded during specified age range	189	0	18,283	0	2,756	0
Episode defining index claim recorded during the query period	189	0	18,283	0	2,756	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	164	25	15,947	2,336	2,286	470
Met inclusion and exclusion criteria	164	0	15,947	0	2,286	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	164	0	15,947	0	2,286	0
Final cohort						
Number of members	164	N/A	15,947	N/A	2,286	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Romosozumab-aqqg		Erdafitinib		Risankizumab-rzaa	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	318,817,616	N/A	318,817,616	N/A	318,817,616	N/A
Had required coverage type (medical and/or drug coverage)	237,760,359	81,057,257	237,760,359	81,057,257	237,760,359	81,057,257
Enrolled during specified age range	237,754,306	6,053	237,754,306	6,053	237,754,306	6,053
Had requestable medical charts	237,754,306	0	237,754,306	0	237,754,306	0
Met demographic requirements (sex, race, and Hispanic origin)	237,667,073	87,233	237,667,073	87,233	237,667,073	87,233
Members with a valid index event						
Had any cohort-defining claim during the query period	93,344	237,573,729	956	237,666,117	89,961	237,577,112
Claim recorded during specified age range	93,344	0	956	0	89,961	0
Episode defining index claim recorded during the query period	93,344	0	956	0	89,961	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	87,634	5,710	848	108	76,821	13,140
Met inclusion and exclusion criteria	87,634	0	848	0	76,821	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	87,634	0	848	0	76,821	0
Final cohort						
Number of members	87,634	N/A	848	N/A	76,821	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Tafamidis Meglumine		Alpelisib		Polatuzumab Vedotin-piiq	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	318,817,616	N/A	318,817,616	N/A	318,817,616	N/A
Had required coverage type (medical and/or drug coverage)	237,760,359	81,057,257	237,760,359	81,057,257	237,760,359	81,057,257
Enrolled during specified age range	237,754,306	6,053	237,754,306	6,053	237,754,306	6,053
Had requestable medical charts	237,754,306	0	237,754,306	0	237,754,306	0
Met demographic requirements (sex, race, and Hispanic origin)	237,667,073	87,233	237,667,073	87,233	237,667,073	87,233
Members with a valid index event						
Had any cohort-defining claim during the query period	12,467	237,654,606	6,931	237,660,142	7,162	237,659,911
Claim recorded during specified age range	12,467	0	6,931	0	7,162	0
Episode defining index claim recorded during the query period	12,467	0	6,931	0	7,162	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	11,217	1,250	6,242	689	6,512	650
Met inclusion and exclusion criteria	11,217	0	6,242	0	6,512	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	11,217	0	6,242	0	6,512	0
Final cohort						
Number of members	11,217	N/A	6,242	N/A	6,512	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Bremelanotide		Selinexor		Imipenem, Cilastatin and Relebactam	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	318,817,616	N/A	318,817,616	N/A	318,817,616	N/A
Had required coverage type (medical and/or drug coverage)	237,760,359	81,057,257	237,760,359	81,057,257	237,760,359	81,057,257
Enrolled during specified age range	237,754,306	6,053	237,754,306	6,053	237,754,306	6,053
Had requestable medical charts	237,754,306	0	237,754,306	0	237,754,306	0
Met demographic requirements (sex, race, and Hispanic origin)	237,667,073	87,233	237,667,073	87,233	237,667,073	87,233
Members with a valid index event						
Had any cohort-defining claim during the query period	2,799	237,664,274	3,728	237,663,345	169	237,666,904
Claim recorded during specified age range	2,799	0	3,728	0	169	0
Episode defining index claim recorded during the query period	2,799	0	3,728	0	169	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	2,426	373	3,486	242	152	17
Met inclusion and exclusion criteria	2,426	0	3,486	0	152	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	2,426	0	3,486	0	152	0
Final cohort						
Number of members	2,426	N/A	3,486	N/A	152	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Ferric Maltol		Darolutamide		Pexidartinib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	318,817,616	N/A	318,817,616	N/A	318,817,616	N/A
Had required coverage type (medical and/or drug coverage)	237,760,359	81,057,257	237,760,359	81,057,257	237,760,359	81,057,257
Enrolled during specified age range	237,754,306	6,053	237,754,306	6,053	237,754,306	6,053
Had requestable medical charts	237,754,306	0	237,754,306	0	237,754,306	0
Met demographic requirements (sex, race, and Hispanic origin)	237,667,073	87,233	237,667,073	87,233	237,667,073	87,233
Members with a valid index event						
Had any cohort-defining claim during the query period	4,703	237,662,370	11,099	237,655,974	187	237,666,886
Claim recorded during specified age range	4,703	0	11,099	0	187	0
Episode defining index claim recorded during the query period	4,703	0	11,099	0	187	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	4,069	634	9,618	1,481	160	27
Met inclusion and exclusion criteria	4,069	0	9,618	0	160	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	4,069	0	9,618	0	160	0
Final cohort						
Number of members	4,069	N/A	9,618	N/A	160	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Pretomanid		Pitolisant		Entrectinib	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	318,817,616	N/A	318,817,616	N/A	318,817,616	N/A
Had required coverage type (medical and/or drug coverage)	237,760,359	81,057,257	237,760,359	81,057,257	237,760,359	81,057,257
Enrolled during specified age range	237,754,306	6,053	237,754,306	6,053	237,754,306	6,053
Had requestable medical charts	237,754,306	0	237,754,306	0	237,754,306	0
Met demographic requirements (sex, race, and Hispanic origin)	237,667,073	87,233	237,667,073	87,233	237,667,073	87,233
Members with a valid index event						
Had any cohort-defining claim during the query period	*****	*****	5,963	237,661,110	686	237,666,387
Claim recorded during specified age range	*****	0	5,963	0	686	0
Episode defining index claim recorded during the query period	*****	0	5,963	0	686	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	*****	*****	5,055	908	602	84
Met inclusion and exclusion criteria	*****	*****	5,055	0	602	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	51	0	5,055	0	602	0
Final cohort						
Number of members	51	N/A	5,055	N/A	602	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Fedratinib		Upadacitinib		Lefamulin	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	318,817,616	N/A	318,817,616	N/A	318,817,616	N/A
Had required coverage type (medical and/or drug coverage)	237,760,359	81,057,257	237,760,359	81,057,257	237,760,359	81,057,257
Enrolled during specified age range	237,754,306	6,053	237,754,306	6,053	237,754,306	6,053
Had requestable medical charts	237,754,306	0	237,754,306	0	237,754,306	0
Met demographic requirements (sex, race, and Hispanic origin)	237,667,073	87,233	237,667,073	87,233	237,667,073	87,233
Members with a valid index event						
Had any cohort-defining claim during the query period	1,130	237,665,943	64,021	237,603,052	233	237,666,840
Claim recorded during specified age range	1,130	0	64,021	0	233	0
Episode defining index claim recorded during the query period	1,130	0	64,021	0	233	0
Members with required pre-index history						
Had sufficient pre-index continuous enrollment	1,055	75	54,390	9,631	209	24
Met inclusion and exclusion criteria	1,055	0	54,390	0	209	0
Members with required post-index follow-up						
Had sufficient post-index continuous enrollment	1,055	0	54,390	0	209	0
Final cohort						
Number of members	1,055	N/A	54,390	N/A	209	N/A

Table 10. Summary of Patient-Level Cohort Attrition in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

	Ga-68-DOTATOC		Istradefylline	
	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements				
Enrolled at any point during the query period	318,817,616	N/A	318,817,616	N/A
Had required coverage type (medical and/or drug coverage)	237,760,359	81,057,257	237,760,359	81,057,257
Enrolled during specified age range	237,754,306	6,053	237,754,306	6,053
Had requestable medical charts	237,754,306	0	237,754,306	0
Met demographic requirements (sex, race, and Hispanic origin)	237,667,073	87,233	237,667,073	87,233
Members with a valid index event				
Had any cohort-defining claim during the query period	389	237,666,684	6,676	237,660,397
Claim recorded during specified age range	389	0	6,676	0
Episode defining index claim recorded during the query period	389	0	6,676	0
Members with required pre-index history				
Had sufficient pre-index continuous enrollment	358	31	6,005	671
Met inclusion and exclusion criteria	358	0	6,005	0
Members with required post-index follow-up				
Had sufficient post-index continuous enrollment	358	0	6,005	0
Final cohort				
Number of members	358	N/A	6,005	N/A

N/A: Not Applicable

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Figure 1a. Patient Entry into Study by Month for PrabotulinumtoxinA-xvfs in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on February 1, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>

Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1b. Patient Entry into Study by Month for Caplacizumab-yhdp in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on February 6, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>

Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1c. Patient Entry into Study by Month for Triclabendazole in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on February 13, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>

Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1d. Patient Entry into Study by Month for Brexanolone in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on March 19, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>

Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1e. Patient Entry into Study by Month for Solriamfetol in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on March 20, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>




Figure 1f. Patient Entry into Study by Month for Siponimod in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on March 26, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>




Figure 1g. Patient Entry into Study by Month for Romosozumab-aqcg in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on April 9, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>




Figure 1h. Patient Entry into Study by Month for Erdafitinib in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on April 12, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>

Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1i. Patient Entry into Study by Month for Risankizumab-rzaa in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on April 23, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>




Figure 1j. Patient Entry into Study by Month for Tafamidis Meglumine in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on May 3, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>




Figure 1k. Patient Entry into Study by Month for Alpelisib in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on May 24, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>




Figure 11. Patient Entry into Study by Month for Polatuzumab Vedotin-piiq in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on June 10, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>




Figure 1m. Patient Entry into Study by Month for Bremelanotide in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on June 21, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>




Figure 1n. Patient Entry into Study by Month for Selinexor in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on July 3, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>




Figure 1o. Patient Entry into Study by Month for Imipenem, Cilastatin and Relebactam in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on July 16, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>

Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1p. Patient Entry into Study by Month for Ferric Maltol in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on July 25, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>




Figure 1q. Patient Entry into Study by Month for Darolutamide in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on July 30, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>




Figure 1r. Patient Entry into Study by Month for Pexidartinib in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on August 2, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>

Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1s. Patient Entry into Study by Month for Pretomanid in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on August 14, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>

Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1t. Patient Entry into Study by Month for Pitolisant in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on August 14, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>




Figure 1u. Patient Entry into Study by Month for Entrectinib in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on August 15, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>

Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1v. Patient Entry into Study by Month for Fedratinib in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on August 16, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>




Figure 1w. Patient Entry into Study by Month for Upadacitinib in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on August 16, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>




Figure 1x. Patient Entry into Study by Month for Lefamulin in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on August 19, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>

Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.


Figure 1y. Patient Entry into Study by Month for Ga-68-DOTATOC in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on August 21, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>

Data are not presented due to a small sample size or to ensure a small cell cannot be recalculated through the data presented.

Figure 1z. Patient Entry into Study by Month for Istradefylline in the Sentinel Distributed Database from January 1, 2019 to December 31, 2024

The FDA approval date for this drug was on August 27, 2019, as listed on the FDA website <https://www.fda.gov/media/147414/download>



Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (May 22, 2025)

Masked DP ID	DP Start Date	DP End Date ¹
DP01	01/01/2004	03/31/2024
DP02	01/01/2005	07/31/2022
DP03	01/01/2008	08/31/2024
DP04	01/01/2006	10/31/2024
DP05	01/01/2000	01/31/2024
DP06	01/01/2000	04/30/2024
DP07	01/01/2000	04/30/2024
DP08	01/01/2000	01/31/2024
DP09	01/01/2000	04/30/2024
DP10	01/01/2007	06/30/2024
DP11	01/01/2014	12/31/2021
DP12	01/01/2008	12/31/2024
DP13	01/01/2010	06/30/2024

¹End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request

Generic Name	Brand Name
PrabotulinumtoxinA-xvfs	
prabotulinumtoxinA-xvfs	Jeuveau
Caplacizumab-yhdp	
caplacizumab-yhdp	Cablivi
Triclabendazole	
triclabendazole	Egaten
Brexanolone	
brexanolone	Zulresso
Solriamfetol	
solriamfetol HCl	Sunosi
Siponimod	
siponimod	Mayzent
siponimod	Mayzent Starter(for 1mg maint)
siponimod	Mayzent Starter(for 2mg maint)
Romosozumab-aqqg	
romosozumab-aqqg	Evenity
Erdaftinib	
erdaftinib	Balversa
Risankizumab-rzaa	
risankizumab-rzaa	Skyrizi
Tafamidis Meglumine	
tafamidis	Vyndama
tafamidis meglumine	Vyndaqel
Polatuzumab Vedotin-piiq	
polatuzumab vedotin-piiq	Polivy
Bremelanotide	
bremelano	Vyleesi
bremelanotide acetate	Vyleesi
Selinexor	
selinexor	Xpovio
Imipenem Cilastatin and Relebactam	
imipenem/cilastatin sodium/relebactam	Recarbrio
Ferric Maltol	
ferric maltol	Accrufer
Darolutamide	
darolutamide	Nubeqa
Pexidartinib	

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request

Generic Name	Brand Name
pexidartinib hydrochloride	Turalio
Pretomanid	
pretomanid	pretomanid
Pitolisant	
pitolisant HCl	Wakix
Entrectinib	
entrectinib	Rozlytrek
Fedratinib	
fedratinib dihydrochloride	Inrebic
Upadacitinib	
upadacitinib	Rinvoq
upadacitinib	Rinvoq ER
upadacitinib	Rinvoq LQ
Lefamulin	
lefamulin acetate	Xenleta
Ga-68-DOTATOC	
gallium Ga-68 dotatoc	gallium Ga-68 dotatoc
Istradefylline	
istradefylline	Nourianz

Appendix C. List of Healthcare Common Procedure Coding System, Level II (HCPCS) and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exposures in this Request

Code	Description	Code Category	Code Type
Caplacizumab-yhdp			
C9047	Injection, caplacizumab-yhdp, 1 mg	Procedure	HCPCS
XW013W5	Introduction of Caplacizumab into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW033W5	Introduction of Caplacizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW043W5	Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
Brexanolone			
C9055	Injection, brexanolone, 1 mg	Procedure	HCPCS
J1632	Injection, brexanolone, 1 mg	Procedure	HCPCS
XW03306	Introduction of Brexanolone into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW04306	Introduction of Brexanolone into Central Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
Romozumab-aqqg			
J3111	Injection, romozumab-aqqg, 1 mg	Procedure	HCPCS
Risankizumab-rzaa			
J2327	Injection, risankizumab-rzaa, intravenous, 1 mg	Procedure	HCPCS
Polatuzumab Vedotin-piiq			
J9309	Injection, polatuzumab vedotin-piiq, 1 mg	Procedure	HCPCS
Imipenem Cilastatin and Relebactam			
J0742	Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg	Procedure	HCPCS
Lefamulin			
C9054	Injection, lefamulin (Xenleta), 1 mg	Procedure	HCPCS
J0691	Injection, lefamulin, 1 mg	Procedure	HCPCS
XW03366	Introduction of Lefamulin Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW04366	Introduction of Lefamulin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 6	Procedure	ICD-10-PCS
XW0DX66	Introduction of Lefamulin Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 6	Procedure	ICD-10-PCS
Ga-68-DOTATOC			
C9067	Gallium Ga-68, Dotatoc, diagnostic, 0.01 mCi	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Acquired Hypothyroidism			
E00.0	Congenital iodine-deficiency syndrome, neurological type	Diagnosis	ICD-10-CM
E00.1	Congenital iodine-deficiency syndrome, myxedematous type	Diagnosis	ICD-10-CM
E00.2	Congenital iodine-deficiency syndrome, mixed type	Diagnosis	ICD-10-CM
E00.9	Congenital iodine-deficiency syndrome, unspecified	Diagnosis	ICD-10-CM
E01.8	Other iodine-deficiency related thyroid disorders and allied conditions	Diagnosis	ICD-10-CM
E02	Subclinical iodine-deficiency hypothyroidism	Diagnosis	ICD-10-CM
E03.0	Congenital hypothyroidism with diffuse goiter	Diagnosis	ICD-10-CM
E03.1	Congenital hypothyroidism without goiter	Diagnosis	ICD-10-CM
E03.2	Hypothyroidism due to medicaments and other exogenous substances	Diagnosis	ICD-10-CM
E03.3	Postinfectious hypothyroidism	Diagnosis	ICD-10-CM
E03.4	Atrophy of thyroid (acquired)	Diagnosis	ICD-10-CM
E03.8	Other specified hypothyroidism	Diagnosis	ICD-10-CM
E03.9	Hypothyroidism, unspecified	Diagnosis	ICD-10-CM
E89.0	Postprocedural hypothyroidism	Diagnosis	ICD-10-CM
Alcohol Abuse			
F10.10	Alcohol abuse, uncomplicated	Diagnosis	ICD-10-CM
F10.11	Alcohol abuse, in remission	Diagnosis	ICD-10-CM
F10.120	Alcohol abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.121	Alcohol abuse with intoxication delirium	Diagnosis	ICD-10-CM
F10.129	Alcohol abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.130	Alcohol abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.131	Alcohol abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F10.132	Alcohol abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.139	Alcohol abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F10.14	Alcohol abuse with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.180	Alcohol abuse with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.182	Alcohol abuse with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.188	Alcohol abuse with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.19	Alcohol abuse with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.20	Alcohol dependence, uncomplicated	Diagnosis	ICD-10-CM
F10.21	Alcohol dependence, in remission	Diagnosis	ICD-10-CM
F10.220	Alcohol dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.221	Alcohol dependence with intoxication delirium	Diagnosis	ICD-10-CM
F10.229	Alcohol dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.230	Alcohol dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.231	Alcohol dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F10.232	Alcohol dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.239	Alcohol dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.24	Alcohol dependence with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.26	Alcohol dependence with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.27	Alcohol dependence with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.280	Alcohol dependence with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.282	Alcohol dependence with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.288	Alcohol dependence with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.29	Alcohol dependence with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.920	Alcohol use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F10.921	Alcohol use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F10.929	Alcohol use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F10.930	Alcohol use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F10.931	Alcohol use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F10.932	Alcohol use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F10.939	Alcohol use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder	Diagnosis	ICD-10-CM
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnestic disorder	Diagnosis	ICD-10-CM
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia	Diagnosis	ICD-10-CM
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder	Diagnosis	ICD-10-CM
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction	Diagnosis	ICD-10-CM
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder	Diagnosis	ICD-10-CM
F10.988	Alcohol use, unspecified with other alcohol-induced disorder	Diagnosis	ICD-10-CM
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder	Diagnosis	ICD-10-CM
G62.1	Alcoholic polyneuropathy	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
K29.20	Alcoholic gastritis without bleeding	Diagnosis	ICD-10-CM
K29.21	Alcoholic gastritis with bleeding	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
R78.0	Finding of alcohol in blood	Diagnosis	ICD-10-CM
T51.0X1A	Toxic effect of ethanol, accidental (unintentional), initial encounter	Procedure	ICD-10-PCS
T51.0X2A	Toxic effect of ethanol, intentional self-harm, initial encounter	Procedure	ICD-10-PCS
T51.0X3A	Toxic effect of ethanol, assault, initial encounter	Procedure	ICD-10-PCS
T51.0X4A	Toxic effect of ethanol, undetermined, initial encounter	Procedure	ICD-10-PCS
Z65.8	Other specified problems related to psychosocial circumstances	Diagnosis	ICD-10-CM
Z71.41	Alcohol abuse counseling and surveillance of alcoholic	Diagnosis	ICD-10-CM
Alzheimers			
G30.0	Alzheimer's disease with early onset	Diagnosis	ICD-10-CM
G30.1	Alzheimer's disease with late onset	Diagnosis	ICD-10-CM
G30.8	Other Alzheimer's disease	Diagnosis	ICD-10-CM
G30.9	Alzheimer's disease, unspecified	Diagnosis	ICD-10-CM
Acute Myocardial Infarction			
I21.01	ST elevation (STEMI) myocardial infarction involving left main coronary artery	Diagnosis	ICD-10-CM
I21.02	ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery	Diagnosis	ICD-10-CM
I21.09	ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall	Diagnosis	ICD-10-CM
I21.11	ST elevation (STEMI) myocardial infarction involving right coronary artery	Diagnosis	ICD-10-CM
I21.19	ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall	Diagnosis	ICD-10-CM
I21.21	ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery	Diagnosis	ICD-10-CM
I21.29	ST elevation (STEMI) myocardial infarction involving other sites	Diagnosis	ICD-10-CM
I21.3	ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I21.4	Non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I21.9	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CM
I21.A1	Myocardial infarction type 2	Diagnosis	ICD-10-CM
I21.A9	Other myocardial infarction type	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I21.B	Myocardial infarction with coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I22.0	Subsequent ST elevation (STEMI) myocardial infarction of anterior wall	Diagnosis	ICD-10-CM
I22.1	Subsequent ST elevation (STEMI) myocardial infarction of inferior wall	Diagnosis	ICD-10-CM
I22.2	Subsequent non-ST elevation (NSTEMI) myocardial infarction	Diagnosis	ICD-10-CM
I22.8	Subsequent ST elevation (STEMI) myocardial infarction of other sites	Diagnosis	ICD-10-CM
I22.9	Subsequent ST elevation (STEMI) myocardial infarction of unspecified site	Diagnosis	ICD-10-CM
I23.0	Hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.1	Atrial septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.2	Ventricular septal defect as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.3	Rupture of cardiac wall without hemopericardium as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.4	Rupture of chordae tendineae as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.5	Rupture of papillary muscle as current complication following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.6	Thrombosis of atrium, auricular appendage, and ventricle as current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
I23.7	Postinfarction angina	Diagnosis	ICD-10-CM
I23.8	Other current complications following acute myocardial infarction	Diagnosis	ICD-10-CM
Anemia			
C94.6	Myelodysplastic disease, not elsewhere classified	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.4	Osteomyelofibrosis	Diagnosis	ICD-10-CM
D50.0	Iron deficiency anemia secondary to blood loss (chronic)	Diagnosis	ICD-10-CM
D50.1	Sideropenic dysphagia	Diagnosis	ICD-10-CM
D50.8	Other iron deficiency anemias	Diagnosis	ICD-10-CM
D50.9	Iron deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D51.0	Vitamin B12 deficiency anemia due to intrinsic factor deficiency	Diagnosis	ICD-10-CM
D51.1	Vitamin B12 deficiency anemia due to selective vitamin B12 malabsorption with proteinuria	Diagnosis	ICD-10-CM
D51.2	Transcobalamin II deficiency	Diagnosis	ICD-10-CM
D51.3	Other dietary vitamin B12 deficiency anemia	Diagnosis	ICD-10-CM
D51.8	Other vitamin B12 deficiency anemias	Diagnosis	ICD-10-CM
D51.9	Vitamin B12 deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D52.0	Dietary folate deficiency anemia	Diagnosis	ICD-10-CM
D52.1	Drug-induced folate deficiency anemia	Diagnosis	ICD-10-CM
D52.8	Other folate deficiency anemias	Diagnosis	ICD-10-CM
D52.9	Folate deficiency anemia, unspecified	Diagnosis	ICD-10-CM
D53.0	Protein deficiency anemia	Diagnosis	ICD-10-CM
D53.1	Other megaloblastic anemias, not elsewhere classified	Diagnosis	ICD-10-CM
D53.2	Scorbutic anemia	Diagnosis	ICD-10-CM
D53.8	Other specified nutritional anemias	Diagnosis	ICD-10-CM
D53.9	Nutritional anemia, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D55.0	Anemia due to glucose-6-phosphate dehydrogenase [G6PD] deficiency	Diagnosis	ICD-10-CM
D55.1	Anemia due to other disorders of glutathione metabolism	Diagnosis	ICD-10-CM
D55.2	Anemia due to disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.21	Anemia due to pyruvate kinase deficiency	Diagnosis	ICD-10-CM
D55.29	Anemia due to other disorders of glycolytic enzymes	Diagnosis	ICD-10-CM
D55.3	Anemia due to disorders of nucleotide metabolism	Diagnosis	ICD-10-CM
D55.8	Other anemias due to enzyme disorders	Diagnosis	ICD-10-CM
D55.9	Anemia due to enzyme disorder, unspecified	Diagnosis	ICD-10-CM
D56.0	Alpha thalassemia	Diagnosis	ICD-10-CM
D56.1	Beta thalassemia	Diagnosis	ICD-10-CM
D56.2	Delta-beta thalassemia	Diagnosis	ICD-10-CM
D56.3	Thalassemia minor	Diagnosis	ICD-10-CM
D56.4	Hereditary persistence of fetal hemoglobin [HPFH]	Diagnosis	ICD-10-CM
D56.5	Hemoglobin E-beta thalassemia	Diagnosis	ICD-10-CM
D56.8	Other thalassemias	Diagnosis	ICD-10-CM
D56.9	Thalassemia, unspecified	Diagnosis	ICD-10-CM
D57.00	Hb-SS disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.01	Hb-SS disease with acute chest syndrome	Diagnosis	ICD-10-CM
D57.02	Hb-SS disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.03	Hb-SS disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.04	Hb-SS disease with dactylitis	Diagnosis	ICD-10-CM
D57.09	Hb-SS disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.1	Sickle-cell disease without crisis	Diagnosis	ICD-10-CM
D57.20	Sickle-cell/Hb-C disease without crisis	Diagnosis	ICD-10-CM
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D57.212	Sickle-cell/Hb-C disease with splenic sequestration	Diagnosis	ICD-10-CM
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.214	Sickle-cell/Hb-C disease with dactylitis	Diagnosis	ICD-10-CM
D57.218	Sickle-cell/Hb-C disease with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.219	Sickle-cell/Hb-C disease with crisis, unspecified	Diagnosis	ICD-10-CM
D57.3	Sickle-cell trait	Diagnosis	ICD-10-CM
D57.40	Sickle-cell thalassemia without crisis	Diagnosis	ICD-10-CM
D57.411	Sickle-cell thalassemia, unspecified, with acute chest syndrome	Diagnosis	ICD-10-CM
D57.412	Sickle-cell thalassemia, unspecified, with splenic sequestration	Diagnosis	ICD-10-CM
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.414	Sickle-cell thalassemia, unspecified, with dactylitis	Diagnosis	ICD-10-CM
D57.418	Sickle-cell thalassemia, unspecified, with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.419	Sickle-cell thalassemia, unspecified, with crisis	Diagnosis	ICD-10-CM
D57.42	Sickle-cell thalassemia beta zero without crisis	Diagnosis	ICD-10-CM
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome	Diagnosis	ICD-10-CM
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration	Diagnosis	ICD-10-CM
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.434	Sickle-cell thalassemia beta zero with dactylitis	Diagnosis	ICD-10-CM
D57.438	Sickle-cell thalassemia beta zero with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.439	Sickle-cell thalassemia beta zero with crisis, unspecified	Diagnosis	ICD-10-CM
D57.44	Sickle-cell thalassemia beta plus without crisis	Diagnosis	ICD-10-CM
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome	Diagnosis	ICD-10-CM
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration	Diagnosis	ICD-10-CM
D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.454	Sickle-cell thalassemia beta plus with dactylitis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D57.458	Sickle-cell thalassemia beta plus with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.459	Sickle-cell thalassemia beta plus with crisis, unspecified	Diagnosis	ICD-10-CM
D57.80	Other sickle-cell disorders without crisis	Diagnosis	ICD-10-CM
D57.811	Other sickle-cell disorders with acute chest syndrome	Diagnosis	ICD-10-CM
D57.812	Other sickle-cell disorders with splenic sequestration	Diagnosis	ICD-10-CM
D57.813	Other sickle-cell disorders with cerebral vascular involvement	Diagnosis	ICD-10-CM
D57.814	Other sickle-cell disorders with dactylitis	Diagnosis	ICD-10-CM
D57.818	Other sickle-cell disorders with crisis with other specified complication	Diagnosis	ICD-10-CM
D57.819	Other sickle-cell disorders with crisis, unspecified	Diagnosis	ICD-10-CM
D58.0	Hereditary spherocytosis	Diagnosis	ICD-10-CM
D58.1	Hereditary elliptocytosis	Diagnosis	ICD-10-CM
D58.2	Other hemoglobinopathies	Diagnosis	ICD-10-CM
D58.8	Other specified hereditary hemolytic anemias	Diagnosis	ICD-10-CM
D58.9	Hereditary hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.0	Drug-induced autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.1	Other autoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.10	Autoimmune hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D59.11	Warm autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.12	Cold autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.13	Mixed type autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.19	Other autoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.2	Drug-induced nonautoimmune hemolytic anemia	Diagnosis	ICD-10-CM
D59.3	Hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.30	Hemolytic-uremic syndrome, unspecified	Diagnosis	ICD-10-CM
D59.31	Infection-associated hemolytic-uremic syndrome	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D59.32	Hereditary hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.39	Other hemolytic-uremic syndrome	Diagnosis	ICD-10-CM
D59.4	Other nonautoimmune hemolytic anemias	Diagnosis	ICD-10-CM
D59.5	Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]	Diagnosis	ICD-10-CM
D59.6	Hemoglobinuria due to hemolysis from other external causes	Diagnosis	ICD-10-CM
D59.8	Other acquired hemolytic anemias	Diagnosis	ICD-10-CM
D59.9	Acquired hemolytic anemia, unspecified	Diagnosis	ICD-10-CM
D60.0	Chronic acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.1	Transient acquired pure red cell aplasia	Diagnosis	ICD-10-CM
D60.8	Other acquired pure red cell aplasias	Diagnosis	ICD-10-CM
D60.9	Acquired pure red cell aplasia, unspecified	Diagnosis	ICD-10-CM
D61.01	Constitutional (pure) red blood cell aplasia	Diagnosis	ICD-10-CM
D61.02	Shwachman-Diamond syndrome	Diagnosis	ICD-10-CM
D61.09	Other constitutional aplastic anemia	Diagnosis	ICD-10-CM
D61.1	Drug-induced aplastic anemia	Diagnosis	ICD-10-CM
D61.2	Aplastic anemia due to other external agents	Diagnosis	ICD-10-CM
D61.3	Idiopathic aplastic anemia	Diagnosis	ICD-10-CM
D61.810	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-10-CM
D61.811	Other drug-induced pancytopenia	Diagnosis	ICD-10-CM
D61.818	Other pancytopenia	Diagnosis	ICD-10-CM
D61.82	Myelophthisis	Diagnosis	ICD-10-CM
D61.89	Other specified aplastic anemias and other bone marrow failure syndromes	Diagnosis	ICD-10-CM
D61.9	Aplastic anemia, unspecified	Diagnosis	ICD-10-CM
D63.0	Anemia in neoplastic disease	Diagnosis	ICD-10-CM
D63.1	Anemia in chronic kidney disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D63.8	Anemia in other chronic diseases classified elsewhere	Diagnosis	ICD-10-CM
D64.0	Hereditary sideroblastic anemia	Diagnosis	ICD-10-CM
D64.1	Secondary sideroblastic anemia due to disease	Diagnosis	ICD-10-CM
D64.2	Secondary sideroblastic anemia due to drugs and toxins	Diagnosis	ICD-10-CM
D64.3	Other sideroblastic anemias	Diagnosis	ICD-10-CM
D64.4	Congenital dyserythropoietic anemia	Diagnosis	ICD-10-CM
D64.81	Anemia due to antineoplastic chemotherapy	Diagnosis	ICD-10-CM
D64.89	Other specified anemias	Diagnosis	ICD-10-CM
D64.9	Anemia, unspecified	Diagnosis	ICD-10-CM
D75.81	Myelofibrosis	Diagnosis	ICD-10-CM
Asthma			
J45.20	Mild intermittent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.21	Mild intermittent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.22	Mild intermittent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.30	Mild persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.31	Mild persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.32	Mild persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.40	Moderate persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.41	Moderate persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.42	Moderate persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.50	Severe persistent asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.51	Severe persistent asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.52	Severe persistent asthma with status asthmaticus	Diagnosis	ICD-10-CM
J45.901	Unspecified asthma with (acute) exacerbation	Diagnosis	ICD-10-CM
J45.902	Unspecified asthma with status asthmaticus	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
J45.909	Unspecified asthma, uncomplicated	Diagnosis	ICD-10-CM
J45.990	Exercise induced bronchospasm	Diagnosis	ICD-10-CM
J45.991	Cough variant asthma	Diagnosis	ICD-10-CM
J45.998	Other asthma	Diagnosis	ICD-10-CM
Atrial Fibrillation			
I48.0	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CM
I48.1	Persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.11	Longstanding persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.19	Other persistent atrial fibrillation	Diagnosis	ICD-10-CM
I48.2	Chronic atrial fibrillation	Diagnosis	ICD-10-CM
I48.20	Chronic atrial fibrillation, unspecified	Diagnosis	ICD-10-CM
I48.21	Permanent atrial fibrillation	Diagnosis	ICD-10-CM
I48.3	Typical atrial flutter	Diagnosis	ICD-10-CM
I48.4	Atypical atrial flutter	Diagnosis	ICD-10-CM
I48.91	Unspecified atrial fibrillation	Diagnosis	ICD-10-CM
Benign Prostatic Hyperplasia			
N40.0	Benign prostatic hyperplasia without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.1	Benign prostatic hyperplasia with lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.2	Nodular prostate without lower urinary tract symptoms	Diagnosis	ICD-10-CM
N40.3	Nodular prostate with lower urinary tract symptoms	Diagnosis	ICD-10-CM
Breast Cancer			
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
D05.00	Lobular carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.01	Lobular carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.02	Lobular carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.10	Intraductal carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.11	Intraductal carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.12	Intraductal carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.80	Other specified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.81	Other specified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.82	Other specified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
D05.90	Unspecified type of carcinoma in situ of unspecified breast	Diagnosis	ICD-10-CM
D05.91	Unspecified type of carcinoma in situ of right breast	Diagnosis	ICD-10-CM
D05.92	Unspecified type of carcinoma in situ of left breast	Diagnosis	ICD-10-CM
Z17.0	Estrogen receptor positive status [ER+]	Diagnosis	ICD-10-CM
Z17.1	Estrogen receptor negative status [ER-]	Diagnosis	ICD-10-CM
Z19.1	Hormone sensitive malignancy status	Diagnosis	ICD-10-CM
Z19.2	Hormone resistant malignancy status	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z86.000	Personal history of in-situ neoplasm of breast	Diagnosis	ICD-10-CM
Cardiac Arrest			
I46.2	Cardiac arrest due to underlying cardiac condition	Diagnosis	ICD-10-CM
I46.8	Cardiac arrest due to other underlying condition	Diagnosis	ICD-10-CM
I46.9	Cardiac arrest, cause unspecified	Diagnosis	ICD-10-CM
I97.120	Postprocedural cardiac arrest following cardiac surgery	Diagnosis	ICD-10-CM
I97.121	Postprocedural cardiac arrest following other surgery	Diagnosis	ICD-10-CM
I97.710	Intraoperative cardiac arrest during cardiac surgery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I97.711	Intraoperative cardiac arrest during other surgery	Diagnosis	ICD-10-CM
Z86.74	Personal history of sudden cardiac arrest	Diagnosis	ICD-10-CM
Chronic Kidney Disease			
A18.11	Tuberculosis of kidney and ureter	Diagnosis	ICD-10-CM
A52.75	Syphilis of kidney and ureter	Diagnosis	ICD-10-CM
B52.0	Plasmodium malariae malaria with nephropathy	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
M10.30	Gout due to renal impairment, unspecified site	Diagnosis	ICD-10-CM
M10.311	Gout due to renal impairment, right shoulder	Diagnosis	ICD-10-CM
M10.312	Gout due to renal impairment, left shoulder	Diagnosis	ICD-10-CM
M10.319	Gout due to renal impairment, unspecified shoulder	Diagnosis	ICD-10-CM
M10.321	Gout due to renal impairment, right elbow	Diagnosis	ICD-10-CM
M10.322	Gout due to renal impairment, left elbow	Diagnosis	ICD-10-CM
M10.329	Gout due to renal impairment, unspecified elbow	Diagnosis	ICD-10-CM
M10.331	Gout due to renal impairment, right wrist	Diagnosis	ICD-10-CM
M10.332	Gout due to renal impairment, left wrist	Diagnosis	ICD-10-CM
M10.339	Gout due to renal impairment, unspecified wrist	Diagnosis	ICD-10-CM
M10.341	Gout due to renal impairment, right hand	Diagnosis	ICD-10-CM
M10.342	Gout due to renal impairment, left hand	Diagnosis	ICD-10-CM
M10.349	Gout due to renal impairment, unspecified hand	Diagnosis	ICD-10-CM
M10.351	Gout due to renal impairment, right hip	Diagnosis	ICD-10-CM
M10.352	Gout due to renal impairment, left hip	Diagnosis	ICD-10-CM
M10.359	Gout due to renal impairment, unspecified hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M10.361	Gout due to renal impairment, right knee	Diagnosis	ICD-10-CM
M10.362	Gout due to renal impairment, left knee	Diagnosis	ICD-10-CM
M10.369	Gout due to renal impairment, unspecified knee	Diagnosis	ICD-10-CM
M10.371	Gout due to renal impairment, right ankle and foot	Diagnosis	ICD-10-CM
M10.372	Gout due to renal impairment, left ankle and foot	Diagnosis	ICD-10-CM
M10.379	Gout due to renal impairment, unspecified ankle and foot	Diagnosis	ICD-10-CM
M10.38	Gout due to renal impairment, vertebrae	Diagnosis	ICD-10-CM
M10.39	Gout due to renal impairment, multiple sites	Diagnosis	ICD-10-CM
M32.14	Glomerular disease in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M32.15	Tubulo-interstitial nephropathy in systemic lupus erythematosus	Diagnosis	ICD-10-CM
M35.04	Sjogren syndrome with tubulo-interstitial nephropathy	Diagnosis	ICD-10-CM
M35.0A	Sjogren syndrome with glomerular disease	Diagnosis	ICD-10-CM
N01.0	Rapidly progressive nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N01.1	Rapidly progressive nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N01.2	Rapidly progressive nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N01.3	Rapidly progressive nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.4	Rapidly progressive nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N01.5	Rapidly progressive nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N01.6	Rapidly progressive nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N01.7	Rapidly progressive nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N01.8	Rapidly progressive nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N01.9	Rapidly progressive nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N01.A	Rapidly progressive nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.0	Recurrent and persistent hematuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N02.1	Recurrent and persistent hematuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N02.2	Recurrent and persistent hematuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.3	Recurrent and persistent hematuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.4	Recurrent and persistent hematuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.5	Recurrent and persistent hematuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.6	Recurrent and persistent hematuria with dense deposit disease	Diagnosis	ICD-10-CM
N02.7	Recurrent and persistent hematuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N02.8	Recurrent and persistent hematuria with other morphologic changes	Diagnosis	ICD-10-CM
N02.9	Recurrent and persistent hematuria with unspecified morphologic changes	Diagnosis	ICD-10-CM
N02.A	Recurrent and persistent hematuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N02.B1	Recurrent and persistent immunoglobulin A nephropathy with glomerular lesion	Diagnosis	ICD-10-CM
N02.B2	Recurrent and persistent immunoglobulin A nephropathy with focal and segmental glomerular lesion	Diagnosis	ICD-10-CM
N02.B3	Recurrent and persistent immunoglobulin A nephropathy with diffuse membranoproliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.B4	Recurrent and persistent immunoglobulin A nephropathy with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N02.B5	Recurrent and persistent immunoglobulin A nephropathy with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N02.B6	Recurrent and persistent immunoglobulin A nephropathy with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N02.B9	Other recurrent and persistent immunoglobulin A nephropathy	Diagnosis	ICD-10-CM
N03.0	Chronic nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N03.1	Chronic nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N03.2	Chronic nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N03.3	Chronic nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N03.4	Chronic nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N03.5	Chronic nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N03.6	Chronic nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N03.7	Chronic nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N03.8	Chronic nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N03.9	Chronic nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N03.A	Chronic nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N04.0	Nephrotic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N04.1	Nephrotic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N04.2	Nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.20	Nephrotic syndrome with diffuse membranous glomerulonephritis, unspecified	Diagnosis	ICD-10-CM
N04.21	Primary membranous nephropathy with nephrotic syndrome	Diagnosis	ICD-10-CM
N04.22	Secondary membranous nephropathy with nephrotic syndrome	Diagnosis	ICD-10-CM
N04.29	Other nephrotic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N04.3	Nephrotic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.4	Nephrotic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N04.5	Nephrotic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N04.6	Nephrotic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N04.7	Nephrotic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N04.8	Nephrotic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N04.9	Nephrotic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N04.A	Nephrotic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N05.0	Unspecified nephritic syndrome with minor glomerular abnormality	Diagnosis	ICD-10-CM
N05.1	Unspecified nephritic syndrome with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N05.2	Unspecified nephritic syndrome with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N05.3	Unspecified nephritic syndrome with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.4	Unspecified nephritic syndrome with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N05.5	Unspecified nephritic syndrome with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N05.6	Unspecified nephritic syndrome with dense deposit disease	Diagnosis	ICD-10-CM
N05.7	Unspecified nephritic syndrome with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N05.8	Unspecified nephritic syndrome with other morphologic changes	Diagnosis	ICD-10-CM
N05.9	Unspecified nephritic syndrome with unspecified morphologic changes	Diagnosis	ICD-10-CM
N05.A	Unspecified nephritic syndrome with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N06.0	Isolated proteinuria with minor glomerular abnormality	Diagnosis	ICD-10-CM
N06.1	Isolated proteinuria with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM
N06.2	Isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.20	Isolated proteinuria with diffuse membranous glomerulonephritis, unspecified	Diagnosis	ICD-10-CM
N06.21	Primary membranous nephropathy with isolated proteinuria	Diagnosis	ICD-10-CM
N06.22	Secondary membranous nephropathy with isolated proteinuria	Diagnosis	ICD-10-CM
N06.29	Other isolated proteinuria with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N06.3	Isolated proteinuria with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.4	Isolated proteinuria with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N06.5	Isolated proteinuria with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N06.6	Isolated proteinuria with dense deposit disease	Diagnosis	ICD-10-CM
N06.7	Isolated proteinuria with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N06.8	Isolated proteinuria with other morphologic lesion	Diagnosis	ICD-10-CM
N06.9	Isolated proteinuria with unspecified morphologic lesion	Diagnosis	ICD-10-CM
N06.A	Isolated proteinuria with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N07.0	Hereditary nephropathy, not elsewhere classified with minor glomerular abnormality	Diagnosis	ICD-10-CM
N07.1	Hereditary nephropathy, not elsewhere classified with focal and segmental glomerular lesions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N07.2	Hereditary nephropathy, not elsewhere classified with diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CM
N07.3	Hereditary nephropathy, not elsewhere classified with diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.4	Hereditary nephropathy, not elsewhere classified with diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CM
N07.5	Hereditary nephropathy, not elsewhere classified with diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CM
N07.6	Hereditary nephropathy, not elsewhere classified with dense deposit disease	Diagnosis	ICD-10-CM
N07.7	Hereditary nephropathy, not elsewhere classified with diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CM
N07.8	Hereditary nephropathy, not elsewhere classified with other morphologic lesions	Diagnosis	ICD-10-CM
N07.9	Hereditary nephropathy, not elsewhere classified with unspecified morphologic lesions	Diagnosis	ICD-10-CM
N07.A	Hereditary nephropathy, not elsewhere classified with C3 glomerulonephritis	Diagnosis	ICD-10-CM
N08	Glomerular disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N14.0	Analgesic nephropathy	Diagnosis	ICD-10-CM
N14.1	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.11	Contrast-induced nephropathy	Diagnosis	ICD-10-CM
N14.19	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CM
N14.2	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CM
N14.3	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CM
N14.4	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CM
N15.0	Balkan nephropathy	Diagnosis	ICD-10-CM
N15.8	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CM
N15.9	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CM
N16	Renal tubulo-interstitial disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
N18.1	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CM
N18.2	Chronic kidney disease, stage 2 (mild)	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
N18.3	Chronic kidney disease, stage 3 (moderate)	Diagnosis	ICD-10-CM
N18.30	Chronic kidney disease, stage 3 unspecified	Diagnosis	ICD-10-CM
N18.31	Chronic kidney disease, stage 3a	Diagnosis	ICD-10-CM
N18.32	Chronic kidney disease, stage 3b	Diagnosis	ICD-10-CM
N18.4	Chronic kidney disease, stage 4 (severe)	Diagnosis	ICD-10-CM
N18.5	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CM
N18.6	End stage renal disease	Diagnosis	ICD-10-CM
N18.9	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CM
N25.1	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CM
N25.89	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CM
N25.9	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CM
N26.1	Atrophy of kidney (terminal)	Diagnosis	ICD-10-CM
N26.9	Renal sclerosis, unspecified	Diagnosis	ICD-10-CM
N99.0	Postprocedural (acute) (chronic) kidney failure	Diagnosis	ICD-10-CM
Q61.02	Congenital multiple renal cysts	Diagnosis	ICD-10-CM
Q61.11	Cystic dilatation of collecting ducts	Diagnosis	ICD-10-CM
Q61.19	Other polycystic kidney, infantile type	Diagnosis	ICD-10-CM
Q61.2	Polycystic kidney, adult type	Diagnosis	ICD-10-CM
Q61.3	Polycystic kidney, unspecified	Diagnosis	ICD-10-CM
Q61.4	Renal dysplasia	Diagnosis	ICD-10-CM
Q61.5	Medullary cystic kidney	Diagnosis	ICD-10-CM
Q61.8	Other cystic kidney diseases	Diagnosis	ICD-10-CM
Colorectal Cancer			
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
D01.0	Carcinoma in situ of colon	Diagnosis	ICD-10-CM
D01.1	Carcinoma in situ of rectosigmoid junction	Diagnosis	ICD-10-CM
D01.2	Carcinoma in situ of rectum	Diagnosis	ICD-10-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Chronic Obstructive Pulmonary Disease			
J40	Bronchitis, not specified as acute or chronic	Diagnosis	ICD-10-CM
J41.0	Simple chronic bronchitis	Diagnosis	ICD-10-CM
J41.1	Mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J41.8	Mixed simple and mucopurulent chronic bronchitis	Diagnosis	ICD-10-CM
J42	Unspecified chronic bronchitis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
J43.0	Unilateral pulmonary emphysema [MacLeod's syndrome]	Diagnosis	ICD-10-CM
J43.1	Panlobular emphysema	Diagnosis	ICD-10-CM
J43.2	Centrilobular emphysema	Diagnosis	ICD-10-CM
J43.9	Emphysema, unspecified	Diagnosis	ICD-10-CM
J44.0	Chronic obstructive pulmonary disease with (acute) lower respiratory infection	Diagnosis	ICD-10-CM
J44.1	Chronic obstructive pulmonary disease with (acute) exacerbation	Diagnosis	ICD-10-CM
J44.81	Bronchiolitis obliterans and bronchiolitis obliterans syndrome	Diagnosis	ICD-10-CM
J44.89	Other specified chronic obstructive pulmonary disease	Diagnosis	ICD-10-CM
J44.9	Chronic obstructive pulmonary disease, unspecified	Diagnosis	ICD-10-CM
J47.0	Bronchiectasis with acute lower respiratory infection	Diagnosis	ICD-10-CM
J47.1	Bronchiectasis with (acute) exacerbation	Diagnosis	ICD-10-CM
J47.9	Bronchiectasis, uncomplicated	Diagnosis	ICD-10-CM
J98.2	Interstitial emphysema	Diagnosis	ICD-10-CM
J98.3	Compensatory emphysema	Diagnosis	ICD-10-CM
Coronary Angioplasty Bypass			
00566	Anesthesia for direct coronary artery bypass grafting; without pump oxygenator	Procedure	CPT-4
00567	Anesthesia for direct coronary artery bypass grafting; with pump oxygenator	Procedure	CPT-4
02104Z3	Bypass Coronary Artery, One Artery from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02114Z3	Bypass Coronary Artery, Two Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02124Z3	Bypass Coronary Artery, Three Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02134Z3	Bypass Coronary Artery, Four or More Arteries from Coronary Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270346	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
027034Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0270356	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027035Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270366	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027036Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0270376	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027037Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
02703GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02703T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02703Z6	Dilation of Coronary Artery, One Artery, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02703ZZ	Dilation of Coronary Artery, One Artery, Percutaneous Approach	Procedure	ICD-10-PCS
0270446	Dilation of Coronary Artery, One Artery, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027044Z	Dilation of Coronary Artery, One Artery with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270456	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027045Z	Dilation of Coronary Artery, One Artery with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270466	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027046Z	Dilation of Coronary Artery, One Artery with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0270476	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027047Z	Dilation of Coronary Artery, One Artery with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
02704D6	Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704DZ	Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704E6	Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704EZ	Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704F6	Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704FZ	Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704G6	Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704GZ	Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704T6	Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704TZ	Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704Z6	Dilation of Coronary Artery, One Artery, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02704ZZ	Dilation of Coronary Artery, One Artery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271346	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
027134Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0271356	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027135Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271366	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027136Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0271376	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027137Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
02713GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02713T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02713Z6	Dilation of Coronary Artery, Two Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02713ZZ	Dilation of Coronary Artery, Two Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
0271446	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027144Z	Dilation of Coronary Artery, Two Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271456	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027145Z	Dilation of Coronary Artery, Two Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271466	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027146Z	Dilation of Coronary Artery, Two Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0271476	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027147Z	Dilation of Coronary Artery, Two Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
02714D6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714DZ	Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714E6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714EZ	Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714F6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714FZ	Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714G6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714GZ	Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714T6	Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714TZ	Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714Z6	Dilation of Coronary Artery, Two Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02714ZZ	Dilation of Coronary Artery, Two Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272346	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
027234Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0272356	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027235Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0272366	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027236Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0272376	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027237Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
02723GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02723T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02723Z6	Dilation of Coronary Artery, Three Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02723ZZ	Dilation of Coronary Artery, Three Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
0272446	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027244Z	Dilation of Coronary Artery, Three Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272456	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027245Z	Dilation of Coronary Artery, Three Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272466	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027246Z	Dilation of Coronary Artery, Three Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0272476	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027247Z	Dilation of Coronary Artery, Three Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
02724D6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724DZ	Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724E6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724EZ	Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724F6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724FZ	Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724G6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724GZ	Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724T6	Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724TZ	Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724Z6	Dilation of Coronary Artery, Three Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02724ZZ	Dilation of Coronary Artery, Three Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273346	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
027334Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0273356	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027335Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0273366	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027336Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
0273376	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
027337Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
02733G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Approach	Procedure	ICD-10-PCS
02733T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
02733Z6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Approach	Procedure	ICD-10-PCS
02733ZZ	Dilation of Coronary Artery, Four or More Arteries, Percutaneous Approach	Procedure	ICD-10-PCS
0273446	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027344Z	Dilation of Coronary Artery, Four or More Arteries with Drug-eluting Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273456	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027345Z	Dilation of Coronary Artery, Four or More Arteries with Two Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273466	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
027346Z	Dilation of Coronary Artery, Four or More Arteries with Three Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0273476	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
027347Z	Dilation of Coronary Artery, Four or More Arteries with Four or More Drug-eluting Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734D6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734DZ	Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734E6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734EZ	Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734F6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734FZ	Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734G6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734GZ	Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734T6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734TZ	Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734Z6	Dilation of Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
02734ZZ	Dilation of Coronary Artery, Four or More Arteries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0644T	Transcatheter removal or debulking of intracardiac mass (eg, vegetations, thrombus) via suction (eg, vacuum, aspiration) device, percutaneous approach, with intraoperative reinfusion of aspirated blood, including imaging guidance, when performed	Procedure	CPT-3
33508	Endoscopy, surgical, including video-assisted harvest of vein(s) for coronary artery bypass procedure (List separately in addition to code for primary procedure)	Procedure	CPT-4
33509	Harvest of upper extremity artery, 1 segment, for coronary artery bypass procedure, endoscopic	Procedure	CPT-4
33510	Coronary artery bypass, vein only; single coronary venous graft	Procedure	CPT-4
33511	Coronary artery bypass, vein only; 2 coronary venous grafts	Procedure	CPT-4
33512	Coronary artery bypass, vein only; 3 coronary venous grafts	Procedure	CPT-4
33513	Coronary artery bypass, vein only; 4 coronary venous grafts	Procedure	CPT-4
33514	Coronary artery bypass, vein only; 5 coronary venous grafts	Procedure	CPT-4
33516	Coronary artery bypass, vein only; 6 or more coronary venous grafts	Procedure	CPT-4
33517	Coronary artery bypass, using venous graft(s) and arterial graft(s); single vein graft (List separately in addition to code for primary procedure)	Procedure	CPT-4
33518	Coronary artery bypass, using venous graft(s) and arterial graft(s); 2 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33519	Coronary artery bypass, using venous graft(s) and arterial graft(s); 3 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33520	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Single Graft	Procedure	CPT-4
33521	Coronary artery bypass, using venous graft(s) and arterial graft(s); 4 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33522	Coronary artery bypass, using venous graft(s) and arterial graft(s); 5 venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4
33523	Coronary artery bypass, using venous graft(s) and arterial graft(s); 6 or more venous grafts (List separately in addition to code for primary procedure)	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
33525	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Two Coronary Grafts	Procedure	CPT-4
33528	Coronary Artery Bypass, Nonautogenous Graft (eg, Synthetic Or Cadaver); Three Or More Coronary Grafts	Procedure	CPT-4
33530	Reoperation, coronary artery bypass procedure or valve procedure, more than 1 month after original operation (List separately in addition to code for primary procedure)	Procedure	CPT-4
33533	Coronary artery bypass, using arterial graft(s); single arterial graft	Procedure	CPT-4
33534	Coronary artery bypass, using arterial graft(s); 2 coronary arterial grafts	Procedure	CPT-4
33535	Coronary artery bypass, using arterial graft(s); 3 coronary arterial grafts	Procedure	CPT-4
33536	Coronary artery bypass, using arterial graft(s); 4 or more coronary arterial grafts	Procedure	CPT-4
33572	Coronary endarterectomy, open, any method, of left anterior descending, circumflex, or right coronary artery performed in conjunction with coronary artery bypass graft procedure, each vessel (List separately in addition to primary procedure)	Procedure	CPT-4
35500	Harvest of upper extremity vein, 1 segment, for lower extremity or coronary artery bypass procedure (List separately in addition to code for primary procedure)	Procedure	CPT-4
35600	Harvest of upper extremity artery, 1 segment, for coronary artery bypass procedure, open	Procedure	CPT-4
4110F	Internal mammary artery graft performed for primary, isolated coronary artery bypass graft procedure (CABG)	Procedure	CPT-2
92920	Percutaneous transluminal coronary angioplasty; single major coronary artery or branch	Procedure	CPT-4
92921	Percutaneous transluminal coronary angioplasty; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92924	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92925	Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
92928	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92929	Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92933	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	CPT-4
92934	Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)	Procedure	CPT-4
92937	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single	Procedure	CPT-4
92938	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each ad	Procedure	CPT-4
92941	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty, including aspirati	Procedure	CPT-4
92943	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	CPT-4
92944	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of intracoronary stent, atherectomy and angioplasty; each additional coronary artery, co	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C9600	Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch	Procedure	HCPCS
C9601	Percutaneous transcatheter placement of drug-eluting intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9602	Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch	Procedure	HCPCS
C9603	Percutaneous transluminal coronary atherectomy, with drug-eluting intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)	Procedure	HCPCS
C9604	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when perfo	Procedure	HCPCS
C9605	Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when perfo	Procedure	HCPCS
C9606	Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, inclu	Procedure	HCPCS
C9607	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; single vessel	Procedure	HCPCS
C9608	Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; each additional corona	Procedure	HCPCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
S2205	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), single coronary arterial graft	Procedure	HCPCS
S2206	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using arterial graft(s), two coronary arterial grafts	Procedure	HCPCS
S2207	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using venous graft only, single coronary venous graft	Procedure	HCPCS
S2208	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using single arterial and venous graft(s), single venous graft	Procedure	HCPCS
S2209	Minimally invasive direct coronary artery bypass surgery involving mini-thoracotomy or mini-sternotomy surgery, performed under direct vision; using two arterial grafts and single venous graft	Procedure	HCPCS
T82.2	Mechanical complication of coronary artery bypass graft and biological heart valve graft	Diagnosis	ICD-10-CM
T82.21	Mechanical complication of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.211	Breakdown (mechanical) of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.211A	Breakdown (mechanical) of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.211D	Breakdown (mechanical) of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.211S	Breakdown (mechanical) of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
T82.212	Displacement of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.212A	Displacement of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.212D	Displacement of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.212S	Displacement of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
T82.213	Leakage of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.213A	Leakage of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.213D	Leakage of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.213S	Leakage of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
T82.218	Other mechanical complication of coronary artery bypass graft	Diagnosis	ICD-10-CM
T82.218A	Other mechanical complication of coronary artery bypass graft, initial encounter	Diagnosis	ICD-10-CM
T82.218D	Other mechanical complication of coronary artery bypass graft, subsequent encounter	Diagnosis	ICD-10-CM
T82.218S	Other mechanical complication of coronary artery bypass graft, sequela	Diagnosis	ICD-10-CM
Z95.1	Presence of aortocoronary bypass graft	Diagnosis	ICD-10-CM
Z95.5	Presence of coronary angioplasty implant and graft	Diagnosis	ICD-10-CM
Z98.61	Coronary angioplasty status	Diagnosis	ICD-10-CM

Dementia

F01.50	Vascular dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.51	Vascular dementia, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F01.511	Vascular dementia, unspecified severity, with agitation	Diagnosis	ICD-10-CM
F01.518	Vascular dementia, unspecified severity, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.52	Vascular dementia, unspecified severity, with psychotic disturbance	Diagnosis	ICD-10-CM
F01.53	Vascular dementia, unspecified severity, with mood disturbance	Diagnosis	ICD-10-CM
F01.54	Vascular dementia, unspecified severity, with anxiety	Diagnosis	ICD-10-CM
F01.A0	Vascular dementia, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.A11	Vascular dementia, mild, with agitation	Diagnosis	ICD-10-CM
F01.A18	Vascular dementia, mild, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.A2	Vascular dementia, mild, with psychotic disturbance	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F01.A3	Vascular dementia, mild, with mood disturbance	Diagnosis	ICD-10-CM
F01.A4	Vascular dementia, mild, with anxiety	Diagnosis	ICD-10-CM
F01.B0	Vascular dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.B11	Vascular dementia, moderate, with agitation	Diagnosis	ICD-10-CM
F01.B18	Vascular dementia, moderate, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.B2	Vascular dementia, moderate, with psychotic disturbance	Diagnosis	ICD-10-CM
F01.B3	Vascular dementia, moderate, with mood disturbance	Diagnosis	ICD-10-CM
F01.B4	Vascular dementia, moderate, with anxiety	Diagnosis	ICD-10-CM
F01.C0	Vascular dementia, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F01.C11	Vascular dementia, severe, with agitation	Diagnosis	ICD-10-CM
F01.C18	Vascular dementia, severe, with other behavioral disturbance	Diagnosis	ICD-10-CM
F01.C2	Vascular dementia, severe, with psychotic disturbance	Diagnosis	ICD-10-CM
F01.C3	Vascular dementia, severe, with mood disturbance	Diagnosis	ICD-10-CM
F01.C4	Vascular dementia, severe, with anxiety	Diagnosis	ICD-10-CM
F02.80	Dementia in other diseases classified elsewhere, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.81	Dementia in other diseases classified elsewhere, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F02.811	Dementia in other diseases classified elsewhere, unspecified severity, with agitation	Diagnosis	ICD-10-CM
F02.818	Dementia in other diseases classified elsewhere, unspecified severity, with other behavioral disturbance	Diagnosis	ICD-10-CM
F02.82	Dementia in other diseases classified elsewhere, unspecified severity, with psychotic disturbance	Diagnosis	ICD-10-CM
F02.83	Dementia in other diseases classified elsewhere, unspecified severity, with mood disturbance	Diagnosis	ICD-10-CM
F02.84	Dementia in other diseases classified elsewhere, unspecified severity, with anxiety	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F02.A0	Dementia in other diseases classified elsewhere, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.A11	Dementia in other diseases classified elsewhere, mild, with agitation	Diagnosis	ICD-10-CM
F02.A18	Dementia in other diseases classified elsewhere, mild, with other behavioral disturbance	Diagnosis	ICD-10-CM
F02.A2	Dementia in other diseases classified elsewhere, mild, with psychotic disturbance	Diagnosis	ICD-10-CM
F02.A3	Dementia in other diseases classified elsewhere, mild, with mood disturbance	Diagnosis	ICD-10-CM
F02.A4	Dementia in other diseases classified elsewhere, mild, with anxiety	Diagnosis	ICD-10-CM
F02.B0	Dementia in other diseases classified elsewhere, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.B11	Dementia in other diseases classified elsewhere, moderate, with agitation	Diagnosis	ICD-10-CM
F02.B18	Dementia in other diseases classified elsewhere, moderate, with other behavioral disturbance	Diagnosis	ICD-10-CM
F02.B2	Dementia in other diseases classified elsewhere, moderate, with psychotic disturbance	Diagnosis	ICD-10-CM
F02.B3	Dementia in other diseases classified elsewhere, moderate, with mood disturbance	Diagnosis	ICD-10-CM
F02.B4	Dementia in other diseases classified elsewhere, moderate, with anxiety	Diagnosis	ICD-10-CM
F02.C0	Dementia in other diseases classified elsewhere, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F02.C11	Dementia in other diseases classified elsewhere, severe, with agitation	Diagnosis	ICD-10-CM
F02.C18	Dementia in other diseases classified elsewhere, severe, with other behavioral disturbance	Diagnosis	ICD-10-CM
F02.C2	Dementia in other diseases classified elsewhere, severe, with psychotic disturbance	Diagnosis	ICD-10-CM
F02.C3	Dementia in other diseases classified elsewhere, severe, with mood disturbance	Diagnosis	ICD-10-CM
F02.C4	Dementia in other diseases classified elsewhere, severe, with anxiety	Diagnosis	ICD-10-CM
F03.90	Unspecified dementia, unspecified severity, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.91	Unspecified dementia, unspecified severity, with behavioral disturbance	Diagnosis	ICD-10-CM
F03.911	Unspecified dementia, unspecified severity, with agitation	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F03.918	Unspecified dementia, unspecified severity, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.92	Unspecified dementia, unspecified severity, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.93	Unspecified dementia, unspecified severity, with mood disturbance	Diagnosis	ICD-10-CM
F03.94	Unspecified dementia, unspecified severity, with anxiety	Diagnosis	ICD-10-CM
F03.A0	Unspecified dementia, mild, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.A11	Unspecified dementia, mild, with agitation	Diagnosis	ICD-10-CM
F03.A18	Unspecified dementia, mild, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.A2	Unspecified dementia, mild, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.A3	Unspecified dementia, mild, with mood disturbance	Diagnosis	ICD-10-CM
F03.A4	Unspecified dementia, mild, with anxiety	Diagnosis	ICD-10-CM
F03.B0	Unspecified dementia, moderate, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.B11	Unspecified dementia, moderate, with agitation	Diagnosis	ICD-10-CM
F03.B18	Unspecified dementia, moderate, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.B2	Unspecified dementia, moderate, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.B3	Unspecified dementia, moderate, with mood disturbance	Diagnosis	ICD-10-CM
F03.B4	Unspecified dementia, moderate, with anxiety	Diagnosis	ICD-10-CM
F03.C0	Unspecified dementia, severe, without behavioral disturbance, psychotic disturbance, mood disturbance, and anxiety	Diagnosis	ICD-10-CM
F03.C11	Unspecified dementia, severe, with agitation	Diagnosis	ICD-10-CM
F03.C18	Unspecified dementia, severe, with other behavioral disturbance	Diagnosis	ICD-10-CM
F03.C2	Unspecified dementia, severe, with psychotic disturbance	Diagnosis	ICD-10-CM
F03.C3	Unspecified dementia, severe, with mood disturbance	Diagnosis	ICD-10-CM
F03.C4	Unspecified dementia, severe, with anxiety	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F05	Delirium due to known physiological condition	Diagnosis	ICD-10-CM
G13.8	Systemic atrophy primarily affecting central nervous system in other diseases classified elsewhere	Diagnosis	ICD-10-CM
G31.01	Pick's disease	Diagnosis	ICD-10-CM
G31.09	Other frontotemporal neurocognitive disorder	Diagnosis	ICD-10-CM
G31.1	Senile degeneration of brain, not elsewhere classified	Diagnosis	ICD-10-CM
G31.2	Degeneration of nervous system due to alcohol	Diagnosis	ICD-10-CM
G31.83	Neurocognitive disorder with Lewy bodies	Diagnosis	ICD-10-CM
G94	Other disorders of brain in diseases classified elsewhere	Diagnosis	ICD-10-CM
R41.81	Age-related cognitive decline	Diagnosis	ICD-10-CM
Depression			
F06.31	Mood disorder due to known physiological condition with depressive features	Diagnosis	ICD-10-CM
F06.32	Mood disorder due to known physiological condition with major depressive-like episode	Diagnosis	ICD-10-CM
F31.0	Bipolar disorder, current episode hypomanic	Diagnosis	ICD-10-CM
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified	Diagnosis	ICD-10-CM
F31.11	Bipolar disorder, current episode manic without psychotic features, mild	Diagnosis	ICD-10-CM
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate	Diagnosis	ICD-10-CM
F31.13	Bipolar disorder, current episode manic without psychotic features, severe	Diagnosis	ICD-10-CM
F31.2	Bipolar disorder, current episode manic severe with psychotic features	Diagnosis	ICD-10-CM
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified	Diagnosis	ICD-10-CM
F31.31	Bipolar disorder, current episode depressed, mild	Diagnosis	ICD-10-CM
F31.32	Bipolar disorder, current episode depressed, moderate	Diagnosis	ICD-10-CM
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.60	Bipolar disorder, current episode mixed, unspecified	Diagnosis	ICD-10-CM
F31.61	Bipolar disorder, current episode mixed, mild	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F31.62	Bipolar disorder, current episode mixed, moderate	Diagnosis	ICD-10-CM
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features	Diagnosis	ICD-10-CM
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features	Diagnosis	ICD-10-CM
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic	Diagnosis	ICD-10-CM
F31.73	Bipolar disorder, in partial remission, most recent episode manic	Diagnosis	ICD-10-CM
F31.75	Bipolar disorder, in partial remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.76	Bipolar disorder, in full remission, most recent episode depressed	Diagnosis	ICD-10-CM
F31.77	Bipolar disorder, in partial remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.78	Bipolar disorder, in full remission, most recent episode mixed	Diagnosis	ICD-10-CM
F31.81	Bipolar II disorder	Diagnosis	ICD-10-CM
F31.89	Other bipolar disorder	Diagnosis	ICD-10-CM
F31.9	Bipolar disorder, unspecified	Diagnosis	ICD-10-CM
F32.0	Major depressive disorder, single episode, mild	Diagnosis	ICD-10-CM
F32.1	Major depressive disorder, single episode, moderate	Diagnosis	ICD-10-CM
F32.2	Major depressive disorder, single episode, severe without psychotic features	Diagnosis	ICD-10-CM
F32.3	Major depressive disorder, single episode, severe with psychotic features	Diagnosis	ICD-10-CM
F32.4	Major depressive disorder, single episode, in partial remission	Diagnosis	ICD-10-CM
F32.5	Major depressive disorder, single episode, in full remission	Diagnosis	ICD-10-CM
F32.8	Other depressive episodes	Diagnosis	ICD-10-CM
F32.89	Other specified depressive episodes	Diagnosis	ICD-10-CM
F32.9	Major depressive disorder, single episode, unspecified	Diagnosis	ICD-10-CM
F32.A	Depression, unspecified	Diagnosis	ICD-10-CM
F33.0	Major depressive disorder, recurrent, mild	Diagnosis	ICD-10-CM
F33.1	Major depressive disorder, recurrent, moderate	Diagnosis	ICD-10-CM
F33.2	Major depressive disorder, recurrent severe without psychotic features	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms	Diagnosis	ICD-10-CM
F33.40	Major depressive disorder, recurrent, in remission, unspecified	Diagnosis	ICD-10-CM
F33.41	Major depressive disorder, recurrent, in partial remission	Diagnosis	ICD-10-CM
F33.42	Major depressive disorder, recurrent, in full remission	Diagnosis	ICD-10-CM
F33.8	Other recurrent depressive disorders	Diagnosis	ICD-10-CM
F33.9	Major depressive disorder, recurrent, unspecified	Diagnosis	ICD-10-CM
F34.0	Cyclothymic disorder	Diagnosis	ICD-10-CM
F34.1	Dysthymic disorder	Diagnosis	ICD-10-CM
F43.21	Adjustment disorder with depressed mood	Diagnosis	ICD-10-CM
F43.23	Adjustment disorder with mixed anxiety and depressed mood	Diagnosis	ICD-10-CM
Diabetes			

E08.00	Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E08.01	Diabetes mellitus due to underlying condition with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E08.10	Diabetes mellitus due to underlying condition with ketoacidosis without coma	Diagnosis	ICD-10-CM
E08.11	Diabetes mellitus due to underlying condition with ketoacidosis with coma	Diagnosis	ICD-10-CM
E08.21	Diabetes mellitus due to underlying condition with diabetic nephropathy	Diagnosis	ICD-10-CM
E08.22	Diabetes mellitus due to underlying condition with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E08.29	Diabetes mellitus due to underlying condition with other diabetic kidney complication	Diagnosis	ICD-10-CM
E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.321	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3219	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.329	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3291	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3292	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3299	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.331	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3319	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.339	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3391	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3392	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3399	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.341	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3419	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.349	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3491	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3492	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3499	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.351	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3519	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.3521	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3522	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3529	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3531	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E08.3532	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E08.3539	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E08.3541	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E08.3542	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E08.3549	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E08.3551	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E08.3552	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.3559	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E08.359	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E08.3599	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E08.36	Diabetes mellitus due to underlying condition with diabetic cataract	Diagnosis	ICD-10-CM
E08.37X1	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E08.37X2	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E08.37X3	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E08.37X9	Diabetes mellitus due to underlying condition with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E08.39	Diabetes mellitus due to underlying condition with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E08.40	Diabetes mellitus due to underlying condition with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E08.41	Diabetes mellitus due to underlying condition with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E08.42	Diabetes mellitus due to underlying condition with diabetic polyneuropathy	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E08.43	Diabetes mellitus due to underlying condition with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E08.44	Diabetes mellitus due to underlying condition with diabetic amyotrophy	Diagnosis	ICD-10-CM
E08.49	Diabetes mellitus due to underlying condition with other diabetic neurological complication	Diagnosis	ICD-10-CM
E08.51	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E08.52	Diabetes mellitus due to underlying condition with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E08.59	Diabetes mellitus due to underlying condition with other circulatory complications	Diagnosis	ICD-10-CM
E08.610	Diabetes mellitus due to underlying condition with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E08.618	Diabetes mellitus due to underlying condition with other diabetic arthropathy	Diagnosis	ICD-10-CM
E08.620	Diabetes mellitus due to underlying condition with diabetic dermatitis	Diagnosis	ICD-10-CM
E08.621	Diabetes mellitus due to underlying condition with foot ulcer	Diagnosis	ICD-10-CM
E08.622	Diabetes mellitus due to underlying condition with other skin ulcer	Diagnosis	ICD-10-CM
E08.628	Diabetes mellitus due to underlying condition with other skin complications	Diagnosis	ICD-10-CM
E08.630	Diabetes mellitus due to underlying condition with periodontal disease	Diagnosis	ICD-10-CM
E08.638	Diabetes mellitus due to underlying condition with other oral complications	Diagnosis	ICD-10-CM
E08.641	Diabetes mellitus due to underlying condition with hypoglycemia with coma	Diagnosis	ICD-10-CM
E08.649	Diabetes mellitus due to underlying condition with hypoglycemia without coma	Diagnosis	ICD-10-CM
E08.65	Diabetes mellitus due to underlying condition with hyperglycemia	Diagnosis	ICD-10-CM
E08.69	Diabetes mellitus due to underlying condition with other specified complication	Diagnosis	ICD-10-CM
E08.8	Diabetes mellitus due to underlying condition with unspecified complications	Diagnosis	ICD-10-CM
E08.9	Diabetes mellitus due to underlying condition without complications	Diagnosis	ICD-10-CM
E09.00	Drug or chemical induced diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E09.01	Drug or chemical induced diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E09.10	Drug or chemical induced diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E09.11	Drug or chemical induced diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.21	Drug or chemical induced diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E09.22	Drug or chemical induced diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E09.29	Drug or chemical induced diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.321	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3219	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.329	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3291	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3292	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3299	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.331	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3319	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.339	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3391	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3392	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3399	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.341	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3419	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.349	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3491	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3492	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3499	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.351	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3519	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.3521	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3522	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3529	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3531	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E09.3532	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E09.3539	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E09.3541	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E09.3542	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E09.3549	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E09.3551	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E09.3552	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E09.3559	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E09.359	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E09.3599	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E09.36	Drug or chemical induced diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E09.37X1	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E09.37X2	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.37X3	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E09.37X9	Drug or chemical induced diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E09.39	Drug or chemical induced diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E09.40	Drug or chemical induced diabetes mellitus with neurological complications with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E09.41	Drug or chemical induced diabetes mellitus with neurological complications with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E09.42	Drug or chemical induced diabetes mellitus with neurological complications with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E09.43	Drug or chemical induced diabetes mellitus with neurological complications with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E09.44	Drug or chemical induced diabetes mellitus with neurological complications with diabetic amyotrophy	Diagnosis	ICD-10-CM
E09.49	Drug or chemical induced diabetes mellitus with neurological complications with other diabetic neurological complication	Diagnosis	ICD-10-CM
E09.51	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E09.52	Drug or chemical induced diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E09.59	Drug or chemical induced diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E09.610	Drug or chemical induced diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E09.618	Drug or chemical induced diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E09.620	Drug or chemical induced diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E09.621	Drug or chemical induced diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E09.622	Drug or chemical induced diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E09.628	Drug or chemical induced diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E09.630	Drug or chemical induced diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E09.638	Drug or chemical induced diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E09.641	Drug or chemical induced diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E09.649	Drug or chemical induced diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E09.65	Drug or chemical induced diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E09.69	Drug or chemical induced diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E09.8	Drug or chemical induced diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E09.9	Drug or chemical induced diabetes mellitus without complications	Diagnosis	ICD-10-CM
E10.10	Type 1 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E10.11	Type 1 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E10.21	Type 1 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E10.22	Type 1 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E10.29	Type 1 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.321	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3219	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.329	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3291	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3292	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3299	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.331	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3319	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.339	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3391	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3392	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3399	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.341	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3419	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.349	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3491	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3492	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3499	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.351	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3519	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.3521	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3522	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3529	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3531	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E10.3532	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E10.3539	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E10.3541	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E10.3542	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.3549	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E10.3551	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E10.3552	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E10.3559	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E10.359	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E10.3599	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E10.36	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E10.37X1	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E10.37X2	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E10.37X3	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E10.37X9	Type 1 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E10.39	Type 1 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E10.40	Type 1 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E10.41	Type 1 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E10.42	Type 1 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E10.43	Type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E10.44	Type 1 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E10.51	Type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E10.52	Type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E10.59	Type 1 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E10.610	Type 1 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E10.618	Type 1 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E10.620	Type 1 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E10.621	Type 1 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E10.622	Type 1 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E10.628	Type 1 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E10.630	Type 1 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E10.638	Type 1 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E10.641	Type 1 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E10.649	Type 1 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E10.65	Type 1 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E10.69	Type 1 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E10.8	Type 1 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E10.9	Type 1 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E11.00	Type 2 diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E11.01	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E11.10	Type 2 diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E11.11	Type 2 diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E11.21	Type 2 diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E11.22	Type 2 diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E11.29	Type 2 diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.321	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3219	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.329	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3291	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3292	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3299	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.331	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3319	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.339	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3391	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3392	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3399	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.341	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3419	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.349	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.3491	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3492	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3499	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.351	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3519	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.3521	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E11.3522	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3529	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3531	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.3532	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM
E11.3539	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E11.3541	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E11.3542	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E11.3549	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E11.3551	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E11.3552	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E11.3559	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E11.359	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E11.3599	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E11.36	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.37X1	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, right eye	Diagnosis	ICD-10-CM
E11.37X2	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, left eye	Diagnosis	ICD-10-CM
E11.37X3	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, bilateral	Diagnosis	ICD-10-CM
E11.37X9	Type 2 diabetes mellitus with diabetic macular edema, resolved following treatment, unspecified eye	Diagnosis	ICD-10-CM
E11.39	Type 2 diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM
E11.40	Type 2 diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E11.41	Type 2 diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E11.42	Type 2 diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E11.43	Type 2 diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E11.44	Type 2 diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E11.51	Type 2 diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E11.52	Type 2 diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E11.59	Type 2 diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E11.610	Type 2 diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E11.618	Type 2 diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E11.620	Type 2 diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E11.621	Type 2 diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E11.622	Type 2 diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E11.628	Type 2 diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E11.630	Type 2 diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E11.638	Type 2 diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E11.641	Type 2 diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E11.649	Type 2 diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E11.65	Type 2 diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E11.69	Type 2 diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E11.8	Type 2 diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E11.9	Type 2 diabetes mellitus without complications	Diagnosis	ICD-10-CM
E13.00	Other specified diabetes mellitus with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)	Diagnosis	ICD-10-CM
E13.01	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CM
E13.10	Other specified diabetes mellitus with ketoacidosis without coma	Diagnosis	ICD-10-CM
E13.11	Other specified diabetes mellitus with ketoacidosis with coma	Diagnosis	ICD-10-CM
E13.21	Other specified diabetes mellitus with diabetic nephropathy	Diagnosis	ICD-10-CM
E13.22	Other specified diabetes mellitus with diabetic chronic kidney disease	Diagnosis	ICD-10-CM
E13.29	Other specified diabetes mellitus with other diabetic kidney complication	Diagnosis	ICD-10-CM
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.321	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3211	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3212	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3219	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.329	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3291	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3292	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3299	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.331	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3311	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3312	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3319	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.339	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3391	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3392	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3399	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.341	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3411	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3412	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3419	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.349	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3491	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3492	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3499	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.351	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema	Diagnosis	ICD-10-CM
E13.3511	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye	Diagnosis	ICD-10-CM
E13.3512	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye	Diagnosis	ICD-10-CM
E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3519	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.3521	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3522	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral	Diagnosis	ICD-10-CM
E13.3529	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3531	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye	Diagnosis	ICD-10-CM
E13.3532	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye	Diagnosis	ICD-10-CM
E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.3539	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye	Diagnosis	ICD-10-CM
E13.3541	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye	Diagnosis	ICD-10-CM
E13.3542	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye	Diagnosis	ICD-10-CM
E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral	Diagnosis	ICD-10-CM
E13.3549	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye	Diagnosis	ICD-10-CM
E13.3551	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, right eye	Diagnosis	ICD-10-CM
E13.3552	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, left eye	Diagnosis	ICD-10-CM
E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, bilateral	Diagnosis	ICD-10-CM
E13.3559	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye	Diagnosis	ICD-10-CM
E13.359	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema	Diagnosis	ICD-10-CM
E13.3591	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye	Diagnosis	ICD-10-CM
E13.3592	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye	Diagnosis	ICD-10-CM
E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral	Diagnosis	ICD-10-CM
E13.3599	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye	Diagnosis	ICD-10-CM
E13.36	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CM
E13.39	Other specified diabetes mellitus with other diabetic ophthalmic complication	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E13.40	Other specified diabetes mellitus with diabetic neuropathy, unspecified	Diagnosis	ICD-10-CM
E13.41	Other specified diabetes mellitus with diabetic mononeuropathy	Diagnosis	ICD-10-CM
E13.42	Other specified diabetes mellitus with diabetic polyneuropathy	Diagnosis	ICD-10-CM
E13.43	Other specified diabetes mellitus with diabetic autonomic (poly)neuropathy	Diagnosis	ICD-10-CM
E13.44	Other specified diabetes mellitus with diabetic amyotrophy	Diagnosis	ICD-10-CM
E13.49	Other specified diabetes mellitus with other diabetic neurological complication	Diagnosis	ICD-10-CM
E13.51	Other specified diabetes mellitus with diabetic peripheral angiopathy without gangrene	Diagnosis	ICD-10-CM
E13.52	Other specified diabetes mellitus with diabetic peripheral angiopathy with gangrene	Diagnosis	ICD-10-CM
E13.59	Other specified diabetes mellitus with other circulatory complications	Diagnosis	ICD-10-CM
E13.610	Other specified diabetes mellitus with diabetic neuropathic arthropathy	Diagnosis	ICD-10-CM
E13.618	Other specified diabetes mellitus with other diabetic arthropathy	Diagnosis	ICD-10-CM
E13.620	Other specified diabetes mellitus with diabetic dermatitis	Diagnosis	ICD-10-CM
E13.621	Other specified diabetes mellitus with foot ulcer	Diagnosis	ICD-10-CM
E13.622	Other specified diabetes mellitus with other skin ulcer	Diagnosis	ICD-10-CM
E13.628	Other specified diabetes mellitus with other skin complications	Diagnosis	ICD-10-CM
E13.630	Other specified diabetes mellitus with periodontal disease	Diagnosis	ICD-10-CM
E13.638	Other specified diabetes mellitus with other oral complications	Diagnosis	ICD-10-CM
E13.641	Other specified diabetes mellitus with hypoglycemia with coma	Diagnosis	ICD-10-CM
E13.649	Other specified diabetes mellitus with hypoglycemia without coma	Diagnosis	ICD-10-CM
E13.65	Other specified diabetes mellitus with hyperglycemia	Diagnosis	ICD-10-CM
E13.69	Other specified diabetes mellitus with other specified complication	Diagnosis	ICD-10-CM
E13.8	Other specified diabetes mellitus with unspecified complications	Diagnosis	ICD-10-CM
E13.9	Other specified diabetes mellitus without complications	Diagnosis	ICD-10-CM
Drug Abuse			
F11.10	Opioid abuse, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F11.11	Opioid abuse, in remission	Diagnosis	ICD-10-CM
F11.120	Opioid abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.121	Opioid abuse with intoxication delirium	Diagnosis	ICD-10-CM
F11.122	Opioid abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.129	Opioid abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.13	Opioid abuse with withdrawal	Diagnosis	ICD-10-CM
F11.14	Opioid abuse with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.181	Opioid abuse with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.182	Opioid abuse with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.188	Opioid abuse with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.19	Opioid abuse with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.20	Opioid dependence, uncomplicated	Diagnosis	ICD-10-CM
F11.220	Opioid dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.221	Opioid dependence with intoxication delirium	Diagnosis	ICD-10-CM
F11.222	Opioid dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.229	Opioid dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.23	Opioid dependence with withdrawal	Diagnosis	ICD-10-CM
F11.24	Opioid dependence with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.259	Opioid dependence with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.281	Opioid dependence with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F11.282	Opioid dependence with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.288	Opioid dependence with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.29	Opioid dependence with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F11.90	Opioid use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F11.920	Opioid use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F11.921	Opioid use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F11.929	Opioid use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F11.93	Opioid use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F11.94	Opioid use, unspecified with opioid-induced mood disorder	Diagnosis	ICD-10-CM
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction	Diagnosis	ICD-10-CM
F11.982	Opioid use, unspecified with opioid-induced sleep disorder	Diagnosis	ICD-10-CM
F11.988	Opioid use, unspecified with other opioid-induced disorder	Diagnosis	ICD-10-CM
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder	Diagnosis	ICD-10-CM
F12.10	Cannabis abuse, uncomplicated	Diagnosis	ICD-10-CM
F12.11	Cannabis abuse, in remission	Diagnosis	ICD-10-CM
F12.120	Cannabis abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.121	Cannabis abuse with intoxication delirium	Diagnosis	ICD-10-CM
F12.122	Cannabis abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.129	Cannabis abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.13	Cannabis abuse with withdrawal	Diagnosis	ICD-10-CM
F12.150	Cannabis abuse with psychotic disorder with delusions	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F12.151	Cannabis abuse with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.159	Cannabis abuse with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.180	Cannabis abuse with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.188	Cannabis abuse with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.19	Cannabis abuse with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.20	Cannabis dependence, uncomplicated	Diagnosis	ICD-10-CM
F12.220	Cannabis dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.221	Cannabis dependence with intoxication delirium	Diagnosis	ICD-10-CM
F12.222	Cannabis dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.229	Cannabis dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.250	Cannabis dependence with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.251	Cannabis dependence with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.259	Cannabis dependence with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.280	Cannabis dependence with cannabis-induced anxiety disorder	Diagnosis	ICD-10-CM
F12.288	Cannabis dependence with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.29	Cannabis dependence with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.90	Cannabis use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F12.920	Cannabis use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F12.921	Cannabis use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F12.929	Cannabis use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F12.950	Cannabis use, unspecified with psychotic disorder with delusions	Diagnosis	ICD-10-CM
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F12.980	Cannabis use, unspecified with anxiety disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F12.988	Cannabis use, unspecified with other cannabis-induced disorder	Diagnosis	ICD-10-CM
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder	Diagnosis	ICD-10-CM
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated	Diagnosis	ICD-10-CM
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission	Diagnosis	ICD-10-CM
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium	Diagnosis	ICD-10-CM
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.130	Sedative, hypnotic or anxiolytic abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.131	Sedative, hypnotic or anxiolytic abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F13.132	Sedative, hypnotic or anxiolytic abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.139	Sedative, hypnotic or anxiolytic abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated	Diagnosis	ICD-10-CM
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium	Diagnosis	ICD-10-CM
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances	Diagnosis	ICD-10-CM
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder	Diagnosis	ICD-10-CM
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnestic disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia	Diagnosis	ICD-10-CM
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder	Diagnosis	ICD-10-CM
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction	Diagnosis	ICD-10-CM
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder	Diagnosis	ICD-10-CM
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder	Diagnosis	ICD-10-CM
F14.10	Cocaine abuse, uncomplicated	Diagnosis	ICD-10-CM
F14.11	Cocaine abuse, in remission	Diagnosis	ICD-10-CM
F14.120	Cocaine abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.121	Cocaine abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F14.122	Cocaine abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.129	Cocaine abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.13	Cocaine abuse, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.14	Cocaine abuse with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.180	Cocaine abuse with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F14.182	Cocaine abuse with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.188	Cocaine abuse with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.19	Cocaine abuse with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.20	Cocaine dependence, uncomplicated	Diagnosis	ICD-10-CM
F14.220	Cocaine dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.221	Cocaine dependence with intoxication delirium	Diagnosis	ICD-10-CM
F14.222	Cocaine dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.229	Cocaine dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.23	Cocaine dependence with withdrawal	Diagnosis	ICD-10-CM
F14.24	Cocaine dependence with cocaine-induced mood disorder	Diagnosis	ICD-10-CM
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.280	Cocaine dependence with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.282	Cocaine dependence with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.288	Cocaine dependence with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.29	Cocaine dependence with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.90	Cocaine use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F14.920	Cocaine use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F14.921	Cocaine use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F14.929	Cocaine use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F14.93	Cocaine use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder	Diagnosis	ICD-10-CM
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction	Diagnosis	ICD-10-CM
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder	Diagnosis	ICD-10-CM
F14.988	Cocaine use, unspecified with other cocaine-induced disorder	Diagnosis	ICD-10-CM
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder	Diagnosis	ICD-10-CM
F15.10	Other stimulant abuse, uncomplicated	Diagnosis	ICD-10-CM
F15.11	Other stimulant abuse, in remission	Diagnosis	ICD-10-CM
F15.120	Other stimulant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.121	Other stimulant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F15.122	Other stimulant abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.129	Other stimulant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.13	Other stimulant abuse with withdrawal	Diagnosis	ICD-10-CM
F15.14	Other stimulant abuse with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.182	Other stimulant abuse with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.188	Other stimulant abuse with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.20	Other stimulant dependence, uncomplicated	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F15.220	Other stimulant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.221	Other stimulant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F15.222	Other stimulant dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.229	Other stimulant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.23	Other stimulant dependence with withdrawal	Diagnosis	ICD-10-CM
F15.24	Other stimulant dependence with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.282	Other stimulant dependence with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.288	Other stimulant dependence with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.90	Other stimulant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F15.921	Other stimulant use, unspecified with intoxication delirium	Diagnosis	ICD-10-CM
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F15.929	Other stimulant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F15.93	Other stimulant use, unspecified with withdrawal	Diagnosis	ICD-10-CM
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder	Diagnosis	ICD-10-CM
F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction	Diagnosis	ICD-10-CM
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder	Diagnosis	ICD-10-CM
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder	Diagnosis	ICD-10-CM
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder	Diagnosis	ICD-10-CM
F16.10	Hallucinogen abuse, uncomplicated	Diagnosis	ICD-10-CM
F16.11	Hallucinogen abuse, in remission	Diagnosis	ICD-10-CM
F16.120	Hallucinogen abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.121	Hallucinogen abuse with intoxication with delirium	Diagnosis	ICD-10-CM
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F16.129	Hallucinogen abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.14	Hallucinogen abuse with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.20	Hallucinogen dependence, uncomplicated	Diagnosis	ICD-10-CM
F16.220	Hallucinogen dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.221	Hallucinogen dependence with intoxication with delirium	Diagnosis	ICD-10-CM
F16.229	Hallucinogen dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.90	Hallucinogen use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F16.921	Hallucinogen use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F16.929	Hallucinogen use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder	Diagnosis	ICD-10-CM
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder	Diagnosis	ICD-10-CM
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)	Diagnosis	ICD-10-CM
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder	Diagnosis	ICD-10-CM
F18.10	Inhalant abuse, uncomplicated	Diagnosis	ICD-10-CM
F18.11	Inhalant abuse, in remission	Diagnosis	ICD-10-CM
F18.120	Inhalant abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.121	Inhalant abuse with intoxication delirium	Diagnosis	ICD-10-CM
F18.129	Inhalant abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.14	Inhalant abuse with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.17	Inhalant abuse with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.180	Inhalant abuse with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.188	Inhalant abuse with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.19	Inhalant abuse with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.20	Inhalant dependence, uncomplicated	Diagnosis	ICD-10-CM
F18.220	Inhalant dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.221	Inhalant dependence with intoxication delirium	Diagnosis	ICD-10-CM
F18.229	Inhalant dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.24	Inhalant dependence with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F18.27	Inhalant dependence with inhalant-induced dementia	Diagnosis	ICD-10-CM
F18.280	Inhalant dependence with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.288	Inhalant dependence with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.29	Inhalant dependence with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.90	Inhalant use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F18.920	Inhalant use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F18.921	Inhalant use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F18.929	Inhalant use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder	Diagnosis	ICD-10-CM
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F18.97	Inhalant use, unspecified with inhalant-induced persisting dementia	Diagnosis	ICD-10-CM
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder	Diagnosis	ICD-10-CM
F18.988	Inhalant use, unspecified with other inhalant-induced disorder	Diagnosis	ICD-10-CM
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder	Diagnosis	ICD-10-CM
F19.10	Other psychoactive substance abuse, uncomplicated	Diagnosis	ICD-10-CM
F19.11	Other psychoactive substance abuse, in remission	Diagnosis	ICD-10-CM
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.121	Other psychoactive substance abuse with intoxication delirium	Diagnosis	ICD-10-CM
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances	Diagnosis	ICD-10-CM
F19.129	Other psychoactive substance abuse with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.130	Other psychoactive substance abuse with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.131	Other psychoactive substance abuse with withdrawal delirium	Diagnosis	ICD-10-CM
F19.132	Other psychoactive substance abuse with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.139	Other psychoactive substance abuse with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.20	Other psychoactive substance dependence, uncomplicated	Diagnosis	ICD-10-CM
F19.21	Other psychoactive substance dependence, in remission	Diagnosis	ICD-10-CM
F19.220	Other psychoactive substance dependence with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.221	Other psychoactive substance dependence with intoxication delirium	Diagnosis	ICD-10-CM
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.229	Other psychoactive substance dependence with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.231	Other psychoactive substance dependence with withdrawal delirium	Diagnosis	ICD-10-CM
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.239	Other psychoactive substance dependence with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnesic disorder	Diagnosis	ICD-10-CM
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.90	Other psychoactive substance use, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated	Diagnosis	ICD-10-CM
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium	Diagnosis	ICD-10-CM
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance	Diagnosis	ICD-10-CM
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified	Diagnosis	ICD-10-CM
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated	Diagnosis	ICD-10-CM
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium	Diagnosis	ICD-10-CM
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance	Diagnosis	ICD-10-CM
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified	Diagnosis	ICD-10-CM
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder	Diagnosis	ICD-10-CM
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions	Diagnosis	ICD-10-CM
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations	Diagnosis	ICD-10-CM
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified	Diagnosis	ICD-10-CM
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnestic disorder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia	Diagnosis	ICD-10-CM
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder	Diagnosis	ICD-10-CM
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction	Diagnosis	ICD-10-CM
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder	Diagnosis	ICD-10-CM
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder	Diagnosis	ICD-10-CM
HZ2ZZZZ	Detoxification Services for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ30ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ31ZZZ	Individual Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ32ZZZ	Individual Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ33ZZZ	Individual Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ34ZZZ	Individual Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ35ZZZ	Individual Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ36ZZZ	Individual Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ37ZZZ	Individual Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ38ZZZ	Individual Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ39ZZZ	Individual Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ3BZZZ	Individual Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ40ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ41ZZZ	Group Counseling for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ42ZZZ	Group Counseling for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
HZ43ZZZ	Group Counseling for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ44ZZZ	Group Counseling for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ45ZZZ	Group Counseling for Substance Abuse Treatment, Vocational	Procedure	ICD-10-PCS
HZ46ZZZ	Group Counseling for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ47ZZZ	Group Counseling for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ48ZZZ	Group Counseling for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ49ZZZ	Group Counseling for Substance Abuse Treatment, Continuing Care	Procedure	ICD-10-PCS
HZ4BZZZ	Group Counseling for Substance Abuse Treatment, Spiritual	Procedure	ICD-10-PCS
HZ50ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive	Procedure	ICD-10-PCS
HZ51ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Behavioral	Procedure	ICD-10-PCS
HZ52ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Cognitive-Behavioral	Procedure	ICD-10-PCS
HZ53ZZZ	Individual Psychotherapy for Substance Abuse Treatment, 12-Step	Procedure	ICD-10-PCS
HZ54ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interpersonal	Procedure	ICD-10-PCS
HZ55ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Interactive	Procedure	ICD-10-PCS
HZ56ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoeducation	Procedure	ICD-10-PCS
HZ57ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Motivational Enhancement	Procedure	ICD-10-PCS
HZ58ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Confrontational	Procedure	ICD-10-PCS
HZ59ZZZ	Individual Psychotherapy for Substance Abuse Treatment, Supportive	Procedure	ICD-10-PCS
HZ5BZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychoanalysis	Procedure	ICD-10-PCS
HZ5CZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychodynamic	Procedure	ICD-10-PCS
HZ5DZZZ	Individual Psychotherapy for Substance Abuse Treatment, Psychophysiological	Procedure	ICD-10-PCS
HZ63ZZZ	Family Counseling for Substance Abuse Treatment	Procedure	ICD-10-PCS
HZ83ZZZ	Medication Management for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ86ZZZ	Medication Management for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ88ZZZ	Medication Management for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
HZ89ZZZ	Medication Management for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
HZ93ZZZ	Pharmacotherapy for Substance Abuse Treatment, Antabuse	Procedure	ICD-10-PCS
HZ96ZZZ	Pharmacotherapy for Substance Abuse Treatment, Clonidine	Procedure	ICD-10-PCS
HZ98ZZZ	Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication	Procedure	ICD-10-PCS
HZ99ZZZ	Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication	Procedure	ICD-10-PCS
O35.5XX0	Maternal care for (suspected) damage to fetus by drugs, not applicable or unspecified	Diagnosis	ICD-10-CM
O35.5XX1	Maternal care for (suspected) damage to fetus by drugs, fetus 1	Diagnosis	ICD-10-CM
O35.5XX2	Maternal care for (suspected) damage to fetus by drugs, fetus 2	Diagnosis	ICD-10-CM
O35.5XX3	Maternal care for (suspected) damage to fetus by drugs, fetus 3	Diagnosis	ICD-10-CM
O35.5XX4	Maternal care for (suspected) damage to fetus by drugs, fetus 4	Diagnosis	ICD-10-CM
O35.5XX5	Maternal care for (suspected) damage to fetus by drugs, fetus 5	Diagnosis	ICD-10-CM
O35.5XX9	Maternal care for (suspected) damage to fetus by drugs, other fetus	Diagnosis	ICD-10-CM
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.0X3A	Poisoning by opium, assault, initial encounter	Diagnosis	ICD-10-CM
T40.0X4A	Poisoning by opium, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.0X5A	Adverse effect of opium, initial encounter	Diagnosis	ICD-10-CM
T40.0X5S	Adverse effect of opium, sequela	Diagnosis	ICD-10-CM
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.1X3A	Poisoning by heroin, assault, initial encounter	Diagnosis	ICD-10-CM
T40.1X4A	Poisoning by heroin, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.2X3A	Poisoning by other opioids, assault, initial encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.3X3A	Poisoning by methadone, assault, initial encounter	Diagnosis	ICD-10-CM
T40.3X4A	Poisoning by methadone, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.3X5A	Adverse effect of methadone, initial encounter	Diagnosis	ICD-10-CM
T40.3X5S	Adverse effect of methadone, sequela	Diagnosis	ICD-10-CM
T40.411A	Poisoning by fentanyl or fentanyl analogs, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.412A	Poisoning by fentanyl or fentanyl analogs, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.413A	Poisoning by fentanyl or fentanyl analogs, assault, initial encounter	Diagnosis	ICD-10-CM
T40.414A	Poisoning by fentanyl or fentanyl analogs, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.415A	Adverse effect of fentanyl or fentanyl analogs, initial encounter	Diagnosis	ICD-10-CM
T40.421A	Poisoning by tramadol, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.422A	Poisoning by tramadol, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.423A	Poisoning by tramadol, assault, initial encounter	Diagnosis	ICD-10-CM
T40.424A	Poisoning by tramadol, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.425A	Adverse effect of tramadol, initial encounter	Diagnosis	ICD-10-CM
T40.491A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.492A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.493A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.494A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.495A	Adverse effect of other synthetic narcotics, initial encounter	Diagnosis	ICD-10-CM
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T40.693A	Poisoning by other narcotics, assault, initial encounter	Diagnosis	ICD-10-CM
T40.694A	Poisoning by other narcotics, undetermined, initial encounter	Diagnosis	ICD-10-CM
T40.711A	Poisoning by cannabis, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.721A	Poisoning by synthetic cannabinoids, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
Z71.51	Drug abuse counseling and surveillance of drug abuser	Diagnosis	ICD-10-CM
Endometrial Cancer			
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
D07.0	Carcinoma in situ of endometrium	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
Glaucoma			
H40.011	Open angle with borderline findings, low risk, right eye	Diagnosis	ICD-10-CM
H40.012	Open angle with borderline findings, low risk, left eye	Diagnosis	ICD-10-CM
H40.013	Open angle with borderline findings, low risk, bilateral	Diagnosis	ICD-10-CM
H40.019	Open angle with borderline findings, low risk, unspecified eye	Diagnosis	ICD-10-CM
H40.021	Open angle with borderline findings, high risk, right eye	Diagnosis	ICD-10-CM
H40.022	Open angle with borderline findings, high risk, left eye	Diagnosis	ICD-10-CM
H40.023	Open angle with borderline findings, high risk, bilateral	Diagnosis	ICD-10-CM
H40.029	Open angle with borderline findings, high risk, unspecified eye	Diagnosis	ICD-10-CM
H40.041	Steroid responder, right eye	Diagnosis	ICD-10-CM
H40.042	Steroid responder, left eye	Diagnosis	ICD-10-CM
H40.043	Steroid responder, bilateral	Diagnosis	ICD-10-CM
H40.049	Steroid responder, unspecified eye	Diagnosis	ICD-10-CM
H40.051	Ocular hypertension, right eye	Diagnosis	ICD-10-CM
H40.052	Ocular hypertension, left eye	Diagnosis	ICD-10-CM
H40.053	Ocular hypertension, bilateral	Diagnosis	ICD-10-CM
H40.059	Ocular hypertension, unspecified eye	Diagnosis	ICD-10-CM
H40.10X0	Unspecified open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.10X1	Unspecified open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.10X2	Unspecified open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.10X3	Unspecified open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.10X4	Unspecified open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1110	Primary open-angle glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1111	Primary open-angle glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.1112	Primary open-angle glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1113	Primary open-angle glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1114	Primary open-angle glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1120	Primary open-angle glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1121	Primary open-angle glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1122	Primary open-angle glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1123	Primary open-angle glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1124	Primary open-angle glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1130	Primary open-angle glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1131	Primary open-angle glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1132	Primary open-angle glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1133	Primary open-angle glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1134	Primary open-angle glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1190	Primary open-angle glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1191	Primary open-angle glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1192	Primary open-angle glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1193	Primary open-angle glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1194	Primary open-angle glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.11X0	Primary open-angle glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.11X1	Primary open-angle glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.11X2	Primary open-angle glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.11X3	Primary open-angle glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.11X4	Primary open-angle glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.1210	Low-tension glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1211	Low-tension glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.1212	Low-tension glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1213	Low-tension glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1214	Low-tension glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1220	Low-tension glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1221	Low-tension glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1222	Low-tension glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1223	Low-tension glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1224	Low-tension glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1230	Low-tension glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1231	Low-tension glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1232	Low-tension glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1233	Low-tension glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1234	Low-tension glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1290	Low-tension glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1291	Low-tension glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1292	Low-tension glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1293	Low-tension glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1294	Low-tension glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1310	Pigmentary glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1311	Pigmentary glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1312	Pigmentary glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1313	Pigmentary glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1314	Pigmentary glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1320	Pigmentary glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1321	Pigmentary glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.1322	Pigmentary glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1323	Pigmentary glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1324	Pigmentary glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1330	Pigmentary glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1331	Pigmentary glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.1332	Pigmentary glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1333	Pigmentary glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1334	Pigmentary glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1390	Pigmentary glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1391	Pigmentary glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1392	Pigmentary glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1393	Pigmentary glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1394	Pigmentary glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1410	Capsular glaucoma with pseudoexfoliation of lens, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1411	Capsular glaucoma with pseudoexfoliation of lens, right eye, mild stage	Diagnosis	ICD-10-CM
H40.1412	Capsular glaucoma with pseudoexfoliation of lens, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.1413	Capsular glaucoma with pseudoexfoliation of lens, right eye, severe stage	Diagnosis	ICD-10-CM
H40.1414	Capsular glaucoma with pseudoexfoliation of lens, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1420	Capsular glaucoma with pseudoexfoliation of lens, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1421	Capsular glaucoma with pseudoexfoliation of lens, left eye, mild stage	Diagnosis	ICD-10-CM
H40.1422	Capsular glaucoma with pseudoexfoliation of lens, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.1423	Capsular glaucoma with pseudoexfoliation of lens, left eye, severe stage	Diagnosis	ICD-10-CM
H40.1424	Capsular glaucoma with pseudoexfoliation of lens, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.1430	Capsular glaucoma with pseudoexfoliation of lens, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.1431	Capsular glaucoma with pseudoexfoliation of lens, bilateral, mild stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.1432	Capsular glaucoma with pseudoexfoliation of lens, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.1433	Capsular glaucoma with pseudoexfoliation of lens, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.1434	Capsular glaucoma with pseudoexfoliation of lens, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.1490	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.1491	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.1492	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.1493	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.1494	Capsular glaucoma with pseudoexfoliation of lens, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.151	Residual stage of open-angle glaucoma, right eye	Diagnosis	ICD-10-CM
H40.152	Residual stage of open-angle glaucoma, left eye	Diagnosis	ICD-10-CM
H40.153	Residual stage of open-angle glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.159	Residual stage of open-angle glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.20X0	Unspecified primary angle-closure glaucoma, stage unspecified	Diagnosis	ICD-10-CM
H40.20X1	Unspecified primary angle-closure glaucoma, mild stage	Diagnosis	ICD-10-CM
H40.20X2	Unspecified primary angle-closure glaucoma, moderate stage	Diagnosis	ICD-10-CM
H40.20X3	Unspecified primary angle-closure glaucoma, severe stage	Diagnosis	ICD-10-CM
H40.20X4	Unspecified primary angle-closure glaucoma, indeterminate stage	Diagnosis	ICD-10-CM
H40.211	Acute angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.212	Acute angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.213	Acute angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.219	Acute angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.2210	Chronic angle-closure glaucoma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2211	Chronic angle-closure glaucoma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.2212	Chronic angle-closure glaucoma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.2213	Chronic angle-closure glaucoma, right eye, severe stage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.2214	Chronic angle-closure glaucoma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2220	Chronic angle-closure glaucoma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2221	Chronic angle-closure glaucoma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.2222	Chronic angle-closure glaucoma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.2223	Chronic angle-closure glaucoma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.2224	Chronic angle-closure glaucoma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.2230	Chronic angle-closure glaucoma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.2231	Chronic angle-closure glaucoma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.2232	Chronic angle-closure glaucoma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.2233	Chronic angle-closure glaucoma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.2234	Chronic angle-closure glaucoma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.2290	Chronic angle-closure glaucoma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.2291	Chronic angle-closure glaucoma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.2292	Chronic angle-closure glaucoma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.2293	Chronic angle-closure glaucoma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.2294	Chronic angle-closure glaucoma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.231	Intermittent angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.232	Intermittent angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.233	Intermittent angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.239	Intermittent angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.241	Residual stage of angle-closure glaucoma, right eye	Diagnosis	ICD-10-CM
H40.242	Residual stage of angle-closure glaucoma, left eye	Diagnosis	ICD-10-CM
H40.243	Residual stage of angle-closure glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.249	Residual stage of angle-closure glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.30X0	Glaucoma secondary to eye trauma, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.30X1	Glaucoma secondary to eye trauma, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.30X2	Glaucoma secondary to eye trauma, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.30X3	Glaucoma secondary to eye trauma, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.30X4	Glaucoma secondary to eye trauma, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.31X0	Glaucoma secondary to eye trauma, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.31X1	Glaucoma secondary to eye trauma, right eye, mild stage	Diagnosis	ICD-10-CM
H40.31X2	Glaucoma secondary to eye trauma, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.31X3	Glaucoma secondary to eye trauma, right eye, severe stage	Diagnosis	ICD-10-CM
H40.31X4	Glaucoma secondary to eye trauma, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.32X0	Glaucoma secondary to eye trauma, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.32X1	Glaucoma secondary to eye trauma, left eye, mild stage	Diagnosis	ICD-10-CM
H40.32X2	Glaucoma secondary to eye trauma, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.32X3	Glaucoma secondary to eye trauma, left eye, severe stage	Diagnosis	ICD-10-CM
H40.32X4	Glaucoma secondary to eye trauma, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.33X0	Glaucoma secondary to eye trauma, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.33X1	Glaucoma secondary to eye trauma, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.33X2	Glaucoma secondary to eye trauma, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.33X3	Glaucoma secondary to eye trauma, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.33X4	Glaucoma secondary to eye trauma, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.40X0	Glaucoma secondary to eye inflammation, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.40X1	Glaucoma secondary to eye inflammation, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.40X2	Glaucoma secondary to eye inflammation, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.40X3	Glaucoma secondary to eye inflammation, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.40X4	Glaucoma secondary to eye inflammation, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.41X0	Glaucoma secondary to eye inflammation, right eye, stage unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.41X1	Glaucoma secondary to eye inflammation, right eye, mild stage	Diagnosis	ICD-10-CM
H40.41X2	Glaucoma secondary to eye inflammation, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.41X3	Glaucoma secondary to eye inflammation, right eye, severe stage	Diagnosis	ICD-10-CM
H40.41X4	Glaucoma secondary to eye inflammation, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.42X0	Glaucoma secondary to eye inflammation, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.42X1	Glaucoma secondary to eye inflammation, left eye, mild stage	Diagnosis	ICD-10-CM
H40.42X2	Glaucoma secondary to eye inflammation, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.42X3	Glaucoma secondary to eye inflammation, left eye, severe stage	Diagnosis	ICD-10-CM
H40.42X4	Glaucoma secondary to eye inflammation, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.43X0	Glaucoma secondary to eye inflammation, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.43X1	Glaucoma secondary to eye inflammation, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.43X2	Glaucoma secondary to eye inflammation, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.43X3	Glaucoma secondary to eye inflammation, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.43X4	Glaucoma secondary to eye inflammation, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.50X0	Glaucoma secondary to other eye disorders, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.50X1	Glaucoma secondary to other eye disorders, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.50X2	Glaucoma secondary to other eye disorders, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.50X3	Glaucoma secondary to other eye disorders, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.50X4	Glaucoma secondary to other eye disorders, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.51X0	Glaucoma secondary to other eye disorders, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.51X1	Glaucoma secondary to other eye disorders, right eye, mild stage	Diagnosis	ICD-10-CM
H40.51X2	Glaucoma secondary to other eye disorders, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.51X3	Glaucoma secondary to other eye disorders, right eye, severe stage	Diagnosis	ICD-10-CM
H40.51X4	Glaucoma secondary to other eye disorders, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.52X0	Glaucoma secondary to other eye disorders, left eye, stage unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.52X1	Glaucoma secondary to other eye disorders, left eye, mild stage	Diagnosis	ICD-10-CM
H40.52X2	Glaucoma secondary to other eye disorders, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.52X3	Glaucoma secondary to other eye disorders, left eye, severe stage	Diagnosis	ICD-10-CM
H40.52X4	Glaucoma secondary to other eye disorders, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.53X0	Glaucoma secondary to other eye disorders, bilateral, stage unspecified	Diagnosis	ICD-10-CM
H40.53X1	Glaucoma secondary to other eye disorders, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.53X2	Glaucoma secondary to other eye disorders, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.53X3	Glaucoma secondary to other eye disorders, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.53X4	Glaucoma secondary to other eye disorders, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.60X0	Glaucoma secondary to drugs, unspecified eye, stage unspecified	Diagnosis	ICD-10-CM
H40.60X1	Glaucoma secondary to drugs, unspecified eye, mild stage	Diagnosis	ICD-10-CM
H40.60X2	Glaucoma secondary to drugs, unspecified eye, moderate stage	Diagnosis	ICD-10-CM
H40.60X3	Glaucoma secondary to drugs, unspecified eye, severe stage	Diagnosis	ICD-10-CM
H40.60X4	Glaucoma secondary to drugs, unspecified eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.61X0	Glaucoma secondary to drugs, right eye, stage unspecified	Diagnosis	ICD-10-CM
H40.61X1	Glaucoma secondary to drugs, right eye, mild stage	Diagnosis	ICD-10-CM
H40.61X2	Glaucoma secondary to drugs, right eye, moderate stage	Diagnosis	ICD-10-CM
H40.61X3	Glaucoma secondary to drugs, right eye, severe stage	Diagnosis	ICD-10-CM
H40.61X4	Glaucoma secondary to drugs, right eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.62X0	Glaucoma secondary to drugs, left eye, stage unspecified	Diagnosis	ICD-10-CM
H40.62X1	Glaucoma secondary to drugs, left eye, mild stage	Diagnosis	ICD-10-CM
H40.62X2	Glaucoma secondary to drugs, left eye, moderate stage	Diagnosis	ICD-10-CM
H40.62X3	Glaucoma secondary to drugs, left eye, severe stage	Diagnosis	ICD-10-CM
H40.62X4	Glaucoma secondary to drugs, left eye, indeterminate stage	Diagnosis	ICD-10-CM
H40.63X0	Glaucoma secondary to drugs, bilateral, stage unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H40.63X1	Glaucoma secondary to drugs, bilateral, mild stage	Diagnosis	ICD-10-CM
H40.63X2	Glaucoma secondary to drugs, bilateral, moderate stage	Diagnosis	ICD-10-CM
H40.63X3	Glaucoma secondary to drugs, bilateral, severe stage	Diagnosis	ICD-10-CM
H40.63X4	Glaucoma secondary to drugs, bilateral, indeterminate stage	Diagnosis	ICD-10-CM
H40.811	Glaucoma with increased episcleral venous pressure, right eye	Diagnosis	ICD-10-CM
H40.812	Glaucoma with increased episcleral venous pressure, left eye	Diagnosis	ICD-10-CM
H40.813	Glaucoma with increased episcleral venous pressure, bilateral	Diagnosis	ICD-10-CM
H40.819	Glaucoma with increased episcleral venous pressure, unspecified eye	Diagnosis	ICD-10-CM
H40.821	Hypersecretion glaucoma, right eye	Diagnosis	ICD-10-CM
H40.822	Hypersecretion glaucoma, left eye	Diagnosis	ICD-10-CM
H40.823	Hypersecretion glaucoma, bilateral	Diagnosis	ICD-10-CM
H40.829	Hypersecretion glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H40.831	Aqueous misdirection, right eye	Diagnosis	ICD-10-CM
H40.832	Aqueous misdirection, left eye	Diagnosis	ICD-10-CM
H40.833	Aqueous misdirection, bilateral	Diagnosis	ICD-10-CM
H40.839	Aqueous misdirection, unspecified eye	Diagnosis	ICD-10-CM
H40.89	Other specified glaucoma	Diagnosis	ICD-10-CM
H40.9	Unspecified glaucoma	Diagnosis	ICD-10-CM
H42	Glaucoma in diseases classified elsewhere	Diagnosis	ICD-10-CM
H44.511	Absolute glaucoma, right eye	Diagnosis	ICD-10-CM
H44.512	Absolute glaucoma, left eye	Diagnosis	ICD-10-CM
H44.513	Absolute glaucoma, bilateral	Diagnosis	ICD-10-CM
H44.519	Absolute glaucoma, unspecified eye	Diagnosis	ICD-10-CM
H47.231	Glaucomatous optic atrophy, right eye	Diagnosis	ICD-10-CM
H47.232	Glaucomatous optic atrophy, left eye	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
H47.233	Glaucomatous optic atrophy, bilateral	Diagnosis	ICD-10-CM
H47.239	Glaucomatous optic atrophy, unspecified eye	Diagnosis	ICD-10-CM
Q15.0	Congenital glaucoma	Diagnosis	ICD-10-CM
Heart Failure			
I09.81	Rheumatic heart failure	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I42.0	Dilated cardiomyopathy	Diagnosis	ICD-10-CM
I42.5	Other restrictive cardiomyopathy	Diagnosis	ICD-10-CM
I42.6	Alcoholic cardiomyopathy	Diagnosis	ICD-10-CM
I42.7	Cardiomyopathy due to drug and external agent	Diagnosis	ICD-10-CM
I42.8	Other cardiomyopathies	Diagnosis	ICD-10-CM
I43	Cardiomyopathy in diseases classified elsewhere	Diagnosis	ICD-10-CM
I50.1	Left ventricular failure, unspecified	Diagnosis	ICD-10-CM
I50.20	Unspecified systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.21	Acute systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.22	Chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.23	Acute on chronic systolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.30	Unspecified diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.31	Acute diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.32	Chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.33	Acute on chronic diastolic (congestive) heart failure	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I50.40	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure	Diagnosis	ICD-10-CM
I50.810	Right heart failure, unspecified	Diagnosis	ICD-10-CM
I50.811	Acute right heart failure	Diagnosis	ICD-10-CM
I50.812	Chronic right heart failure	Diagnosis	ICD-10-CM
I50.813	Acute on chronic right heart failure	Diagnosis	ICD-10-CM
I50.814	Right heart failure due to left heart failure	Diagnosis	ICD-10-CM
I50.82	Biventricular heart failure	Diagnosis	ICD-10-CM
I50.83	High output heart failure	Diagnosis	ICD-10-CM
I50.84	End stage heart failure	Diagnosis	ICD-10-CM
I50.89	Other heart failure	Diagnosis	ICD-10-CM
I50.9	Heart failure, unspecified	Diagnosis	ICD-10-CM
P29.0	Neonatal cardiac failure	Diagnosis	ICD-10-CM
Hyperlipidemia			
E78.0	Pure hypercholesterolemia	Diagnosis	ICD-10-CM
E78.00	Pure hypercholesterolemia, unspecified	Diagnosis	ICD-10-CM
E78.01	Familial hypercholesterolemia	Diagnosis	ICD-10-CM
E78.1	Pure hyperglyceridemia	Diagnosis	ICD-10-CM
E78.2	Mixed hyperlipidemia	Diagnosis	ICD-10-CM
E78.3	Hyperchylomicronemia	Diagnosis	ICD-10-CM
E78.4	Other hyperlipidemia	Diagnosis	ICD-10-CM
E78.41	Elevated Lipoprotein(a)	Diagnosis	ICD-10-CM
E78.49	Other hyperlipidemia	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
E78.5	Hyperlipidemia, unspecified	Diagnosis	ICD-10-CM
Hypertension			
H35.031	Hypertensive retinopathy, right eye	Diagnosis	ICD-10-CM
H35.032	Hypertensive retinopathy, left eye	Diagnosis	ICD-10-CM
H35.033	Hypertensive retinopathy, bilateral	Diagnosis	ICD-10-CM
H35.039	Hypertensive retinopathy, unspecified eye	Diagnosis	ICD-10-CM
I10	Essential (primary) hypertension	Diagnosis	ICD-10-CM
I11.0	Hypertensive heart disease with heart failure	Diagnosis	ICD-10-CM
I11.9	Hypertensive heart disease without heart failure	Diagnosis	ICD-10-CM
I12.0	Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease	Diagnosis	ICD-10-CM
I12.9	Hypertensive chronic kidney disease with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.0	Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.10	Hypertensive heart and chronic kidney disease without heart failure, with stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease	Diagnosis	ICD-10-CM
I13.11	Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I13.2	Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease	Diagnosis	ICD-10-CM
I15.0	Renovascular hypertension	Diagnosis	ICD-10-CM
I15.1	Hypertension secondary to other renal disorders	Diagnosis	ICD-10-CM
I15.2	Hypertension secondary to endocrine disorders	Diagnosis	ICD-10-CM
I15.8	Other secondary hypertension	Diagnosis	ICD-10-CM
I15.9	Secondary hypertension, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I1A.0	Resistant hypertension	Diagnosis	ICD-10-CM
I67.4	Hypertensive encephalopathy	Diagnosis	ICD-10-CM
N26.2	Page kidney	Diagnosis	ICD-10-CM
Ischemic Heart Disease			
I20.0	Unstable angina	Diagnosis	ICD-10-CM
I20.1	Angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I20.2	Refractory angina pectoris	Diagnosis	ICD-10-CM
I20.8	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I20.81	Angina pectoris with coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I20.89	Other forms of angina pectoris	Diagnosis	ICD-10-CM
I24.0	Acute coronary thrombosis not resulting in myocardial infarction	Diagnosis	ICD-10-CM
I24.1	Dressler's syndrome	Diagnosis	ICD-10-CM
I24.8	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I24.81	Acute coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I24.89	Other forms of acute ischemic heart disease	Diagnosis	ICD-10-CM
I25.10	Atherosclerotic heart disease of native coronary artery without angina pectoris	Diagnosis	ICD-10-CM
I25.110	Atherosclerotic heart disease of native coronary artery with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.111	Atherosclerotic heart disease of native coronary artery with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.112	Atherosclerotic heart disease of native coronary artery with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.118	Atherosclerotic heart disease of native coronary artery with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.119	Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.3	Aneurysm of heart	Diagnosis	ICD-10-CM
I25.41	Coronary artery aneurysm	Diagnosis	ICD-10-CM
I25.42	Coronary artery dissection	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I25.5	Ischemic cardiomyopathy	Diagnosis	ICD-10-CM
I25.6	Silent myocardial ischemia	Diagnosis	ICD-10-CM
I25.700	Atherosclerosis of coronary artery bypass graft(s), unspecified, with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.701	Atherosclerosis of coronary artery bypass graft(s), unspecified, with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.702	Atherosclerosis of coronary artery bypass graft(s), unspecified, with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.708	Atherosclerosis of coronary artery bypass graft(s), unspecified, with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.710	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.711	Atherosclerosis of autologous vein coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.712	Atherosclerosis of autologous vein coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.718	Atherosclerosis of autologous vein coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.719	Atherosclerosis of autologous vein coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.720	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM
I25.721	Atherosclerosis of autologous artery coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.722	Atherosclerosis of autologous artery coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.728	Atherosclerosis of autologous artery coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.729	Atherosclerosis of autologous artery coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.730	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I25.731	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.732	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.738	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.739	Atherosclerosis of nonautologous biological coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.750	Atherosclerosis of native coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.751	Atherosclerosis of native coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.752	Atherosclerosis of native coronary artery of transplanted heart with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.758	Atherosclerosis of native coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.759	Atherosclerosis of native coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.760	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unstable angina	Diagnosis	ICD-10-CM
I25.761	Atherosclerosis of bypass graft of coronary artery of transplanted heart with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.762	Atherosclerosis of bypass graft of coronary artery of transplanted heart with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.768	Atherosclerosis of bypass graft of coronary artery of transplanted heart with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.769	Atherosclerosis of bypass graft of coronary artery of transplanted heart with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.790	Atherosclerosis of other coronary artery bypass graft(s) with unstable angina pectoris	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I25.791	Atherosclerosis of other coronary artery bypass graft(s) with angina pectoris with documented spasm	Diagnosis	ICD-10-CM
I25.792	Atherosclerosis of other coronary artery bypass graft(s) with refractory angina pectoris	Diagnosis	ICD-10-CM
I25.798	Atherosclerosis of other coronary artery bypass graft(s) with other forms of angina pectoris	Diagnosis	ICD-10-CM
I25.799	Atherosclerosis of other coronary artery bypass graft(s) with unspecified angina pectoris	Diagnosis	ICD-10-CM
I25.810	Atherosclerosis of coronary artery bypass graft(s) without angina pectoris	Diagnosis	ICD-10-CM
I25.811	Atherosclerosis of native coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.812	Atherosclerosis of bypass graft of coronary artery of transplanted heart without angina pectoris	Diagnosis	ICD-10-CM
I25.82	Chronic total occlusion of coronary artery	Diagnosis	ICD-10-CM
I25.83	Coronary atherosclerosis due to lipid rich plaque	Diagnosis	ICD-10-CM
I25.84	Coronary atherosclerosis due to calcified coronary lesion	Diagnosis	ICD-10-CM
I25.85	Chronic coronary microvascular dysfunction	Diagnosis	ICD-10-CM
I25.89	Other forms of chronic ischemic heart disease	Diagnosis	ICD-10-CM
I25.9	Chronic ischemic heart disease, unspecified	Diagnosis	ICD-10-CM
Liver Disease CCW			
K70	Alcoholic liver disease	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.1	Alcoholic hepatitis	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.3	Alcoholic cirrhosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.4	Alcoholic hepatic failure	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
K71.0	Toxic liver disease with cholestasis	Diagnosis	ICD-10-CM
K71.11	Toxic liver disease with hepatic necrosis, with coma	Diagnosis	ICD-10-CM
K71.7	Toxic liver disease with fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K71.8	Toxic liver disease with other disorders of liver	Diagnosis	ICD-10-CM
K71.9	Toxic liver disease, unspecified	Diagnosis	ICD-10-CM
K72	Hepatic failure, not elsewhere classified	Diagnosis	ICD-10-CM
K72.0	Acute and subacute hepatic failure	Diagnosis	ICD-10-CM
K72.00	Acute and subacute hepatic failure without coma	Diagnosis	ICD-10-CM
K72.01	Acute and subacute hepatic failure with coma	Diagnosis	ICD-10-CM
K72.1	Chronic hepatic failure	Diagnosis	ICD-10-CM
K72.10	Chronic hepatic failure without coma	Diagnosis	ICD-10-CM
K72.11	Chronic hepatic failure with coma	Diagnosis	ICD-10-CM
K72.9	Hepatic failure, unspecified	Diagnosis	ICD-10-CM
K72.90	Hepatic failure, unspecified without coma	Diagnosis	ICD-10-CM
K72.91	Hepatic failure, unspecified with coma	Diagnosis	ICD-10-CM
K74	Fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K74.0	Hepatic fibrosis	Diagnosis	ICD-10-CM
K74.00	Hepatic fibrosis, unspecified	Diagnosis	ICD-10-CM
K74.01	Hepatic fibrosis, early fibrosis	Diagnosis	ICD-10-CM
K74.02	Hepatic fibrosis, advanced fibrosis	Diagnosis	ICD-10-CM
K74.1	Hepatic sclerosis	Diagnosis	ICD-10-CM
K74.2	Hepatic fibrosis with hepatic sclerosis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K74.3	Primary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.4	Secondary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.5	Biliary cirrhosis, unspecified	Diagnosis	ICD-10-CM
K74.6	Other and unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.60	Unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.69	Other cirrhosis of liver	Diagnosis	ICD-10-CM
K75.0	Abscess of liver	Diagnosis	ICD-10-CM
K75.1	Phlebitis of portal vein	Diagnosis	ICD-10-CM
K75.8	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.81	Nonalcoholic steatohepatitis (NASH)	Diagnosis	ICD-10-CM
K75.89	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.9	Inflammatory liver disease, unspecified	Diagnosis	ICD-10-CM
K76.0	Fatty (change of) liver, not elsewhere classified	Diagnosis	ICD-10-CM
K76.1	Chronic passive congestion of liver	Diagnosis	ICD-10-CM
K76.2	Central hemorrhagic necrosis of liver	Diagnosis	ICD-10-CM
K76.3	Infarction of liver	Diagnosis	ICD-10-CM
K76.5	Hepatic veno-occlusive disease	Diagnosis	ICD-10-CM
K76.6	Portal hypertension	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
K76.8	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.81	Hepatopulmonary syndrome	Diagnosis	ICD-10-CM
K76.82	Hepatic encephalopathy	Diagnosis	ICD-10-CM
K76.89	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.9	Liver disease, unspecified	Diagnosis	ICD-10-CM
K77	Liver disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K80.30	Calculus of bile duct with cholangitis, unspecified, without obstruction	Diagnosis	ICD-10-CM
K80.31	Calculus of bile duct with cholangitis, unspecified, with obstruction	Diagnosis	ICD-10-CM
K80.32	Calculus of bile duct with acute cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.33	Calculus of bile duct with acute cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.34	Calculus of bile duct with chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.35	Calculus of bile duct with chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.36	Calculus of bile duct with acute and chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.37	Calculus of bile duct with acute and chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K83.0	Cholangitis	Diagnosis	ICD-10-CM
R16.0	Hepatomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
R16.2	Hepatomegaly with splenomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
Z48.23	Encounter for aftercare following liver transplant	Diagnosis	ICD-10-CM
Z94.4	Liver transplant status	Diagnosis	ICD-10-CM
Liver Disease Extended DX List			
K70	Alcoholic liver disease	Diagnosis	ICD-10-CM
K70.0	Alcoholic fatty liver	Diagnosis	ICD-10-CM
K70.1	Alcoholic hepatitis	Diagnosis	ICD-10-CM
K70.10	Alcoholic hepatitis without ascites	Diagnosis	ICD-10-CM
K70.11	Alcoholic hepatitis with ascites	Diagnosis	ICD-10-CM
K70.2	Alcoholic fibrosis and sclerosis of liver	Diagnosis	ICD-10-CM
K70.3	Alcoholic cirrhosis of liver	Diagnosis	ICD-10-CM
K70.30	Alcoholic cirrhosis of liver without ascites	Diagnosis	ICD-10-CM
K70.31	Alcoholic cirrhosis of liver with ascites	Diagnosis	ICD-10-CM
K70.4	Alcoholic hepatic failure	Diagnosis	ICD-10-CM
K70.40	Alcoholic hepatic failure without coma	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K70.41	Alcoholic hepatic failure with coma	Diagnosis	ICD-10-CM
K70.9	Alcoholic liver disease, unspecified	Diagnosis	ICD-10-CM
K71	Toxic liver disease	Diagnosis	ICD-10-CM
K71.0	Toxic liver disease with cholestasis	Diagnosis	ICD-10-CM
K71.1	Toxic liver disease with hepatic necrosis	Diagnosis	ICD-10-CM
K71.10	Toxic liver disease with hepatic necrosis, without coma	Diagnosis	ICD-10-CM
K71.11	Toxic liver disease with hepatic necrosis, with coma	Diagnosis	ICD-10-CM
K71.2	Toxic liver disease with acute hepatitis	Diagnosis	ICD-10-CM
K71.3	Toxic liver disease with chronic persistent hepatitis	Diagnosis	ICD-10-CM
K71.4	Toxic liver disease with chronic lobular hepatitis	Diagnosis	ICD-10-CM
K71.5	Toxic liver disease with chronic active hepatitis	Diagnosis	ICD-10-CM
K71.50	Toxic liver disease with chronic active hepatitis without ascites	Diagnosis	ICD-10-CM
K71.51	Toxic liver disease with chronic active hepatitis with ascites	Diagnosis	ICD-10-CM
K71.6	Toxic liver disease with hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K71.7	Toxic liver disease with fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K71.8	Toxic liver disease with other disorders of liver	Diagnosis	ICD-10-CM
K71.9	Toxic liver disease, unspecified	Diagnosis	ICD-10-CM
K72	Hepatic failure, not elsewhere classified	Diagnosis	ICD-10-CM
K72.0	Acute and subacute hepatic failure	Diagnosis	ICD-10-CM
K72.00	Acute and subacute hepatic failure without coma	Diagnosis	ICD-10-CM
K72.01	Acute and subacute hepatic failure with coma	Diagnosis	ICD-10-CM
K72.1	Chronic hepatic failure	Diagnosis	ICD-10-CM
K72.10	Chronic hepatic failure without coma	Diagnosis	ICD-10-CM
K72.11	Chronic hepatic failure with coma	Diagnosis	ICD-10-CM
K72.9	Hepatic failure, unspecified	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K72.90	Hepatic failure, unspecified without coma	Diagnosis	ICD-10-CM
K72.91	Hepatic failure, unspecified with coma	Diagnosis	ICD-10-CM
K73	Chronic hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.0	Chronic persistent hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.1	Chronic lobular hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.2	Chronic active hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.8	Other chronic hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K73.9	Chronic hepatitis, unspecified	Diagnosis	ICD-10-CM
K74	Fibrosis and cirrhosis of liver	Diagnosis	ICD-10-CM
K74.0	Hepatic fibrosis	Diagnosis	ICD-10-CM
K74.00	Hepatic fibrosis, unspecified	Diagnosis	ICD-10-CM
K74.01	Hepatic fibrosis, early fibrosis	Diagnosis	ICD-10-CM
K74.02	Hepatic fibrosis, advanced fibrosis	Diagnosis	ICD-10-CM
K74.1	Hepatic sclerosis	Diagnosis	ICD-10-CM
K74.2	Hepatic fibrosis with hepatic sclerosis	Diagnosis	ICD-10-CM
K74.3	Primary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.4	Secondary biliary cirrhosis	Diagnosis	ICD-10-CM
K74.5	Biliary cirrhosis, unspecified	Diagnosis	ICD-10-CM
K74.6	Other and unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.60	Unspecified cirrhosis of liver	Diagnosis	ICD-10-CM
K74.69	Other cirrhosis of liver	Diagnosis	ICD-10-CM
K75	Other inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.0	Abscess of liver	Diagnosis	ICD-10-CM
K75.1	Phlebitis of portal vein	Diagnosis	ICD-10-CM
K75.2	Nonspecific reactive hepatitis	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K75.3	Granulomatous hepatitis, not elsewhere classified	Diagnosis	ICD-10-CM
K75.4	Autoimmune hepatitis	Diagnosis	ICD-10-CM
K75.8	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.81	Nonalcoholic steatohepatitis (NASH)	Diagnosis	ICD-10-CM
K75.89	Other specified inflammatory liver diseases	Diagnosis	ICD-10-CM
K75.9	Inflammatory liver disease, unspecified	Diagnosis	ICD-10-CM
K76	Other diseases of liver	Diagnosis	ICD-10-CM
K76.0	Fatty (change of) liver, not elsewhere classified	Diagnosis	ICD-10-CM
K76.1	Chronic passive congestion of liver	Diagnosis	ICD-10-CM
K76.2	Central hemorrhagic necrosis of liver	Diagnosis	ICD-10-CM
K76.3	Infarction of liver	Diagnosis	ICD-10-CM
K76.4	Peliosis hepatis	Diagnosis	ICD-10-CM
K76.5	Hepatic veno-occlusive disease	Diagnosis	ICD-10-CM
K76.6	Portal hypertension	Diagnosis	ICD-10-CM
K76.7	Hepatorenal syndrome	Diagnosis	ICD-10-CM
K76.8	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.81	Hepatopulmonary syndrome	Diagnosis	ICD-10-CM
K76.82	Hepatic encephalopathy	Diagnosis	ICD-10-CM
K76.89	Other specified diseases of liver	Diagnosis	ICD-10-CM
K76.9	Liver disease, unspecified	Diagnosis	ICD-10-CM
K77	Liver disorders in diseases classified elsewhere	Diagnosis	ICD-10-CM
K80.30	Calculus of bile duct with cholangitis, unspecified, without obstruction	Diagnosis	ICD-10-CM
K80.31	Calculus of bile duct with cholangitis, unspecified, with obstruction	Diagnosis	ICD-10-CM
K80.32	Calculus of bile duct with acute cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.33	Calculus of bile duct with acute cholangitis with obstruction	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
K80.34	Calculus of bile duct with chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.35	Calculus of bile duct with chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K80.36	Calculus of bile duct with acute and chronic cholangitis without obstruction	Diagnosis	ICD-10-CM
K80.37	Calculus of bile duct with acute and chronic cholangitis with obstruction	Diagnosis	ICD-10-CM
K83.0	Cholangitis	Diagnosis	ICD-10-CM
R16.0	Hepatomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
R16.2	Hepatomegaly with splenomegaly, not elsewhere classified	Diagnosis	ICD-10-CM
Z48.23	Encounter for aftercare following liver transplant	Diagnosis	ICD-10-CM
Z94.4	Liver transplant status	Diagnosis	ICD-10-CM
Liver Disease Procedures			
06L20ZZ	Occlusion of Gastric Vein, Open Approach	Procedure	ICD-10-PCS
06L23ZZ	Occlusion of Gastric Vein, Percutaneous Approach	Procedure	ICD-10-PCS
06L24ZZ	Occlusion of Gastric Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
06L30ZZ	Occlusion of Esophageal Vein, Open Approach	Procedure	ICD-10-PCS
06L33ZZ	Occlusion of Esophageal Vein, Percutaneous Approach	Procedure	ICD-10-PCS
06L34ZZ	Occlusion of Esophageal Vein, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9S30Z	Drainage of Greater Omentum with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9S3ZZ	Drainage of Greater Omentum, Percutaneous Approach	Procedure	ICD-10-PCS
0D9S40Z	Drainage of Greater Omentum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9S4ZZ	Drainage of Greater Omentum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9T30Z	Drainage of Lesser Omentum with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9T3ZZ	Drainage of Lesser Omentum, Percutaneous Approach	Procedure	ICD-10-PCS
0D9T40Z	Drainage of Lesser Omentum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9T4ZZ	Drainage of Lesser Omentum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9V30Z	Drainage of Mesentery with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D9V3ZZ	Drainage of Mesentery, Percutaneous Approach	Procedure	ICD-10-PCS
0D9V40Z	Drainage of Mesentery with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9V4ZZ	Drainage of Mesentery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9W30Z	Drainage of Peritoneum with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0D9W3ZZ	Drainage of Peritoneum, Percutaneous Approach	Procedure	ICD-10-PCS
0D9W40Z	Drainage of Peritoneum with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D9W4ZZ	Drainage of Peritoneum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DL57DZ	Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DL58DZ	Occlusion of Esophagus with Intraluminal Device, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0W9F30Z	Drainage of Abdominal Wall with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0W9F3ZZ	Drainage of Abdominal Wall, Percutaneous Approach	Procedure	ICD-10-PCS
0W9F40Z	Drainage of Abdominal Wall with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9F4ZZ	Drainage of Abdominal Wall, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9G30Z	Drainage of Peritoneal Cavity with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0W9G3ZZ	Drainage of Peritoneal Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0W9G40Z	Drainage of Peritoneal Cavity with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9G4ZZ	Drainage of Peritoneal Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9J30Z	Drainage of Pelvic Cavity with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0W9J3ZZ	Drainage of Pelvic Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
Lung Cancer			
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
D02.20	Carcinoma in situ of unspecified bronchus and lung	Diagnosis	ICD-10-CM
D02.21	Carcinoma in situ of right bronchus and lung	Diagnosis	ICD-10-CM
D02.22	Carcinoma in situ of left bronchus and lung	Diagnosis	ICD-10-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
Obesity			
0D16079	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1607L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160J9	Bypass Stomach to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JB	Bypass Stomach to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D160K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160Z9	Bypass Stomach to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D160ZB	Bypass Stomach to Ileum, Open Approach	Procedure	ICD-10-PCS
0D160ZL	Bypass Stomach to Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0D16479	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1647L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164J9	Bypass Stomach to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JA	Bypass Stomach to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JB	Bypass Stomach to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D164KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164Z9	Bypass Stomach to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZB	Bypass Stomach to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D164ZL	Bypass Stomach to Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D16879	Bypass Stomach to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687B	Bypass Stomach to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1687L	Bypass Stomach to Transverse Colon with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168J9	Bypass Stomach to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JA	Bypass Stomach to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JB	Bypass Stomach to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168JL	Bypass Stomach to Transverse Colon with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168K9	Bypass Stomach to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D168KB	Bypass Stomach to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168KL	Bypass Stomach to Transverse Colon with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168Z9	Bypass Stomach to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZB	Bypass Stomach to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D168ZL	Bypass Stomach to Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D19079	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1907B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190JB	Bypass Duodenum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D190K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D190Z9	Bypass Duodenum to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D190ZA	Bypass Duodenum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D190ZB	Bypass Duodenum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D19479	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1947B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D194J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194JB	Bypass Duodenum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194Z9	Bypass Duodenum to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZA	Bypass Duodenum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D194ZB	Bypass Duodenum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D19879	Bypass Duodenum to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987A	Bypass Duodenum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1987B	Bypass Duodenum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198J9	Bypass Duodenum to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JA	Bypass Duodenum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198JB	Bypass Duodenum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198K9	Bypass Duodenum to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D198KA	Bypass Duodenum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198KB	Bypass Duodenum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198Z9	Bypass Duodenum to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZA	Bypass Duodenum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D198ZB	Bypass Duodenum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A07A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A07B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0JB	Bypass Jejunum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1A0ZA	Bypass Jejunum to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D1A0ZB	Bypass Jejunum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1A47A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A47B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4JB	Bypass Jejunum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZA	Bypass Jejunum to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1A4ZB	Bypass Jejunum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D1A87A	Bypass Jejunum to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A87B	Bypass Jejunum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JA	Bypass Jejunum to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8JB	Bypass Jejunum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KA	Bypass Jejunum to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8KB	Bypass Jejunum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZA	Bypass Jejunum to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZB	Bypass Jejunum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1A8ZH	Bypass Jejunum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B07B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0JB	Bypass Ileum to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1B0ZB	Bypass Ileum to Ileum, Open Approach	Procedure	ICD-10-PCS
0D1B47B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4JB	Bypass Ileum to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B4ZB	Bypass Ileum to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1B87B	Bypass Ileum to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8JB	Bypass Ileum to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
0D1B8KB	Bypass Ileum to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZB	Bypass Ileum to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1B8ZH	Bypass Ileum to Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB80ZZ	Excision of Small Intestine, Open Approach	Procedure	ICD-10-PCS
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DBB0ZZ	Excision of Ileum, Open Approach	Procedure	ICD-10-PCS
0DQ64ZZ	Repair Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DV64CZ	Restriction of Stomach with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
0TRB07Z	Replacement of Bladder with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
43644	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and Roux-en-Y gastroenterostomy (roux limb 150 cm or less)	Procedure	CPT-4
43645	Laparoscopy, surgical, gastric restrictive procedure; with gastric bypass and small intestine reconstruction to limit absorption	Procedure	CPT-4
43770	Laparoscopy, surgical, gastric restrictive procedure; placement of adjustable gastric restrictive device (eg, gastric band and subcutaneous port components)	Procedure	CPT-4

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
43842	Gastric restrictive procedure, without gastric bypass, for morbid obesity; vertical-banded gastroplasty	Procedure	CPT-4
43843	Gastric restrictive procedure, without gastric bypass, for morbid obesity; other than vertical-banded gastroplasty	Procedure	CPT-4
43845	Gastric restrictive procedure with partial gastrectomy, pylorus-preserving duodenoileostomy and ileoileostomy (50 to 100 cm common channel) to limit absorption (biliopancreatic diversion with duodenal switch)	Procedure	CPT-4
43846	Gastric restrictive procedure, with gastric bypass for morbid obesity; with short limb (150 cm or less) Roux-en-Y gastroenterostomy	Procedure	CPT-4
43847	Gastric restrictive procedure, with gastric bypass for morbid obesity; with small intestine reconstruction to limit absorption	Procedure	CPT-4
E66.01	Morbid (severe) obesity due to excess calories	Diagnosis	ICD-10-CM
E66.09	Other obesity due to excess calories	Diagnosis	ICD-10-CM
E66.1	Drug-induced obesity	Diagnosis	ICD-10-CM
E66.2	Morbid (severe) obesity with alveolar hypoventilation	Diagnosis	ICD-10-CM
E66.8	Other obesity	Diagnosis	ICD-10-CM
E66.9	Obesity, unspecified	Diagnosis	ICD-10-CM
K95.01	Infection due to gastric band procedure	Diagnosis	ICD-10-CM
K95.09	Other complications of gastric band procedure	Diagnosis	ICD-10-CM
K95.81	Infection due to other bariatric procedure	Diagnosis	ICD-10-CM
K95.89	Other complications of other bariatric procedure	Diagnosis	ICD-10-CM
O99.210	Obesity complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.211	Obesity complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.212	Obesity complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.213	Obesity complicating pregnancy, third trimester	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
O99.214	Obesity complicating childbirth	Diagnosis	ICD-10-CM
O99.215	Obesity complicating the puerperium	Diagnosis	ICD-10-CM
O99.840	Bariatric surgery status complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.841	Bariatric surgery status complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.842	Bariatric surgery status complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.843	Bariatric surgery status complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.844	Bariatric surgery status complicating childbirth	Diagnosis	ICD-10-CM
O99.845	Bariatric surgery status complicating the puerperium	Diagnosis	ICD-10-CM
Z68.30	Body mass index (BMI) 30.0-30.9, adult	Diagnosis	ICD-10-CM
Z68.31	Body mass index (BMI) 31.0-31.9, adult	Diagnosis	ICD-10-CM
Z68.32	Body mass index (BMI) 32.0-32.9, adult	Diagnosis	ICD-10-CM
Z68.33	Body mass index (BMI) 33.0-33.9, adult	Diagnosis	ICD-10-CM
Z68.34	Body mass index (BMI) 34.0-34.9, adult	Diagnosis	ICD-10-CM
Z68.35	Body mass index (BMI) 35.0-35.9, adult	Diagnosis	ICD-10-CM
Z68.36	Body mass index (BMI) 36.0-36.9, adult	Diagnosis	ICD-10-CM
Z68.37	Body mass index (BMI) 37.0-37.9, adult	Diagnosis	ICD-10-CM
Z68.38	Body mass index (BMI) 38.0-38.9, adult	Diagnosis	ICD-10-CM
Z68.39	Body mass index (BMI) 39.0-39.9, adult	Diagnosis	ICD-10-CM
Z68.41	Body mass index (BMI) 40.0-44.9, adult	Diagnosis	ICD-10-CM
Z68.42	Body mass index (BMI) 45.0-49.9, adult	Diagnosis	ICD-10-CM
Z68.43	Body mass index (BMI) 50-59.9, adult	Diagnosis	ICD-10-CM
Z68.44	Body mass index (BMI) 60.0-69.9, adult	Diagnosis	ICD-10-CM
Z68.45	Body mass index (BMI) 70 or greater, adult	Diagnosis	ICD-10-CM
Osteoporosis			

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M80.00XA	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.011A	Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.012A	Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.019A	Age-related osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.021A	Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.022A	Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.029A	Age-related osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.031A	Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.032A	Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.039A	Age-related osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.041A	Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.042A	Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.049A	Age-related osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M80.051A	Age-related osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.052A	Age-related osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.059A	Age-related osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.061A	Age-related osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.062A	Age-related osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.069A	Age-related osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.071A	Age-related osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.072A	Age-related osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.079A	Age-related osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.08XA	Age-related osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0AXA	Age-related osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0B1A	Age-related osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.0B2A	Age-related osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M80.0B9A	Age-related osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.80XA	Other osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.811A	Other osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.812A	Other osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.819A	Other osteoporosis with current pathological fracture, unspecified shoulder, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.821A	Other osteoporosis with current pathological fracture, right humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.822A	Other osteoporosis with current pathological fracture, left humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.829A	Other osteoporosis with current pathological fracture, unspecified humerus, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.831A	Other osteoporosis with current pathological fracture, right forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.832A	Other osteoporosis with current pathological fracture, left forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.839A	Other osteoporosis with current pathological fracture, unspecified forearm, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.841A	Other osteoporosis with current pathological fracture, right hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.842A	Other osteoporosis with current pathological fracture, left hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.849A	Other osteoporosis with current pathological fracture, unspecified hand, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.851A	Other osteoporosis with current pathological fracture, right femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.852A	Other osteoporosis with current pathological fracture, left femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.859A	Other osteoporosis with current pathological fracture, unspecified femur, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.861A	Other osteoporosis with current pathological fracture, right lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.862A	Other osteoporosis with current pathological fracture, left lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M80.869A	Other osteoporosis with current pathological fracture, unspecified lower leg, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.871A	Other osteoporosis with current pathological fracture, right ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.872A	Other osteoporosis with current pathological fracture, left ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.879A	Other osteoporosis with current pathological fracture, unspecified ankle and foot, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.88XA	Other osteoporosis with current pathological fracture, vertebra(e), initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8AXA	Other osteoporosis with current pathological fracture, other site, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8B1A	Other osteoporosis with current pathological fracture, right pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8B2A	Other osteoporosis with current pathological fracture, left pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M80.8B9A	Other osteoporosis with current pathological fracture, unspecified pelvis, initial encounter for fracture	Diagnosis	ICD-10-CM
M81.0	Age-related osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
M81.6	Localized osteoporosis [Lequesne]	Diagnosis	ICD-10-CM
M81.8	Other osteoporosis without current pathological fracture	Diagnosis	ICD-10-CM
Overweight			
E66.3	Overweight	Diagnosis	ICD-10-CM
Z68.25	Body mass index (BMI) 25.0-25.9, adult	Diagnosis	ICD-10-CM
Z68.26	Body mass index (BMI) 26.0-26.9, adult	Diagnosis	ICD-10-CM
Z68.27	Body mass index (BMI) 27.0-27.9, adult	Diagnosis	ICD-10-CM
Z68.28	Body mass index (BMI) 28.0-28.9, adult	Diagnosis	ICD-10-CM
Z68.29	Body mass index (BMI) 29.0-29.9, adult	Diagnosis	ICD-10-CM
Prostate			

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
D07.5	Carcinoma in situ of prostate	Diagnosis	ICD-10-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
Rheumatoid Arthritis			
L40.50	Arthropathic psoriasis, unspecified	Diagnosis	ICD-10-CM
L40.51	Distal interphalangeal psoriatic arthropathy	Diagnosis	ICD-10-CM
L40.54	Psoriatic juvenile arthropathy	Diagnosis	ICD-10-CM
L40.59	Other psoriatic arthropathy	Diagnosis	ICD-10-CM
M05.00	Felty's syndrome, unspecified site	Diagnosis	ICD-10-CM
M05.011	Felty's syndrome, right shoulder	Diagnosis	ICD-10-CM
M05.012	Felty's syndrome, left shoulder	Diagnosis	ICD-10-CM
M05.019	Felty's syndrome, unspecified shoulder	Diagnosis	ICD-10-CM
M05.021	Felty's syndrome, right elbow	Diagnosis	ICD-10-CM
M05.022	Felty's syndrome, left elbow	Diagnosis	ICD-10-CM
M05.029	Felty's syndrome, unspecified elbow	Diagnosis	ICD-10-CM
M05.031	Felty's syndrome, right wrist	Diagnosis	ICD-10-CM
M05.032	Felty's syndrome, left wrist	Diagnosis	ICD-10-CM
M05.039	Felty's syndrome, unspecified wrist	Diagnosis	ICD-10-CM
M05.041	Felty's syndrome, right hand	Diagnosis	ICD-10-CM
M05.042	Felty's syndrome, left hand	Diagnosis	ICD-10-CM
M05.049	Felty's syndrome, unspecified hand	Diagnosis	ICD-10-CM
M05.051	Felty's syndrome, right hip	Diagnosis	ICD-10-CM
M05.052	Felty's syndrome, left hip	Diagnosis	ICD-10-CM
M05.059	Felty's syndrome, unspecified hip	Diagnosis	ICD-10-CM
M05.061	Felty's syndrome, right knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.062	Felty's syndrome, left knee	Diagnosis	ICD-10-CM
M05.069	Felty's syndrome, unspecified knee	Diagnosis	ICD-10-CM
M05.071	Felty's syndrome, right ankle and foot	Diagnosis	ICD-10-CM
M05.072	Felty's syndrome, left ankle and foot	Diagnosis	ICD-10-CM
M05.079	Felty's syndrome, unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.09	Felty's syndrome, multiple sites	Diagnosis	ICD-10-CM
M05.10	Rheumatoid lung disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.111	Rheumatoid lung disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.112	Rheumatoid lung disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.119	Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.121	Rheumatoid lung disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.122	Rheumatoid lung disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.129	Rheumatoid lung disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.131	Rheumatoid lung disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.132	Rheumatoid lung disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.139	Rheumatoid lung disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.141	Rheumatoid lung disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.142	Rheumatoid lung disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.149	Rheumatoid lung disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.151	Rheumatoid lung disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.152	Rheumatoid lung disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.159	Rheumatoid lung disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.161	Rheumatoid lung disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.162	Rheumatoid lung disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.169	Rheumatoid lung disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.171	Rheumatoid lung disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.172	Rheumatoid lung disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.179	Rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.19	Rheumatoid lung disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.20	Rheumatoid vasculitis with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.211	Rheumatoid vasculitis with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.212	Rheumatoid vasculitis with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.219	Rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.221	Rheumatoid vasculitis with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.222	Rheumatoid vasculitis with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.229	Rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.231	Rheumatoid vasculitis with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.232	Rheumatoid vasculitis with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.239	Rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.241	Rheumatoid vasculitis with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.242	Rheumatoid vasculitis with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.249	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.251	Rheumatoid vasculitis with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.252	Rheumatoid vasculitis with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.259	Rheumatoid vasculitis with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.261	Rheumatoid vasculitis with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.262	Rheumatoid vasculitis with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.269	Rheumatoid vasculitis with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.271	Rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.272	Rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.279	Rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.29	Rheumatoid vasculitis with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.30	Rheumatoid heart disease with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.311	Rheumatoid heart disease with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.312	Rheumatoid heart disease with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.319	Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.321	Rheumatoid heart disease with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.322	Rheumatoid heart disease with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.329	Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.331	Rheumatoid heart disease with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.332	Rheumatoid heart disease with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.339	Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.341	Rheumatoid heart disease with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.342	Rheumatoid heart disease with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.349	Rheumatoid heart disease with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.351	Rheumatoid heart disease with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.352	Rheumatoid heart disease with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.359	Rheumatoid heart disease with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.361	Rheumatoid heart disease with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.362	Rheumatoid heart disease with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.369	Rheumatoid heart disease with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.371	Rheumatoid heart disease with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.372	Rheumatoid heart disease with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.379	Rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.39	Rheumatoid heart disease with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.40	Rheumatoid myopathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.411	Rheumatoid myopathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM
M05.412	Rheumatoid myopathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.419	Rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.421	Rheumatoid myopathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.422	Rheumatoid myopathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.429	Rheumatoid myopathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.431	Rheumatoid myopathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.432	Rheumatoid myopathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.439	Rheumatoid myopathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.441	Rheumatoid myopathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.442	Rheumatoid myopathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.449	Rheumatoid myopathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.451	Rheumatoid myopathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.452	Rheumatoid myopathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.459	Rheumatoid myopathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.461	Rheumatoid myopathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.462	Rheumatoid myopathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.469	Rheumatoid myopathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.471	Rheumatoid myopathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.472	Rheumatoid myopathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.479	Rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.49	Rheumatoid myopathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.50	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M05.511	Rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.512	Rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder	Diagnosis	ICD-10-CM
M05.519	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder	Diagnosis	ICD-10-CM
M05.521	Rheumatoid polyneuropathy with rheumatoid arthritis of right elbow	Diagnosis	ICD-10-CM
M05.522	Rheumatoid polyneuropathy with rheumatoid arthritis of left elbow	Diagnosis	ICD-10-CM
M05.529	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow	Diagnosis	ICD-10-CM
M05.531	Rheumatoid polyneuropathy with rheumatoid arthritis of right wrist	Diagnosis	ICD-10-CM
M05.532	Rheumatoid polyneuropathy with rheumatoid arthritis of left wrist	Diagnosis	ICD-10-CM
M05.539	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist	Diagnosis	ICD-10-CM
M05.541	Rheumatoid polyneuropathy with rheumatoid arthritis of right hand	Diagnosis	ICD-10-CM
M05.542	Rheumatoid polyneuropathy with rheumatoid arthritis of left hand	Diagnosis	ICD-10-CM
M05.549	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand	Diagnosis	ICD-10-CM
M05.551	Rheumatoid polyneuropathy with rheumatoid arthritis of right hip	Diagnosis	ICD-10-CM
M05.552	Rheumatoid polyneuropathy with rheumatoid arthritis of left hip	Diagnosis	ICD-10-CM
M05.559	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip	Diagnosis	ICD-10-CM
M05.561	Rheumatoid polyneuropathy with rheumatoid arthritis of right knee	Diagnosis	ICD-10-CM
M05.562	Rheumatoid polyneuropathy with rheumatoid arthritis of left knee	Diagnosis	ICD-10-CM
M05.569	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee	Diagnosis	ICD-10-CM
M05.571	Rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot	Diagnosis	ICD-10-CM
M05.572	Rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot	Diagnosis	ICD-10-CM
M05.579	Rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.59	Rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites	Diagnosis	ICD-10-CM
M05.60	Rheumatoid arthritis of unspecified site with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.611	Rheumatoid arthritis of right shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.612	Rheumatoid arthritis of left shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.619	Rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.621	Rheumatoid arthritis of right elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.622	Rheumatoid arthritis of left elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.629	Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.631	Rheumatoid arthritis of right wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.632	Rheumatoid arthritis of left wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.639	Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.641	Rheumatoid arthritis of right hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.642	Rheumatoid arthritis of left hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.649	Rheumatoid arthritis of unspecified hand with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.651	Rheumatoid arthritis of right hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.652	Rheumatoid arthritis of left hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.659	Rheumatoid arthritis of unspecified hip with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.661	Rheumatoid arthritis of right knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.662	Rheumatoid arthritis of left knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.669	Rheumatoid arthritis of unspecified knee with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.671	Rheumatoid arthritis of right ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.672	Rheumatoid arthritis of left ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.679	Rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.69	Rheumatoid arthritis of multiple sites with involvement of other organs and systems	Diagnosis	ICD-10-CM
M05.70	Rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.711	Rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.712	Rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.719	Rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement	Diagnosis	ICD-10-CM
M05.721	Rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.722	Rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.729	Rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement	Diagnosis	ICD-10-CM
M05.731	Rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.732	Rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.739	Rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement	Diagnosis	ICD-10-CM
M05.741	Rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.742	Rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.749	Rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement	Diagnosis	ICD-10-CM
M05.751	Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.752	Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.759	Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement	Diagnosis	ICD-10-CM
M05.761	Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.762	Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.769	Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement	Diagnosis	ICD-10-CM
M05.771	Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.772	Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.779	Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement	Diagnosis	ICD-10-CM
M05.79	Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement	Diagnosis	ICD-10-CM
M05.7A	Rheumatoid arthritis with rheumatoid factor of other specified site without organ or systems involvement	Diagnosis	ICD-10-CM
M05.80	Other rheumatoid arthritis with rheumatoid factor of unspecified site	Diagnosis	ICD-10-CM
M05.811	Other rheumatoid arthritis with rheumatoid factor of right shoulder	Diagnosis	ICD-10-CM
M05.812	Other rheumatoid arthritis with rheumatoid factor of left shoulder	Diagnosis	ICD-10-CM
M05.819	Other rheumatoid arthritis with rheumatoid factor of unspecified shoulder	Diagnosis	ICD-10-CM
M05.821	Other rheumatoid arthritis with rheumatoid factor of right elbow	Diagnosis	ICD-10-CM
M05.822	Other rheumatoid arthritis with rheumatoid factor of left elbow	Diagnosis	ICD-10-CM
M05.829	Other rheumatoid arthritis with rheumatoid factor of unspecified elbow	Diagnosis	ICD-10-CM
M05.831	Other rheumatoid arthritis with rheumatoid factor of right wrist	Diagnosis	ICD-10-CM
M05.832	Other rheumatoid arthritis with rheumatoid factor of left wrist	Diagnosis	ICD-10-CM
M05.839	Other rheumatoid arthritis with rheumatoid factor of unspecified wrist	Diagnosis	ICD-10-CM
M05.841	Other rheumatoid arthritis with rheumatoid factor of right hand	Diagnosis	ICD-10-CM
M05.842	Other rheumatoid arthritis with rheumatoid factor of left hand	Diagnosis	ICD-10-CM
M05.849	Other rheumatoid arthritis with rheumatoid factor of unspecified hand	Diagnosis	ICD-10-CM
M05.851	Other rheumatoid arthritis with rheumatoid factor of right hip	Diagnosis	ICD-10-CM
M05.852	Other rheumatoid arthritis with rheumatoid factor of left hip	Diagnosis	ICD-10-CM
M05.859	Other rheumatoid arthritis with rheumatoid factor of unspecified hip	Diagnosis	ICD-10-CM
M05.861	Other rheumatoid arthritis with rheumatoid factor of right knee	Diagnosis	ICD-10-CM
M05.862	Other rheumatoid arthritis with rheumatoid factor of left knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M05.869	Other rheumatoid arthritis with rheumatoid factor of unspecified knee	Diagnosis	ICD-10-CM
M05.871	Other rheumatoid arthritis with rheumatoid factor of right ankle and foot	Diagnosis	ICD-10-CM
M05.872	Other rheumatoid arthritis with rheumatoid factor of left ankle and foot	Diagnosis	ICD-10-CM
M05.879	Other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot	Diagnosis	ICD-10-CM
M05.89	Other rheumatoid arthritis with rheumatoid factor of multiple sites	Diagnosis	ICD-10-CM
M05.8A	Other rheumatoid arthritis with rheumatoid factor of other specified site	Diagnosis	ICD-10-CM
M05.9	Rheumatoid arthritis with rheumatoid factor, unspecified	Diagnosis	ICD-10-CM
M06.00	Rheumatoid arthritis without rheumatoid factor, unspecified site	Diagnosis	ICD-10-CM
M06.011	Rheumatoid arthritis without rheumatoid factor, right shoulder	Diagnosis	ICD-10-CM
M06.012	Rheumatoid arthritis without rheumatoid factor, left shoulder	Diagnosis	ICD-10-CM
M06.019	Rheumatoid arthritis without rheumatoid factor, unspecified shoulder	Diagnosis	ICD-10-CM
M06.021	Rheumatoid arthritis without rheumatoid factor, right elbow	Diagnosis	ICD-10-CM
M06.022	Rheumatoid arthritis without rheumatoid factor, left elbow	Diagnosis	ICD-10-CM
M06.029	Rheumatoid arthritis without rheumatoid factor, unspecified elbow	Diagnosis	ICD-10-CM
M06.031	Rheumatoid arthritis without rheumatoid factor, right wrist	Diagnosis	ICD-10-CM
M06.032	Rheumatoid arthritis without rheumatoid factor, left wrist	Diagnosis	ICD-10-CM
M06.039	Rheumatoid arthritis without rheumatoid factor, unspecified wrist	Diagnosis	ICD-10-CM
M06.041	Rheumatoid arthritis without rheumatoid factor, right hand	Diagnosis	ICD-10-CM
M06.042	Rheumatoid arthritis without rheumatoid factor, left hand	Diagnosis	ICD-10-CM
M06.049	Rheumatoid arthritis without rheumatoid factor, unspecified hand	Diagnosis	ICD-10-CM
M06.051	Rheumatoid arthritis without rheumatoid factor, right hip	Diagnosis	ICD-10-CM
M06.052	Rheumatoid arthritis without rheumatoid factor, left hip	Diagnosis	ICD-10-CM
M06.059	Rheumatoid arthritis without rheumatoid factor, unspecified hip	Diagnosis	ICD-10-CM
M06.061	Rheumatoid arthritis without rheumatoid factor, right knee	Diagnosis	ICD-10-CM
M06.062	Rheumatoid arthritis without rheumatoid factor, left knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M06.069	Rheumatoid arthritis without rheumatoid factor, unspecified knee	Diagnosis	ICD-10-CM
M06.071	Rheumatoid arthritis without rheumatoid factor, right ankle and foot	Diagnosis	ICD-10-CM
M06.072	Rheumatoid arthritis without rheumatoid factor, left ankle and foot	Diagnosis	ICD-10-CM
M06.079	Rheumatoid arthritis without rheumatoid factor, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.08	Rheumatoid arthritis without rheumatoid factor, vertebrae	Diagnosis	ICD-10-CM
M06.09	Rheumatoid arthritis without rheumatoid factor, multiple sites	Diagnosis	ICD-10-CM
M06.0A	Rheumatoid arthritis without rheumatoid factor, other specified site	Diagnosis	ICD-10-CM
M06.1	Adult-onset Still's disease	Diagnosis	ICD-10-CM
M06.20	Rheumatoid bursitis, unspecified site	Diagnosis	ICD-10-CM
M06.211	Rheumatoid bursitis, right shoulder	Diagnosis	ICD-10-CM
M06.212	Rheumatoid bursitis, left shoulder	Diagnosis	ICD-10-CM
M06.219	Rheumatoid bursitis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.221	Rheumatoid bursitis, right elbow	Diagnosis	ICD-10-CM
M06.222	Rheumatoid bursitis, left elbow	Diagnosis	ICD-10-CM
M06.229	Rheumatoid bursitis, unspecified elbow	Diagnosis	ICD-10-CM
M06.231	Rheumatoid bursitis, right wrist	Diagnosis	ICD-10-CM
M06.232	Rheumatoid bursitis, left wrist	Diagnosis	ICD-10-CM
M06.239	Rheumatoid bursitis, unspecified wrist	Diagnosis	ICD-10-CM
M06.241	Rheumatoid bursitis, right hand	Diagnosis	ICD-10-CM
M06.242	Rheumatoid bursitis, left hand	Diagnosis	ICD-10-CM
M06.249	Rheumatoid bursitis, unspecified hand	Diagnosis	ICD-10-CM
M06.251	Rheumatoid bursitis, right hip	Diagnosis	ICD-10-CM
M06.252	Rheumatoid bursitis, left hip	Diagnosis	ICD-10-CM
M06.259	Rheumatoid bursitis, unspecified hip	Diagnosis	ICD-10-CM
M06.261	Rheumatoid bursitis, right knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M06.262	Rheumatoid bursitis, left knee	Diagnosis	ICD-10-CM
M06.269	Rheumatoid bursitis, unspecified knee	Diagnosis	ICD-10-CM
M06.271	Rheumatoid bursitis, right ankle and foot	Diagnosis	ICD-10-CM
M06.272	Rheumatoid bursitis, left ankle and foot	Diagnosis	ICD-10-CM
M06.279	Rheumatoid bursitis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.28	Rheumatoid bursitis, vertebrae	Diagnosis	ICD-10-CM
M06.29	Rheumatoid bursitis, multiple sites	Diagnosis	ICD-10-CM
M06.30	Rheumatoid nodule, unspecified site	Diagnosis	ICD-10-CM
M06.311	Rheumatoid nodule, right shoulder	Diagnosis	ICD-10-CM
M06.312	Rheumatoid nodule, left shoulder	Diagnosis	ICD-10-CM
M06.319	Rheumatoid nodule, unspecified shoulder	Diagnosis	ICD-10-CM
M06.321	Rheumatoid nodule, right elbow	Diagnosis	ICD-10-CM
M06.322	Rheumatoid nodule, left elbow	Diagnosis	ICD-10-CM
M06.329	Rheumatoid nodule, unspecified elbow	Diagnosis	ICD-10-CM
M06.331	Rheumatoid nodule, right wrist	Diagnosis	ICD-10-CM
M06.332	Rheumatoid nodule, left wrist	Diagnosis	ICD-10-CM
M06.339	Rheumatoid nodule, unspecified wrist	Diagnosis	ICD-10-CM
M06.341	Rheumatoid nodule, right hand	Diagnosis	ICD-10-CM
M06.342	Rheumatoid nodule, left hand	Diagnosis	ICD-10-CM
M06.349	Rheumatoid nodule, unspecified hand	Diagnosis	ICD-10-CM
M06.351	Rheumatoid nodule, right hip	Diagnosis	ICD-10-CM
M06.352	Rheumatoid nodule, left hip	Diagnosis	ICD-10-CM
M06.359	Rheumatoid nodule, unspecified hip	Diagnosis	ICD-10-CM
M06.361	Rheumatoid nodule, right knee	Diagnosis	ICD-10-CM
M06.362	Rheumatoid nodule, left knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M06.369	Rheumatoid nodule, unspecified knee	Diagnosis	ICD-10-CM
M06.371	Rheumatoid nodule, right ankle and foot	Diagnosis	ICD-10-CM
M06.372	Rheumatoid nodule, left ankle and foot	Diagnosis	ICD-10-CM
M06.379	Rheumatoid nodule, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.38	Rheumatoid nodule, vertebrae	Diagnosis	ICD-10-CM
M06.39	Rheumatoid nodule, multiple sites	Diagnosis	ICD-10-CM
M06.80	Other specified rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M06.811	Other specified rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M06.812	Other specified rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M06.819	Other specified rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M06.821	Other specified rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M06.822	Other specified rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M06.829	Other specified rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M06.831	Other specified rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M06.832	Other specified rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M06.839	Other specified rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M06.841	Other specified rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M06.842	Other specified rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M06.849	Other specified rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M06.851	Other specified rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M06.852	Other specified rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M06.859	Other specified rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M06.861	Other specified rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M06.862	Other specified rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M06.869	Other specified rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M06.871	Other specified rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M06.872	Other specified rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M06.879	Other specified rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M06.88	Other specified rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M06.89	Other specified rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M06.8A	Other specified rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M06.9	Rheumatoid arthritis, unspecified	Diagnosis	ICD-10-CM
M08.00	Unspecified juvenile rheumatoid arthritis of unspecified site	Diagnosis	ICD-10-CM
M08.011	Unspecified juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.012	Unspecified juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.019	Unspecified juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.021	Unspecified juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.022	Unspecified juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.029	Unspecified juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.031	Unspecified juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.032	Unspecified juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.039	Unspecified juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.041	Unspecified juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.042	Unspecified juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.049	Unspecified juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.051	Unspecified juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.052	Unspecified juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.059	Unspecified juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.061	Unspecified juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.062	Unspecified juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.069	Unspecified juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.071	Unspecified juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.072	Unspecified juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.079	Unspecified juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.08	Unspecified juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.09	Unspecified juvenile rheumatoid arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.0A	Unspecified juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.1	Juvenile ankylosing spondylitis	Diagnosis	ICD-10-CM
M08.20	Juvenile rheumatoid arthritis with systemic onset, unspecified site	Diagnosis	ICD-10-CM
M08.211	Juvenile rheumatoid arthritis with systemic onset, right shoulder	Diagnosis	ICD-10-CM
M08.212	Juvenile rheumatoid arthritis with systemic onset, left shoulder	Diagnosis	ICD-10-CM
M08.219	Juvenile rheumatoid arthritis with systemic onset, unspecified shoulder	Diagnosis	ICD-10-CM
M08.221	Juvenile rheumatoid arthritis with systemic onset, right elbow	Diagnosis	ICD-10-CM
M08.222	Juvenile rheumatoid arthritis with systemic onset, left elbow	Diagnosis	ICD-10-CM
M08.229	Juvenile rheumatoid arthritis with systemic onset, unspecified elbow	Diagnosis	ICD-10-CM
M08.231	Juvenile rheumatoid arthritis with systemic onset, right wrist	Diagnosis	ICD-10-CM
M08.232	Juvenile rheumatoid arthritis with systemic onset, left wrist	Diagnosis	ICD-10-CM
M08.239	Juvenile rheumatoid arthritis with systemic onset, unspecified wrist	Diagnosis	ICD-10-CM
M08.241	Juvenile rheumatoid arthritis with systemic onset, right hand	Diagnosis	ICD-10-CM
M08.242	Juvenile rheumatoid arthritis with systemic onset, left hand	Diagnosis	ICD-10-CM
M08.249	Juvenile rheumatoid arthritis with systemic onset, unspecified hand	Diagnosis	ICD-10-CM
M08.251	Juvenile rheumatoid arthritis with systemic onset, right hip	Diagnosis	ICD-10-CM
M08.252	Juvenile rheumatoid arthritis with systemic onset, left hip	Diagnosis	ICD-10-CM
M08.259	Juvenile rheumatoid arthritis with systemic onset, unspecified hip	Diagnosis	ICD-10-CM
M08.261	Juvenile rheumatoid arthritis with systemic onset, right knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.262	Juvenile rheumatoid arthritis with systemic onset, left knee	Diagnosis	ICD-10-CM
M08.269	Juvenile rheumatoid arthritis with systemic onset, unspecified knee	Diagnosis	ICD-10-CM
M08.271	Juvenile rheumatoid arthritis with systemic onset, right ankle and foot	Diagnosis	ICD-10-CM
M08.272	Juvenile rheumatoid arthritis with systemic onset, left ankle and foot	Diagnosis	ICD-10-CM
M08.279	Juvenile rheumatoid arthritis with systemic onset, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.28	Juvenile rheumatoid arthritis with systemic onset, vertebrae	Diagnosis	ICD-10-CM
M08.29	Juvenile rheumatoid arthritis with systemic onset, multiple sites	Diagnosis	ICD-10-CM
M08.2A	Juvenile rheumatoid arthritis with systemic onset, other specified site	Diagnosis	ICD-10-CM
M08.3	Juvenile rheumatoid polyarthritis (seronegative)	Diagnosis	ICD-10-CM
M08.40	Pauciarticular juvenile rheumatoid arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.411	Pauciarticular juvenile rheumatoid arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.412	Pauciarticular juvenile rheumatoid arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.419	Pauciarticular juvenile rheumatoid arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.421	Pauciarticular juvenile rheumatoid arthritis, right elbow	Diagnosis	ICD-10-CM
M08.422	Pauciarticular juvenile rheumatoid arthritis, left elbow	Diagnosis	ICD-10-CM
M08.429	Pauciarticular juvenile rheumatoid arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.431	Pauciarticular juvenile rheumatoid arthritis, right wrist	Diagnosis	ICD-10-CM
M08.432	Pauciarticular juvenile rheumatoid arthritis, left wrist	Diagnosis	ICD-10-CM
M08.439	Pauciarticular juvenile rheumatoid arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.441	Pauciarticular juvenile rheumatoid arthritis, right hand	Diagnosis	ICD-10-CM
M08.442	Pauciarticular juvenile rheumatoid arthritis, left hand	Diagnosis	ICD-10-CM
M08.449	Pauciarticular juvenile rheumatoid arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.451	Pauciarticular juvenile rheumatoid arthritis, right hip	Diagnosis	ICD-10-CM
M08.452	Pauciarticular juvenile rheumatoid arthritis, left hip	Diagnosis	ICD-10-CM
M08.459	Pauciarticular juvenile rheumatoid arthritis, unspecified hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.461	Pauciarticular juvenile rheumatoid arthritis, right knee	Diagnosis	ICD-10-CM
M08.462	Pauciarticular juvenile rheumatoid arthritis, left knee	Diagnosis	ICD-10-CM
M08.469	Pauciarticular juvenile rheumatoid arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.471	Pauciarticular juvenile rheumatoid arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.472	Pauciarticular juvenile rheumatoid arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.479	Pauciarticular juvenile rheumatoid arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.48	Pauciarticular juvenile rheumatoid arthritis, vertebrae	Diagnosis	ICD-10-CM
M08.4A	Pauciarticular juvenile rheumatoid arthritis, other specified site	Diagnosis	ICD-10-CM
M08.80	Other juvenile arthritis, unspecified site	Diagnosis	ICD-10-CM
M08.811	Other juvenile arthritis, right shoulder	Diagnosis	ICD-10-CM
M08.812	Other juvenile arthritis, left shoulder	Diagnosis	ICD-10-CM
M08.819	Other juvenile arthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M08.821	Other juvenile arthritis, right elbow	Diagnosis	ICD-10-CM
M08.822	Other juvenile arthritis, left elbow	Diagnosis	ICD-10-CM
M08.829	Other juvenile arthritis, unspecified elbow	Diagnosis	ICD-10-CM
M08.831	Other juvenile arthritis, right wrist	Diagnosis	ICD-10-CM
M08.832	Other juvenile arthritis, left wrist	Diagnosis	ICD-10-CM
M08.839	Other juvenile arthritis, unspecified wrist	Diagnosis	ICD-10-CM
M08.841	Other juvenile arthritis, right hand	Diagnosis	ICD-10-CM
M08.842	Other juvenile arthritis, left hand	Diagnosis	ICD-10-CM
M08.849	Other juvenile arthritis, unspecified hand	Diagnosis	ICD-10-CM
M08.851	Other juvenile arthritis, right hip	Diagnosis	ICD-10-CM
M08.852	Other juvenile arthritis, left hip	Diagnosis	ICD-10-CM
M08.859	Other juvenile arthritis, unspecified hip	Diagnosis	ICD-10-CM
M08.861	Other juvenile arthritis, right knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.862	Other juvenile arthritis, left knee	Diagnosis	ICD-10-CM
M08.869	Other juvenile arthritis, unspecified knee	Diagnosis	ICD-10-CM
M08.871	Other juvenile arthritis, right ankle and foot	Diagnosis	ICD-10-CM
M08.872	Other juvenile arthritis, left ankle and foot	Diagnosis	ICD-10-CM
M08.879	Other juvenile arthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.88	Other juvenile arthritis, other specified site	Diagnosis	ICD-10-CM
M08.89	Other juvenile arthritis, multiple sites	Diagnosis	ICD-10-CM
M08.90	Juvenile arthritis, unspecified, unspecified site	Diagnosis	ICD-10-CM
M08.911	Juvenile arthritis, unspecified, right shoulder	Diagnosis	ICD-10-CM
M08.912	Juvenile arthritis, unspecified, left shoulder	Diagnosis	ICD-10-CM
M08.919	Juvenile arthritis, unspecified, unspecified shoulder	Diagnosis	ICD-10-CM
M08.921	Juvenile arthritis, unspecified, right elbow	Diagnosis	ICD-10-CM
M08.922	Juvenile arthritis, unspecified, left elbow	Diagnosis	ICD-10-CM
M08.929	Juvenile arthritis, unspecified, unspecified elbow	Diagnosis	ICD-10-CM
M08.931	Juvenile arthritis, unspecified, right wrist	Diagnosis	ICD-10-CM
M08.932	Juvenile arthritis, unspecified, left wrist	Diagnosis	ICD-10-CM
M08.939	Juvenile arthritis, unspecified, unspecified wrist	Diagnosis	ICD-10-CM
M08.941	Juvenile arthritis, unspecified, right hand	Diagnosis	ICD-10-CM
M08.942	Juvenile arthritis, unspecified, left hand	Diagnosis	ICD-10-CM
M08.949	Juvenile arthritis, unspecified, unspecified hand	Diagnosis	ICD-10-CM
M08.951	Juvenile arthritis, unspecified, right hip	Diagnosis	ICD-10-CM
M08.952	Juvenile arthritis, unspecified, left hip	Diagnosis	ICD-10-CM
M08.959	Juvenile arthritis, unspecified, unspecified hip	Diagnosis	ICD-10-CM
M08.961	Juvenile arthritis, unspecified, right knee	Diagnosis	ICD-10-CM
M08.962	Juvenile arthritis, unspecified, left knee	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M08.969	Juvenile arthritis, unspecified, unspecified knee	Diagnosis	ICD-10-CM
M08.971	Juvenile arthritis, unspecified, right ankle and foot	Diagnosis	ICD-10-CM
M08.972	Juvenile arthritis, unspecified, left ankle and foot	Diagnosis	ICD-10-CM
M08.979	Juvenile arthritis, unspecified, unspecified ankle and foot	Diagnosis	ICD-10-CM
M08.98	Juvenile arthritis, unspecified, vertebrae	Diagnosis	ICD-10-CM
M08.99	Juvenile arthritis, unspecified, multiple sites	Diagnosis	ICD-10-CM
M08.9A	Juvenile arthritis, unspecified, other specified site	Diagnosis	ICD-10-CM
M15.0	Primary generalized (osteo)arthritis	Diagnosis	ICD-10-CM
M15.1	Heberden's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.2	Bouchard's nodes (with arthropathy)	Diagnosis	ICD-10-CM
M15.3	Secondary multiple arthritis	Diagnosis	ICD-10-CM
M15.4	Erosive (osteo)arthritis	Diagnosis	ICD-10-CM
M15.8	Other polyosteoarthritis	Diagnosis	ICD-10-CM
M15.9	Polyosteoarthritis, unspecified	Diagnosis	ICD-10-CM
M16.0	Bilateral primary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.10	Unilateral primary osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.11	Unilateral primary osteoarthritis, right hip	Diagnosis	ICD-10-CM
M16.12	Unilateral primary osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.2	Bilateral osteoarthritis resulting from hip dysplasia	Diagnosis	ICD-10-CM
M16.30	Unilateral osteoarthritis resulting from hip dysplasia, unspecified hip	Diagnosis	ICD-10-CM
M16.31	Unilateral osteoarthritis resulting from hip dysplasia, right hip	Diagnosis	ICD-10-CM
M16.32	Unilateral osteoarthritis resulting from hip dysplasia, left hip	Diagnosis	ICD-10-CM
M16.4	Bilateral post-traumatic osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.50	Unilateral post-traumatic osteoarthritis, unspecified hip	Diagnosis	ICD-10-CM
M16.51	Unilateral post-traumatic osteoarthritis, right hip	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M16.52	Unilateral post-traumatic osteoarthritis, left hip	Diagnosis	ICD-10-CM
M16.6	Other bilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.7	Other unilateral secondary osteoarthritis of hip	Diagnosis	ICD-10-CM
M16.9	Osteoarthritis of hip, unspecified	Diagnosis	ICD-10-CM
M17.0	Bilateral primary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.10	Unilateral primary osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.11	Unilateral primary osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.12	Unilateral primary osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.2	Bilateral post-traumatic osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.30	Unilateral post-traumatic osteoarthritis, unspecified knee	Diagnosis	ICD-10-CM
M17.31	Unilateral post-traumatic osteoarthritis, right knee	Diagnosis	ICD-10-CM
M17.32	Unilateral post-traumatic osteoarthritis, left knee	Diagnosis	ICD-10-CM
M17.4	Other bilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.5	Other unilateral secondary osteoarthritis of knee	Diagnosis	ICD-10-CM
M17.9	Osteoarthritis of knee, unspecified	Diagnosis	ICD-10-CM
M18.0	Bilateral primary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.10	Unilateral primary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.11	Unilateral primary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.12	Unilateral primary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.2	Bilateral post-traumatic osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.30	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM
M18.31	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.32	Unilateral post-traumatic osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.4	Other bilateral secondary osteoarthritis of first carpometacarpal joints	Diagnosis	ICD-10-CM
M18.50	Other unilateral secondary osteoarthritis of first carpometacarpal joint, unspecified hand	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M18.51	Other unilateral secondary osteoarthritis of first carpometacarpal joint, right hand	Diagnosis	ICD-10-CM
M18.52	Other unilateral secondary osteoarthritis of first carpometacarpal joint, left hand	Diagnosis	ICD-10-CM
M18.9	Osteoarthritis of first carpometacarpal joint, unspecified	Diagnosis	ICD-10-CM
M19.011	Primary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.012	Primary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.019	Primary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.021	Primary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.022	Primary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.029	Primary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.031	Primary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.032	Primary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.039	Primary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.041	Primary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.042	Primary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.049	Primary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.071	Primary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.072	Primary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.079	Primary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.09	Primary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.111	Post-traumatic osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.112	Post-traumatic osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.119	Post-traumatic osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.121	Post-traumatic osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.122	Post-traumatic osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.129	Post-traumatic osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M19.131	Post-traumatic osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.132	Post-traumatic osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.139	Post-traumatic osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.141	Post-traumatic osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.142	Post-traumatic osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.149	Post-traumatic osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.171	Post-traumatic osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.172	Post-traumatic osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.179	Post-traumatic osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM
M19.19	Post-traumatic osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.211	Secondary osteoarthritis, right shoulder	Diagnosis	ICD-10-CM
M19.212	Secondary osteoarthritis, left shoulder	Diagnosis	ICD-10-CM
M19.219	Secondary osteoarthritis, unspecified shoulder	Diagnosis	ICD-10-CM
M19.221	Secondary osteoarthritis, right elbow	Diagnosis	ICD-10-CM
M19.222	Secondary osteoarthritis, left elbow	Diagnosis	ICD-10-CM
M19.229	Secondary osteoarthritis, unspecified elbow	Diagnosis	ICD-10-CM
M19.231	Secondary osteoarthritis, right wrist	Diagnosis	ICD-10-CM
M19.232	Secondary osteoarthritis, left wrist	Diagnosis	ICD-10-CM
M19.239	Secondary osteoarthritis, unspecified wrist	Diagnosis	ICD-10-CM
M19.241	Secondary osteoarthritis, right hand	Diagnosis	ICD-10-CM
M19.242	Secondary osteoarthritis, left hand	Diagnosis	ICD-10-CM
M19.249	Secondary osteoarthritis, unspecified hand	Diagnosis	ICD-10-CM
M19.271	Secondary osteoarthritis, right ankle and foot	Diagnosis	ICD-10-CM
M19.272	Secondary osteoarthritis, left ankle and foot	Diagnosis	ICD-10-CM
M19.279	Secondary osteoarthritis, unspecified ankle and foot	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M19.29	Secondary osteoarthritis, other specified site	Diagnosis	ICD-10-CM
M19.90	Unspecified osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.91	Primary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.92	Post-traumatic osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M19.93	Secondary osteoarthritis, unspecified site	Diagnosis	ICD-10-CM
M45.0	Ankylosing spondylitis of multiple sites in spine	Diagnosis	ICD-10-CM
M45.1	Ankylosing spondylitis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.2	Ankylosing spondylitis of cervical region	Diagnosis	ICD-10-CM
M45.3	Ankylosing spondylitis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.4	Ankylosing spondylitis of thoracic region	Diagnosis	ICD-10-CM
M45.5	Ankylosing spondylitis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.6	Ankylosing spondylitis lumbar region	Diagnosis	ICD-10-CM
M45.7	Ankylosing spondylitis of lumbosacral region	Diagnosis	ICD-10-CM
M45.8	Ankylosing spondylitis sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.9	Ankylosing spondylitis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A0	Non-radiographic axial spondyloarthritis of unspecified sites in spine	Diagnosis	ICD-10-CM
M45.A1	Non-radiographic axial spondyloarthritis of occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M45.A2	Non-radiographic axial spondyloarthritis of cervical region	Diagnosis	ICD-10-CM
M45.A3	Non-radiographic axial spondyloarthritis of cervicothoracic region	Diagnosis	ICD-10-CM
M45.A4	Non-radiographic axial spondyloarthritis of thoracic region	Diagnosis	ICD-10-CM
M45.A5	Non-radiographic axial spondyloarthritis of thoracolumbar region	Diagnosis	ICD-10-CM
M45.A6	Non-radiographic axial spondyloarthritis of lumbar region	Diagnosis	ICD-10-CM
M45.A7	Non-radiographic axial spondyloarthritis of lumbosacral region	Diagnosis	ICD-10-CM
M45.A8	Non-radiographic axial spondyloarthritis of sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M45.AB	Non-radiographic axial spondyloarthritis of multiple sites in spine	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M46.80	Other specified inflammatory spondylopathies, site unspecified	Diagnosis	ICD-10-CM
M46.81	Other specified inflammatory spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.82	Other specified inflammatory spondylopathies, cervical region	Diagnosis	ICD-10-CM
M46.83	Other specified inflammatory spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M46.84	Other specified inflammatory spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M46.85	Other specified inflammatory spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M46.86	Other specified inflammatory spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M46.87	Other specified inflammatory spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M46.88	Other specified inflammatory spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.89	Other specified inflammatory spondylopathies, multiple sites in spine	Diagnosis	ICD-10-CM
M46.90	Unspecified inflammatory spondylopathy, site unspecified	Diagnosis	ICD-10-CM
M46.91	Unspecified inflammatory spondylopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M46.92	Unspecified inflammatory spondylopathy, cervical region	Diagnosis	ICD-10-CM
M46.93	Unspecified inflammatory spondylopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M46.94	Unspecified inflammatory spondylopathy, thoracic region	Diagnosis	ICD-10-CM
M46.95	Unspecified inflammatory spondylopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M46.96	Unspecified inflammatory spondylopathy, lumbar region	Diagnosis	ICD-10-CM
M46.97	Unspecified inflammatory spondylopathy, lumbosacral region	Diagnosis	ICD-10-CM
M46.98	Unspecified inflammatory spondylopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M46.99	Unspecified inflammatory spondylopathy, multiple sites in spine	Diagnosis	ICD-10-CM
M47.011	Anterior spinal artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.012	Anterior spinal artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.013	Anterior spinal artery compression syndromes, cervicothoracic region	Diagnosis	ICD-10-CM
M47.014	Anterior spinal artery compression syndromes, thoracic region	Diagnosis	ICD-10-CM
M47.015	Anterior spinal artery compression syndromes, thoracolumbar region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M47.016	Anterior spinal artery compression syndromes, lumbar region	Diagnosis	ICD-10-CM
M47.019	Anterior spinal artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.021	Vertebral artery compression syndromes, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.022	Vertebral artery compression syndromes, cervical region	Diagnosis	ICD-10-CM
M47.029	Vertebral artery compression syndromes, site unspecified	Diagnosis	ICD-10-CM
M47.10	Other spondylosis with myelopathy, site unspecified	Diagnosis	ICD-10-CM
M47.11	Other spondylosis with myelopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.12	Other spondylosis with myelopathy, cervical region	Diagnosis	ICD-10-CM
M47.13	Other spondylosis with myelopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.14	Other spondylosis with myelopathy, thoracic region	Diagnosis	ICD-10-CM
M47.15	Other spondylosis with myelopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.16	Other spondylosis with myelopathy, lumbar region	Diagnosis	ICD-10-CM
M47.20	Other spondylosis with radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.21	Other spondylosis with radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.22	Other spondylosis with radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.23	Other spondylosis with radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.24	Other spondylosis with radiculopathy, thoracic region	Diagnosis	ICD-10-CM
M47.25	Other spondylosis with radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.26	Other spondylosis with radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.27	Other spondylosis with radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.28	Other spondylosis with radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region	Diagnosis	ICD-10-CM
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region	Diagnosis	ICD-10-CM
M47.814	Spondylosis without myelopathy or radiculopathy, thoracic region	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
M47.815	Spondylosis without myelopathy or radiculopathy, thoracolumbar region	Diagnosis	ICD-10-CM
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region	Diagnosis	ICD-10-CM
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region	Diagnosis	ICD-10-CM
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.819	Spondylosis without myelopathy or radiculopathy, site unspecified	Diagnosis	ICD-10-CM
M47.891	Other spondylosis, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M47.892	Other spondylosis, cervical region	Diagnosis	ICD-10-CM
M47.893	Other spondylosis, cervicothoracic region	Diagnosis	ICD-10-CM
M47.894	Other spondylosis, thoracic region	Diagnosis	ICD-10-CM
M47.895	Other spondylosis, thoracolumbar region	Diagnosis	ICD-10-CM
M47.896	Other spondylosis, lumbar region	Diagnosis	ICD-10-CM
M47.897	Other spondylosis, lumbosacral region	Diagnosis	ICD-10-CM
M47.898	Other spondylosis, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M47.899	Other spondylosis, site unspecified	Diagnosis	ICD-10-CM
M47.9	Spondylosis, unspecified	Diagnosis	ICD-10-CM
M48.8X1	Other specified spondylopathies, occipito-atlanto-axial region	Diagnosis	ICD-10-CM
M48.8X2	Other specified spondylopathies, cervical region	Diagnosis	ICD-10-CM
M48.8X3	Other specified spondylopathies, cervicothoracic region	Diagnosis	ICD-10-CM
M48.8X4	Other specified spondylopathies, thoracic region	Diagnosis	ICD-10-CM
M48.8X5	Other specified spondylopathies, thoracolumbar region	Diagnosis	ICD-10-CM
M48.8X6	Other specified spondylopathies, lumbar region	Diagnosis	ICD-10-CM
M48.8X7	Other specified spondylopathies, lumbosacral region	Diagnosis	ICD-10-CM
M48.8X8	Other specified spondylopathies, sacral and sacrococcygeal region	Diagnosis	ICD-10-CM
M48.8X9	Other specified spondylopathies, site unspecified	Diagnosis	ICD-10-CM

Smoking

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
1034F	Current tobacco smoker (CAD, CAP, COPD, PV) (DM)	Procedure	CPT-2
4001F	Tobacco use cessation intervention, pharmacologic therapy (COPD, CAD, CAP, PV, Asthma) (DM) (PV)	Procedure	CPT-2
4004F	Patient screened for tobacco use and received tobacco cessation intervention (counseling, pharmacotherapy, or both), if identified as a tobacco user (PV, CAD)	Procedure	CPT-2
99406	Smoking and tobacco use cessation counseling visit; intermediate, greater than 3 minutes up to 10 minutes	Procedure	CPT-4
99407	Smoking and tobacco use cessation counseling visit; intensive, greater than 10 minutes	Procedure	CPT-4
F17.200	Nicotine dependence, unspecified, uncomplicated	Diagnosis	ICD-10-CM
F17.201	Nicotine dependence, unspecified, in remission	Diagnosis	ICD-10-CM
F17.203	Nicotine dependence unspecified, with withdrawal	Diagnosis	ICD-10-CM
F17.208	Nicotine dependence, unspecified, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.209	Nicotine dependence, unspecified, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.210	Nicotine dependence, cigarettes, uncomplicated	Diagnosis	ICD-10-CM
F17.211	Nicotine dependence, cigarettes, in remission	Diagnosis	ICD-10-CM
F17.213	Nicotine dependence, cigarettes, with withdrawal	Diagnosis	ICD-10-CM
F17.218	Nicotine dependence, cigarettes, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.219	Nicotine dependence, cigarettes, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.223	Nicotine dependence, chewing tobacco, with withdrawal	Diagnosis	ICD-10-CM
F17.228	Nicotine dependence, chewing tobacco, with other nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.229	Nicotine dependence, chewing tobacco, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
F17.290	Nicotine dependence, other tobacco product, uncomplicated	Diagnosis	ICD-10-CM
F17.291	Nicotine dependence, other tobacco product, in remission	Diagnosis	ICD-10-CM
F17.293	Nicotine dependence, other tobacco product, with withdrawal	Diagnosis	ICD-10-CM
F17.298	Nicotine dependence, other tobacco product, with other nicotine-induced disorders	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
F17.299	Nicotine dependence, other tobacco product, with unspecified nicotine-induced disorders	Diagnosis	ICD-10-CM
G0436	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intermediate, greater than 3 minutes, up to 10 minutes	Procedure	HCPCS
G0437	Smoking and tobacco cessation counseling visit for the asymptomatic patient; intensive, greater than 10 minutes	Procedure	HCPCS
G9016	Smoking cessation counseling, individual, in the absence of or in addition to any other evaluation and management service, per session (6-10 minutes) [demo project code only]	Procedure	HCPCS
G9276	Documentation that patient is a current tobacco user	Procedure	HCPCS
G9458	Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or	Procedure	HCPCS
O99.330	Smoking (tobacco) complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM
O99.331	Smoking (tobacco) complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O99.332	Smoking (tobacco) complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O99.333	Smoking (tobacco) complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O99.334	Smoking (tobacco) complicating childbirth	Diagnosis	ICD-10-CM
O99.335	Smoking (tobacco) complicating the puerperium	Diagnosis	ICD-10-CM
S4995	Smoking cessation gum	Procedure	HCPCS
S9075	Smoking cessation treatment	Procedure	HCPCS
S9453	Smoking cessation classes, nonphysician provider, per session	Procedure	HCPCS
T65.221A	Toxic effect of tobacco cigarettes, accidental (unintentional), initial encounter	Diagnosis	ICD-10-CM
T65.222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter	Diagnosis	ICD-10-CM
T65.223A	Toxic effect of tobacco cigarettes, assault, initial encounter	Diagnosis	ICD-10-CM
T65.224A	Toxic effect of tobacco cigarettes, undetermined, initial encounter	Diagnosis	ICD-10-CM
Z71.6	Tobacco abuse counseling	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
Z87.891	Personal history of nicotine dependence	Diagnosis	ICD-10-CM
Transient Ischemic Attack			
G45.0	Vertebro-basilar artery syndrome	Diagnosis	ICD-10-CM
G45.1	Carotid artery syndrome (hemispheric)	Diagnosis	ICD-10-CM
G45.2	Multiple and bilateral precerebral artery syndromes	Diagnosis	ICD-10-CM
G45.3	Amaurosis fugax	Diagnosis	ICD-10-CM
G45.8	Other transient cerebral ischemic attacks and related syndromes	Diagnosis	ICD-10-CM
G45.9	Transient cerebral ischemic attack, unspecified	Diagnosis	ICD-10-CM
G46.0	Middle cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.1	Anterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.2	Posterior cerebral artery syndrome	Diagnosis	ICD-10-CM
G46.3	Brain stem stroke syndrome	Diagnosis	ICD-10-CM
G46.4	Cerebellar stroke syndrome	Diagnosis	ICD-10-CM
G46.5	Pure motor lacunar syndrome	Diagnosis	ICD-10-CM
G46.6	Pure sensory lacunar syndrome	Diagnosis	ICD-10-CM
G46.7	Other lacunar syndromes	Diagnosis	ICD-10-CM
G46.8	Other vascular syndromes of brain in cerebrovascular diseases	Diagnosis	ICD-10-CM
G97.31	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure	Diagnosis	ICD-10-CM
G97.32	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure	Diagnosis	ICD-10-CM
I60.00	Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.01	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.02	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation	Diagnosis	ICD-10-CM
I60.10	Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I60.11	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery	Diagnosis	ICD-10-CM
I60.12	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery	Diagnosis	ICD-10-CM
I60.2	Nontraumatic subarachnoid hemorrhage from anterior communicating artery	Diagnosis	ICD-10-CM
I60.20	Nontraumatic subarachnoid hemorrhage from unspecified anterior communicating artery	Diagnosis	ICD-10-CM
I60.21	Nontraumatic subarachnoid hemorrhage from right anterior communicating artery	Diagnosis	ICD-10-CM
I60.22	Nontraumatic subarachnoid hemorrhage from left anterior communicating artery	Diagnosis	ICD-10-CM
I60.30	Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery	Diagnosis	ICD-10-CM
I60.31	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery	Diagnosis	ICD-10-CM
I60.32	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery	Diagnosis	ICD-10-CM
I60.4	Nontraumatic subarachnoid hemorrhage from basilar artery	Diagnosis	ICD-10-CM
I60.50	Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery	Diagnosis	ICD-10-CM
I60.51	Nontraumatic subarachnoid hemorrhage from right vertebral artery	Diagnosis	ICD-10-CM
I60.52	Nontraumatic subarachnoid hemorrhage from left vertebral artery	Diagnosis	ICD-10-CM
I60.6	Nontraumatic subarachnoid hemorrhage from other intracranial arteries	Diagnosis	ICD-10-CM
I60.7	Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery	Diagnosis	ICD-10-CM
I60.8	Other nontraumatic subarachnoid hemorrhage	Diagnosis	ICD-10-CM
I60.9	Nontraumatic subarachnoid hemorrhage, unspecified	Diagnosis	ICD-10-CM
I61.0	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CM
I61.1	Nontraumatic intracerebral hemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CM
I61.2	Nontraumatic intracerebral hemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CM
I61.3	Nontraumatic intracerebral hemorrhage in brain stem	Diagnosis	ICD-10-CM
I61.4	Nontraumatic intracerebral hemorrhage in cerebellum	Diagnosis	ICD-10-CM
I61.5	Nontraumatic intracerebral hemorrhage, intraventricular	Diagnosis	ICD-10-CM
I61.6	Nontraumatic intracerebral hemorrhage, multiple localized	Diagnosis	ICD-10-CM
I61.8	Other nontraumatic intracerebral hemorrhage	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I61.9	Nontraumatic intracerebral hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.00	Nontraumatic subdural hemorrhage, unspecified	Diagnosis	ICD-10-CM
I62.01	Nontraumatic acute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.02	Nontraumatic subacute subdural hemorrhage	Diagnosis	ICD-10-CM
I62.9	Nontraumatic intracranial hemorrhage, unspecified	Diagnosis	ICD-10-CM
I63.00	Cerebral infarction due to thrombosis of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.011	Cerebral infarction due to thrombosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.012	Cerebral infarction due to thrombosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.013	Cerebral infarction due to thrombosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.019	Cerebral infarction due to thrombosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.02	Cerebral infarction due to thrombosis of basilar artery	Diagnosis	ICD-10-CM
I63.031	Cerebral infarction due to thrombosis of right carotid artery	Diagnosis	ICD-10-CM
I63.032	Cerebral infarction due to thrombosis of left carotid artery	Diagnosis	ICD-10-CM
I63.033	Cerebral infarction due to thrombosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.039	Cerebral infarction due to thrombosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.09	Cerebral infarction due to thrombosis of other precerebral artery	Diagnosis	ICD-10-CM
I63.10	Cerebral infarction due to embolism of unspecified precerebral artery	Diagnosis	ICD-10-CM
I63.111	Cerebral infarction due to embolism of right vertebral artery	Diagnosis	ICD-10-CM
I63.112	Cerebral infarction due to embolism of left vertebral artery	Diagnosis	ICD-10-CM
I63.113	Cerebral infarction due to embolism of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.119	Cerebral infarction due to embolism of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.12	Cerebral infarction due to embolism of basilar artery	Diagnosis	ICD-10-CM
I63.131	Cerebral infarction due to embolism of right carotid artery	Diagnosis	ICD-10-CM
I63.132	Cerebral infarction due to embolism of left carotid artery	Diagnosis	ICD-10-CM
I63.133	Cerebral infarction due to embolism of bilateral carotid arteries	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.139	Cerebral infarction due to embolism of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.19	Cerebral infarction due to embolism of other precerebral artery	Diagnosis	ICD-10-CM
I63.20	Cerebral infarction due to unspecified occlusion or stenosis of unspecified precerebral arteries	Diagnosis	ICD-10-CM
I63.211	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery	Diagnosis	ICD-10-CM
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery	Diagnosis	ICD-10-CM
I63.213	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries	Diagnosis	ICD-10-CM
I63.219	Cerebral infarction due to unspecified occlusion or stenosis of unspecified vertebral artery	Diagnosis	ICD-10-CM
I63.22	Cerebral infarction due to unspecified occlusion or stenosis of basilar artery	Diagnosis	ICD-10-CM
I63.231	Cerebral infarction due to unspecified occlusion or stenosis of right carotid arteries	Diagnosis	ICD-10-CM
I63.232	Cerebral infarction due to unspecified occlusion or stenosis of left carotid arteries	Diagnosis	ICD-10-CM
I63.233	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries	Diagnosis	ICD-10-CM
I63.239	Cerebral infarction due to unspecified occlusion or stenosis of unspecified carotid artery	Diagnosis	ICD-10-CM
I63.29	Cerebral infarction due to unspecified occlusion or stenosis of other precerebral arteries	Diagnosis	ICD-10-CM
I63.30	Cerebral infarction due to thrombosis of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.311	Cerebral infarction due to thrombosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.312	Cerebral infarction due to thrombosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.313	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.319	Cerebral infarction due to thrombosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.321	Cerebral infarction due to thrombosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.322	Cerebral infarction due to thrombosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.323	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.329	Cerebral infarction due to thrombosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.331	Cerebral infarction due to thrombosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.332	Cerebral infarction due to thrombosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.333	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.339	Cerebral infarction due to thrombosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.341	Cerebral infarction due to thrombosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.342	Cerebral infarction due to thrombosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.343	Cerebral infarction due to thrombosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.349	Cerebral infarction due to thrombosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.39	Cerebral infarction due to thrombosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.40	Cerebral infarction due to embolism of unspecified cerebral artery	Diagnosis	ICD-10-CM
I63.411	Cerebral infarction due to embolism of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.412	Cerebral infarction due to embolism of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.413	Cerebral infarction due to embolism of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.419	Cerebral infarction due to embolism of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.421	Cerebral infarction due to embolism of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.422	Cerebral infarction due to embolism of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.423	Cerebral infarction due to embolism of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.429	Cerebral infarction due to embolism of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.431	Cerebral infarction due to embolism of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.432	Cerebral infarction due to embolism of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.433	Cerebral infarction due to embolism of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.439	Cerebral infarction due to embolism of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.441	Cerebral infarction due to embolism of right cerebellar artery	Diagnosis	ICD-10-CM
I63.442	Cerebral infarction due to embolism of left cerebellar artery	Diagnosis	ICD-10-CM
I63.443	Cerebral infarction due to embolism of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.449	Cerebral infarction due to embolism of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.49	Cerebral infarction due to embolism of other cerebral artery	Diagnosis	ICD-10-CM
I63.50	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I63.511	Cerebral infarction due to unspecified occlusion or stenosis of right middle cerebral artery	Diagnosis	ICD-10-CM
I63.512	Cerebral infarction due to unspecified occlusion or stenosis of left middle cerebral artery	Diagnosis	ICD-10-CM
I63.513	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries	Diagnosis	ICD-10-CM
I63.519	Cerebral infarction due to unspecified occlusion or stenosis of unspecified middle cerebral artery	Diagnosis	ICD-10-CM
I63.521	Cerebral infarction due to unspecified occlusion or stenosis of right anterior cerebral artery	Diagnosis	ICD-10-CM
I63.522	Cerebral infarction due to unspecified occlusion or stenosis of left anterior cerebral artery	Diagnosis	ICD-10-CM
I63.523	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries	Diagnosis	ICD-10-CM
I63.529	Cerebral infarction due to unspecified occlusion or stenosis of unspecified anterior cerebral artery	Diagnosis	ICD-10-CM
I63.531	Cerebral infarction due to unspecified occlusion or stenosis of right posterior cerebral artery	Diagnosis	ICD-10-CM
I63.532	Cerebral infarction due to unspecified occlusion or stenosis of left posterior cerebral artery	Diagnosis	ICD-10-CM
I63.533	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries	Diagnosis	ICD-10-CM
I63.539	Cerebral infarction due to unspecified occlusion or stenosis of unspecified posterior cerebral artery	Diagnosis	ICD-10-CM
I63.541	Cerebral infarction due to unspecified occlusion or stenosis of right cerebellar artery	Diagnosis	ICD-10-CM
I63.542	Cerebral infarction due to unspecified occlusion or stenosis of left cerebellar artery	Diagnosis	ICD-10-CM
I63.543	Cerebral infarction due to unspecified occlusion or stenosis of bilateral cerebellar arteries	Diagnosis	ICD-10-CM
I63.549	Cerebral infarction due to unspecified occlusion or stenosis of unspecified cerebellar artery	Diagnosis	ICD-10-CM
I63.59	Cerebral infarction due to unspecified occlusion or stenosis of other cerebral artery	Diagnosis	ICD-10-CM
I63.6	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CM
I63.8	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.81	Other cerebral infarction due to occlusion or stenosis of small artery	Diagnosis	ICD-10-CM
I63.89	Other cerebral infarction	Diagnosis	ICD-10-CM
I63.9	Cerebral infarction, unspecified	Diagnosis	ICD-10-CM
I67.841	Reversible cerebrovascular vasoconstriction syndrome	Diagnosis	ICD-10-CM
I67.848	Other cerebrovascular vasospasm and vasoconstriction	Diagnosis	ICD-10-CM
I67.89	Other cerebrovascular disease	Diagnosis	ICD-10-CM

Appendix D. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System, Level II (HCPCS), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Covariates in this Request

Code	Description	Code Category	Code Type
I97.810	Intraoperative cerebrovascular infarction during cardiac surgery	Diagnosis	ICD-10-CM
I97.811	Intraoperative cerebrovascular infarction during other surgery	Diagnosis	ICD-10-CM
I97.820	Postprocedural cerebrovascular infarction following cardiac surgery	Diagnosis	ICD-10-CM
I97.821	Postprocedural cerebrovascular infarction following other surgery	Diagnosis	ICD-10-CM

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
Obesity	
benzphetamine HCl	Regimex
benzphetamine HCl	benzphetamine
diethylpropion HCl	diethylpropion
liraglutide	Saxenda
liraglutide	Victoza 2-Pak
liraglutide	Victoza 3-Pak
liraglutide	liraglutide
lorcaserin HCl	Belviq
lorcaserin HCl	Belviq XR
naltrexone HCl/bupropion HCl	Contrave
orlistat	Alli
orlistat	Xenical
phendimetrazine tartrate	phendimetrazine tartrate
phentermine HCl	Adipex-P
phentermine HCl	Lomaira
phentermine HCl	phentermine
phentermine HCl/topiramate	Qsymia
semaglutide	Ozempic
semaglutide	Wegovy
tirzepatide	Mounjaro
tirzepatide	Zepbound
Smoking	
nicotine	Nicoderm CQ
nicotine	Nicotrol
nicotine	Nicotrol NS
nicotine	nicotine
nicotine bitartrate	Nicotine Tartrate
nicotine polacrilex	Nicorelief
nicotine polacrilex	Nicorette
nicotine polacrilex	Quit 2
nicotine polacrilex	Quit 4
nicotine polacrilex	Stop Smoking Aid
nicotine polacrilex	nicotine (polacrilex)
nicotine polacrilex	nicotine polacrilex (bulk)
varenicline tartrate	Chantix
varenicline tartrate	Chantix Continuing Month Box

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Covariates in this Request

Generic Name	Brand Name
varenicline tartrate	Chantix Starting Month Box
varenicline tartrate	Tyrvaya
varenicline tartrate	varenicline tartrate

Appendix F. Technical Specifications Used in this Request

Specifications for Type 5 Request: cder_mpl1r_wp295

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool 14.2.0 to assess utilization and uptake of the 2019 (part 1) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).

<p>Query period: 01/01/2019 - 12/31/2024</p> <p>Coverage requirement: Medical and Drug Coverage</p> <p>Minimum Pre-Index Enrollment Days: 183 days</p> <p>Minimum Post-Index Required Days: 0 days</p> <p>Enrollment Gap: 45 days</p> <p>Age Groups: 0-17, 18-24, 25-40, 41-64, 65+ years</p> <p>Sex: M, F</p> <p>Other Demographic Restrictions: Restrict cohort to specific demographic values</p> <p>Stratifications: Age group, Sex, Calendar Month</p> <p>Data Restrictions: No</p> <p>Chart Availability Restriction Indicator: No</p> <p>Envelope macro: Reclassify encounters during inpatient stay as inpatient</p> <p>Freeze data: No</p> <p>Drop Censor Output Indicator: Yes</p>					
Exposure					
Scenario	Group	Index Exposure	Cohort definition	Type 5 Exposure Washout Period	Exclude Evidence of Days Supply if Event Washout Includes Dispensings
1	prabo	PrabotulinumtoxinA-xvfs	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
2	capla	Caplacizumab-yhdp	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
3	tric	Triclabendazole	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
4	brex	Brexanolone	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A

Appendix F. Technical Specifications Used in this Request

Specifications for Type 5 Request: cder_mpl1r_wp295

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool 14.2.0 to assess utilization and uptake of the 2019 (part 1) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).

Exposure					
Scenario	Group	Index Exposure	Cohort definition	Type 5 Exposure Washout Period	Exclude Evidence of Days Supply if Event Washout Includes Dispensings
5	solri	Solriamfetol	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
6	sipo	Siponimod	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
7	romo	Romozumab-aqqg	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
8	erdaf	Erdafitinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
9	risan	Risankizumab-rzaa	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
10	tafa_meg	Tafamidis Meglumine	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
11	alpe	Alpelisib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
12	pola	Polatuzumab Vedotin-piiq	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
13	brem	Bremelanotide	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A

Appendix F. Technical Specifications Used in this Request

Specifications for Type 5 Request: cder_mpl1r_wp295

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool 14.2.0 to assess utilization and uptake of the 2019 (part 1) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).

Exposure					
Scenario	Group	Index Exposure	Cohort definition	Type 5 Exposure Washout Period	Exclude Evidence of Days Supply if Event Washout Includes Dispensings
14	selin	Selinexor	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
15	imip_cila	Imipenem, Cilastatin and Relebactam	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
16	ferric	Ferric Maltol	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
17	daro	Darolutamide	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
18	pexid	Pexidartinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
19	preto	Pretomanid	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
20	pito	Pitolisant	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
21	entre	Entrectinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
22	fedra	Fedratinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A

Appendix F. Technical Specifications Used in this Request

Specifications for Type 5 Request: cder_mpl1r_wp295

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool 14.2.0 to assess utilization and uptake of the 2019 (part 1) New Molecular Entities (NMEs) to inform FDA in the Sentinel Distributed Database (SDD).

Exposure					
Scenario	Group	Index Exposure	Cohort definition	Type 5 Exposure Washout Period	Exclude Evidence of Days Supply if Event Washout Includes Dispensings
23	upad	Upadacitinib	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
24	lefa	Lefamulin	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
25	dotat	Ga-68-DOTATOC	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A
26	istra	Istradefylline	Include all valid exposure episodes during query period; only the first valid exposure episode's incidence is assessed using washout criteria	0	N/A

Appendix F. Technical Specifications Used in this Request

Specifications for Type 5 Request: cder_mpl1r_wp295						
The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool 14.2.0 to assess utilization						
Exposure						
Scenario	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
1	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
2	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
3	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
4	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
5	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
6	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
7	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
8	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
9	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Technical Specifications Used in this Request

Specifications for Type 5 Request: cder_mpl1r_wp295

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool 14.2.0 to assess utilization

Exposure						
Scenario	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
10	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
11	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
12	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
13	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
14	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
15	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
16	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
17	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
18	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
19	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date

Appendix F. Technical Specifications Used in this Request


Specifications for Type 5 Request: cder_mpl1r_wp295

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool 14.2.0 to assess utilization

Exposure						
Scenario	Care Setting and Diagnosis Position Requirements	Treatment Episode Gap Type	Exposure Episode Gap	Exposure Episode Extension Period	Create Baseline Table?	End At-Risk Period at Evidence of
20	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
21	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
22	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
23	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
24	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
25	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
26	Any care setting, any diagnosis position	Fixed	0 days	0 days	Yes	Disenrollment; Death; Data Partner End Date; Query End Date
International Classification of Diseases, Ninth Revision (ICD-9), International Classification of Diseases, Tenth Revision (ICD-10), Healthcare Common Procedure Coding System (HCPCS), and CPT (Current Procedural Terminology) codes are provided by Optum360.						
National Drug Codes (NDCs) are checked against FirstDataBank's FDBMedKnowledge®						
N/A: Not applicable						

Appendix G. Design Diagram Used in this Request

Cohort Design for QF-8898¹



¹ Includes all valid exposure during the query period; only the first valid episode's incidence is assessed using the washout period.

² 26 scenarios defined on initiation of NMEs approved in 2019 part 1 (one scenario per NME); Cohort entry date = first dispensing date for qualifying NME.

³ Baseline characteristics:

Window I: Age, Sex, Year

Window II: Chronic Conditions Data Warehouse (CCW): Acute Myocardial Infarction, Alzheimer's Disease, Non-Alzheimer's Dementia, Atrial Fibrillation, Diabetes, Heart Failure, Hyperlipidemia, Hypertension, Depression, Ischemic Heart Disease, Rheumatoid Arthritis/Osteoarthritis, Stroke/Transient Ischemic Attack (TIA), Breast Cancer, Colorectal Cancer, Prostate Cancer, Lung Cancer, Endometrial Cancer, Acquired Hypothyroidism, Anemia, Asthma, Benign Prostatic Hyperplasia, Chronic Kidney Disease, Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis, Glaucoma, Osteoporosis; and Other: Obesity (Diagnosis or Procedure Codes), Obesity (Dispensing Codes), Overweight, Smoking (Diagnosis or Procedure Codes), Smoking (Dispensing Codes), Alcohol Abuse or Dependence, Drug Abuse or Dependence, History of Cardiac Arrest, History of Coronary Angioplasty or Bypass, Liver Disease CCW, and Liver Disease Extended

⁴ Censoring: earliest of death, disenrollment, data partner data end date, query end date

Appendix H. Health Characteristics used to Define Covariates in this Request

Utilization				
Group	Medical Utilization Evaluation Period Start	Medical Utilization Evaluation Period End	Drug Utilization Evaluation Period Start	Drug Utilization Evaluation Period End
All groups	-183	-1	-183	-1

Baseline Characteristics					
Covariate Name	Covariate Number	Code Category	Care Setting and Diagnosis Position Requirements	Complex Covariates	Covariate Should be Found in Evaluation Period
<i>Chronic Conditions Data Warehouse</i>					
Acute Myocardial Infarction	1	DX	IPP, IPS		1
Alzheimer's Disease	2	DX	Any		1
Non-Alzheimer's Dementia	3	DX	Any		1
Atrial Fibrillation	4	DX	IPP, IPS		1
	5	DX	AV*, ED*, OA*		2
	6	CC		4 or 5	1
Diabetes	7	DX	IP*, IS*		1
	8	DX	AV*, ED*, OA*		2
	9	CC		7 or 8	1
Heart Failure	10	DX	IP*, AV*, ED*, OA*		1
Hyperlipidemia	11	DX	IP*, IS*		1
	12	DX	AV*, ED*, OA*		2
	13	CC		11 or 12	1
Hypertension	14	DX	IP*, IS*		1
	15	DX	AV*, ED*, OA*		2
	16	CC		14 or 15	1
Depression	17	DX	Any		1
Ischemic Heart Disease	18	DX	Any		1
Rheumatoid Arthritis/Osteoarthritis	19	DX	Any		2
Stroke/Transient Ischemic Attack (TIA)	20	DX	IP*		1
	21	DX	AV*, ED*, OA*		2
	22	CC		20 or 21	1
Breast Cancer	23	DX	IP*, IS*		1
	24	DX	AV*, ED*, OA*		2

Appendix H. Health Characteristics used to Define Covariates in this Request

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Care Setting and Diagnosis Position Requirements	Complex Covariates	Covariate Should be Found in Evaluation Period
<i>Chronic Conditions Data Warehouse</i>					
Colorectal Cancer	26	DX	IP*, IS*		1
	27	DX	AV*, ED* OA*		2
	28	CC		26 or 27	1
Prostate Cancer	29	DX	IP*, IS*		1
	30	DX	AV*, ED* OA*		2
	31	CC		28 or 29	1
Lung Cancer	32	DX	IP*, IS*		1
	33	DX	AV*, ED* OA*		2
	34	CC		32 or 33	1
Endometrial Cancer	35	DX	IP*, IS*		1
	36	DX	AV*, ED* OA*		2
	37	CC		35 or 36	1
Acquired Hypothyroidism	38	DX	IP*, IS*		1
	39	DX	AV*, ED* OA*		2
	40	CC		38 or 39	1
Anemia	41	DX	Any		1
Asthma	42	DX	IP*, IS*,		1
	43	DX	AV*, ED* OA*		2
	44	CC		42 or 43	1
Benign Prostatic Hyperplasia	45	DX	IP*, IS*		1
	46	DX	AV*, ED* OA*		2
	47	CC		45 or 46	1
Chronic Kidney Disease	48	DX	IP*, IS*		1
	49	DX	AV*, ED* OA*		2
	50	CC		48 or 49	1
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	51	DX	IP*, IS*		1
	52	DX	AV*, ED* OA*		2
	53	CC		51 or 52	1
Glaucoma	54	DX	AV*, ED*, OA*		1
Osteoporosis	55	DX	IP*, IS*,		1
	56	DX	AV*, ED* OA*		2

Appendix H. Health Characteristics used to Define Covariates in this Request

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Care Setting and Diagnosis Position Requirements	Complex Covariates	Covariate Should be Found in Evaluation Period
	57	CC		55 or 56	1
<i>Other</i>					
Obesity (Diagnosis or Procedure Codes)	58	DX, PX	Any		1
Obesity (Dispensing Codes)	59	RX	Any		1
Overweight	60	DX	Any		1
Smoking (Diagnosis or Procedure Codes)	61	DX, PX	Any		1
Smoking (Dispensing Codes)	62	RX	Any		1
Alcohol Abuse or Dependence	63	DX, PX	Any		1
Drug Abuse or Dependence	64	DX, PX	Any		1
History of Cardiac Arrest	65	DX	Any		1
History of Coronary Angioplasty or Bypass	66	DX, PX	Any		1
Liver Disease CCW	67	DX	IP*, IS*		1
	68	DX	AV*, ED* OA*		2
	69	CC		67 or 68	1
	70	PX	AV*		1
	71	DX	AV*		1
	72	CC		70 and 71	1
	73	PX	ED*		1
	74	DX	ED*		1
	75	CC		73 and 74	1
	76	PX	OA*		1
	77	DX	OA*		1
	78	CC		76 and 77	1
	79	PX	IS*		1
	80	DX	IS*		1
	81	CC		79 and 80	1
	82	CC		69 or 72 or 75 or 78 or 81	1
	83	DX	IP*, IS*		1
	84	DX	AV*, ED* OA*		2
	85	CC		83 or 84	1
	86	PX	AV*		1
	87	DX	AV*		1

Appendix H. Health Characteristics used to Define Covariates in this Request

Baseline Characteristics

Covariate Name	Covariate Number	Code Category	Care Setting and Diagnosis Position Requirements	Complex Covariates	Covariate Should be Found in Evaluation Period
Liver Disease Extended	88	CC		86 and 87	1
	89	PX	ED*		1
	90	DX	ED*		1
	91	CC		89 and 90	1
	92	PX	OA*		1
	93	DX	OA*		1
	94	CC		92 and 93	1
	95	PX	IS*		1
	96	DX	IS*		1
	97	CC		95 and 96	1
	98	CC		85 or 88 or 91 or 94 or 97	1

Appendix H. Health Characteristics used to Define Covariates in this Request

Baseline Characteristics

Covariate Name	Covariate Evaluation Period		Forced Supply to Attach to a	
	Start	Covariate Evaluation Period End	Code (only applies to RX codes)	Lookback Period Date Only
<i>Chronic Conditions Data Warehouse</i>				
Acute Myocardial Infarction	-183	-1	N/A	Y
Alzheimer's Disease	-183	-1	N/A	Y
Non-Alzheimer's Dementia	-183	-1	N/A	Y
Atrial Fibrillation	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
Diabetes	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
Heart Failure	-183	-1	N/A	Y
Hyperlipidemia	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
Hypertension	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
Depression	-183	-1	N/A	Y
Ischemic Heart Disease	-183	-1	N/A	Y
Rheumatoid Arthritis/Osteoarthritis	-183	-1	N/A	Y
Stroke/Transient Ischemic Attack (TIA)	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
Breast Cancer	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
Colorectal Cancer	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
Prostate Cancer	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y

Appendix H. Health Characteristics used to Define Covariates in this Request

Baseline Characteristics

Covariate Name	Covariate Evaluation Period		Forced Supply to Attach to a	
	Start	Covariate Evaluation Period End	Code (<i>only applies to RX codes</i>)	Lookback Period Date Only
Lung Cancer	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
Endometrial Cancer	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
Acquired Hypothyroidism	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
Anemia	-183	-1	N/A	Y
Asthma	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
Benign Prostatic Hyperplasia	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
Chronic Kidney Disease	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
Glaucoma	-183	-1	N/A	Y
Osteoporosis	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
<i>Other</i>				
Obesity (Diagnosis or Procedure Codes)	-183	-1	N/A	Y
Obesity (Dispensing Codes)	-183	-1	N/A	Y
Overweight	-183	-1	N/A	Y
Smoking (Diagnosis or Procedure Codes)	-183	-1	N/A	Y
Smoking (Dispensing Codes)	-183	-1	N/A	Y
Alcohol Abuse or Dependence	-183	-1	N/A	Y

Appendix H. Health Characteristics used to Define Covariates in this Request

Baseline Characteristics

Covariate Name	Covariate Evaluation Period		Forced Supply to Attach to a Code <i>(only applies to RX codes)</i>	Lookback Period Date Only
	Start	Covariate Evaluation Period End		
Drug Abuse or Dependence	-183	-1	N/A	Y
History of Cardiac Arrest	-183	-1	N/A	Y
History of Coronary Angioplasty or Bypass	-183	-1	N/A	Y
Liver Disease CCW	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y

Appendix H. Health Characteristics used to Define Covariates in this Request

Baseline Characteristics

Covariate Name	Covariate Evaluation Period		Forced Supply to Attach to a Code <i>(only applies to RX codes)</i>	Lookback Period Date Only
	Start	Covariate Evaluation Period End		
Liver Disease Extended	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y
	-183	-1	N/A	Y

Appendix H. Health Characteristics used to Define Covariates in this Request

RX: Drug code	IP*: inpatient hospital stays, any diagnoses	N: Lookback period should search for evidence of a date or interval	L: Lab Date	<=X: less than or equal to X
DX: Diagnosis code	IS*: non-acute institutional stays, any diagnoses	Y: Lookback period should search for evidence of a date only	O: Order Date	<X: less than X
PX: Procedure code	ED*: emergency department encounters		R: Result Date	>=X: greater than or equal to X
CC: Complex covariates (multiple COVARNUM values are used to define a covariate)	AV*: ambulatory visits		Blank: if CODECAT is not LB	>X: greater than X
	OA*: other ambulatory visits			~=X: not equal to X
				X:Y: between X and Y
				BORDERLINE
				POSITIVE
				NEGATIVE
				UNDETERMINED
				Start\end unit: range
				Blank: if CODECat is not LB

The wildcard symbol () can be used to represent 'any' values of either the care setting or principal discharge diagnosis flag. Wildcard does not restrict a specific principal diagnosis position. The principal discharge diagnosis flag is only relevant for diagnosis codes.

The (P) at the end of the care setting refers to the primary diagnosis position, while the (S) refers to the secondary diagnosis position. This indicates that only the first or second diagnosis on the claims should be used for specified codes. For example, IPP (Inpatient Primary) uses the first diagnosis position, and IPS (Inpatient Scndary) uses the second diagnosis position.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Care setting/PDX parameter.

N/A: Not applicable